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Summary 
 
Vector transmitted diseases such as the tropical helminth infections onchocerciasis and lymphatic 
filariasis (LF) affect more than 150 million people worldwide and are both considered major public 
health concerns. In order to guarantee the fulfillment of their complex lifecycle, adult filarial nematodes 
release millions of microfilariae (MF), which are engulfed by mosquito vectors and the current strategy 
to eliminate filarial infections focuses upon interrupting this transmission through annual mass drug 
administration (MDA). Nevertheless, repeated rounds of drug intake are needed to interrupt the 
lifecycle and gathering information about immunological processes could reveal alternative 
approaches in order to break transmission. Filariasis results in different pathological outcomes ranging 
from asymptomatic individuals to patients with severe pathology. Recently, a subgroup of 
asymptomatic latently infected patients has become apparent in LF; these individuals are 
amicrofilaremic despite chronic infection. With regards to immunological aspects, this subgroup has 
been neglected so far even though they are of special interest since they represent a roadblock in 
terms of parasite transmission. Moreover, immunological facets of asymptomatic microfilaremic 
(patent) individuals have been intensively described in the literature but usually in comparison to 
patients suffering from severe pathology. In onchocerciasis, most patients are patently infected and 
are characterized by weak or even absent inflammation. Interestingly, however, some infected 
individuals who lack severe pathology are amicrofilaremic and is considered to be a result of repeated 
MDA. Therefore, the present thesis aimed at analyzing the immune responses of a large cohort of LF 
or onchocerciasis infected individuals characterized by the absence or presence of MF. In addition, 
the signaling pathway of interleukin 10 (IL-10) was investigated since it is known from the literature 
that this immunosuppressive cytokine is a key player during filariasis. Results from infected individuals 
were compared with those from infection-free volunteers from the same endemic areas. In cases of 
infection with LF, immune profiles were also determined following the administration of different 
treatment regimes. Within this thesis it was shown that amicrofilaremic individuals could be 
characterized by lower parasite burden but increased immune responses with regards to their cytokine 
and antigen-specific immunoglobulin levels. In contrast, the presence of worm offspring was 
associated with a down-regulation of these immune responses but was not sufficient to induce the 
same immunomodulation in cells from non-endemic healthy blood donors in in vitro experiments. 
Moreover, analyzing gene expression profiles of regulatory, CD4+ and CD8+ T cell populations from 
individuals with patent and latent LF infection strengthened the observation that both groups of 
individuals cannot only be separated due to the presence or absence of MF per se but also due to 
differences in their immune profiles. These data provide novel insights into possible mechanisms 
which either actively hinder the release of MF from adult worms or their migration to the periphery in 
amicrofilaremic infected patients. Further research into these aspects may broaden the range of 
strategies currently employed to reduce transmission and in turn eliminate filariasis. 
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Zusammenfassung 
 
Vektorübertragene Erkrankungen wie die tropischen Helmintheninfektionen Onchozerkose und 
Lymphatische Filariose (LF) beeinträchtigen weltweit mehr als 150 Millionen Menschen und werden 
daher als schwerwiegende Gesundheitsprobleme eingestuft. Während ihres komplexen Lebenszyklus 
scheiden adulte Filarien Millionen von Mikrofilarien (MF) aus, welche von Mücken aufgenommen 
werden. Die derzeitige Strategie zur Eliminierung von Filarieninfektionen konzentriert sich auf eine 
Unterbrechung der Transmission durch jährliche Massentherapiebehandlungen. Allerdings sind zur 
Unterbindung des Lebenszyklus mehrfache Wiederholungen dieser Behandlung notwendig, daher 
könnten zusätzliche Informationen über die immunologischen Prozesse während der Infektion 
alternative Ansätze zur Unterbrechung der Transmission ermöglichen. Filariosen haben verschiedene 
pathologische Ausprägungen, die von asymptomatischen Individuen bis hin zu Patienten mit schwerer 
Pathologie reichen können. Innerhalb der LF Patienten wurde vor kurzem eine weitere Subgruppe von 
asymptomatischen, latent infizierten Individuen erkennbar; diese Individuen sind trotz einer 
chronischen Infektion MF-. Obwohl diese Subgruppe von Patienten eine Sackgasse im Hinblick auf die 
Transmission des Parasiten darstellt, wurden sie bisher in Bezug auf eine detaillierte immunologische 
Analyse vernachlässigt. Ferner wurden die immunologischen Facetten der asymptomatischen, MF+ 
(patenten) Individuen bereits intensiv in der Literatur beschrieben, jedoch meist im Vergleich zu 
Patienten mit schwerer Pathologie. Die meisten Onchozerkose Patienten weisen eine patente 
Infektion auf und sind durch eine schwache oder eine fehlende Entzündungsreaktion gekennzeichnet. 
Interessanterweise gibt es allerdings auch MF- Individuen ohne schwerwiegende Pathologie, was auf 
eine wiederholte Massentherapiebehandlungen zurückzuführen sein könnte. Das Ziel der 
vorliegenden Arbeit war es, die Immunantworten einer großen Kohorte von Patienten zu analysieren, 
die eine Onchozerkose oder LF Infektion aufweisen und durch die An- oder Abwesenheit von MF 
charakterisiert sind. Zusätzlich wurde der Signalweg des Zytokins Interleukin-10 (IL-10) untersucht, da 
bereits aus der Literatur bekannt ist, dass IL-10 eine Schlüsselrolle bei Filarieninfektionen spielt. Die 
Ergebnisse der infizierten Individuen wurden mit denen von gesunden Freiwilligen aus den gleichen 
Endemiegebieten verglichen. Im Falle der Infektion mit LF wurden zusätzlich die Immunprofile nach 
einer Behandlung der Patienten mit verschiedenen Therapien bestimmt. In der vorliegenden 
Doktorarbeit konnte gezeigt werden, dass MF- Patienten eine niedrigere Parasitenlast sowie eine 
verstärkte Immunantwort im Hinblick auf ihre Zytokinfreisetzung und ihre antigen-spezifischen 
Immunglobulinproduktion aufweisen. Im Gegensatz dazu war in MF+ Individuen die Präsenz des 
Wurmnachwuchses mit einer verminderten Immunantwort assoziiert; allerdings war diese nicht 
ausreichend, um die gleiche Immunmodulation in Zellen von gesunden Blutspendern in in vitro 
Experimenten zu induzieren. Des Weiteren untermauerte die Analyse der Genexpressionsprofile von 
regulatorischen, CD4+ und CD8+ T-Zellen von MF+ und MF- LF infizierten Individuen die in vitro 
Beobachtung, dass beide Gruppen von Patienten nicht nur aufgrund der An- oder Abwesenheit der 
MF per se zu unterscheiden sind, sondern auch aufgrund der Unterschiede bezüglich ihres 
immunologischen Profils. Diese Daten bieten neue Einblicke in die möglichen Mechanismen, welche 
innerhalb der infizierten MF- Patienten entweder direkt eine Freisetzung der MF aus adulten Würmern 
oder deren Migration in die Peripherie verhindern. Eine weitere Erforschung dieser Aspekte könnte 
das Spektrum der derzeitig verwendeten Strategien zur Reduktion der Transmission erweitern und 
somit langfristig zur Eliminierung von Filariosen beitragen. 
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1. Introduction 
A unique aspect of filarial nematodes is the dwelling of the endosymbiotic Wolbachia. This 
relationship further complicates the deciphering of already complex immune responses. The 
following section provides an overview of current knowledge surrounding the filarial 
manifestations termed onchocerciasis and lymphatic filariasis (LF). In addition to 
epidemiological and current treatment regimes the chapter also includes a comprehensive 
summary of the immunological aspects touching on both innate and adaptive responses. In 
part, these data provided the basis for the studies conducted in the following chapters which 
determined the immune profiles of differentially infected patients.  
 
 
1.1. Onchocerciasis 
 
1.1.1 Parasite biology and epidemiology 
Onchocerciasis is a chronic helminth disease caused by the tissue-invading filariae 
Onchocerca volvulus (O. volvulus) which is transmitted by blood-feeding black flies of the 
genus Simulium. Onchocerciasis is endemic in 34 countries and more than 37 million people 
are infected [1]. The infection is most abundant in Africa (more than 99% of cases), but there 
are also small foci in Southern and Central America (figure 1.1). Approximately 90 million 
people are at risk of infection with O. volvulus which can lead to debilitating skin disease like 
dermatitis and ocular inflammation which can ultimately end in blindness [2].  
 
 
 
 
 Figure 1.1. Global distribution of Onchocerca volvulus. Depicted are African countries with endemic 
onchocerciasis (left part) and endemic foci in Latin America (right part). Countries participating in the former 
Onchocerciasis Control Program region are shown in green and those participating in the African Program for 
Onchocerciasis Control are depicted in yellow. Adapted from http://www.mectizan.org/onchocerciasis-maps. 
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The highest rates of infection and disease manifestations are found in communities adjacent 
to rivers, hence the designation “river blindness” [1], which is the world’s fourth leading cause 
of preventable blindness. In general, onchocerciasis contributes to higher mortality and 
economic loss making it a major public health concern as well as a social stigmatism [3, 4].  
Onchocerca filariae have to fulfil a five-stage life cycle which begins with the transmission of 
infective third stage larvae (L3) from the small obligate vector of the genus Simulium, which 
breeds close to fast-flowing rivers (figure 1.2). Since the flight range of these vectors is 
approximately 12 km, transmission areas are localized to this radius around the breeding 
sites [3]. The transmitted larvae moult twice in the host and develop over a year into white 
thread-like adult worms, that live coiled in subcutaneous or deeper tissues forming 
characteristic fibrous nodules (onchocercomas) [3, 5]. These onchocercomas are defined as 
capsules of connective skin tissue in which several parasites are aggregated [6]. In contrast 
to the sessile females which are 30–80 cm in length, the ten times shorter adult males do not 
induce the formation of nodules but travel within the subcutaneous tissue, entering and 
leaving the nodules to inseminate a number of resident females, which then start to produce 
their offspring (first stage larvae, also called microfilariae, MF). On average, a nodule houses 
2-50 female worms, but only 1-10 males [7]. Filariae have an average life of 10-15 years and 
the number of females in any one infected may range from 1 to over 60.  
 
   
 Figure 1.2. Life cycle of Onchocerca volvulus. Adapted from [3].  
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Fertilized female worms are able to release 1,000 to 3,000 MF per day resulting in an 
enormous reproductive capacity of the worms [7]. These offspring migrate to the skin and 
other tissues where they can live for up to 18 months until they are engulfed by their vectors 
during a blood meal [8, 9]. Inside their intermediate host they undergo another two moulting 
steps over 10-12 days before reaching the infectious L3 stage. 
 
1.1.2 Pathology of Onchocerciasis 
In general, given that the principle of parasitism is long-term coexistence, it is actually 
advantageous for both the host and parasite to avoid pro-inflammatory immune responses. 
Therefore, any arising pathology in the host may be viewed as a failure of appropriate anti-
inflammatory mechanisms [10]. In the case of O. volvulus, the long-term persistence of the 
parasite indicates that it has evolved highly adapted mechanisms of immune evasion [7]. 
Nevertheless, the spectrum of disease manifestations in infected individuals is quite varied 
and the diversity of clinical responses is thought to reflect the intensity and type of immune 
response to the parasite itself or to the parasite’s products [1, 11]. Adult filarial worms are not 
considered strong inducers of inflammation. Therefore, the appearance of pathology is 
generally linked to migrating MF or more precisely to reactions to degraded or moribund MF 
in the skin or in the eye. Even subcutaneous nodules, consisting of host immune cells and 
tissues trigger few or no clinical symptoms [3, 12]. The most severe disease manifestation is 
actually elicited by the death of MF passing through the cornea [12, 13]. During their 
migration, MF may invade the conjunctiva, cornea and the posterior regions of the eye. 
Increasing numbers of degenerating MF can induce the release of multiple somatic antigens 
that in turn provoke inflammatory responses of resident cells due to a breakdown of the 
immune privilege, which normally prevents inflammation [7]. Around dead MF punctate 
keratitis (inflammation of the cornea, figure 1.3) can develop and permanent exposure can 
lead to iridocyclitis (inflammation of the iris) which results in permanent visual impairment or 
in its most severe form blindness [1]. 
 
  
 Figure 1.3. Pathology of Onchocerca volvulus. Left and middle picture show typical dermatitis and the right 
image depicts a sclerosing keratitis. Adapted from [3] and from [14]. 
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Nowadays, loss of sight induced by O. volvulus is rarely found; however, affected individuals 
show a broad range of other clinical manifestations. Studies on human onchocerciasis tend 
to classify patients into three groups: 1) asymptomatic individuals, persons with so called 
generalized onchocerciasis or GEO who have palpable nodules in their skin; 2) patients with 
severe pathology (termed hyperreactive form or sowda) and 3) putative immune individuals 
(PI, also termed endemic normals or EN) who never develop any signs of parasitemia or 
clinical onchocerciasis, despite their lifelong exposure to the parasite [5]. The majority of 
infected individuals in endemic areas belong to the asymptomatic form of onchocerciasis. 
These individuals are hyporesponsive and tolerate high loads of MF [11]. Although they do 
not kill viable MF, they can mount strong immune responses towards damaged adult worms 
or MF [7, 10]. Between the two polar forms (hypo- and hyperreactive form) there is a variety 
of individuals presenting intermediate symptoms, including those with primary infections, who 
are able to kill MF, but present a low degree of hyporesponsiveness [9]. Interestingly, there is 
evidence for a further group of hyporesponsive individuals who are are also MF- probably as 
a result of repeated rounds of treatment intake or increased vector control. This phenomenon 
is designated as post-patent, occult or expiring infection [15, 16]. In contrast to 
hyporesponsiveness, hyperreactivity on the other hand appears seldomly [2]. If pathology 
arises, it is principally located at the skin, since the skin contains masses of MF [5, 7]. Skin 
pathology is characterized by rashes, lesions and troublesome itching (figure 1.3). 
Furthermore, affected individuals can suffer from disfiguring skin disease lesions and in 
association, the intense psychosocial implications of chronic pruritus. Induction of these 
symptoms results from the destruction of cutaneous MF by strong local and systemic 
immune responses. If the dermal reaction is not limited, it can be accompanied by 
depigmentation (“leopard skin”) as well as by loss of skin elasticity and structure, resulting in 
signs of premature skin ageing (e.g. “lizard skin” or “hanging groin”). A further type of 
hyperreactivity in the skin is the so called sowda form, which is defined by severe chronic 
papular dermatitis and hyperpigmentation which appears unilaterally [7]. Occurrence of the 
sowda form is focused in certain geographically regions (it is most common in Yemen and 
Sudan) and moreover it has been correlated with specific genetic polymorphisms [3, 17]. 
Interestingly, individuals affected by hyperreactivity are characterized by low numbers of 
parasites (less than 10 MF per mg of skin or the absence of worm offspring). The low 
numbers of adult worms are further linked with lower frequencies of nodules and increased 
immune responses, particularly of type 2 helper (Th2) T cells [1, 7, 9].  
 
1.1.3 Immune responses during infection with Onchocerca volvulus 
One of the most interesting aspects for immunologists is the question how adult worms 
manage to be tolerated for up to 15 years in the human body and produce 5 to 10 million MF 
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during this time [18]. Nevertheless, there is a broad range of immune responses in infected 
individuals which in part reflects the diverse disease manifestations.  
Helminth infections are associated with humoral or Th2 responses and it is believed that Th2 
immunity actually evolved in response to such infections in order to counterbalance classical 
cell mediated Th1 responses which certainly damage worms, but also cause collateral 
damage to host tissue [19, 20]. Therefore, the Th2 response has some sort of “protective” 
function in terms of avoiding severe pathology. Previous studies have assigned the cytokines 
interleukin (IL)-3, IL-4, IL-5, IL-9, IL-10 and IL-13 and the antibody isotypes immunoglobulin 
(Ig)G1, IgG4 and IgE to these Th2 responses. Nowadays, IL-10 is allocated to regulatory 
immune responses [21] whereas IL-9 belongs to a further subgroup of T cells, namely Th9 
cells whose function and specific transcription factor are not known so far [22]. 
Patients with the generalized form of the disease tolerate high loads of MF, however they are 
characterized by mild or moderate skin dermatitis [7]. Peripheral blood mononuclear cells 
(PBMCs) of these individuals produce low levels of the hallmark Th1 cytokine interferon 
(IFN)-gamma and show no or weak parasite-specific proliferative immune cell responses 
when re-stimulated with O. volvulus extract [3, 23, 24]. Thus, it was previously thought that 
these patients have elevated Th2 immune responses [13, 15], but today it is known that in 
GEO patients immunomodulatory mechanisms exist that limit and control Th2 immune 
responses in order to prevent damaging effects [25, 26]. These effects are probably 
mediated by adult female worms in order to protect their offspring and to establish long-
lasting parasitic infections [18, 25, 27]. Due to the fact that there is a calculated turnover of 
1,000-3,000 MF per day from each female worm in patent GEO individuals, down-regulation 
of proliferation responses and suppression of pro-inflammatory cytokines seems to be an 
essential step to avoid extensive immune responses that could damage both host and 
parasite [24]. To add an additional level of complication, in O. volvulus, all individual worms 
and all life cycle stages contain an intracellular bacterial symbiont (Wolbachia, see section 
1.3) that is essential for worm fertility and survival. These bacteria were shown to induce pro-
inflammatory innate responses via Toll-like receptors (TLR), specialized pattern-recognition 
receptors (PRRs), which detect conserved structures of pathogens [28]. Since host 
inflammatory responses to MF and Wolbachia are thought to be the driving force behind 
onchocercal keratitis and dermatitis [5], adverse immune reactions induced by Wolbachia 
have to be counterbalanced in order to guarantee the worm’s survival. It is hypothesized that 
consistently increasing the exposure of the host’s immune system to worm antigen results in 
hyporesponsiveness, which in turn results in unresponsiveness to bystander antigens [25]. 
For example, in vitro experiments demonstrated that the amount of skin MF was negatively 
associated with the levels of secreted Th2 cytokines of PBMCs from onchocerciasis patients 
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stimulated with O. volvulus extract [29] whereas the magnitude of Th2 responses augments 
with increasing severity of pathology but this is not strictly correlated [5].  
Studies have elucidated several mechanisms and cell types that are thought to play a role in 
modulating immune responses in asymptomatic filarial infected individuals. Amongst them 
are regulatory T cells (Tregs), alternatively activated macrophages (AAMs), regulation of TLR 
that sense Wolbachia and anti-inflammatory cytokines like transforming growth factor beta 
(TGF- and IL-10 [18, 30-33]. During the last years, Tregs expressing the transcription 
factor forkhead box P3 (Foxp3) have become a central focus of attention because they are 
indispensable for immunological unresponsiveness to self-antigens and in suppressing 
excessive immune responses deleterious to the host [34]. They are a subpopulation of helper 
CD4+ T cells and are able to suppress overly active Th1 and Th2 cells. Unlike Th1, Th2 and 
Th17 T cells, which all mediate pro-inflammatory effects and activate further T- and B-cell 
populations, regulatory T cells inhibit pro-inflammatory immune responses by eliciting anti-
inflammatory signals via cell to cell contact through glucocorticoid-induced tumour-necrosis 
factor receptor-related protein (GITR) or cytotoxic T lymphocyte antigen 4 (CTLA-4) or via 
the secretion of regulatory cytokines (like IL-10 and TGF-. Multiple studies have implicated 
an important function of Tregs during helminth infection. For example, it was shown that the 
majority of T cell clones generated from onchocercomas of GEO individuals had a 
suppressive profile and moreover immunohistochemistry revealed the local presence of 
Tregs inside nodules [9, 18]. 
Alongside Tregs, AAMs also play an important role during filarial infections. In contrast to 
conventional macrophages, which mediate pro-inflammatory immune reactions, AAMs are 
characterized by their diminished immune response to TLR stimuli and by reduced 
expression of the genes associated with in antigen presentation and processing. Upon 
activation they induce less pro-inflammatory cytokines but more TGF- and in general they 
seem to block Th1 immune responses. Moreover, they can contribute to wound healing 
which is important during filarial infections since the penetrating parasites can cause 
extensive damage as they pass through tissue, releasing proteolytic enzymes that injure 
cells and tissue [34-38]. In accordance with these effects, AAMs are found to be up-regulated 
in asymptomatic patients infected with the closely related filariae W. bancrofti and they could 
probably account for the diminished parasite antigen-specific T cell responses seen in these 
individuals [31]. Moreover, macrophages with an alternative activation phenotype were also 
found in onchocercomas of hyporeactive individuals [32]. 
As mentioned above, TLRs belong to PRRs and recognize conserved structures derived 
from microbes. Murine models of ocular onchocerciasis have linked the induction of corneal 
pathology with the triggering of TLR2 and TLR4 [39, 40]. Human studies revealed that LF 
infected MF+ patients expressed decreased baseline levels of TLRs on their B and T cells 
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compared to uninfected controls. B cells and also monocytes of these infected persons were 
both characterized by decreased expression of TLRs following stimulation with the helminth 
antigen and diminished cytokine secretion following TLR stimulation compared to uninfected 
individuals [33, 36]. In contrast, LF patients suffering from severe pathology were shown to 
express higher levels of TLR indicating that TLR expression is associated with disease 
manifestations [41, 42]. These data provide evidence that parasites also induce regulation of 
TLR expression in order to evade detrimental immune responses, albeit only for infections 
with LF so far. 
TGF-β is a highly conserved regulatory cytokine with pleiotropic effects on cell proliferation, 
differentiation, migration, and survival and appears to play a role in multiple biological 
processes including development, carcinogenesis, fibrosis, wound healing, and immune 
responses [43]. Its function includes the reduction of inflammation, immunosuppression, 
regulation of cell proliferation, differentiation and migration, and regulation of extracellular 
matrix production [44]. The involvement of TGF- during filarial infections stemmed from 
studies which demonstrated that there were increased levels of TGF- in the onchocercomas 
of hyporeactive patients which could theoretically suppress defensive Th2 responses and 
counterbalance immunopathology. In contrast, levels of TGF- are decreased in 
hyperreactive individuals [9]. Interestingly, it was also demonstrated that levels of this 
cytokine increased with the onset of MF production and with worm burden per se [32]. 
Immunohistology of nodules also demonstrated that numerous cell types release TGF-β 
including T cells, plasma/B cells, macrophages, mast cells, fibrocytes and vascular 
endothelial cells [32] and as mentioned above it can also be secreted by AAMs [37]. 
Generation of antigen-specific regulatory T cell clones (Tr1) from onchocercomas showed 
that these cells induce peripheral tolerance through the production of TGF- [18] although 
neutralization of TGF- enhanced but did not completely restore proliferation in re-stimulation 
assays with PBMCs from GEO individuals [24]. Further studies demonstrated that filariae 
also possess tgf- genes and produce TGF-β homologues that may contribute to the 
maintenance of the physiological integrity of worm tissues [45]. All these results emphasize a 
key role of TGF- during onchocerciasis although they also indicate the involvement of 
additional suppressive mechanisms.  
IL-10 is another generally known immunosuppressive cytokine that can limit potential tissue 
damage caused by inflammation and can inhibit both innate and adaptive immune 
responses. This cytokine is produced by various cells of the innate and adaptive immune 
system, including dendritic cells, macrophages, mast cells, natural killer (NK) cells, 
eosinophils, neutrophils, CD4+ and CD8+ T cells, and B cells. Signal transducer and 
transcription activator 3 (STAT3) is the key downstream transcription factor used by IL-10 
[46]. The IL-10 receptor (IL-10R) is composed of two different chains (IL-10R1 and IL-10R2) 
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and upon IL-10 binding to the IL-10R complex, the IL-10/IL-10R1 interaction changes the 
cytokine conformation allowing the association of IL-10R2 (see figure 1.4). Subsequently, 
two members of the Janus kinase family are activated namely Janus kinase 1 (Jak1) and 
Tyrosine kinase 2 (Tyk2), presumably by cross-phosphorylation of two tyrosine residues (Tyr 
446 and Tyr 496) on the intracellular domain of the IL-10 receptor 1 (IL-10R1). These 
phosphorylated tyrosines mediate the direct interaction of STAT3 via their SH2 domain to the 
IL-10 receptor complex. Additionally, STAT1 and, in certain cell types, STAT5 molecules are 
activated in IL-10-treated cells. These transcription factors build homo- and heterodimers that 
migrate into the cell nucleus and bind to the STAT binding elements of various promoters in 
order to induce transcription of the corresponding genes [21, 47]. The important role of IL-10 
during filarial infections was demonstrated in several studies. For example, it was shown that 
neutralization of IL-10 during in vitro experiments restored the proliferative capacity of 
PBMCs from hyporeactive patients [24, 48]. In addition, CD4+ T cell clones from nodules of 
GEO individuals were shown to be strong producers of IL-10 [18]. Furthermore, IL-10 is 
associated with the induction of IgG4 indicating that IL-10 influences both cellular and 
humoral immune responses [49]. For example, in vitro generated regulatory T cell clones that 
preferentially induce IgG4 by B cells were inhibited in their IgG4 production if IL-10 was  
 
   
 Figure 1.4. IL-10 signaling pathway. IL-10 binds first to IL-10R1. This interaction leads to a conformation change 
of the cytokine creating a binding site for IL-10R2. The close proximity of both receptor components leads to the 
reciprocal activation of the receptor-associated Jak1 and Tyk2. Following the tyrosine phosphorylation of the 
cytoplasmatic part of IL-10R1, STAT3 molecules are bound and phosphorylated by the Janus kinases. 
Additionally, STAT1 and, STAT5 molecules are activated. STAT homo- or heterodimers immigrate into the nucleus 
where they bind to the STAT binding elements of various promoters in order to induce transcription of the 
corresponding genes. Adapted from [21]. 
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blocked. Interestingly, the same effect was observed, if the interaction between GITR and its 
ligand were blocked [50]. In general, hyporeactive GEO individuals are characterized by high 
IgG4 production [49, 51]. IgG4 is a poor inducer of antibody-dependent cell-mediated 
cytotoxicity (ADCC) since it does not fix the complement system and binds rather weakly to 
effector cell Fc receptors [51, 52]. However, IgG4 can compete with IgE for antigenic binding 
sites and has a higher affinity than IgE [53] thereby preventing the host from pro-
inflammatory immune responses by saturating IgE receptors and preventing the bridging of 
O. volvulus specific IgE which avoids mast cell degranulation [7]. Thus, induction of IgG4 is 
believed to represent one of the major mechanisms used by filarial parasites to evade 
destruction by their host’s immune system [54]. In line with these facts, staining of 
onchocercomas of GEO individuals revealed an increase of IgG4 producing plasma cells 
compared to the hyperreactive form of the infection [9]. In conclusion, individuals with the 
GEO form are characterized by strong immune regulatory mechanisms which prevent the 
attack of live MF in order to protect host and parasite. 
In contrast to the hyporeactive form of onchocerciasis, mechanisms inducing tolerance are 
considered damaged or inhibited in hyperreactive individuals. Interestingly, this form of the 
disease clusters in families and is associated with distinct gene variants [17]. Affected 
individuals are further defined by strong Th2 cytokine responses and eosinophilia [17]. 
Eosinophils are known to attack filarial larvae through the release of cytotoxic cationic 
proteins as well as mediators like oxygen radicals thereby also damaging host cells. Many of 
the eosinophil-specific mediators act directly on mast cells and aggravate inflammation [43]. 
Indeed, eosinophils can be found around the few live or disintegrating MF in hyperreactive 
patients [7]. Moreover, analysis of the onchocercomas from hyperreactive individuals 
revealed that they contain massive infiltration of lymphocytes (like plasma cells), eosinophils, 
neutrophils, macrophages and mast cells in contrast to nodules of GEO individuals which are 
characterized by moderate inflammation [13, 55]. In addition, it could be shown in 
immunohistochemical stainings that hyperreactive individuals have less TGF- in their 
nodules than GEO patients which could induce immunosuppression [9]. Concerning the 
humoral immune response, it has also been described that hyperreactive patients are 
characterized by high levels of IgE but interestingly, also increased levels of IgG1 and IgG3 
in their sera [5]. Immunohistochemical stainings of the nodules confirmed the presence of 
increased amounts of IgG1 and IgE producing plasma cells [9]. In conclusion, hyperreactive 
individuals obviously have the capacity to kill MF, but this is associated with severe pro-
inflammatory responses. 
In the third group, consisting of naturally resistant or putatively immune persons, individuals 
show a different immunological profile composed of a strong mix of Th1 and Th2 responses 
which is mainly characterized by the production of IFN- and IL-5 [13]. This increased 
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Th1/Th2 immune response prevents the development of patent infections, in contrast to 
individuals with the generalized form of onchocerciasis. It could be shown that PBMCs from 
PI individuals secrete more cytokines upon re-stimulation with a larval antigen or adult worm 
antigen than GEO patients [13, 15, 24, 56, 57]. Moreover, PBMCs from PI individuals show 
higher proliferative activity and they secrete less IL-10 than those from hyporeactive 
individuals [15, 58]. Furthermore, it is known that the levels of Fc receptor- and complement-
binding IgG3-type antibodies are higher in PI individuals compared to those of GEO 
individuals [13] and in general they have higher levels of circulating antigen-specific IgG1 
and IgG3. Both are regarded as being possibly protective since they are involved in antibody-
dependent cellular cytotoxicity reactions against filarial larvae [59]. 
 
 
1.2 Lymphatic filariasis 
 
1.2.1 Parasite biology and epidemiology 
Lymphatic filariasis is a major neglected tropical disease that causes acute and chronic 
morbidity. It is spread across 81 countries and 120 million people are infected (see figure 
1.5) with a third of the latter seriously incapacitated and disfigured by the disease [60]. In 
addition, an estimated 1.34 billion people live in areas where filariasis is endemic and are at 
risk of infection [61, 62]. Approximately 65% of infected individuals live in South-East Asia,  
 
 
 
 
 Figure 1.5. Global distribution of LF and status of mass drug administration. Adapted from [61].  
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30% in Africa and the remainder in other tropical areas [http://www.who.int/mediacentre/ 
factsheets/fs102/en/index.html]. Lymphatic filariasis is prevalent in both urban and rural 
areas, but the majority of cases occur among the poor. Mortality is uncommon but the 
morbidity associated with this infection can be considerable and lifelong [63] since individuals 
suffer from severe functional impairment that ranges from loss of working time to completely 
giving up an occupation [64]. The consequential socioeconomic impact has therefore 
designated this infection a major public health concern. Lymphatic filariasis is provoked by 
infection with the threadlike nematodes Wuchereria bancrofti, Brugia malayi or Brugia timori 
which are transmitted by anopheline and culicine mosquitoes. More than 90% of infections 
are caused by W. bancrofti [65]. The infective L3 enter the host during the blood meal of the 
vector and migrate through the lymphatics (figure 1.6). The L3 moult into L4 and finally into 
sexual dimorphic adult worms [66], which exist for up to 8 years in their hosts. The site of 
adult worm parasitism is in dilated nests within the lymphatic vessels which are most 
commonly found in the extremities and male genitalia. Here, inseminated females start to 
produce millions of MF which are 200-250 m in length and circulate in periodical patterns in 
the blood to coincide with the vector’s feeding habits [1]. During another blood meal these 
MF can be ingested again by the vector mosquito. 
 
   
 Figure 1.6. Life cycle of W. bancrofti. Adapted from http://www.dpd.cdc.gov/dpdx.  
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1.2.2 Pathology of lymphatic filariasis 
Lymphatic filariasis is a chronic and persistent disease that endures over many years. 
Comparable to infections with O. volvulus the majority of infected individuals elicit very few 
signs of disease [67], but in general the spectrum of clinical presentations found among 
individuals in endemic regions of LF is extremely broad.  
The most common clinical manifestation, the asymptomatic (patent) form, is associated with 
high levels of MF and circulating filarial antigen but with absence of obvious pathology [68]. 
These patients serve as the reservoir for continued transmission of the parasite. In contrast, 
individuals with severe pathology have few or no MF but vigorous specific immune 
responses [69]. In addition to the asymptomatic and symptomatic form, the disease can be 
further divided into acute (or early) and chronic phases but of course it has proven difficult to 
focus on acute or early infections because the time of infection cannot be easily ascertained 
[70]. Furthermore, some individuals remain free of infections despite lifelong exposure to the 
parasites; these individuals are referred to as EN. 
In the early phase of infection there are two different acute manifestations of LF: acute filarial 
lymphangitis (AFL) and acute dermatolymphangioadenitis (ADLA) [71]. The former one is 
induced by the death of the filarial worms and may end in hydrocele formation (accumulation 
of lymph fluid in the tunica vaginalis, occurs only in bancroftian filariasis, figure 1.7) whereas 
ADLA is not induced by the worm per se but is associated with bacterial infections that may 
induce lymphedema (accumulation of lymph fluid in the legs, scrotum, breasts and arms, 
figure 1.7) [72, 73]. However, in contrast to onchocerciasis, pathology in LF is mainly caused 
by the adult stage of the worm [2]. There is almost no immune reaction to adult worms as 
long as they are alive but inflammation does occur when adult worms die; either drug-
induced or spontaneously resulting in local necrosis around the parasite [74, 75]. Dead 
parasites are then either completely absorbed or partially calcified. Inside the affected tissues 
they provoke changes that induce dilation of the lymphatics and thickening of the lymphatic 
vessel wall as well as fibrosis and lymphatic obstruction [1, 70, 76]. Granuloma formation, 
defined as infiltration of plasma cells, eosinophils, neutrophils and macrophages, has also 
been demonstrated in and around these infected vessels by histological stainings [70]. If 
these induced immune reactions are not limited (see below) they can lead to different 
irreversible clinical manifestations such as lymphedema which may progress to the most 
severe disease form, called elephantiasis (non reversible edema, with skin thickening and 
nodular or warty excrescences), to urogenital disorders or to hydroceles [77]. These 
individuals are often referred to as chronic pathology (CP) patients. In fact, the occurrence of 
lymphedema and hydrocele is not mutually exclusive and both are characterized by dilation 
of the lymphatic vessels and extravasation of fluid from the vessels into the surrounding 
tissues. The enlargement of the lymph vessels results in less efficient lymph flow which in the 
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 Figure 1.7. Aspects of severe pathology elicited by LF infection. Left picture shows severe lymphedema in the 
right leg whereas the right picture depicts an example of hydrocele. Adapted from [78] and from 
http://www.dolf.wustl.edu. 
 
 
legs is always orientated against gravity. In contrast to hydrocele patients, lymphedema 
affected individuals become more vulnerable to opportunistic microorganisms that may enter 
the lymphatics through smaller wounds; these little injuries would be usually unnoticed in 
people without lymphatic disease [74]. Besides these secondary bacterial or fungal 
infections, other studies have provided evidence that pathology is a genetic trait since its 
development is seen in clusters of families and several distinct polymorphisms have been 
identified. Moreover, genetic traits have also been correlated with parasite burden and the 
susceptibility to infection per se [44, 74, 79]. 
A further rare form of pathology, that is present in less than 1% of all LF infected individuals, 
is the so called tropical pulmonary eosinophilia (TPE) [80]. This type of illness reflects an 
immunological hyperresponsiveness of the host. Affected patients suffer from cough, fever, 
and hepatosplenomegaly [81]. They are characterized by the absence of MF in the 
bloodstream because the worm offspring is rapidly opsonized with anti-microfilarial 
antibodies and finally cleared in the pulmonary vasculature. Trapped MF degenerate and 
release antigenic components that trigger local inflammatory processes with accumulation 
and activation of eosinophils in the lungs. Consequently, asthmatic symptoms are induced as 
a result of pulmonary allergic responses mediated by specific IgE antibodies directed against 
the MF [76, 80, 82]. 
 
1.2.3 Immune responses during infection with lymphatic filariasis 
The immune system of individuals living in endemic areas of LF is permanently exposed to 
incoming larvae, dying adult worms and degenerating embryos released from fecund adult 
female worms and to the endosymbiotic Wolbachia (see section 1.3). All these factors lead to 
low-level but constant triggering of innate and adaptive immune cascades and it seems that 
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the frequency and intensity of the host’s response is related to the degree of clinical disease 
and pathology [2, 74, 83]. 
Responses of affected individuals can be pinpointed to the phase of infection since there are 
stage specific reactions to antigens from larvae, MF and adult worms. Antigens of these 
distinct stages stimulate the release of diverse patterns of cytokines and therefore immune 
responses are different in the acute and chronic phase [84]. For example, in vitro studies 
have demonstrated that antigenic extracts of MF influence dendritic cell (DC) characteristics 
during their differentiation process. Indeed, alteration of DC function by MF resulted in less 
efficient activation of T cells and modified cytokine release [85]. In addition, live MF have 
been shown to induce apoptosis in immature DCs; this diminishes their capacity to function 
appropriately which in turn has significant consequences on the activation of CD4+ T cells 
[86]. In association, live L3 decrease the capacity of epidermal Langerhans cells to stimulate 
CD4+ T cells and another report revealed that they rather induced Th1 dominated responses 
in T cells from uninfected persons in the presence of antigen presenting cells [87, 88]. 
Studies with patients suffering from AFL have demonstrated that they have significantly 
increased levels of TNF in their sera compared to microfilaremic individuals or those with 
chronic pathology. The level of this pro-inflammatory cytokine has been correlated to the 
severity of the acute disease [70, 89].  
However, the majority of the previous studies focused on comparing microfilaremic 
individuals versus CP patients because these two groups represent the major poles of 
infection. Down-regulation of proliferation in response to parasite-specific antigen stimulation 
is a hallmark of patent infection, although the ability to respond to non-parasite antigens and 
mitogens is equivalent to those observed in asymptomatic MF+ individuals and those with 
chronic lymphatic pathology [90]. This T cell hyporesponsiveness is further reflected by the 
decreased production of IFN- and IL-2 from cells of infected individuals with no clinical signs 
of disease [91]. King et al demonstrated an association of this down-regulated immune 
response in asymptomatic individuals with a lower frequency of parasite-specific T and B 
cells of microfilaremic individuals compared to CP patients [92]. Besides the down-regulated 
Th1 immune responses, asymptomatic microfilaremic patients have earlier been 
characterized by dominant Th2 immune responses (typified by increased levels of IL-4 and 
IL-5) [70] but nowadays increased Treg responses (high levels of immunosuppressive 
cytokines like IL-10 and increased Foxp3-positive T cells) are associated with patent 
infections [1]. In fact, PBMCs from patent individuals spontaneously secrete higher levels of 
IL-10 compared to individuals with chronic pathology. Furthermore, IL-10 production by 
PBMCs in response to parasite antigens was also found to be significantly increased in 
asymptomatic MF+ individuals than in individuals with lymphatic pathology. In contrast, IL-10 
production to non parasite antigens was equivalent in the two groups [90, 93]. Use of 
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blocking antibodies against IL-10 reversed the lack of proliferation in PBMCs from 
microfilaremic patients. The same effect was seen using anti-TGF- antibodies, although to a 
lesser degree but caused no enhanced responses by T cells of CP individuals [94]. All these 
mechanisms are thought to be driven by the helminth in order to evade host defenses and 
ensure survival [67, 83, 94, 95]. Therefore, LF patients with elevated levels of regulatory 
responses and an altered balance between Th1 and Th2 cytokines are thought to tolerate 
higher parasite burdens and show low pathological symptoms. In contrast, individuals with 
few or no parasites and deliberating pathology mount strong filarial-specific immune 
responses [67, 96]. Patients with severe pathology also display stronger Th1 immune 
responses (IL-6 and IL-8) or even increased Th17 responses when compared to 
microfilaremic individuals [41, 95, 97, 98]. These pro-inflammatory cytokines and their 
receptors are associated with the induction of vascular endothelial growth factors (VEGFs) 
[99, 100] which have been shown in previous studies to be linked with lymphangiogenesis 
and vascular permeability [78]. In fact, investigations revealed that a single nuclear 
polymorphism in VEGF-A is significantly higher in hydrocele patients than in microfilaremic or 
lymphedema individuals [79]. Interestingly, patients suffering from severe pathology also 
have different single nucleotide polymorphisms (SNPs) for TGF- than asymptomatic 
individuals indicating that genetic traits are also responsible for these overt reactions [44]. 
Furthermore, the immunosuppression of the microfilaremic patients is characterized by 
higher IgG4 production in comparison to individuals with severe pathology, which is in line 
with patients infected with the generalized form of onchocerciasis (see section 1.1.3). It is 
described that an active LF infection promotes the production of IgG4 and limits the levels of 
IgE in contrast to severe pathology where the development of pathology is associated with 
higher IgE:IgG4 ratios [101]. In fact, the proportion of the parasite specific IgE differs in the 
various clinical states of LF: the highest levels are found in patients with TPE and the lowest 
in those with asymptomatic microfilaremia [102]. Previous studies have revealed that CP 
individuals are characterized by increased levels of filarial-specific IgG1 antibodies but no 
significant differences were seen in IgG2 or IgG3 levels compared to the microfilaremic 
patients [59, 103]. Therefore, the induction of IgG4 in the asymptomatic individuals seems to 
represent one major mechanism used by filarial parasites to evade destruction by their host’s 
immune system [54].  
In EN, the immune responses are comparable to those of the putatively immune individuals 
found in onchocerciasis areas. Thus, these subjects remain free of demonstrable filarial 
infection and do not present any of the immune traits found in either acute or chronic filarial 
disease manifestations [104]. PBMCs of EN proliferate significantly more in response to the 
specific antigen and moreover they secrete higher levels of IL-2 and IFN- compared to the 
microfilaremic and amicrofilaremic patients [105]. Furthermore these individuals contain 
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higher levels of IgG1 and IgG2, but decreased levels of IgG4 in their sera compared to MF+ 
patients [106].  
 
1.3 Wolbachia 
Lymphatic filariasis and onchocerciasis causing helminths live in mutual symbiosis with 
Wolbachia endobacteria, which belong to the order Rickettsiales. In contrast to most 
arthropod-Wolbachia associations, where Wolbachia have parasitic habits, the 
endosymbiosis of W. bancrofti, B. malayi, B. timori and O. volvulus with Wolbachia is 
obligate, implying an indispensable role of the endobacteria for fertility, reproduction, larval 
moulting and the survival of the helminths [7, 107, 108]. These bacteria can be detected in all 
development stages, they are restricted to the hypodermis and reproductive tissues of the 
female worm, including the oocytes (see figure 1.8) and they are transmitted transovarially 
from one worm generation to the next [7, 109].  
Previous observations have associated the presence of this endobacteria with the induction 
of pathogenesis since it could be shown that Wolbachia, released from larvae or adults, are 
potent inducers of innate inflammation. Murine and human in vitro studies have confirmed 
that these endosymbiotic bacteria lead to classic activation of macrophages and promote 
recruitment and activation of neutrophils thereby triggering pro-inflammatory cytokines, such 
as TNF, IL-1 and IL-6, and nitric oxide mainly via the TLR2 pathway [5, 12, 28, 39, 74, 110-
112]. Furthermore, it was shown that these pro-inflammatory cytokines could in turn mediate 
the upregulation of VEGFs which are associated with the development of pathology [78]. 
Recent research has also focused on the unique relationship since the residing 
endosymbionts are also a target for anthelmintic therapy and the application of antibiotics 
(tetracyclines) has been shown to efficiently deplete Wolbachia and in turn cause worm 
death (see section 1.5). Indeed, depletion of Wolbachia with doxycycline was actually shown 
to improve pathology and decrease levels of VEGFs [78]. 
 
 
Figure 1.8. A female O. volvulus worm with 
Wolbachia endosymbionts. Depicted is a 
transverse section through a female O. volvulus 
worm with Wolbachia stained in red using antibodies 
against Wolbachia surface protein. Courtesy of Dr. 
Sabine Specht. 
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1.4 Diagnosis of onchocerciasis and lymphatic filariasis 
The traditional way to diagnose infection with the parasite O. volvulus is the palpation of 
nodules. In patients from Latin America, the parasite is transmitted by the vector Simulium 
ochraceum. These mosquitoes typically bite the upper region of the patient; therefore, 
nodules are often located on the head and upper body. In contrast, in African individuals 
nodules are mostly found over the hips, over the sacral bone and lower limbs, but also on the 
thorax and near the knee because the vector Simulium damnosum bites the lower parts of 
the body [3]. In order to detect MF, small skin biopsies are taken with a corneoscleral punch. 
These small biopsies (also called skin snips) are restricted to the upper dermis and thus 
should not reach blood capillaries since contamination of a skin snip with blood may result in 
detection of other blood-borne MF species [3]. Motile MF migrate out of the small biopsies 
and can be counted under a dissecting microscope [113]. In general, skin snips are a 
common tool to identify an established infection in patently infected individuals [1]. 
Diagnosis of LF traditionally relies on the determination of blood circulating MF. In order to 
identify asymptomatic LF, nocturnal venous blood is checked for the presence of MF using 
membrane filters to enrich the worm offspring [114]. The detection of MF has been essential 
for diagnosing the disease but this method is limited to patent infections. Therefore, other 
tests have been developed such as a specific enzyme linked immunosorbent assay (ELISA), 
or the rapid card test that measures circulating filarial antigen (CFA), which are released from 
adult worms and can be detected in plasma samples of W. bancrofti infected individuals 
[115-117]. In contrast to the diagnosis of O. volvulus and to infections with Brugia worms it is 
possible to identify cryptic or latent infections with W. bancrofti using these tests. Besides the 
determination of latent infection, the CFA even allows the identification of individuals with low 
parasitemia which could occur, for example, after treatment with microfilaricidal drugs. The 
CFA tests have revealed that there are roughly equal proportions of MF+ and MF- individuals 
and due to the lack of pathology, the latter group has remained largely undetected and 
excluded from many former studies [117].  
An additional diagnostic parameter for W. bancrofti infection is the visualization of active 
nematodes via ultrasonography since adult worms show characteristic pattern of movements 
within the lymphatic vessels of the scrotum of male patients. This is termed filarial dance sign 
(FDS) [118, 119]. In patients infected with B. malayi ultrasonic imaging of adult filaria is of 
limited use because these worm nests are not stable over time and are not localized in 
distinct parts of the body [120, 121], thus, worm nests will be detected only in a fraction of 
patients. However, with these tools it is now possible to differentiate in bancroftian filariasis 
between patent and latent infected individuals and in addition, confirm the prevalence of live 
nematodes. Although these methods are not applicable for brugian infections serology 
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assays can be performed by analyzing brugia-specific immunoglobulins in ELISAs [101, 
122].  
 
1.5 Treatment of onchocerciasis and lymphatic filariasis 
There remains no vaccine against helminth infections. Thus, besides vector control, 
chemotherapy is the method of choice to eliminate the disease [123]. In the last two 
decades, diethylcarbamazine (DEC), ivermectin (IVM) and albendazole (ALB) have been 
used for successful mass drug administration (MDA) against filarial infections. These 
standard drugs are used in order to interrupt transmission with a consequent reduction in the 
burden of infection and to diminish morbidity [2].  
The mode of functioning of DEC is not completely understood but it is known that this drug 
results in the sequestration of MF and their final destruction by the immune system. Murine 
and human in vitro studies suggest that DEC blocks the cyclooxygenase pathway in 
parasites which leads to death of MF [2, 124]. Ivermectin is a well tolerated macrocyclic 
lactone which acts by hyperpolarization of parasitic glutamate-sensitive channels thereby 
preventing neuronal transmission resulting in muscle paralysis [125, 126]. In contrast to 
DEC, IVM treatment does not induce local destruction of MF. Recently, IVM was shown to 
decrease the amount of proteins released by the excretory/secretory vesicles of MF 
preventing the secretion of immunomodulatory molecules by the worm offspring which 
usually block the host’s immune response [123]. Finally, ALB is a broad-spectrum 
anthelmintic drug against flatworms, nematodes and cestodes that inhibits the polymerization 
of worm -tubulin and microtubule formation [127].  
In order to treat LF, DEC or IVM each in combination with ALB, are used by the global 
programme to eliminate lymphatic filariasis (GPELF). Given as a single dose DEC is effective 
in reducing acute and chronic cases of microfilaraemia for at least one year, and this is the 
basis of MDA in areas without co-endemic onchocerciasis. Diethylcarbamazine cannot be 
used in endemic regions of the latter since its administration causes MF death and leads to 
irreversible local ocular damage [128] therefore, in onchocerciasis endemic areas IVM is 
used in combination with ALB in order to treat LF. In the case of onchocerciasis infections, 
IVM is the sole drug given annually or biannually by the African Programme of 
Onchocerciasis Control (APOC) and the Onchocerciasis Elimination Programme for the 
Americas (OEPA) [1, 60, 129-131]. 
Although DEC, IVM and ALB have been successfully used in the past to kill MF, these drugs 
show no (in case of IVM in O. volvulus infections) or only moderate (valid for ALB in LF) 
macrofilaricidal effects [132]. That is, they do not kill adult worms which would in essence 
eliminate the infection. Therefore, repeated rounds of treatment have been given in order to 
break transmission. For success, such treatment would need to occur for many years at least 
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as long as adult worms are alive which can exceed 15 years in onchocerciasis and 8 years in 
LF. Long-term treatment however has severe drawbacks since there is evidence for drug 
resistance [133]. In addition, treatment with IVM or DEC causes microfilarial death, resulting 
in adverse reactions like fever, headache, dizziness, myalgia, arthralgia and lymph node 
enlargement because Wolbachia are released into the blood where they induce pro-
inflammatory immune responses [134]. 
As mentioned above, Wolbachia are essential for worm survival. This unique relationship has 
provided an alternative avenue for chemotherapeutic treatment since it is known that 
tetracyclines are effective against these Rickettsia-like bacteria [7, 135]. Previous animal 
studies demonstrated that depletion of Wolbachia by tetracycline leads to degeneration and 
sterility of adult worms [109, 135, 136]. Furthermore, in contrast to the mainly microfilaricidal 
drugs mentioned above, therapy with tetracycline antibiotics directly targets the Wolbachia 
leading to the inhibition of worm development, embryogenesis, fertility and viability [135, 
137]. These anti-wolbachial effects of doxycycline have been addressed in several field 
studies and have demonstrated that treatment regimes of 3-8 weeks leads to elimination of 
MF, sterile female filariae and worm death indicating macrofilaricidal effects as well [78, 137-
142]. However, since doxycycline is contraindicated for children below 9 years, pregnant or 
breastfeeding women, and in general not practical for MDA because of huge logistical 
challenges and the length of required treatment regimes, there is still the need for new 
effective drugs with macrofilaricidal activity and long-lasting suppression of embryo 
production [62]. Nevertheless, doxycycline is considered an effective tool for individual drug 
treatment. 
The further registered antibiotic rifampicin has also shown promising activity in experimental 
trials with mice [143] and was therefore investigated in human pilot studies where it could be 
demonstrated that rifampicin lead to significant reduction of Wolbachia loads, albeit less 
efficient than doxycycline [144]. Although rifampicin (like doxycycline) is clearly not feasible 
for MDA it may be useful for the individual treatment of children since it can be taken by 
children under the age of 9 years. An additional study was conducted in order to test if the 
combination of doxycycline and rifampicin would increase the beneficial effects on filariae 
infected individuals. This pilot study demonstrated a moderate macrofilaricidal activity [129] 
but still there is the urgent need to develop improved micro- and macrofilaricidal drugs in 
order to reduce the amount of filarial infected individuals and to break transmission.  
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1.6 Aims and objectives 
Collectively, the tropical helminth infections LF and onchocerciasis affect more than 150 
million people worldwide and are considered major public health concerns [1]. Whilst 
perusing the literature it became clear that several results with regards to immunological 
responses could not be compared since these analyses have mainly focused on the 
assessment of MF+ individuals compared to CP patients or of EN compared to one of these 
two groups. Indeed, the determination of any immunological differences in LF infected 
asymptomatic MF+ or MF- patients has so far been neglected. A reason for such disregard so 
far, at least in W. bancrofti infections, has been the fact that the number of latently infected 
individuals was underestimated because they were not detected with former diagnostic tools. 
However, the application of new diagnostic tests has revealed that the percentages of W. 
bancrofti infected latent and patent individuals are almost equally distributed. MF- infected 
individuals represent a dead end in terms of transmission and moreover, it remained unclear 
how these patients maintain their latent phenotype. That is, whether host mechanisms 
actively prevent MF from reaching the peripheral blood (in LF) or the skin (onchocerciasis). 
Further research into these aspects may broaden the range of strategies currently employed 
to reduce transmission and in turn eliminate filariasis. With respect to onchocerciasis, the 
present study was also able to investigate the profiles of MF+ and MF- individuals even 
though the latter is not the normal situation. Here, the lack of MF relates perhaps to the 
number of rounds of MDA which is mainly microfilaricidal.  
Therefore, the main aim of this thesis was the characterisation of immunological aspects of 
asymptomatic LF and onchocerciasis infected individuals. These aspects included the 
assessment of immunological profiles following re-stimulation of isolated PBMCs with filarial 
or bystander antigens and the prevalence of filarial-specific Ig subclasses. Moreover, 
elucidating mechanisms inducing protective Igs (e.g. IgG4) was also of interest, especially a 
possible role of GITR which has been previously shown by our group to be a key player 
mediating the production of IgG4. The possible role of GITR was also analysed in context of 
the IL-10 signaling pathway because this cytokine is associated with protective immune 
processes during filariasis. In addition, genetic profiles of three distinct T cell subpopulations 
(Tregs, CD4+ and CD8+ T cells) of amicrofilaremic and microfilaremic LF infected patients 
were analysed since these would give a hint which molecules are important in preventing 
patency and furthermore which molecules could be central targets for future studies with 
regards to the development of new therapeutic strategies. 
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2. Patients, Materials and Methods 
This section highlights the variety of materials that were used throughout the study, 
beginning with clarification about how blood samples were collected for each study followed 
by remarks about the plastic ware and the required antibodies. Afterwards, there is a report 
of the preparation of different worm extracts, the parasitological examinations of study 
participants, and the isolation of different cell populations followed by a depiction of the 
isolation of MF. Furthermore, this sections covers cell culture and immunological assays and 
molecular biology procedures. The protocols for the use of various equipment, chemicals, 
reagents, buffers and solutions referred to in this chapter are described in appendices A-D. 
 
 
2.1 Patients 
 
2.1.1 Onchocerciasis 
Blood samples from helminth infected patients and appropriate EN were collected as a part 
of a collaboration project with partners at the University of Science and Technology, Kumasi 
(KNUST) Ghana and the Liverpool School of Tropical Medicine. A cohort of 481 individuals 
was recruited in the Central Region of Ghana (Upper- and Lower Denkyira Districts, Dunkwa 
on Offin; Amansie Central and Adanse South Districts, Ashanti Region). This area is 
endemic for onchocerciasis but not for other human filarial infections. Rivers in this areas are 
breeding sites of the vector black flies Simulium sanctipauli that have flight ranges up to 12 
km [108]. Individuals eligible for participation were adult men and women aged 18 to 55 
years, who were infected with Onchocerca volvulus. To inform the target communities, there 
was first a meeting held with village elders, where the study procedures and rationale were 
explained. After general consent, the study procedures were explained to the villagers in 
English by the responsible physician and then again in the local Twi language. Informed 
consent was obtained from participants and documented by the signatures of two witnesses. 
A patient questionnaire was completed for each participant and included a patient ID, a 
village number, age, the time living in the endemic area and history of anti-filarial drug intake 
during the last two years. Exclusion criteria were absence of onchocercoma, abnormal 
hepatic and renal enzymes and creatinine, pregnancy, breast-feeding, alcohol or drug abuse. 
In total, the study included 384 MF+, 83 MF- as well as 14 volunteer individuals (EN). The 
latter subjects were non-infected members of the population. 
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2.1.2 Lymphatic filariasis  
Blood samples from helminth infected patients and appropriate EN were collected as a part 
of a collaboration project with partners at the University of Science and Technology, Kumasi 
(KNUST) Ghana and the Liverpool School of Tropical Medicine. 
In the first study with LF infected patients, samples were obtained in context of a randomized 
double-blind placebo-controlled trial. A cohort population of 299 male individuals (18-50 
years) from an area in the Western region of Ghana (Ahanta West District), which were 
infected with Wuchereria bancrofti, was investigated. No other filarial species were endemic 
in this area [78]. Informed consent was obtained as described for the onchocerciasis study 
participants (see above). Participants were chosen based on the presence of at least one 
ultrasonographically detectable worm nest. Out of the 299 included patients from the study 
cohort, 159 individuals were examined in further immunological studies before treatment; 
these included 92 MF+ and 67 MF- individuals and in addition 22 EN. Within the scope of 
MDA, patients included in this study had had an average of two rounds of anti-filarial therapy 
(ALB and IVM) with the last intake at least 10 months before blood was taken. Included 
participants were also screened for other helminth infections via stool and urine analysis. Out 
of 159 infected individuals 10 (n= 6 MF+ and n= 4 MF-) were also positive for other helminth 
infections (Ascaris lumricoides n= 8, Strongyloides stercoralis n= 1, Trichuris trichiura n= 1). 
Furthermore, participants were tested for active malaria (Giemsa staining and measurement 
of body temperature) and subclinical malaria (NADAL Medical test, nal von minden, Moers, 
Germany). 20 of 181 individuals resulted positive for this subclinical malaria test. 
In a second study within a LF endemic area, samples were obtained from a cohort population 
of 150 individuals (18-60 years) also from the Ahanta West District in Ghana. Fifty of the 
participants were uninfected individuals who were negative for the CFA test (see section 
2.3.1.2) and also for MF (see section 2.3.1.4). The remaining 100 participants were positive 
in the CFA test, half of them were amicrofilaremic and the other half was patently infected. 
Exclusion criteria were negative CFA test, abnormal hepatic and renal enzymes and 
creatinine, pregnancy, breast-feeding, alcohol or drug abuse. 
 
2.1.3 Blood samples 
Blood samples used in this study for STAT3 and in vitro experiments with MF were collected 
from healthy European donors and were kindly provided by the Institute for Experimental 
Haematology and Transfusion Medicine, University Clinic Bonn, Germany. Collection and 
use of the samples was approved by the University Clinics ethic committee 
(“Ethikkommission der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-
Universität Bonn”). PBMCs were separated from heparinized venous blood by gradient 
centrifugation on Ficoll Plaque (density 1.077; PAA, Pasching, Austria).  
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2.2 Material 
 
2.2.1 Plastic and glassware 
Unless otherwise stated, all plastic and glassware equipment were supplied by one of the 
following companies: Eppendorf (Hamburg, Germany), Becton Dickinson (Heidelberg, 
Germany), Nunc (Roskilde, Denmark) or Greiner (Frickenhausen, Germany). 
 
2.2.2 Antibodies and microbeads 
Blocking anti-GITR, anti-GITR ligand and their corresponding isotypes controls were 
obtained from R&D systems (Wiesbaden, Germany). APC-conjugated anti-Foxp3, anti-CD4 
FITC, anti-CD8 APC, anti-CD19 PE, anti-CD20 PerCP-Cy5.5, anti-GITR APC and anti-GITR-
L APC were from eBioscience (San Diego USA). Anti-CD14 FITC, anti-CD20 PerCP-Cy5.5 
and anti-pSTAT3 Alexa Fluor 647 were purchased from BD Biosciences (Heidelberg, 
Germany); anti-CD25 PE from Miltenyi (Bergisch Gladbach, Germany). Anti-CD3/anti-CD28 
T cell expansion beads as well as magnetic cell sorting beads were supplied by Invitrogen 
(Karlsruhe, Germany). Anti-STAT3 and anti-pSTAT3 were obtained from R&D systems, 
(Wiesbaden, Germany). Anti-mouse and anti-goat secondary antibodies both coupled to 
alkaline phosphatase were purchased from DAKO (Hamburg, Germany). 
 
2.2.3 Onchocerca volvulus extract 
Aqueous soluble O. volvulus extract (O.v. extract) was prepared from adult worms that were 
isolated from O. volvulus nodules from infected patients. Worms were isolated by 
collagenase digestion of the nodules and afterwards shock frozen in liquid nitrogen [145]. All 
steps of the extract preparation were fulfilled on ice and with pre-cooled solutions. Thawed 
worms were carefully transferred to a Petri dish pre-filled with sterile PBS (PAA, Pasching, 
Austria). Worms were washed in PBS and then placed inside a glass mortar (VWR, 
Langenfeld, Germany). Depending on the amount of worms, 3-5 ml of medium (RPMI without 
supplements) were added and worms were crushed until the solution was homogenous. The 
extract was then centrifuged for 10 minutes at 300 x g (4°C) in order to remove insoluble 
material and the resulting supernatant was carefully transferred to a new tube. The protein 
concentration was determined by Bradford assay (Advanced Protein Assay™, Cytosceleton, 
Denver, USA) and the extract was stored at -80°C. All procedures were conducted under 
sterile conditions. 
 
2.2.4 Brugia malayi extract 
Brugia malayi extract (B.m. extract) was kindly provided by John McCall (University of 
Georgia, Athens, GA) and it was prepared from adult worms of the human filarial parasite B. 
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malayi that were maintained in jirds (Meriones unguiculatus). This parasite is closely related 
to W. bancrofti, whose adult worms are generally difficult to obtain since the parasite cannot 
be maintained in a rodent host and are not easily obtained from man. B.m. extract was tested 
for its endotoxin levels using the kinetic Limulus amoebocyte lysate assay (Charles River, 
Charleston, SC) and level was below 0.16 EU/ml final concentration. 
 
2.2.5 Litomosoides sigmodontis extract 
For the preparation of aqueous soluble extract of L. sigmodontis extract (L.s. extract) worms 
were isolated from the thoracic cavity of infected cotton rats (Sigmodon hispidus) and rinsed 
in sterile PBS before being mechanically minced. Insoluble material was removed by 
centrifugation for 10 minutes at 300 x g (4°C). Protein concentrations of crude extracts were 
determined using the Advanced Protein Assay (Cytoskeleton). All procedures were 
conducted under sterile conditions. 
 
2.3 Methods 
 
2.3.1 Parasitological assessment 
 
2.3.1.1 Examination of onchocercomas 
The traditional way to diagnose infection with the parasite O. volvulus is palpation of nodules, 
i.e. capsules of connective tissue in which several parasites aggregate in the skin of infected 
people [6]. Onchocercomas were found mainly over the hips, over the sacral bone and lower 
limbs, but also on the thorax and near the knee. All patients included in the onchocerciasis 
study had at least one palpable nodule. 
 
2.3.1.2 CFA ELISA 
All patients included in the LF studies were positive for CFA tested by the TropBio® ELISA 
(TropBio, Townsville, Australia) according to the manufacturer’s protocol. In brief, 100 l of 
plasma were added to 300 l of diluent provided by the company. Samples were boiled for 5 
minutes at 100°C and then centrifuged for 15 minutes at 2,000 x g to dissociate 
antigen/antibody complexes. 50 l/well of the clear supernatant containing the heat stable 
antigen were transferred to the pre-coated 96-well plates and incubated together with the 
appropriate standards for 90 minutes in a humid chamber at room temperature (RT). After 
three washing steps with the included washing buffer, 50 l/well of the polyclonal rabbit anti-
Onchocerca antibody were added and incubated for one hour. Afterwards, plates were 
washed three times and then incubated for one hour with the diluted anti-rabbit antibody (50 
l/well) conjugated with horseradish peroxidase (HRP). Subsequently, plates were washed 
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again three times and then 100 l of substrate (ABTS Chromagen) was added and incubated 
for one hour. The plates were measured using the SpectraMAX ELISA reader (Molecular 
devices, Sunyvale, USA with wavelength correction (405 nm and 492 nm).  
 
2.3.1.3 Determination of skin microfilariae 
In order to determine the microfilarial load of O. volvulus infected individuals, two skin snips 
from the upper part of each buttock were taken with a corneoscleral (Holth) punch (Koch, 
Hamburg, Germany), since the worm offspring can be found there. Each skin snip was 
weighed using an analytical balance (Sartorius electronic balance, Göttingen, Germany) and 
placed in individual wells of a 96-well microtitre plate and incubated in 100 µl 0.9% NaCl for 
6–20 hours at RT. Thereafter, MF were counted at 63-fold magnification using a microscope 
(Leica Microsystems GmbH, Wetzlar, Germany) [146]. Microfilarial load was calculated per 
mg of skin. 
 
2.3.1.4 Determination of microfilaremia 
Microfilarial burden of W. bancrofti infected individuals was determined from venous blood 
samples taken between 21-23 h since MF show a nocturnal periodicity. Therefore, 1 ml of 
blood was filtered through a Whatman Nucleopore filter (5 m pores; Karl Roth, Karlsruhe, 
Germany) to hold back the worm offspring. Microfilariae were stained using the Giemsa 
method (Merck KGAA, Darmstadt, Germany) and stained MF on the filters were directly 
counted using a microscope (Leica Microsystems GmbH, Wetzlar, Germany).  
 
2.3.1.5 Ultrasonography 
Additionally to a positive CFA test, all patients in the first study of LF harbored at least one 
detectable worm nest and were therefore positive for FDS. The number of worm nests was 
determined by detecting the typical movement pattern of adult worms in the Pulse Wave 
Doppler mode using a portable ultrasound machine (SONOSITE 180 Plus; Sonosite, Bothell, 
USA) equipped with a 7.5 MHZ linear transducer. All ultrasound examinations were 
performed by Dr. med. Sabine Mand.  
Furthermore, examinations of lymph dilation in the scrotal area were conducted according to 
defined parameters. In brief, dilation of lymphatics and lymphatic vessels at the position of 
the worm nest and the maximum dilation of a lymphatic vessel (without worms) in the 
supratesticular area were measured in all participants (n=181). This latter parameter was 
evaluated using a grading system as follows: stage 0, patients without dilation of the scrotal 
lymphatics; stage 1, patients with minimal dilation up to 0.2 cm; stage 2, patients with mild 
dilation of 0.21–0.5 cm; stage 3, moderate dilation of 0.51–1 cm; and stage 4, severe dilation 
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>1 cm [147]. In addition, patients were also screened for the presence of hydrocele 
according to the staging system described by Mand et al [147]. 
 
2.3.2 Isolation of PBMCs  
Peripheral blood mononuclear cells from heparinized venous blood were isolated using the 
ficoll based density gradient separation method [148, 149]. The entire procedure was carried 
out on ice. In brief, blood was diluted 1:2 with PBS (PAA, Pasching, Austria) and then 
carefully transferred onto a 50 ml falcon tube pre-filled with 15 ml ficoll. The suspension was 
centrifuged for 20 minutes at 4°C at 800 x g without brake. Thereafter, the white cell layer 
containing the leucocytes was gently collected with a 5 ml pipette and transferred into a new 
50 ml falcon tube. Cell suspensions were filled up with 40 ml complete medium (Appendix C) 
and washed for 8 minutes at 400 x g and 4°C to remove residual ficoll. The supernatant was 
discarded and the washing step repeated. Cells were then resuspended in 10 ml cell culture 
medium (Appendix C). The isolated PBMCs were either immediately used or cryo-preserved 
(see section 2.3.4). 
During field work in Ghana leucosep tubes (Greiner Bio-one, Frickenhausen, Germany) were 
used to isolate PBMCs. These tubes were already filled with ficoll and contained a porous 
barrier. 7 ml of patient blood were poured into the leucosep tubes and centrifuged for 20 
minutes, 800 x g at 24 °C. Afterwards, plasma samples were removed from the upper phase 
of the gradient, first stored at -20°C in 1.8 ml cryo tubes (Nunc, Roskilde, Denmark) and then 
transferred to liquid nitrogen. Plasma samples were used for Ig measurements described in 
sections 2.3.11 and 2.3.12. The white cell layer was pipetted into a new 15 ml falcon tube 
and cells were washed twice with PBS. Afterwards, cells were resuspended in 1 ml of cell 
culture medium and counted. 
 
2.3.3 Cell viability and counting 
The number of living cells was determined using the trypan blue (Sigma-Aldrich, Munich, 
Germany) exclusion method. In short, a small portion of cells was diluted 1:5 or 1:10 with 
0.4% trypan blue. Thereafter, 10 l of the diluted cells were transferred to a cell counting 
chamber or haemocytometer (LO Laboroptik GmbH, Bad Homburg, Germany). Living cells 
(non-coloured) were counted and expressed as cell number per ml. Cells were only used if 
less than 5% of the cells were dead (blue). 
 
2.3.4 Freezing of isolated cells 
Cryo-conservation was performed on cell concentration between 5x 106 and 1x 108 cells per 
ml. All steps were fulfilled on ice. Freezing medium (Appendix C) was freshly prepared, pre-
cooled on ice and added drop-wise to 1 ml of cells. Thereafter, cell suspensions were mixed 
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and 2 ml of cell suspensions were quickly transferred to cryo tubes and frozen at -80°C for 
up to one week and then moved to liquid nitrogen. 
 
2.3.5 Thawing of isolated cells 
Again all steps were fulfilled on ice. Cryo tubes with frozen cells were taken from the -80°C or 
the liquid nitrogen and quickly thawed 2-3 minutes between the palms of both hands. 
Thawed suspensions were pipetted into a new 15 ml falcon tube and then filled up slowly 
with 10 ml of pre-cooled complete medium under frequent mixing. Cells were centrifuged for 
8 minutes at 400 x g (4°C) and then washed again to remove residual freezing medium, 
which is toxic for the cells. Thereafter, the supernatant was discarded and cells were 
resuspended in 1 ml of cell culture medium, counted and used for further experiments. 
 
2.3.6 Magnetic cell sorting 
 
2.3.6.1 Isolation of CD4+T cells 
CD4+ T cells were isolated using the positive isolation kit from Invitrogen (Darmstadt, 
Germany) according to the manufacturer’s protocol. In brief, 25 l of Dynabeads were added 
to 1x 107 PBMCs and washed with 1 ml of buffer 1 (1x PBS/0.1% FCS) using the Dynal MPC 
magnet (Dynal magnetic particle concentrator). Afterwards, cells were resuspended in 1 ml 
of buffer 1 and co-incubated with prepared beads for 20 minutes at 4°C with gentle tilting and 
mixing (Dynal Mixer MX1, Invitrogen GmbH, Darmstadt, Germany). Rosetted cells were then 
washed three times with buffer 1 and resuspended in 100 µl of buffer 2 (complete RPMI/1% 
FCS). 10 µl of DETACHaBEADS (Invitrogen (Darmstadt, Germany) were added per 1x 107 
cells; the suspensions were mixed by inversion and incubated for 45 minutes at RT in the 
mixer MX1. Tubes containing the suspension of the detached beads and the free CD4+ T 
cells were then decanted on the magnet (two times) and the solutions containing the CD4+ T 
cells were collected in a new tube, centrifuged, counted and adjusted to the desired 
concentration. To analyse the purity of the isolated cells, small fractions were stained before 
and after isolation with FITC-labelled anti-CD4 antibody. Fluorescence was measured using 
a FACSCanto I flow cytometer (BD, Heidelberg, Germany) and analysis was performed 
using the FACS Diva software (see section 2.3.7.1). The purity of the isolation was routinely 
> 97%. 
 
2.3.6.2 Isolation of CD19+ B cells 
CD19+ B cells were isolated using the positive isolation kit from Invitrogen (Darmstadt, 
Germany). Briefly, 25 µl of specific Dynabeads were placed into a 15 ml tube and washed 
twice with 1 ml of buffer 1 (1x PBS/0.1% FCS) using the Dynal MPC magnet. Thereafter, 
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beads were resuspended in the same amount of buffer 1 as the initial volume of Dynabeads. 
Approximately, 1x 107 PBMCs were added to CD19+ Dynabeads and incubated for 20 
minutes at 4°C under gentle vortexing using the mixer MX1. The rosetted cells were washed 
three times with buffer 1 and resuspended in 100 µl of buffer 2 (complete RPMI/1% FCS). 
Then, 10 µl of CD19 DETACHaBEADS (Invitrogen, Darmstadt, Germany) were added and 
incubated for 45 minutes at RT under gentle rotation in the mixer. The suspensions 
containing the detached beads detached beads and the free CD19+ cells were then decanted 
on the magnet (two times) and the solutions containing the CD19+ cells were collected in a 
new tube. To analyse the purity of the isolated cells, small fractions were stained before and 
after isolation with PE-labelled anti-CD19 antibody. Fluorescence was measured using a 
FACSCanto I flow cytometer and analysis was performed using the FACS Diva software (see 
section 2.3.7.1). Purity of isolated B cells was routinely >97%. 
 
2.3.6.3 Isolation of CD14+ cells 
CD14+ monocytes were isolated by using the CD14 positive isolation kit from Miltenyi (CD14 
Microbeads, Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) according to the 
manufacturer’s protocol. In brief, 1x 107 PBMCs were resuspended in 80 l of autoMACS 
running buffer (Miltenyi, Bergisch Gladbach, Germany). Afterwards, 20 l of CD14 
microbeads were added to the cells, mixed and incubated for 15 minutes inside the 
refrigerator (2-8°C). Cells were washed with 2 ml of running buffer and centrifuged for 10 
minutes at 400 x g (4°C). Supernatants were discarded and labelled cells were resuspended 
in 500 l of running buffer. MS columns (MS column, Miltenyi Biotech GmbH, Bergisch 
Gladbach, Germany) were placed in the magnetic field of a suitable MACS separator 
(Miltenyi Biotech, Bergisch Gladbach, Germany) and prepared by washing them with 500 l 
of running buffer. Thereafter, 500 l of cell suspensions were applied onto the column, flow-
through was collected as CD14- cells. Columns were washed three times with 500 l running 
buffer in each washing step. After the last washing step, column was removed from the 
separator and placed onto a 15 ml falcon tube. Finally, 1 ml of running buffer was pipetted 
onto the column and labelled cell fractions were flushed out by firmly pushing the plungers 
into the columns. Collected CD14+ cells were checked for their purity by flow cytometry. 
Therefore, small fractions were stained before and after isolation with FITC-labelled anti-
CD14 antibody. Fluorescence was measured using a FACSCanto I flow cytometer and 
analysis was performed using the FACS Diva software (see section 2.3.7.1). Purity of 
isolated CD14+ cells was routinely >95%. 
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2.3.7 Flow cytometry 
 
2.3.7.1 Surface markers 
In order to stain surface markers, up to 1x 106 cells per sample were resuspended in 50 l 
FACS buffer and blocked with 2 l normal rat serum (eBioscience, San Diego, USA) for 15 
minutes at 4°C. Cells were stained for 30 minutes with the desired antibody at 4°C, followed 
by two washing steps with 2 ml FACS buffer. Cells were resuspended in 300 l fixation buffer 
1x PBS/4% PFA (Merck KGAA, Darmstadt, Germany). Cells were analysed using the 
FACSCanto I flow cytometer (BD, Heidelberg, Germany). At least 10,000 events were 
acquired for each sample. Data were evaluated with the FACSDiva software (BD, 
Heidelberg, Germany). 
 
2.3.7.2 Intracellular Staining 
Intracellular staining of the transcription factor Foxp3 was performed using a Foxp3 kit 
(eBioscience, San Diego, USA) according to the manufacturer’s protocol. To identify Tregs, 
1x 105 to 1x106 cells were first stained with surface markers CD4 and CD25 as described in 
section 2.3.7.1. Cells were permeabilized for 30 minutes using 1 ml of 1:4 diluted 
fixation/permeabilization buffer (provided by the supplier). Afterwards, cells were washed 
twice with 1:10 diluted permeabilization buffer (provided by the supplier), blocked with 2 l of 
normal rat serum for 15 minutes in a maximal volume of 100 l and then stained with 5 l of 
anti-Foxp3 antibody for 30 minutes at 4°C. After two additional washing steps, cells were 
resuspended in approximately 300 l fixation buffer and acquired with the FACSCanto flow 
cytometer. Foxp3 expression of T cells was analysed after gating on CD4+CD25high cells. 
Intracellular staining of the signaling protein pSTAT3 was performed using the Phosflow kit 
(BD, Heidelberg, Germany) according to the manufacturer’s protocol. In brief, cells were 
stained on their surface (CD4 FITC or CD20 PerCP-Cy5.5) and after an incubation period of 
maximal one hour they were fixed with the equal amount of pre-warmed BD Cytofix Buffer for 
10 minutes at 37°C. Cells were then centrifuged for 8 minutes at 400 x g, the supernatant 
was discarded and the pellet was incubated for 30 minutes with 1 ml of BD Phosflow Perm 
Buffer, afterwards washed twice and resuspended in BD Pharmingen Stain Buffer. 
Subsequently cells were stained with 20 l of anti-pSTAT3 antibody (Alexa Fluor 647) for 30 
minutes on ice and finally washed with 1 ml staining buffer and resuspended in FACS buffer. 
 
2.3.7.3 Sorting of lymphocytes 
PBMCs from healthy blood donors were thawed and counted as described in sections 2.3.3 
and 2.3.5. Cells were stained with either CD20 PerCP-Cy5.5 or CD4 PE and sorted with the 
FACSDiva cytometer (BD, Heidelberg, Germany). Sorted T and B cells were used for 
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subsequent analysis of pSTAT3. Furthermore, cryo-conserved cells from LF infected patients 
(MF+ and MF-) as well as cells from endemic controls were thawed and cell surfaces were 
stained with anti-CD4 FITC, anti-CD25 PE and anti-CD8 APC according to the protocol 
described in section 2.3.7.1. CD4+CD25+, CD4+CD25- and CD8+ were sorted using the FACS 
MoFlo cytometer (Beckman Coulter, Miami, USA). Sorted CD4+CD25+, CD4+CD25- and 
CD8+ cells of each patient were centrifuged and resuspended in 1 ml Qiazol lysis reagent 
(Qiagen, Hilden, Germany) and subsequently frozen at -80°C to further isolate mRNA. 
 
2.3.8 In vitro experiments with microfilariae 
 
2.3.8.1 Isolation of microfilariae 
In order to test MF in human in vitro assays, the well established animal model of L. 
sigmodontis was used to gain the worm offspring. Peripheral blood from L. sigmodontis 
infected cotton rats (S. hispidus) was passed through a saccharose gradient (Sigma-Aldrich, 
Munich, Germany) to extract MF. In brief, blood was diluted 1:2 with PBS and carefully 
loaded onto a 15 ml falcon tube pre-filled with 3 ml of 30% and 25% gradients (maximal 
volume of diluted blood was 5 ml). The prepared suspensions were centrifuged for 30 
minutes without brake at RT at 400 x g. After separation, a white layer between the 25% and 
30% gradients was aspirated with a sterile 1 ml pipette and transferred into a new 15 ml 
falcon tube. Isolated MF were washed twice with RPMI (without supplements) for 8 minutes 
at 400 x g at 4°C. After the second washing step they were resuspended in 1 ml fresh ice-
cold RPMI medium without supplements. MF were counted with the counting chamber and 
immediately frozen. 
 
2.3.8.2 Freezing and thawing of microfilariae 
1 ml of pre-cooled freezing medium containing 6% DMSO and 15%FCS was directly added 
to 1x 106 of freshly isolated MF [150-152] and immediately frozen at -80 °C. 
Frozen MF were thawed by warming the cryo tubes between the palms of both hands. 
Thawed MF-freezing suspensions were quickly added to 14 ml of cold RPMI medium without 
supplements and then centrifuged at 400 x g for 8 minutes at 4°C. The supernatant was 
discarded, the pellet resuspended in a further 14 ml of cold medium and washed again. After 
centrifugation the pellet was resuspended in 1 ml RPMI/10% FCS (without antibiotic 
supplements). Microfilariae were kept 15-30 minutes at 37°C counted afterwards with the 
Neubauer chamber. Only living (moving) MF were counted and aliquots were only taken if at 
least 95% of MF were alive.  
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2.3.9 Cell culture  
For in vitro cytokine analysis of PBMCs originated from Ghanaian patients and their 
appropriate control individuals, 2x 105 of total PBMCs/well were plated into a 96-well plate 
(U-shaped, Greiner Bio-One, Frickenhausen, Germany) in triplicate and cells were either left 
unstimulated or stimulated with the following stimuli: O. volvulus extract (O.v. extract, 5 
µg/ml, kind gift of Dr. Satoguina and Dr. Büttner), B. malayi extract (B.m. extract, 5 µg/ml), B. 
malayi female extract (B.m. female extract, 5 µg/ml, kind gift of Dr. Taylor), anti-CD3/anti-
CD28 (10 µg/ml and 2.5 µg/ml), recombinant full-length Plasmodium falciparum merozoite 
surface protein (MSP-1, 0.25 g/ml, peptide pool, kindly provided by Prof. Hermann Bujard, 
ZMBH, University Heidelberg, Germany), 50 ng/ml lipopolysaccharide (LPS, Serratia 
marescens, Sigma L6136, Taufkirchen, Germany) and 10 g/ml purified protein derivative of 
Mycobacterium (PPD, Statens Serum Institut, Copenhagen, Denmark). Cells were incubated 
for 72 hours at 37°C and 5% CO2. Supernatants from triplicates were pooled, frozen for one 
day in cryo tubes (Nunc, Roskilde, Denmark) at -20°C and afterwards transferred to liquid 
nitrogen for long time storage. In order to determine the cytokine release of PBMCs 
stimulated with L.s. extract or MF, 2x 105 of PBMCs/well from healthy European blood 
donors were incubated for 24 hours with 50 g/ml L.s. extract or living MF (10,000 MF/well). 
Afterwards, cells were additionally stimulated for 72 hours with anti-CD3/anti-CD28 (10 g/ml 
and 2.5 g/ml respectively). 
 
2.3.10 Cytokine ELISA 
Cultures supernatants from stimulated PBMCs obtained from infected Ghanaian and their 
appropriate non-infected control individuals were analysed for the production of IL-4, IL-5, IL-
6, IL-10, IL-13, IL-17, IFN-, TNF and TGF- using R&D Duo sets (R&D Systems, 
Wiesbaden-Nordenstadt, Germany) as indicated by the manufacturer. In brief, ELISA plates 
(Greiner Bio-One, Germany) were coated with 50 µl capture antibody per well overnight. 
Plates were washed four times with washing buffer (Appendix C) and then blocked for one 
hour with blocking buffer (Appendix C). The wash step was repeated and subsequently, 
plates were incubated for two hours with 50 µl/well supernatants and standards. After a 
further washing step, plates were incubated for two hours with 50 l/well of detection 
antibody. The washing step was repeated and plates were afterwards incubated with 50 
µl/well Streptavidin-HRP for 20 minutes in the dark. After a final washing step, 50 µl/well 
substrate solution containing tetramethylbenzidine (TMB) were added to the plates, 30 
minutes later the reaction was stopped with 25 µl/well 2N H2SO4 (Merck KGAA, Darmstadt, 
Germany). All steps were fulfilled at RT. Optical density was measured using the 
SpectraMAX ELISA reader (Molecular devices, Sunyvale, USA with wavelength correction 
(450 nm and 570 nm). Data were analysed with SOFTmax Pro 3.0 software. 
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Supernatants from PBMCs of European donors stimulated with L.s. extract and MF each in 
combination with anti-CD3/anti-CD28 were analysed using eBioscience ELISA kits (Ready-
SET-Go, eBioscience, San Diego, USA). These ELISAs were basically performed as 
mentioned above, but blocking was carried out with 1x assay diluted (provided by the 
manufacturer) and the incubation time with the secondary antibody was one hour instead 
two. Incubation with avidin-HRP was performed for 30 minutes.  
 
2.3.11 Cytometric Bead Array 
Plasma of participants from the LF study were investigated for their amount of total Ig 
subclasses (total IgG, IgG1, IgG2, IgG3, IgG4 and IgE) using the Cytometric Bead Assay 
Flex Set (CBA; Becton Dickinson Heidelberg, Germany). In accordance to the manual, 
plasma were diluted in complete RPMI (IgG total 1:100,000, IgG1 1:100,000, IgG2-4 
1:20,000, IgE 1:2,000) and incubated with their appropriate beads (each diluted in the 
adequate dilution buffer) for one hour at RT. Afterwards, samples were washed with 500 l 
washing buffer for 5 minutes at 400 x g and then incubated for two hours in the dark with 
their appropriate detection antibody (included in the kit). In the last step, samples were 
washed again, resuspended in 200 l washing buffer and acquired. Data were analysed 
using FCAP-Array software and BD FACSArray Bioanalyzer (BD, Heidelberg, Germany). 
 
2.3.12 Antigen-specific Ig ELISA 
Individual plasma samples from Ghanaian patients were analysed with regards to their levels 
of filarial-specific IgE and IgG1-4. In brief, 96-well polysorb plates (Nunc, Roskilde, Denmark) 
were coated overnight at 4°C with 50 l/well of 5 g/ml B.m. extract diluted in PBS at pH 9.6. 
Plates were washed 3 times in washing buffer (Appendix C) and once in PBS. Plates were 
blocked with 200 l/well blocking buffer (Appendix C) for one hour at RT. Following an 
additional washing step, 50 l/well of diluted plasma was added in triplicate (1:500 for 
specific IgG1-4 and 1:20 for specific IgE) and incubated overnight at 4°C. After the next 
washing step, 50 l/well of the biotinylated secondary antibodies were added for two hours at 
RT (IgG1-4, Sigma-Aldrich, Germany, IgG1 1: 1,000, IgG2 1:15,000, IgG3 1:4,000, IgG4 
1:15,000; IgE Southern Biotech, USA 1:1,000). Following another washing step, 50 l/well 
Streptavidin-HRP (Roche Diagnostics, Mannheim, Germany; 1:5,000) were incubated for 45 
minutes at RT. After the last wash, 50 l/well substrate solution containing TMB were added 
to the wells for 15 minutes and thereafter reaction was stopped with 25 l/well 2N H2SO4 
(Merck KGAA, Darmstadt, Germany). Optical density was measured as mentioned before in 
section 2.3.10. Pooled plasma samples from 10 patients were used for the generation of 
calibration curves and assigned in arbitrary units (AU) for the specific anti-filarial antibodies. 
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In plasma samples from healthy European donors filarial IgG1-4 and IgE were not 
detectable. 
 
2.3.13 Measurement of VEGFs 
In order to analyze VEGF-A and VEGF-C, Quantikine Kits from R&D (R&D Systems, 
Wiesbaden-Nordenstadt, Germany) were used according to the manufacturer’s protocol. 
Briefly, pre-coated plates were incubated for two hours with indicated standards and 
undiluted plasma of W. bancrofti infected patients at RT. After four washing steps, plates 
were incubated for further two hours with 200 l conjugate per well. Subsequently, plates 
were washed again four times and 200 l of substrate were added. Reactions were stopped 
with 50 l stop solution and plates were read using the SpectraMAX ELISA reader (Molecular 
devices, Sunyvale, USA with wavelength correction (450 nm and 570 nm). Data were 
analysed with SOFTmax Pro 3.0 software. 
 
2.3.14 Analysis of sVEGFR3 
Individual plasma samples of Ghanaian patients were analysed for their levels of soluble 
VEGF receptor 3 using R&D Duo sets (R&D Systems, Wiesbaden-Nordenstadt, Germany). 
Procedure was performed as indicated by the manufacturer and described in section 2.3.10. 
Plasma samples were diluted 1:5 in 1% BSA in PBS. 
 
2.3.15 Intervention/treatment of lymphatic filariasis patients 
All W. bancrofti patients included in the randomized, double-blind, placebo-controlled trial 
were treated with one of the following treatment regimens: 
Treatment 1: 4 weeks doxycycline 200 mg 
Treatment 2: 5 weeks doxycycline 100 mg  
Treatment 3: 4 weeks doxycycline 100 mg  
Treatment 4: 3 weeks doxycycline 200 mg/rifampicin (10 mg/kg body weight)  
Treatment 5: 2 weeks doxycycline 200 mg/rifampicin (10 mg/kg body weight)  
Treatment 6: 10 days doxycycline 200 mg/rifampicin (10 mg/kg body weight)  
Treatment 7: placebo  
All patients received the same amount of capsules per day which were depending on the 
treatment arm replaced by placebo capsules. 4 months after finishing the treatment, all 
patients received MDA (IVM/ALB). 
 
2.3.16 Stimulation of cells for Western blot analysis 
Indicated numbers of cells were stimulated with recombinant human IL-10 (R&D Systems, 
Wiesbaden-Nordenstadt, Germany) for one hour at 37°C and 5% CO2 in a 12-well plate. In 
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some experiments PBMCs or CD4+ T cells were additionally pre-incubated for 24 hours with 
anti-GITR (2-20 g/ml) or anti-GITR-L (15 g/ml) antibody (R&D Systems, Wiesbaden, 
Germany) before recombinant IL-10 was added. 
 
2.3.17 Lysis of cells 
All steps were fulfilled on ice. After the incubation with the appropriate stimulus, cells were 
harvested and centrifuged at 400 x g for 8 minutes at 4°C. The supernatant was discarded 
and the pellet was resuspended in 50 l RIPA lysis buffer supplemented with 
phenylmethanesulfonyl fluoride (PMSF), protease inhibitors and sodium orthovanadate 
(Santa Cruz Biotechnology, Inc., Heidelberg, Germany). Cells were incubated for 30 minutes 
on ice and passed several times through a 21G needle (Becton Dickinson Heidelberg, 
Germany). Lysates were then incubated for additional 30 minutes on ice. Afterwards, all 
samples were centrifuged for 10 minutes at 10,000 x g at 4°C. The supernatant was 
transferred into new tubes and stored at -20°C until required. 
If SDS gel electrophoresis was performed (see following section) equal amounts of cell 
lysates and 5x loading dye (Appendix C) were mixed and incubated for 5 minutes at 95°C. 
Finally, suspensions were centrifuged for 10 minutes at 10,000 x g at RT. 
 
2.3.18 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)  
SDS-PAGE gel electrophoresis was performed in accordance with Laemmli et al [153]. All 
equipment required for gel electrophoresis was purchased from Bio-Rad (Munich, Germany). 
Clean glass plates were coupled together with 1.5 mm spacers. A 7% resolving gel solution 
(Appendix C) was prepared and poured into the apparatus. Whilst the gel was setting, a layer 
of 10% isopropanol was added. After 20 minutes, isopropanol was discarded and the 
stacking gel solution (Appendix C) was loaded. Combs of appropriate size and numbers 
were inserted into the stacking gel layer which was then left to set for 30 minutes. After 
carefully removing the combs, the gels were assembled into a running tank. Running buffer 
(Appendix C) was added and the samples and protein markers (MagicMark, Invitrogen, and 
Darmstadt, Germany) were loaded. The level of the running buffer solution was maintained 
to ensure good connection between the gels and electrodes. Samples were separated by 
vertical electrophoresis at 100 V for 15 minutes and then the voltage was increased up to 
150 V for approximately 30 minutes. 
 
2.3.19 Western blot 
After separating proteins as described above, gels were first soaked in distilled water for 5 
minutes. Meanwhile the nitrocellulose membrane (Sigma-Aldrich, Munich, Germany) was 
saturated for 15 seconds with methanol. Both gel and membrane were soaked twice for 5 
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minutes in protein transfer buffer (Appendix C). The separated proteins were transferred onto 
the nitrocellulose paper using the SD semi-dry electrophoretic transfer cell (Bio-Rad, Munich 
Germany). The membrane, the gel and two blotting papers were stacked and the protein 
transfer was carried out at 0.8 mA/cm2 for one hour. The nitrocellulose membranes were 
afterwards blocked in Roti-Block (Carl Roth, Karlsruhe, Germany) for one hour followed by 
three washing steps 10 minutes each with the appropriate wash buffer (Appendix C). The 
membrane was then shrink-wrapped in wrapping film (Staples Advantage, Cologne, 
Germany) to reduce the amount of used antibody and incubated overnight with the primary 
antibody (anti-STAT3, anti-pSTAT3 or anti-biotin antibody, all Santa Cruz Biotechnology, 
Inc., Heidelberg, Germany) on a rocker (Bio-Rad Munich, Germany), each appropriately 
diluted in 1x Roti-Block. After three 10 minute washes with wash buffer, the membrane was 
shrink-wrapped again and the appropriate species specific alkaline phosphatase (AP)-
labelled secondary antibodies (DAKO, Hamburg, Germany) were added at a dilution of 1:750 
and incubated for 90 minutes at RT. After further washings the membranes were placed, in 
the correct orientation, inside plastic coverings and Immun-Star AP substrate (Bio-Rad, 
Munich, Germany) reagent was added for two minutes. After different periods of exposure 
time to Kodak films (Kodak, Stuttgart, Germany), the films were developed manually. In brief, 
films were soaked for two minutes in developer solution (Kodak, Stuttgart, Germany) 
followed by a two minutes washing step with water. Thereafter, films were incubated for two 
minutes with fixer solution and finally washed again with water for two minutes. Films were 
scanned (Microtek, Willich, Germany) and blots were analysed with the fiji software. 
 
2.3.20 Extraction of RNA 
RNA of sorted cells from patients and controls of the LF study was extracted using the 
miRNeasy Kit from Qiagen (Qiagen, Hilden, Germany) according to the manufacturer’s 
protocol. In brief, samples (each 1 ml) were thawed at RT and 200 l of chloroform (Sigma-
Aldrich GmbH, Munich, Germany) were added. Tubes were shaken for 15 seconds and then 
placed for further 3 minutes at RT. Thereafter, samples were centrifuged for 15 minutes at 
1,000 x g (4°C) and the upper aqueous phase was transferred to a new collection tube. 600 
l of ethanol (Merck KGAA, Darmstadt, Germany) were added to each sample, probes were 
pipetted into RNeasy Mini columns and centrifuged at 8,000 x g for 30 seconds at RT. 700 l 
of RWT buffer were added, samples were centrifuged for 30 seconds at RT at 8,000 x g. 
Flow through was discarded and the wash steps were repeated with 500 l of buffer RWT. 
Then, 500 l of buffer RPE were pipetted to the columns and samples were centrifuged for 
two minutes at 8,000 x g at RT. Finally columns were centrifuged at 14,000 x g for 1 minute 
to get rid of residual fluid. Columns were placed on new labelled tubes and RNA was eluted 
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with 50 l of RNase-free water (Qiagen, Hilden, Germany) by centrifugation at 8,000 x g for 
one minute.  
 
2.3.21 Measurement of RNA concentration 
Concentration of RNA was first determined using the NanoDrop1000 (Peqlab, Erlangen, 
Germany) by measuring 1 l of extracted RNA and afterwards RNA was re-measured 
because of low concentration with the more sensitive Agilent RNA 6000 Pico Kit (Agilent 
Technologies, Waldbronn, Germany). For the latter application, 2 l of each sample were 
heat denatured for two minutes at 70°C. In-between the gel matrix was prepared according 
to the manufacturer’s protocol. In brief, 550 l RNA gel matrix were pipetted into a spin filter 
and centrifuged at 1,500 x g for 10 minutes at RT. 1 l of a dye concentrate was transferred 
to 65 l of the gel matrix and vortexed for 10 seconds. Thereafter, the gel was centrifuged for 
10 minutes at 13,000 x g at RT. 9 l of the prepared gel-dye mix was loaded onto the chip in 
the marked position and the chip was primed with the appropriate plunger. In addition, 9 l of 
a conditioning solution and two times 9 l of gel-dye mix were transferred to the marked 
positions. 5 l of the Pico marker were pipetted into every well and finally, 1 l of each 
sample and 1 l of the ladder were loaded onto the chip. The chip was vortexed (Agilent 
Technologies, Waldbronn, Germany) for one minute at 2400 rpm and then measured with 
the Agilent 2100 bioanalyzer. 
 
2.3.22 RNA amplification 
Extracted RNA was further amplified using the TargetAmp 2-Round biotin-aRNA 
Amplification Kit 3.0 (Epicentre Biotechnologies, Madison, USA) according to the 
manufacturer’s protocol. In brief, 500 pg of poly(A) RNA were first transcribed into first strand 
cDNA using a T7-oligo(dt) primer. Therefore, 1 l of the T7-oligo(dt) primer was added to 2 l 
of RNA and incubated for 5 minutes at 65°C in a thermocycler. Afterwards, reaction was 
chilled on ice for one minute and then centrifuged. The master mix for the first strand cDNA 
synthesis was prepared, which consists of 1.25 l reverse transcription preMix, 0.25 l 
RNase inhibitor, 0.25 l dithiothreitol (DTT) and 0.25 l SuperScript III reverse transcriptase 
(200 U/ml, Invitrogen GmbH, Darmstadt, Germany). 2 l of this master mix were added to 
each reaction, gently mixed and incubated for 30 minutes at 50°C in a thermocycler 
(Biometra GmbH, Göttingen, Germany). Afterwards, the second strand cDNA synthesis was 
performed by adding 5 l of ice cold master mix (composed of 4.5 l TargetAmp DNA 
polymerase preMix1, 0.5 l TargetAmp DNA polymerase) to each sample. Reactions were 
gently mixed and then first incubated for 10 minutes at 65°C in the thermocycler followed by 
an incubation step at 80°C for 3 minutes. After a short centrifugation step (5,000 x g, 10 
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seconds), 1 l of TargetAmp cDNA finishing solution was added to each reaction and 
incubated for 10 minutes at 37°C followed by an incubation step of 3 minutes at 80 °C (both 
steps were performed in the thermocycler). Reactions were chilled on ice before starting with 
the in vitro transcription. Therefore, all used components were warmed to RT and then the 
master mix was prepared (4 l of TargetAmp T7 transcription buffer 1, 27 l NTP preMix 1, 4 
l DTT, and 4 l TargetAmp T7 polymerase). 39 l of the master mix were added to each 
sample and incubated for 4 hours at 42°C in the thermocycler. Subsequently, 2 l of RNase-
free DNase I were added to each reaction and incubated for 15 minutes at 37°C followed by 
the RNA purification step using the RNA Clean & Concentrator™-5 Kit (Zymo Research 
Cooperation, Irvine, USA) according to the manufacturer’s protocol (see section 2.3.23). 
Afterwards 2 l of TargetAmp random primers were added to the purified RNA, which was 
eluted in 8 l of RNase-free water and incubated for 5 minutes at 65°C in the thermocycler. 
Samples were chilled on ice for one minute followed by a brief centrifugation (5000 x g, 10 
seconds). Meanwhile the master mix for the second round of first strand cDNA synthesis was 
prepared (1.5 l TargetAmp reverse transcription preMix, 0.25 l DTT and 0.25 l 
SuperScript II reverse transcriptase). 2 l of this master mix were added to each sample and 
after gently mixing, reactions were incubated for 10 minutes at RT followed by an incubation 
of one hour at 37°C in the thermocycler. 0.5 l of TargetAmp RNase H were added to each 
samples and incubated for further 20 minutes at 37°C in the thermocycler followed by an 
incubation step of 2 minutes at 95°C. Samples were chilled on ice for one minute and then 
the second round of second-strand cDNA synthesis was performed by adding 1 l of the 
TargetAmp T7-oligo(dt) primer 2. Reactions were gently mixed and incubated for 5 minutes 
at 70°C and then for 10 minutes at 42°C in the thermocycler. Samples were briefly 
centrifuged and in-between the second-strand cDNA synthesis master mix was prepared (13 
l TargetAmp DNA polymerase PreMix 2, 0.5 l TargetAmp DNA polymerase 2). 13.5 l of 
this master mix were added to each sample, incubated for 10 minutes at 37°C and then for 3 
minutes at 80°C in the thermocycler. Samples were briefly centrifuged and the in vitro 
transcription of biotin-aRNA was performed. Therefore, the master mix was prepared (7.5 l 
TargetAmp T7 transcription buffer 2, 4.5 l biotin-UTP, 20 l NTP PreMix2, 4 l DTT and 4 l 
TargetAmp T7 RNA polymerase) at RT and 40 l of this master mix were added to each 
reaction followed by an incubation step of 9 hours at 42°C in the thermocycler. Subsequently, 
2 l of RNase-free DNase I were added to each reaction and the samples were incubated for 
15 minutes at 37°C. Afterwards, the biotin-aRNA was purified (see section 2.3.24) and the 
concentration of biotin-aRNA was determined finally, by measuring the OD with the 
NanoDrop (see section 2.3.21). 
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2.3.23 RNA purification I 
In order to clean and purify the RNA before performing the second first-strand DNA 
synthesis, the RNA Clean and Concentrator-5 Kit (Zymo Research Cooperation, Irvine, USA) 
was used according to the manufacturer’ s protocol. In brief, 2 volumes of RNA Binding 
Buffer were added to each volume of RNA sample. Afterwards, 1 volume ethanol (100%) 
was added to the mixture from step 1 and mixed well. The mixture from the second step was 
transferred to the Zymo-Spin IC column in a collection tube and centrifuged at 12,000 x g for 
1 minute. Flow-through was discarded and 400 µl of RNA Prep Buffer were added to the 
column and centrifuged at 12,000 x g for 1 minute. Flow-through was discarded again and 
800 µl of RNA wash buffer were added to the column and centrifuged at 12,000 x g for 30 
seconds. Flow-through was discarded another time and the wash step repeated with 400 µl 
RNA wash buffer. The Zymo-Spin IC column was centrifuged in an emptied collection tube at 
12,000 x g for 2 minutes and the Zymo-Spin IC column was carefully removed from the 
collection tube and transferred into an RNase-free tube. Finally, 8 µl (as recommended in the 
TargetAmp 2-Round biotin-aRNA Amplification Kit) of DNase/RNase-free water were added 
directly to the column matrix and incubate for one minute at RT. The reaction was 
centrifuged at 10,000 x g for 30 seconds and the eluted RNA was used for further 
application. 
 
2.3.24 RNA purification II 
In order to purify the biotin-aRNA, the Qiagen RNeasy MiniElute Cleanup kit (Qiagen, Hilden, 
Germany) was utilized. Therefore, RLT/-ME solution was prepared by combining 1 ml of 
RLT buffer with 10 l of -mercaptoethanol. 350 l of this buffer in combination with 38 l of 
RNase-free water and 250 l 100% ethanol were added to each reaction. Samples were 
applied to the purification kit’s spin columns and centrifuged for 15 seconds at 8,000 x g. 
Flow-through was discarded and 700 l of RPE solution were applied onto the columns. 
Centrifugation was repeated for 2 minutes. Flow-through was discarded once more and the 
spin columns were transferred to a new collection tube and centrifuged at 16,000 x g for one 
minute. Afterwards the RNA was eluted by applying 20 l of RNase-free water followed by 2 
minutes incubation and centrifugation at 16,000 x g for one minute. The elution step was 
repeated under the same conditions.  
 
2.3.25 Quality control of amplified cRNA 
A polymerase chain reaction (PCR) was performed in order to control the bands of the 
housekeeping gene -actin in the amplified RNA. Therfore, 300 ng of cRNA were transcribed 
with SuperScript III Reverse Transcriptase (200 U/ml, Invitrogen GmbH, Darmstadt, 
Germany) into cDNA. 300 ng of amplified RNA in a total volume of 11 l were added to 1 l 
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of random decamer primers (50 M, Ambion, Darmstadt, Germany) and 1 l of dNTP Mix (10 
mM each dATP, dGTP, dCTP, dTTP at neutral pH; Invitrogen GmbH, Darmstadt, Germany). 
The mixture was incubated for 5 minutes at 65°C following by incubation for one minute on 
ice. Afterwards, 7 l of a master mix consisting of 4 l 5x First-Strand Buffer, 1 l 0.1 M DTT, 
1 l RNaseOUT recombinant RNase Inhibitor (all Invitrogen GmbH, Darmstadt, Germany) 
and 1 l of the SuperScript III RT were added to each sample. The reactions were mixed 
gently and then incubated for 5 minutes at 25°C. Subsequently, samples were incubated for 
45 minutes at 50°C and afterwards for 15 minutes at 70°C in a thermocycler.  
The transcribed cDNA was further used in a multiplex PCR in order to amplify two fragments 
of the -actin gene, one is localized in the 5’ region and one in the 3’ region (primer 
sequence: see Appendix D). Therefore, 12.5 l of the master mix consisting of 3 l 10x 
buffer, 4.5 l MgCL2 (both Sigma-Aldrich, Munich, Germany), 0.7 l dNTPs (Invitrogen 
GmbH, Darmstadt, Germany), 4 l primer and 0.3 l Taq polymerase (Sigma-Aldrich, 
Munich, Germany) for each reaction were added to 17.5 l of cDNA (2 l DNA diluted in 15.5 
l RNase-free water). -actin amplification was performed under the following conditions: 
initial denaturation at 95°C for 10 minutes, 18 cycles of 95°C for 30 seconds, 58°C for 45 
seconds and 72°C for 45 seconds followed by 15 cycles of 95°C for 30 seconds, 40°C for 45 
seconds and 72°C for 45 seconds. Subsequently, a final extension of 72°C for 5 minutes was 
performed. Afterwards, a 1% agarose gel was prepared by dissolving 0.5 g of agarose 
(Fermentas, St. Leon-Rot, Germany) in 50 ml of tris/borate/EDTA (TBE) buffer (Biomol 
GmbH, Hamburg, Germany) and 2.5 l of Redsafe (HISS Diagnostics GmbH, Freiburg, 
Germany). Afterwards, the solution was heated in a microwave and then poured to an 
appropriate gel chamber. 10 µl of the PCR product were mixed with 2 µl 6x DNA loading dye 
(NEW ENGLAND BioLabs, Frankfurt, Germany) and applied into the slots of the gel. The 
molecular weight was standardized with a DNA molecular weight marker (Quick load 100 bp 
DNA ladder, NEW ENGLAND BioLabs, Frankfurt, Germany) run on the same gel. 
Electrophoresis was performed at 150 V for 40 minutes in TBE buffer. Visualization of the 
two -actin bands was performed using the BioDocAnalyze digital gel documentation device 
(Biometra GmbH, Göttingen, Germany). Furthermore the quality of the amplified RNA was 
monitored with the Agilent RNA 6000 Pico Kit (Agilent Technologies, Waldbronn) as 
mentioned in section 2.3.21. 
 
2.3.26 Microarray 
Microarrays were performed in collaboration with the LIMES institute in Bonn using the 
Illumina Whole-Genome Gene Expression Direct Hybridization Assay system kit (Direct 
Hybridization Assay, Illumina Inc., San Diego, USA) according to the manufacturer’s 
protocol. In brief, 750 ng of each sample were prepared for the hybridization by pre-heating 
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the cRNA for 5 minutes at 65°C, followed by vortexing and pulsed centrifugation step at 250 
x g. RNase free water was used to resuspend each sample in a total volume of 5 l and 
afterwards 10 l of the hybridization buffer were added to each sample. The chamber gasket 
was placed into the hybridization chamber and 200 µl of the humidity control buffer were 
added into the eight humidifying buffer reservoirs in the hybridization chamber. 15 l of the 
DNA sample were pipetted onto the centre of each inlet port and the sample loaded 
BeadChips were placed into each hybridization chamber which were then put into the 
Illumina hybridization oven at 58°C for 14-20 hours. BeadChips were washed with diluted 
E1BC wash buffer inside a beaker. The cover seal from the BeadChip was removed under 
the buffer and the BeadChip were transferred to a slide rack submerged containing 250 ml 
wash solution and subsequently placed into the Hybex water bath containing high-
temperature wash buffer where they were incubated for 10 minutes. After this incubation time 
slide racks were transferred to a staining dish containing 250 ml of fresh wash buffer. The 
staining dish was put on an orbital shaker and shaked at RT for 5 minutes followed by a 
wash step in 100% ethanol under the same conditions. Furthermore the BeadChips were 
washed at RT for 2 minutes in fresh wash buffer followed by incubation with 4 ml of block 
buffer for 10 minutes on a rocker mixer. Finally, BeadChips were washed with distilled water 
before they were incubated with 2 ml Cy3-Straptavidin (diluted 1:1,000) for 10 minutes on a 
rocker mixer. Afterwards, BeadChips were washed 5 minutes with wash buffer at room RT 
and then centrifuged for 4 minutes at 1,400 rpm in order to dry the BeadChips before they 
were scanned with the HiScan SQ (Illumina Inc., San Diego, USA). 
 
2.3.27 Statistical analysis 
Statistics were performed using PRISM 5 programme (GraphPad Software, Inc., La Jolla, 
USA), SPSS 19 programme (SPSS Schweiz Ag, Zurich, Switzerland) and SAS version 9.2 
(SAS Institute Inc. Cary, NC, USA). Statistical significances between different groups were 
tested with ANOVA and in case of significance followed by t-test in case of Gaussian 
distribution. If values were non parametric, significance was first analysed with the Kruskal-
Wallis followed by the Mann-Whitney test. P values of 0.05 or less were considered 
significant. Where indicated the Cochran-Armitage test was used to determine a trend. 
Cytokine and Ig data were assessed using a generalized linear model analysis using age as 
a covariate where indicated. 
Raw data analysis for Illumina BeadChips was conducted using Illumina BeadStudio 
software version 3.1.3.0. All data analysis was performed using R statistical language and 
packages from the Bioconductor project and IlliminaGUI as described in Debey-Pascher et al 
[154].  
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3. Results 
This chapter is divided into four main segments and the first section deals with different 
findings obtained from immunological aspects of O. volvulus infected patients. An immune 
parameter which is consistently associated with onchocerciasis infections is IL-10, especially 
with regards to the induction of IgG4. Therefore, the second part describes in vitro 
experiments concerning the signaling pathways of IL-10. Interestingly, the critical source of 
IL-10 in filariasis is not limited to regulatory cells but also effector T cells produce this 
immunosuppressive cytokine [155]. To elucidate dominant cytokine and Ig production, 
immune profiling was also performed in a large cohort of patent and latent LF infected 
individuals that did not suffer from lymphedema. Within this study cohort, the effect of 
antibiotic treatment on immune responses was also assessed. Finally, to gain greater insight 
into the T cell subsets of LF patients gene expression profiles of Tregs, CD4+ and CD8+ T 
cells were investigated. 
 
 
3.1 Onchocerciasis 
In the present study clinical parameters and immunological profiles were investigated in a 
cohort of 467 infected individuals and 14 EN from the Central region of Ghana. Participants 
were part of a clinical study that was conducted in order to improve current drug therapy. 
Since adult O. volvulus filariae form characteristic nodules in the subcutaneous tissue of their 
hosts [3] patients were recruited to the study if they harbored at least one palpable nodule. 
To substantiate the field studies, volunteers residing in the same villages (EN) also took part 
and were free of palpable nodules and skin MF. The focus of the work described here is an 
analysis of immunological profiles of the individuals before treatment. The analysis of 
nodules and nodule sites was essential for the study since these two parameters were 
monitored following treatment to test the efficacy of the applied drugs and moreover, to 
determine the extent of Wolbachia death within surgically removed nodules. These data are 
not included in this thesis since the studies are still ongoing. 
 
3.1.1 Clinical evaluation of Onchocerca volvulus infected patients 
Infected individuals of the study cohort were palpated as described in section 2.3.1.1. 
Thereafter, patients were subdivided into microfilariae positive (MF+, n=384) and microfilariae 
negative (MF-, n=83) individuals according to the presence of MF observed in skin snips as 
described in section 2.3.1.3. Table 3.1 depicts the characteristics of the study population. 
Within both infection groups percentages of male and female participants were similar (MF+: 
76.82% males and 23.18% females; MF-: 71.08% males and 28.92% females). Levels of MF 
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  MF+ (n=384) MF- (n= 83) EN (n=14) 
age (mean and range) 37.34 (18-55) 39.34 (19-55) n.d. 
number of nodules (mean)  4.07  3.01 0.00 
number of sites (mean)  2.35  1.82 0.00 
rounds of IVM (mean)  1.17  1.97 n.d. 
MF/mg of skin (mean and range) 26.08 (0.06-330.81)  0.00 0.00  
 
 Table 3.1. Characteristics of the study population.  
 
differed greatly between patent individuals which is not an unusual phenomenon. It was also 
determined whether MF influenced any clinical manifestation during infection. Thus, carriers 
and non-carriers of worm offspring were compared concerning their nodule and site burden, 
the latter one defined as the position of palpable nodules. Both parameters reflect the 
amount and tissue distribution of adult worms. The number of sites (figure 3.1A) and the 
number of palpable nodules (figure 3.1B) were compared in both infected groups. In addition, 
the rounds of ivermectin treatment were documented and evaluated, since these drugs are 
given annually as part of the mass drug administration (figure 3.1C). As shown in figure 3.1A 
patent infected participants harboured significantly more sites in comparison to MF- infected 
individuals and in addition the former group also had significantly more nodules (figure 3.1B). 
Moreover, MF- individuals were characterized by a significant numerous intake of IVM (figure 
3.1C). 
 
3.1.2 MF loads correlate with the number of sites, nodules and rounds of ivermectin 
Since there were significant differences between patent and MF- infected individuals 
concerning their clinical parameters, we addressed whether the amount of MF correlated 
with the number of sites, the amount of nodules or the rounds of IVM intake. Indeed, despite 
low correlation coefficients there were significant positive correlations between MF load and 
the number of sites (figure 3.2A) and also with the number of nodules (figure 3.2B). 
 
   
 Figure 3.1. MF+ patients have more worms than MF- individuals. Infected individuals were examined for (A) the 
number of sites and (B) the number of nodules by palpation. In addition, participants were also analysed for (C) 
rounds of IVM intake. Graphs show box whiskers with median, interquartile ranges and outliers. Statistical 
significances between the indicated groups were obtained after Mann-Whitney tests and significant differences are 
indicated in the figures. 
 
Kathrin Arndts   Results 
 43 
0 100 200 300
0
2
4
6
8
10
p < 0.001
r = 0.238
A
MF/mg
no
. o
f s
ite
s
0 100 200 300
0
10
20
30
p < 0.001
r = 0.192
B
MF/mg
no
. o
f n
od
ul
es
0 100 200 300
0
2
4
6
8
p < 0.001
r = - 0.473
C
MF/mg
no
. o
f t
re
at
m
en
ts
In contrast, the amount of MF was negatively correlated with the number of previous IVM 
treatments which is shown in figure 3.2C. If the rounds of IVM intake of all infected patients 
were correlated with both pathological outcomes, there was only a weak negative correlation 
between the drug intake and the number of sites (r= -0.096, p= 0.048, data not shown). 
 
   
 Figure 3.2. Amount of MF correlates with clinical outcome. Microfilarial load was correlated to (A) the number 
of sites, (B) the number of nodules and (C) the number of IVM treatments. Analysis was performed using the 
Spearman correlation test. Correlation coefficients r and p values are shown. 
 
 
3.1.3 Decreased antigen-specific IL-5 secretion in MF+ patients 
Helminth infections and in accordance the presentation of their antigens are associated with 
inducing Th2 responses which are detected by cytokines like IL-5 and IL-13 [20]. Therefore,  
PBMCs from MF+ and MF- infected individuals and also from EN were monitored for their 
release of IL-5 (figure 3.3) and IL-13 (figure 3.4) following restimulation with various antigens 
(O.v. extract, anti-CD3/anti-CD28, B.m. female extract, MSP-1, LPS and PPD). PBMCs were 
stimulated with both specific O.v. extract and B.m. female extract as well in order to see if 
these different filarial extracts induce similar cytokine profiles because of conserved 
structures. Numbers in brackets below the graphs indicate how many patients from each 
group were stimulated with each stimulus. Numbers of patients stimulated with O.v. extract 
are lower than numbers for other applied stimuli since three different batches of O.v. extract 
were used during the study. Therefore, only results for one batch of O. v. extract are depicted 
and correspond to the results obtained when using the batch for the uninfected controls. 
Infected individuals produced significantly more IL-5 when compared to EN if their PBMCs 
were stimulated with antigen-specific O.v. extract (figure 3.3A), the related B.m. female 
extract (figure 3.3C) and the T-cell stimulus anti-CD3/anti-CD28 (figure 3.3B). In addition, 
PBMCs from patently infected people secreted significantly less IL-5 than MF- infected 
persons after stimulation with either helminth extracts whereas similar levels of IL-5 secretion 
were obtained after stimulation with anti-CD3/anti-CD28 (figure 3.3B). There were no 
significant differences between the three groups concerning their IL-5 release after  
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 Figure 3.3 Decreased IL-5 productions in patent individuals following filarial-specific stimulation. Isolated 
PBMCs (2x 105/well) from EN or O.v. infected MF+ or MF- patients were stimulated with either (A) O.v. extract (5 
g/ml), (B) anti-CD3/anti-CD28 (10 µg/ml; 2.5 µg/ml), (C) B.m. female extract (5 g/ml), (D) MSP-1 (0.25 g/ml), 
(E) LPS (50 ng/ml) or (F) PPD (10 g/ml) for 72 hours. Thereafter, levels of IL-5 were measured in the culture 
supernatants via ELISA. Graphs show box whiskers with median, interquartile ranges and outliers after 
background subtraction. Statistical significances between the indicated groups were obtained after Kruskal-Wallis 
and Mann-Whitney tests. Numbers in brackets on the x axis legend indicate the amount of stimulated patients 
within each group. 
 
 
stimulation with MSP-1 (figure 3.3D), LPS (figure 3.3E) or PPD (figure 3.3F). Percentages of 
patent and MF- individuals responding to these stimuli were comparable (MSP-1: 17.9% MF+ 
versus 18.5% MF-; LPS: 14.0% MF+ versus 8.6% MF-; PPD: 41.1% MF+ versus 42.6% MF-). 
Figure 3.4 shows the results obtained upon measurement of IL-13. Significant differences 
were observed following anti-CD3/anti-CD28 stimulation between the infected individuals 
compared to endemic controls. More precisely, infected individuals produced more IL-13 
than the control group but within the infected group there was no significant disparity (figure 
3.4B). Additionally, percentages of patients reacting to this stimulation were similar (85.0% 
MF+ versus 84.3% MF-). Antigen-specific stimulation with O.v. extract resulted in higher 
percentages of infected individuals producing IL-13 compared to EN (30.8% EN versus 
85.0% MF+ versus 84.3% MF-) but there were no significant differences between the worm 
infected groups. All other applied stimuli did not result in any significant differences in IL-13 
secretion and percentages of patients responding to the applied stimuli were also 
comparable (data not shown). 
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 Figure 3.4. Infected individuals secrete higher levels of IL-13. Isolated PBMCs (2x 105/well) from EN or O.v. 
infected MF+ or MF- patients were stimulated with either (A) O.v. extract (5 g/ml), (B) anti-CD3/anti-CD28 (10 
µg/ml; 2.5 µg/ml), (C) B.m. female extract (5 g/ml), (D) MSP-1 (0.25 g/ml), (E) LPS (50 ng/ml) or (F) PPD (10 
g/ml) for 72 hours. Thereafter, levels of IL-13 were measured in the culture supernatants via ELISA. Graphs 
show box whiskers with median, interquartile ranges and outliers after background subtraction. Statistical 
significances between the indicated groups were obtained after Kruskal-Wallis and Mann-Whitney tests. Numbers 
in brackets on the x axis legend indicate the amount of stimulated patients within each group. 
 
 
3.1.4 Increased antigen-specific IL-10 production in patent infected individuals 
IL-10 is one of the most prominent cytokines in helminthic infections as it is associated with 
the suppression of pro-inflammatory immune responses and found to be increased in 
patients with the generalized form of onchocerciasis who do not show any signs of pathology 
[7]. Thus, stimulated PBMCs from patients within the three different groups were analysed 
with regards to their levels of secreted IL-10. Their cells were treated as mentioned in section 
3.1.3 and IL-10 was measured after 72 hours of cell culture. PBMCs from infected 
participants secreted significantly more of this immunosuppressive cytokine than uninfected 
controls upon stimulation with either O.v. extract (figure 3.5A) or B.m. female extract (figure 
3.5C). IL-10 responses following MSP-1 stimulation were also higher in infected populations 
(figure 3.5D). Furthermore, the MF+ patients produced significantly more IL-10 after 
stimulation with O.v. extract than MF- infected patients (figure 3.5A) and also in response to 
the LPS stimulus (figure 3.5E). Stimulation with anti-CD3/anti-CD28 (figure 3.5B) or PPD 
(figure 3.5F) did not result in significant differences although there was an observable trend  
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 Figure 3.5. MF+ patients produce higher levels of IL-10. Isolated PBMCs (2x 105/well) from EN or filarial 
infected MF+ or MF- patients were stimulated with either (A) O.v. extract (5 g/ml), (B) anti-CD3/anti-CD28 (10 
µg/ml; 2.5 µg/ml), (C) B.m. female extract (5 g/ml), (D) MSP-1 (0.25 g/ml), (E) LPS (50 ng/ml) or (F) PPD (10 
g/ml) for 72 hours. Thereafter, levels of IL-10 were measured in the culture supernatants via ELISA. Graphs 
show box whiskers with median, interquartile ranges and outliers after background subtraction. Statistical 
significances between the indicated groups were obtained after Kruskal-Wallis and Mann-Whitney tests. Numbers 
in brackets on the x axis legend indicate the amount of stimulated patients within each group. 
 
 
in terms of higher IL-10 production following anti-CD3/anti-CD28 stimulation in the MF+ group 
compared to the control group (p= 0.065; figure 3.5B). 
 
3.1.5 Infected individuals show increased IFN- secretion to stimulation with MSP-1 
As mentioned above, helminthic infections are associated with increased Th2 cytokines 
which are thought to counterbalance Th1 immune responses that could be detrimental to the 
host [20]. Moreover, it was shown in LF infections that increased Th1 and Th17 responses 
are associated with severe pathology (lymphedema) [41]. Therefore, it was analysed if 
participants of this study produce distinct Th1 and Th17 cytokine responses even though the 
selected patients did not suffer from severe pathology (like dermatitis or blindness). To 
address to this question, isolated PBMCs were cultured with the above mentioned panel of 
stimuli followed by measurement of IFN- (figure 3.6) and IL-17 levels (figure 3.7) after three 
days of incubation. The production of IFN- was similar throughout the groups when cells 
were treated with O.v. extract (figure 3.6A), anti-CD3/anti-CD28 (figure 3.6B), B.m. female  
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 Figure 3.6. Increased IFN- production in infected individuals following MSP-1 stimulation. Isolated PBMCs 
(2x 105/well) from EN or filarial infected MF+ or MF- patients were stimulated with either (A) O.v. extract (5 g/ml), 
(B) anti-CD3/anti-CD28 (10 µg/ml; 2.5 µg/ml), (C) B.m. female extract (5 g/ml), (D) MSP-1 (0.25 g/ml), (E) LPS 
(50 ng/ml) or (F) PPD (10 g/ml) for 72 hours. Thereafter, levels of IFN- were measured in the culture 
supernatants via ELISA. Graphs show box whiskers with median, interquartile ranges and outliers after 
background subtraction. Statistical significances between the indicated groups were obtained after Kruskal-Wallis 
and Mann-Whitney tests. Numbers in brackets on the x axis legend indicate the amount of stimulated patients 
within each group. 
 
 
extract (figure 3.6C) and PPD (figure 3.6F). Both patient groups, however, showed a 
significantly increased secretion of IFN- if their cells were stimulated with MSP-1 (figure 
3.6D). In addition, the patent infected group released significantly more IFN- than the EN 
group when LPS was used as stimulus (figure 3.6E). In terms of IL-17 there were no 
significant differences between the three groups for any of the stimuli (figure 3.7A-F) 
although a higher percentage of MF+ individuals responded to the stimulation with MSP-1 
(21.4% EN versus 37.1% MF+ versus 32.9% MF-) and LPS (14.3% EN versus 26.3% MF+ 
versus 19.5% MF-). 
 
3.1.6 Filarial infected patients display strong pro-inflammatory cytokine profiles upon 
stimulation 
Pro-inflammatory cytokines are described to play a role in the development of pathogenesis 
in filarial infections and have been shown to be induced by the endosymbiotic bacteria  
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 Figure 3.7. Levels of IL-17 secretion are comparable between the analysed groups. Isolated PBMCs (2x 
105/well) from EN or filarial infected MF+ or MF- patients were stimulated with either (A) O.v. extract (5 g/ml), (B) 
anti-CD3/anti-CD28 (10 µg/ml; 2.5 µg/ml), (C) B.m. female extract (5 g/ml), (D) MSP-1 (0.25 g/ml), (E) LPS (50 
ng/ml) or (F) PPD (10 g/ml) for 72 hours. Thereafter, levels of IL-17 were measured in the culture supernatants 
via ELISA. Graphs show box whiskers with median, interquartile ranges and outliers after background subtraction. 
Statistical significances between the indicated groups were analysed using Kruskal-Wallis and Mann-Whitney 
tests. Numbers in brackets on the x axis legend indicate the amount of stimulated patients within each group. 
 
 
Wolbachia [28, 98]. Isolated PBMCs from controls, patent or MF- infected patients were 
investigated for their secretion of IL-6 (figure 3.8) or TNF (figure 3.9) in the same manner as 
described in the previous sections. Incubation of PBMCs from both patient groups with O.v. 
extract resulted in a significant increase of IL-6 and TNF when compared to the response 
from EN but not in comparison to one another (figure 3.8A and figure 3.9 A). In contrast, 
treatment with B.m. female extract did not lead to any differences between the tested groups 
with regards to either cytokines (figure 3.8C and figure 3.9C). In the case of stimulation with 
anti-CD3/anti-CD28 there was also a significant increase in the production of IL-6 in both 
patient groups compared to the uninfected controls (figure 3.8B) but there were no 
differences between the infected groups themselves. Regarding TNF release following anti-
CD3/anti-CD28 stimulation (figure 3.9B) there were no significant differences at all using the 
Kruskal-Wallis test. If only TNF production of the control group and the MF+ group were 
compared, the latter one showed in the Mann-Whitney test an increased secretion (p= 0.038; 
figure 3.9B, not depicted in the graph). 
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 Figure 3.8. Increased IL-6 secretion in helminth infected patients. Isolated PBMCs (2x 105/well) from EN or 
filarial infected MF+ or MF- patients were stimulated with either (A) O.v. extract (5 g/ml), (B) anti-CD3/anti-CD28 
(10 µg/ml; 2.5 µg/ml), (C) B.m. female extract (5 g/ml), (D) MSP-1 (0.25 g/ml), (E) LPS (50 ng/ml) or (F) PPD 
(10 g/ml) for 72 hours. Thereafter, levels of IL-6 were measured in the culture supernatants via ELISA. Graphs 
show box whiskers with median, interquartile ranges and outliers after background subtraction. Statistical 
significances between the indicated groups were obtained after Kruskal-Wallis and Mann-Whitney tests. Numbers 
in brackets on the x axis legend indicate the amount of stimulated patients within each group. 
 
 
Stimulation of cells with MSP-1 caused a significant increase in the release of both IL-6 and 
TNF in the patient groups compared to the uninfected group (figure 3.8D and figure 3.9D). 
Stimulation with LPS induced the same effects as MSP-1 in terms of a significantly up-
regulated secretion in patent and MF- infected individuals when compared to EN (figure 3.8E 
and figure 3.9E). 
Furthermore, MF+ patients produced significantly more TNF and IL-6 than the MF- individuals 
(figure 3.8E and figure 3.9E). Treatment with PPD induced a significant increase in IL-6 
secretion from both patient groups in comparison to controls (figure 3.8F). There was the 
same outcome for TNF following PPD stimulation albeit not significant (figure 3.9F). In 
summary, both antigen-specific and bystander stimuli induced secretion of IL-6 and TNF in 
PBMCs from infected individuals when compared to controls. Interestingly, LPS stimuli 
elevated the release of both of these innate cytokines in MF+ patients significantly compared 
to MF- individuals. 
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 Figure 3.9. Up-regulation of TNF secretion in helminth infected individuals. Isolated PBMCs (2x 105/well) 
from EN or filarial infected MF+ or MF- patients were stimulated with either (A) O.v. extract (5 g/ml), (B) anti-
CD3/anti-CD28 (10 µg/ml; 2.5 µg/ml), (C) B.m. female extract (5 g/ml), (D) MSP-1 (0.25 g/ml), (E) LPS (50 
ng/ml) or (F) PPD (10 g/ml) for 72 hours. Thereafter, levels of TNF were measured in the culture supernatants via 
ELISA. Graphs show box whiskers with median, interquartile ranges and outliers after background subtraction. 
Statistical significances between the indicated groups were obtained after Kruskal-Wallis and Mann-Whitney tests. 
Numbers in brackets on the x axis legend indicate the amount of stimulated patients within each group. 
 
 
3.1.7 Negative correlation of IL-5 with MF burden following filarial stimulation 
Previous publications have shown that IL-5 and IL-13 are negatively correlated with the 
amount of MF if cells were stimulated with the O.v. specific extract [29]. In order to confirm 
these data and to expand analysis also for MF- individuals, correlation analysis were 
performed and revealed that indeed the amount of MF was significantly negative correlated 
to IL-5 secretion after stimulation with O.v. extract (figure 3.10A) and furthermore, when cells 
were stimulated with the related B.m. female extract (figure 3.10B). These negative 
correlations were not found for IL-13 (data not shown). Interestingly, the amount of secreted 
IL-10 correlated positively with the amount of MF after O.v. extract stimulation (figure 3.10C). 
In addition, levels of secreted cytokines following antigen-specific re-stimulation of all 
infected patients were also correlated to the rounds of IVM intake and revealed a negative 
correlation of the latter one with the production of IL-10 (r= -0.177, p= 0.011, data not 
shown). Since MF- and patent infected individuals differed significantly with regards to the  
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 Figure 3.10. MF correlate with cytokine expression. Microfilarial load was correlated to the IL-5 secretion 
following stimulation with (A) O.v. extract (5 g/ml) and (B) B.m. female extract (5 g/ml). Moreover, MF were 
correlated to (C) the IL-10 production following O.v. extract stimulation. Analysis was performed using Spearman 
correlation test. Correlation coefficients r and p values are shown. 
 
 
intake of IVM (see figure 3.1C), correlation analysis was also performed for each subgroup 
and showed a stronger negative correlation for MF- infected patients with regards to 
secretion levels of IL-10 (r= -0.425, p= 0.003, data not shown) whereas there was no such 
correlation observable for MF+ patients. There was also no correlation of the amount of 
nodules or sites with IL-5 or IL-10 following O.v. or B.m. female extract stimulation. 
 
3.1.8 Specific immunoglobulin profiles in O. volvulus infected individuals 
The existence of defined immunoglobulin profiles with the asymptomatic filarial infections has 
been well-established since the early 1980’s [51, 102]. More precisely, asymptomatic 
infected individuals show increased levels of filarial-specific IgG4 in contrast to hyperreactive 
patients, the latter ones defined by up-regulated levels of IgE, IgG1 and IgG3 [54]. However, 
the majority of previous studies have focused on the comparison of Ig levels in hyperreactive 
individuals and patients with GEO form of the disease. Within this work a comparison was 
performed concerning the immunoglobulin profiles between infected individuals (without 
severe pathology) versus EN. Moreover, the infected individuals were further subdivided into 
those presenting MF or not. Levels of filarial-specific Igs from plasma samples were  
 
  
 Figure 3.11. Strong production of antigen-specific Igs in helminth infected individuals. Plasma samples 
from all participants were investigated for the presence of helminth-specific Igs by ELISA. Plates were coated 
overnight with 5 g/ml O.v. extract in PBS (pH = 9.6), incubated with patient and control plasma overnight and 
analysed for specific (A-D) IgG1-4 and (E) IgE. Data are depicted as absolute values expressed in arbitrary units 
[AU]. Graphs show box whiskers with median, interquartile ranges and outliers. Statistical significances between 
the indicated groups were obtained after Kruskal-Wallis and Mann-Whitney tests. 
 
Kathrin Arndts   Results 
 52 
MF + MF -
0
2
4
6
8
60
120
A
ra
tio
 Ig
G
4/
Ig
E
MF + MF -
0
1
2
3
4
5
6
8
10
12
14
B
ra
tio
 Ig
G
4/
Ig
G
1
MF + MF -
0
1
2
3
4
5
10
20
C
ra
tio
 Ig
G
4/
Ig
G
2
MF + MF -
0
5
10
15
300
600
D
ra
tio
 Ig
G
4/
Ig
G
3
measured and expressed in arbitrary units (AU). As depicted in figure 3.11A-E all infected 
individuals had significantly increased levels of specific IgE and IgG subclasses when 
compared to the control individuals. Upon comparing total levels between the two patient 
groups, there were only significant differences between specific IgG3 responses, that is, 
there were higher amounts of circulating IgG3 in patently infected individuals (figure 3.11C). 
IgG4 and IgE are often directed at the same antigenic epitope and deciphering the ratio 
between these two isotypes provides insightful information when determining whether the 
antigen triggers an IgE-mediated hypersensitivity response or whether IgG4 can act as a 
blocking antibody [69]. Therefore, the ratios of IgG4 to IgE and to other IgG subclasses were 
compared for the infected individuals (figure 3.12). Analysing the ratio of IgG4 to the other Ig 
subclasses revealed no significant differences at all between patent and MF- individuals 
(figure 3.12A-C). The ratio of IgG4/IgE was increased in MF+ patients compared to MF-
individuals albeit not significantly (p= 0.085) as demonstrated in figure 3.12D. This was also 
reflected by the percentages of patients giving a signal for IgG4 in the specific ELISA, thus 
85.90% of MF+ gave a positive signal compared to only 74.07% of MF- individuals (for IgE: 
MF+: 92.81 and MF- 92.59) indicating that MF+ individuals are more “protected” from 
developing inflammation. Correlating IL-10 and IgG4 did not reveal any significant result 
(data not shown). 
 
 
 
 
 Figure 3.12. Determination of IgG4 ratios. Plasma samples from all participants were investigated for the 
presence of helminth-specific Igs by ELISA. Plates were coated overnight with 5 g/ml O.v. extract in PBS (pH = 
9.6), incubated with patient and control plasma overnight and analysed for specific IgG1-4 and IgE. A-D show the 
ratio of the antigen-specific antibodies IgG4/IgE (A), IgG4/IgG1 (B), IgG4/IgG2 (C) and IgG4/IgG3 (D). Graphs 
show box whiskers with median, interquartile ranges and outliers. Statistical significances were analysed using 
Kruskal-Wallis and Mann-Whitney tests. 
 
 
3.2 Analysis of pSTAT3 expression 
Previous studies from our department have revealed an important role of IL-10 during filarial 
infections since this immunoregulatory cytokine is involved in the induction of 
immunosuppression in hyporesponsive patients [18]. In the results mentioned above, it was 
demonstrated that O. volvulus infected patients produce significantly more IL-10 than the 
control individuals. Additionally, it was also shown in previous experiments that regulatory T 
cell clones from hyporeactive patients are characterized by high expression of IL-10 which in 
turn facilitates their ability to induce IgG4 from B cells [18, 49]. Besides cell-cell contact this 
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Treg:B cell interaction is dependent on GITR and its ligand and also on the interaction of 
TGF- with its receptor. In brief, in vitro experiments using cell clones of human IL-10-
producing Tregs, in co-culture with autologous B cells, demonstrated that blocking GITR or 
GITR-L selectively prevented IgG4 production [50]. The same outcome was found after 
adding anti-IL-10 and anti-TGF- antibodies to the Treg:B cell co-cultures. In order to 
investigate more in-depth the mechanisms of IL-10 in inducing IgG4 production, the signaling 
pathway of IL-10 was analysed with regards to pSTAT3 since its phosphorylation reflects 
activation of the IL-10 pathway [21]. The long term aim was to determine in co-culture assays 
of B cells and Tregs which cell population is activated via the IL-10 pathway. Furthermore, 
the influence of GITR and its ligand should be investigated. 
 
3.2.1 Dose-dependent induction of pSTAT3 by IL-10 in PBMCs 
First of all a system was established to induce the phosphorylation of STAT3. Therefore, 
PBMCs of healthy blood donors were isolated as mentioned in section 2.3.2. In brief, 2x 106 
cells per well were stimulated for one hour with IL-10 (concentrations ranged from 3 ng/ml to 
100 ng/ml). Thereafter, cells were harvested, lysed and loaded onto SDS gels before further 
analysis by Western blot as described in section 2.3.19. Data in figure 3.13 show cells 
unstimulated and stimulated with different concentrations of recombinant IL-10. There was a  
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 Figure 3.13. Dose dependent phosphorylation of STAT3 by IL-10 in PBMCs. 2x 106 PBMCs were either left 
unstimulated or stimulated for one hour in the presence of increasing doses of recombinant IL-10 followed by SDS 
gel electrophoresis and Western blotting. Depicted are results from one representative of two independent donors. 
Bars in the upper part show pixel intensity, whereas the lower part shows Western blot bands. Analysis of blot 
bands was performed using fiji software.  
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clear dose-dependent induction of pSTAT3 in PBMCs upon activation with recombinant IL-10 
peaking at a dose of 50 ng/ml. However, even 6 ng/ml of IL-10 induced the phosphorylation 
of STAT3. Stimulation with 3 ng/ml of IL-10 did not result in a clear band on the Western blot 
(data not shown). In conclusion, stimulation of PBMCs for one hour with at least 6 ng/ml of 
recombinant IL-10 was sufficient to induce phosphorylation of STAT3. 
 
3.2.2 Phosphorylation of STAT3 in T and B cells 
The results mentioned above showed phosphorylation of STAT3 following stimulation with 
100 ng/ml IL-10. Thus, the same experiment was performed with CD4+ T and CD19+ B cells 
instead of PBMCs because the long-term aim was the setup of a co-culture system of T and 
B cells. Cells were isolated as described in section 2.3.6.1 and 2.3.6.2. Purity of enriched 
cells was routinely >95%. 1x 106 cells per well were stimulated for one hour with 100 ng/ml 
IL-10 and afterwards harvested, lysed and loaded onto SDS gels before analysed by 
Western blot. Data in figure 3.14 depict pSTAT3 expression in unstimulated and stimulated 
cells of both subpopulations, each graph consisting of data from three donors. Following IL-
10 stimulation STAT3 was phosphorylated in CD4+ T cells (figure 3.14A) and also in CD19+ B 
cells (figure 3.14B) albeit to a much lesser extent than in PBMCs. 
 
 
 
Figure 3.14. Phosphorylation of 
STAT3 in T and B cells. 1x 106 
enriched (A) CD4+ T (n=3) or (B) 
CD19+ B cells (n=3) were either left 
unstimulated or stimulated for one 
hour with 100 ng/ml recombinant IL-
10 followed by SDS gel 
electrophoresis and Western blot 
analysis. 
 
 
3.2.3 No significant alteration of pSTAT3 following blockade of GITR or GITR-L 
In order to determine the effect of anti-GITR (figure 3.15A) or anti-GITR-L (figure 3.15B) 
antibodies during the signaling process of IL-10, PBMCs from healthy donors were incubated 
in presence of these blocking antibodies. 2x 106 cells per well of six donors were either left 
untreated or treated for 24 hours with 1 g/ml of anti-GITR antibody or 15 ng/ml anti-GITR-L 
antibody. The concentrations of the antibodies were chosen on their ability to block activity of 
IgG4 production in the co-culture assays mentioned above [50]. Afterwards, cells were left 
unstimulated or stimulated for one hour with 50 ng/ml recombinant IL-10, then lysed and 
used for subsequent Western blot analysis. Normalization was performed by calculating the 
ratio of pixel intensity of stimulated cells compared to the intensity of unstimulated cells with 
the fiji software. The same experimental setup was performed with isolated CD4+ T cells. 
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  Figure 3.15. No significant effect 
of GITR or GITR-L on 
phosphorylation status of 
STAT3. 2x 106 PBMCs were 
incubated for 24 hours in presence 
of (A) 2 g/ml GITR (n=6) or (B) 
15 g/ml GITR-L (n=3) followed 
by stimulation with 100 ng/ml IL-10 
for one hour. SDS gel electro-
phoresis and Western blot analysis 
were conducted. Normalization was 
performed by calculating the ratio 
of pixel intensity of stimulated cells 
compared to the intensity of 
unstimulated cells using fiji 
software. 
 
 
As shown in figure 3.15A and B, there was an induction of pSTAT3 when cells were 
stimulated with IL-10 alone. As expected, treatment with anti-GITR (figure 3.15A) or anti-
GITR-L antibody alone (figure 3.15B) did not trigger the phosphorylation of STAT3. The 
results obtained with prior blocking of the cells with anti-GITR or anti-GITR-L before 
stimulation with IL-10 proved difficult to interpret since the phosphorylation status was only 
partially reduced (figure 3.15A and B). In addition, blocking of GITR did not modulate the 
phosphorylation of STAT3 in isolated CD4+ T cells significantly (data not shown).  
 
3.2.4 No effect of anti-GITR with decreasing doses of IL-10 
As can be seen from figure 3.15, distribution of pSTAT3 expression was heterogeneous in 
anti-GITR/IL-10 stimulated cells of different blood donors. As mentioned above, levels of 
pSTAT3 expression were compared on the individual donor level and the obtained results 
were contradictory regarding the effect of anti-GITR. More precisely, although some donors 
showed a down-regulation of pSTAT3 signal following GITR blockage others did not. 
Therefore, increasing concentrations of anti-GITR antibody were applied and concentrations 
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Figure 3.16. Increasing doses of 
GITR do not alter 
phosphorylation status of 
STAT3. 2x 106 PBMCs were 
incubated for 24 hours with 2-20 
g/ml GITR followed by 
stimulation with (A) 12.5 ng/ml 
(n=6) or (B) 25 ng/ml IL-10 (n=3) 
for one hour. Then, SDS gel 
electrophoresis and Western blot 
analysis were conducted. 
Normalization was performed by 
calculating the ratio of pixel 
intensity of bands of pSTAT3 
against those of -actin using fiji 
software. 
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of recombinant IL-10 were decreased to 12.5 ng/ml (figure 3.16A) and 25 ng/ml (figure 
3.16B). The described titration assay at the beginning of this section showed clear bands of 
pSTAT3 following stimulation with these lower doses of recombinant IL-10. PBMCs from 
healthy donors were isolated and 2x 106 cells were stimulated with either 12.5 or 25 ng/ml IL-
10 in the absence or presence of increasing concentrations of anti-GITR antibody (2-20 
ng/ml) as shown in figure 3.16A and B respectively. Bands of stimulated cells were 
normalized against bands of -actin. As can be seen in figure 3.16 there were no significant 
reductions of pSTAT3 in the presence of increasing doses of blocking anti-GITR antibody 
independent of the IL-10 concentration. Again, analysis of individual donors revealed 
different results, thus in some individuals blocking GITR might play a role regarding the 
phosphorylation of STAT3 whereas in other donors the signaling pathway is not directly 
influenced by GITR. 
 
3.2.5 Recombinant GITR does not alter phosphorylation of STAT3 
In a further Western blot experiment concerning the possible effect of GITR on the IL-10 
signaling pathway, recombinant GITR was added to PBMCs of healthy donors in order to see 
if this application would increase the phosphorylation of STAT3. PBMCs were pre-incubated 
for 24 hours with increasing doses of recombinant human GITR (5-100 ng/ml) and afterwards 
stimulated with IL-10 (12.5 ng/ml) for one hour. Bands of stimulated cells were normalized 
against the bands of -actin. As depicted in figure 3.17, there were no significant alterations 
in the expression of pSTAT3 in the presence of recombinant GITR, independent of the 
applied concentrations. In conclusion, there appears to be no direct influence of recombinant 
GITR on the expression of pSTAT3. 
 
  
Figure 3.17. Increasing doses of 
recombinant GITR do not alter the 
phosphorylation status of STAT3. 2x 106 
PBMCs were incubated for 24 hours with 
increasing concentrations of recombinant 
human (r.h.) GITR (5-100 ng/ml) followed 
by stimulation with 12.5 ng/ml IL-10 (n=2) 
for one hour. Subsequently SDS gel 
electrophoresis and Western blot analysis 
were performed. Normalization was done by 
calculating the ratio of pixel intensity of 
bands of pSTAT3 against those of -actin 
using fiji software. 
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3.2.6 Cell surface expression of GITR and GITR-L 
In order to see if PBMCs of individual donors express GITR and GITR-L in comparable 
amounts, cell surface expression of these markers was determined. Hence, isolated PBMCs 
from 16 blood donors were stained for their GITR and GITR-L cell surface expression as 
described in section 2.3.7.1 and results are depicted in figure 3.18. Measurement of GITR 
and GITR-L revealed different percentages in individual PBMCs ranging from less than 30 
and up to 67% for GITR and between 42 and 77% for GITR-L respectively. These data 
highlight that different background expression patterns might be a possible explanation for 
the inconclusive results obtained from the blocking experiments with anti-GITR. Further 
analysis on B and T cells should be performed. 
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Figure 3.18. Cell surface expression 
of GITR and GITR-L in PBMCs. 2x 105 
PBMCs of healthy blood donors were 
analysed by FACS for their expression 
of GITR or GITR-L. Bars represent 
percentages of GITR or GITR-L for 
each individual blood donor (n=16) after 
gating on lymphocyte gate. Data were 
analysed with FACS Diva software. 
 
 
3.2.7 Phosflow experiments 
As mentioned above, previous studies have shown that co-cultivation of B cells and IL-10-
producing Tregs induce the secretion of IgG4 in a cell-contact-dependent-manner [49, 50]. 
Blocking antibodies against IL-10 or TGF- decreased the production of IgG4. In parallel to 
the Western blot studies described above, an attempt to elucidate which of these two cell 
populations is activated via IL-10 was conducted using intracellular FACS staining to 
determine phosphorylation status of STAT3. PBMCs of healthy individuals were isolated and 
B cell and T cell fractions were sorted after staining with their appropriate surface markers 
(CD20 and CD4 respectively) as described in section 2.3.7.3. 1x 106 lymphocytes per well 
were incubated for one hour in the presence or absence of 100 ng/ml IL-10. Cells were 
subsequently stained for pSTAT3 as described in section 2.3.7.2. In contrast to the results 
from Western blot assays (figure 3.13) stimulation of sorted cells with IL-10 did not result in 
any increase of pSTAT3 signal. Figure 3.19 shows a representative flow cytometry analysis 
of pSTAT3 staining in PBMCs, isolated CD4+ T cells and isolated CD20+ B cells. There was 
only a weak signal for pSTAT3 but even with increasing doses of IL-10 or elongated 
incubation times the fluorescence could not be significantly intensified (data not shown) 
indicating that cells were not optimally treated to receive an increased signal for pSTAT3. 
Therefore, no conclusions could be drawn from these experiments.  
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Figure 3.19. No increase of pSTAT3 signals 
following IL-10 stimulation. 1x 106 cells were 
either left unstimulated (left panel) or stimulated 
for one hour with 100 ng/ml recombinant IL-10 
(right panel) and analysed for the presence of 
pSTAT3. Phosphorylated STAT3 expression of 
PBMCs (upper row), sorted CD4+ T (middle row) 
or sorted CD20+ B cells (lower row) was 
determined. Data were analysed using FACS 
Diva software. In case of the CD4+ T cells 
(middle row), only pre-gated CD4+ T cells are 
depicted. 
 
 
3.3 Lymphatic filariasis 
Within this section, aspects of the immunological status of a cohort of W. bancrofti infected 
patients are highlighted pre- and post-treatment. In this study, male individuals from the 
Western region of Ghana were investigated for the presence of CFA and for the presence of 
detectable worm nests in the scrotal area. All included participants did not suffer from 
lymphedema determined according to Debrah et al [78]. The study cohort consisted of 181 
individuals that were subdivided into 92 microfilaremic and 67 amicrofilaremic patients and 
22 endemic individuals. Before included individuals were treated with different treatment 
regiments, cytokine secretion levels were assessed upon antigen-specific or bystander 
stimulation. In addition, unspecific and antigen-specific Ig levels of included individuals were 
determined using plasma samples. Moreover, 12 months post-treatment, alterations in Ig 
profiles or cytokine levels following antigen-specific and bystander stimulations were also 
assessed in the differently treated groups. This parameter was also analysed 24 months 
after treatment. 
 
3.3.1 Clinical evaluation of Wuchereria bancrofti infected patients 
Infection with W. bancrofti leads to dilation of lymphatic vessels since adult worms residue 
inside the vascular system [140]. In order to investigate the level of dilation of lymph vessels 
and the actual number of worm nests within the scrotal region ultrasonography was 
performed (see section 2.3.1.5) on the above mentioned cohort. The number of worm nests 
was determined by detecting the movement of adult worms, termed filarial dance sign. 
Dilation of lymphatics and lymphatic vessels at the position of the worm nest and the  
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  MF+ (n=92) MF- (n= 67) EN (n=22) 
age (mean and range) 34.68 (18-50) 34.61 (19-55) 32.50 (19-45) 
FDS positive positive negative 
CFA positive positive negative 
rounds of IVM/ALB (mean) 2.17 2.09 n.d. 
number of scrotal worm nests (mean) 1.80 1.28 0.00 
m-mode average (cm, mean) 0.41 0.36 0.00 
MF/ml (mean and range) 971.16 (1-7,590) 0.00 0.00  
 
 Table 3.2. Characteristics of the study population.  
 
maximum dilation of a lymphatic vessel (without worms) in the supratesticular area were 
evaluated using a grading system from stage 0 to stage 4 according to Debrah et al [78] as 
described in section 2.3.1.5. Determination of hydroceles was also performed and revealed 
12 patients with clinical hydrocele (MF+ n= 7 and MF- n=5) according to Mand et al [147] but 
all patients were negative for lymphedema. Table 3.2 depicts the characteristics of the study 
population which includes the degree of clinical manifestations within each group and the 
rounds of MDA for the CFA positive groups that was determined using the CFA test. In 
contrast to the onchocerciasis study, only males were included since the presence of at least 
one scrotal worm nest was an inclusion criterion. With regards to CFA, we found a positive 
correlation (r= 0.68, p<0.001, data not shown) between the concentration of CFA and MF. No 
significant differences could be observed in the extent of dilation of lymphatic vessels at 
worm nest locations between the MF+ and MF- groups (figure 3.20A). However, the 
microfilaremic patients showed a significant increase in the number of scrotal worm nests in 
comparison to MF- patients (figure 3.20B), which was confirmed by the Cochran-Armitage 
trend test (p<0.001). Whereas figure 3.20A illustrates the local dilation of lymphatic vessels 
around the detected worm nests, figure 3.20C depicts the maximal detectable lymph dilation 
within the whole scrotal tissue, including the area of the spermatic cord which is not 
necessarily co-localized with the position of the worm nest. No significant differences 
between the two W. bancrofti infected groups could be detected (MF+ versus MF- p= 0.180,  
 
   
 Figure 3.20. Active circulation of MF is associated with the number of worm nests. Using ultrasound, 
participants were examined for dilation of lymphatic vessels around the worm nests (A) and for the amount of 
worm nests (B). They were also examined for the maximum degree of dilation of supratesticular lymph vessels 
(C), presented as a staging system. Box whisker plots in A show median, interquartile ranges and outliers of 
individually tested patients. Bars in B and C show the number of patients and their correlating amount of worm 
nests or lymph dilation. Data in B were tested for significance with the Cochran-Armitage trend test (p< 0.001). 
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figure 3.20C). In EN individuals, which were CFA, MF and FDS negative, the maximal 
dilation of scrotal lymphatic vessels was also assessed and they displayed dilation of 
lymphatic vessels between grades 0 and 2, but these individuals had significantly less 
dilation of lymphatic vessels than either the patent or the latent group (MF+ versus EN: p= 
0.001, MF- versus EN: p= 0.006; figure 3.20C). The number of detectable worm nests 
however, was positively correlated with the amount of circulating MF (r = 0.356, p<0.001, 
figure 3.21B) whereas there was no such correlation with any of the dilation parameters, 
neither at the worm nests nor at the maximal detectable dilation of lymphatic vessels (figure 
3.21A and C). Moreover, there were no correlations found between the rounds of drug intake 
and any of the clinical parameters (data not shown). 
 
   
 Figure 3.21. The amount of MF correlates with the number of worm nests. Microfilarial load was correlated to 
the dilation of lymphatic vessels (A), the number of worm nests (B) and the maximal dilation of lymphatic vessels 
(C). Analysis was performed using Spearman correlation test. Correlation coefficients r are only shown if p values 
were <0.05. 
 
 
3.3.2 Similar numbers of PBMCs in infected and uninfected individuals 
PBMCs of W. bancrofti infected patients were isolated as described in section 2.3.2 and 
subsequently incubated with various stimuli for three days in order to investigate their 
cytokine profiles. The amount of isolated cells from each individual from all three groups was 
compared and is depicted in figure 3.22. There were no significant differences in terms of 
higher or lower cell concentrations. 
 
 
EN MF + MF -
0
1
2
3
4
C
el
ls
/ m
l [
x 
10
6 ]
 
Figure 3.22. Similar amounts of PBMCs in infected and 
uninfected individuals. PBMCs of EN, MF+ and MF- 
individuals were isolated using ficoll gradients. The amount of 
viable cells was determined using the trypan blue exclusion 
method. Graphs show box whiskers with median, interquartile 
ranges and outliers. Statistical significances between the 
indicated groups were tested using Kruskal-Wallis and Mann-
Whitney tests. 
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3.3.3 Filarial-specific IL-5 responses are elevated in latently infected individuals 
Although much is known about the immunological differences between patients presenting 
low and severe pathology, little is known about the differences in antigen-specific responses 
of MF+ and MF- groups. To address the immunological profile of MF+ and MF- patients, 
PBMCs were stimulated with anti-CD3/anti-CD28, B.m. extract, MSP-1 and LPS. As 
mentioned in section 2.2.5, B.m. extract was used instead of W. bancrofti extract because 
the latter parasite cannot be maintained in a rodent host in contrast to the closely related B. 
malayi. Since Th2 cytokines are typical hallmarks of helminth infections, levels of IL-5 (figure 
3.23A-D) and IL-13 (figure 3.23E-H) were determined. Levels of IL-4 were also measured but 
the obtained results were all under the ELISA detection limit (data not shown). Figure 3.23A 
and E show that upon T cell activation, all groups produced IL-5 and IL-13 and there were no 
differences between the infected groups or to EN. With regards to filarial-specific responses, 
MF- patients made significantly more IL-5 than MF+ individuals (figure 3.23B), whereas EN 
hardly responded to this antigen at all. IL-13 was also strongly produced by all infected 
individuals in response to the filarial extract but no significant differences between the MF+ 
and MF- groups could be determined. Both groups, however, secreted significantly higher 
levels of IL-13 when compared to EN (figure 3.23F). In response to MSP-1 and LPS, there 
were no significant alterations between the two infection groups (figure 3.23C, D, G and H). 
However, in contrast to IL-5 there was secretion of IL-13 upon stimulation with MSP-1 and 
 
 
 
 
 Figure 3.23. Patent infection alters filarial-specific Th2 responses. Isolated PBMCs (2x 105/well) from EN or 
W. bancrofti infected MF+ or MF- patients were stimulated with either anti-CD3/anti-CD28 (10 µg/ml; 2.5 µg/ml; A 
and E), B.m. extract (5 g/ml; B and F), MSP-1 (0.25 g/ml; C and G) or LPS (50 ng/ml; D and H) for 72 hours. 
Thereafter, levels of IL-5 (A-D) or IL-13 (E-H) were measured in the culture supernatants via ELISA. Graphs show 
box whiskers with median, interquartile ranges and outliers after background subtraction. Statistical significances 
between the indicated groups were obtained after Kruskal-Wallis and Mann-Whitney tests. 
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LPS. In conclusion, these data show that there is a distinct filaria-specific expression of the 
key cytokine IL-5 between amicrofilaremic and patent individuals. 
 
3.3.4 Amicrofilaremic patients present elevated Th-17 responses 
To observe whether there were any alterations in the Th1 and Th17 profiles of microfilaremic 
and amicrofilaremic patients the secreted levels of IFN- (figure 3.24A-D) and IL-17 (figure 
3.24E-H) were also measured. Only a limited number of patients presented cytokine 
responses upon re-stimulation with B.m. extract (figure 3.24B and F). Similarly few 
responders were observed upon stimulation with MSP-1 (figure 3.24C and G) or LPS (figure 
3.24D and H). Indeed, only MF- patients responded to MSP-1 in terms of IL-17 production. 
These responders did not correlate with those patients that had a subclinical plasmodial 
infection. Albeit only a small portion of the study cohort (20/181), further statistical analysis 
revealed that these subclinical malaria patients did not differ in any of their responses when 
compared to the malaria negative patients. Interestingly, when compared to patently infected 
patients and EN, the MF- group also showed significantly elevated IL-17 responses upon 
anti-CD3/anti-CD28 stimulation (figure 3.24E). Although non-significant, after stimulation with 
anti-CD3/anti-CD28 the IFN- response of MF+ patients was lower than either of the other 
two groups (figure 3.24A). This result emphasizes again that upon MF production host 
adaptive responses are dampened. 
 
   
 Figure 3.24. Latent infected patients show elevated Th17 but not Th1 responses. Isolated PBMCs (2x 
105/well) from EN) or MF+ or MF- patients suffering from LF were stimulated with either anti-CD3/anti-CD28 (10 
µg/ml; 2.5µg/ml; A and E), B.m. extract (5 g/ml; B and F), MSP-1 (0.25 g/ml; C and G) or LPS (50 ng/ml; D and 
H) for 72 hours. Thereafter, levels of IFN- (A-D) or IL-17 (E-H) were measured in the culture supernatants via 
ELISA. Graphs show box whiskers with median, interquartile ranges and outliers after background subtraction. 
Statistical significances between the indicated groups were obtained after Kruskal-Wallis and Mann-Whitney 
tests. 
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3.3.5 Filarial-specific IL-10 is enhanced in latently infected individuals 
Next, the IL-10 and TGF- production from stimulated PBMCs of infected patients were 
analysed since increased levels of TGF- and IL-10 have been associated with the 
asymptomatic form of LF [41, 156]. In the patient cohort, IL-10 responses from MF+ patients 
were lower than those from MF- patients irrespective of the applied stimulus. Interestingly, 
there was a significantly up-regulated IL-10 response in the latent group following antigen- 
specific stimulation compared to the MF+ individuals. Moreover, in response to malaria 
peptides (figure 3.25C) and LPS (figure 3.25D) MF+ patients produced significantly lower 
amounts of IL-10 when compared to responses from EN and MF- patients. These data 
indicate that MF are able to immunomodulate responses upon filarial-specific stimulation, 
upon TLR triggering and in response to other parasitic antigens such as those derived from 
malaria species. Due to high background production of TGF-, no differences could be 
determined within the different groups, irrespective of antigen stimulus (data not shown). 
With regards to IL-6, there was a general down-regulation in the microfilaremic patients when 
compared to uninfected individuals independent of the applied stimulus (figure 3.25E-H). In 
the case of T cell activation with anti-CD3/anti-CD28 there was also a significant difference 
between the two infection groups concerning the release of IL-6 (figure 3.25E). 
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 Figure 3.25. Regulatory responses are enhanced in latently-infected individuals. Isolated PBMCs (2x 
105/well) from EN or patients infected with W. bancrofti were stimulated with anti-CD3/anti-CD28 (10 µg/ml; 2.5 
µg/ml; A), B.m. extract (5 g/ml, B), MSP-1 (0.25 g/ml; C) or LPS (50 ng/ml, D) for 72 hours. Thereafter, culture 
supernatant was tested via ELISA for cytokine release of IL-10 and IL-6. Graphs show box whiskers with median, 
interquartile ranges and outliers after background subtraction. Statistical significances between the indicated 
groups were obtained after Kruskal-Wallis and Mann-Whitney tests. 
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3.3.6 Circulating MF dampen TNF responses 
The TNF production has been shown to be a feature of acute infection during human 
bancroftian filariasis [98] but intriguingly in vitro studies have implicated that the elicited TNF 
stems from the endosymbiotic bacteria and not the worm [157]. Therefore, stimulated 
PBMCs were investigated for the production of this cytokine. Strikingly, after stimulation with 
anti-CD3/anti-CD28, MSP-1 or LPS there was a significant suppression of TNF release from 
cells of MF+ patients when compared to EN or the latent infected group (figure 3.26A, C and 
D). Upon stimulation with B.m. extract, significant differences could be detected between the 
two infected groups (figure 3.26B). These data highlight, that by dampening TNF responses, 
whether adaptive or innate, there is a potential benefit for the helminth since reduced 
responses to MF, either directly or indirectly, would enhance the chances for its survival and 
in essence completion of the life-cycle.  
 
 
 
 
 Figure 3.26. Circulating MF dampen release of TNF. Isolated PBMCs (2x 105/well) from EN or patients 
suffering from LF were stimulated with (A) anti-CD3/anti-CD28 (10 µg/ml; 2.5 µg/ml), (B), B.m. extract (5 g/ml), 
(C) LPS (50 ng/ml) or with (D) MSP-1 (0.25 g/m) for 72 hours. Thereafter, culture supernatant was tested via 
ELISA for cytokine release of TNF. Graphs show box whiskers with median, interquartile ranges and outliers after 
background subtraction. Statistical significances between the indicated groups were obtained after Kruskal-Wallis 
and Mann-Whitney tests. 
 
 
3.3.7 Microfilariae stimulate IL-1 and IL-17 release from PBMCs of healthy donors 
Since the results obtained above indicated that circulating MF are able to suppress cytokine 
responses, additional experiments with PBMCs from European blood donors were performed 
in order to investigate if the worm’s offspring is competent in immunomodulating T cell 
dependent responses. Microfilariae from infected cotton rats were freshly isolated using a 
saccharose gradient as described in section 2.3.8.1. Furthermore, an antigen extract from 
adult L. sigmodontis worms was used in the same setup of experiments which was prepared 
as described in section 2.2.6. Cells from 13 different blood donors were incubated for 24 
hours in the presence or absence of live MF (5,000/well) or L.s. extract (50 g/ml) in order to 
mimic the situation of a patent or latent infection. Afterwards, cells were stimulated with anti-
CD3/anti-CD28 (10 and 2.5 g/ml respectively) for additional 72 hours. 
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 Figure 3.27. MF increase IL-1 and IL-17 secretion in PBMCs from healthy individuals. 2x 105 isolated 
PBMCs from healthy blood donors (n=13) were either left unstimulated or incubated with L.s. extract (50 g/ml) or 
MF (5,000/well) for 24 hours followed by stimulated with anti-CD3/anti-CD28 (10 µg/ml; 2.5 µg/ml) for further 72 
hours. Thereafter, culture supernatant was tested via ELISA for cytokine release of (A) IL-1, (B) IL-10, (C) IL-17, 
(D) IFN- or (E) TNF. Cytokine data are depicted as fold increase over anti-CD3/anti-CD28 stimulation. Graphs 
show box whiskers with median, interquartile ranges and outliers. Statistical significances between the indicated 
groups were obtained after Kruskal-Wallis and Mann-Whitney tests. 
 
 
Cytokine data are shown as fold increase over basal anti-CD3/anti-CD28 stimulation levels. 
As depicted in figure 3.27 the presence of MF was not sufficient to suppress anti-CD3/anti-
CD28 induced cytokine responses. However, there was a significant up-regulation of IL-1 
(figure 3.27A) and IL-17 (figure 3.27C) secretion when MF were used in combination with 
anti-CD3/anti-CD28. Interestingly, incubation with L.s. extract resulted in the same outcome 
concerning the production of IL-1 (figure 3.27A) and IL-17 (figure 3.27C) but in contrast 
reduced the levels of TNF significantly (figure 3.27E). Secreted levels of IL-10 were not 
significantly altered by MF or the L.s. extract (figure 3.27B) but the IFN- response was 
significantly decreased in presence of L.s. extract (figure 3.27 D). In summary, the initial 
presence of MF is not sufficient enough to induce strong immunosuppression in healthy 
donors. 
 
3.3.8 Quantitative assessment of IgG and IgE levels 
Alongside IL-5, elevated levels of IgE are a hallmark of helminth infection but as mentioned 
above most LF studies have focused on the comparison between patients with severe 
pathology and microfilaremic individuals. Since the cytokine levels of infected patients 
differed between the amicrofilaremic and microfilaremic individuals, concentrations of total 
IgG and total IgE were investigated to determine whether the presence of MF also modulates 
the humoral immune responses. Thus, levels of unspecific IgE and IgG subclasses from all 
study participants and from the uninfected volunteers were measured and compared (figure 
3.28). Microfilaremic patients had significantly more IgE when compared to EN (figure 
3.28A). In addition, these levels were also more pronounced when compared to the latent 
infected group (figure 3.28A). With regards to the IgG subclasses, no differences in levels of 
total IgG1 and IgG3 could be observed between individuals of any of the study groups (figure  
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 Figure 3.28. Patently infected individuals present elevated levels of total IgE. Plasma samples from all three 
groups were analysed for the production of total IgG1 (A), IgG2 (B), IgG3 (C), IgG4 (D) and IgE (E) with the 
Cytometric Bead Array. Figure 6G shows the ratio of IgG4 and IgE. Graphs show box whiskers with median, 
interquartile ranges and outliers. Statistical significances between the indicated groups were obtained after 
Kruskal-Wallis and Mann-Whitney tests. 
 
 
3.28B and D). However, both patient groups showed a significant reduction of IgG2 when 
compared to EN (figure 3.28C). In addition, in comparison to amicrofilaremic individuals there 
was a decrease in IgG2 levels in the MF+ patients albeit non significant (p = 0.058).No 
differences could be observed in the concentration of IgG4 (figure 3.28E) but the ratio of 
IgG4 and IgE was significantly reduced in the microfilaremic group when compared to MF- 
and EN individuals (figure 3.28F). 
 
3.3.9 MF+ patients display a predominant antigen-specific IgG4 phenotype 
Finally, individual patients were analysed for their helminth-specific IgG and IgE levels (figure 
3.29). Determination of the absolute values of antigen-specific IgE and IgG subclasses 
revealed no significant differences between the patent and latent infected individuals (figure  
 
 
EN MF + MF -
0.0
0.5
1.0
1.5
2.0
2
3
4
5 p = 0.001
p = 0.001
A
Ig
G
1 
[A
U]
EN MF + MF -
0.0
0.5
1.0
1.5
2.0
B
Ig
G
2 
[A
U]
EN MF + MF -
0.0
0.5
1.0
1.5
2.0
2.5 p = 0.007
p = 0.033
C
Ig
G
3 
[A
U]
EN MF + MF -
0.0
0.5
1.0
1.5
2.0 p < 0.001
p < 0.001
D
Ig
G
4 
[A
U]
EN MF + MF -
0
1
2
3
4
5
E
Ig
E 
[A
U]
 
 
 Figure 3.29. Infected individuals have higher levels of specific IgG1, IgG3 and IgG4 than EN. Plasma 
samples from all participants were investigated for the presence of helminth-specific immunoglobulins by ELISA. 
Plates were coated overnight with 5 g/ml B.m. extract in PBS (pH = 9.6), incubated with patient and control 
plasma overnight and analysed for specific IgG1-4 and IgE. Data are depicted as absolute values expressed in 
arbitrary units [AU]. Graphs show box whiskers with median, interquartile ranges and outliers. Statistical 
significances between the indicated groups were obtained after Kruskal-Wallis and Mann-Whitney tests. 
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3.29A-E) but both patient groups were characterized by increased levels of IgG1 (figure 
3.29A), IgG3 (figure 3.29C) and IgG4 (figure 3.29D) when compared to EN. Since IgG4 and 
IgE compete for the same binding sites, determining the ratio provides an indication about 
the pathophysiological conditions, that is, whether the antigen triggers an IgE mediated 
hypersensitivity response, or whether this response can be blocked by IgG4 [59]. Patients 
within the control group were characterized by having only background levels of specific 
helminth antibodies. In contrast to the data generated on the presence of total IgE and IgG4  
(figure 3.28), MF+ patients showed a dominant expression of helminth-specific IgG4 rather 
than IgE (figure 3.30D and E). In fact, ratios of antigen-specific IgG4/IgE, IgG4/IgG1, 
IgG4/IgG2 and IgG4/IgG3 (figure 3.30A-D) in the microfilaremic group were all significantly 
higher compared to the EN group. Significant differences between MF+ and MF- groups were 
found in the ratios of IgG4/IgE (figure 3.30A), IgG4/IgG2 (figure 3.30C) and IgG4/IgG3 (figure 
3.30D). In summary, patently infected individuals display a strong expression of filarial-
specific IgG4 indicating that circulating MF also influence B cell responses. 
 
 
 
 
 Figure 3.30. Patent infected patients produce more filarial-specific IgG4. Plasma samples from all participants 
were investigated for the presence of helminth-specific immunoglobulins by ELISA. Plates were coated overnight with 
5 g/ml B.m. extract in PBS (pH = 9.6), incubated with patient and control plasma overnight and analysed for specific 
IgG1-4 and IgE. A-D show the ratio of the antigen-specific antibodies IgG4/IgE (A), IgG4/IgG1 (B), IgG4/IgG2 (C) and 
IgG4/IgG3 (D). Graphs show box whiskers with median, interquartile ranges and outliers. Statistical significances 
between the indicated groups were obtained after Kruskal-Wallis and Mann-Whitney tests. 
 
 
3.3.10 Elevated immune responses of MF- patients are independent of age  
Age has been shown to play a role with regards to cytokine production during filariasis [158] 
which was also seen within our LF study group, more precisely, an increase in age correlated 
with increased immune responses. Of note, age distribution was equal between the infected 
groups (figure 3.31). Therefore, a regression analysis was performed using age as a 
covariate and all data were log transformed [log (concentration+0.5)] to correct for skewness 
[159, 160]. Statistically correction for age did not change the overall results, that is, PBMCs 
from latently infected individuals had elevated levels of cytokines upon re-stimulation with 
various stimuli and also the results for the immunoglobulin responses stayed the same. An 
additional significant differences did become apparent in the scenario of IL-10 production 
following anti-CD3/anti-CD28 stimulation since MF+ patients produced significantly less IL-10 
when compared to MF- individuals (p=0.005) which was in line with the statistical responses  
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Figure 3.31. Equal age distribution amongst filarial-infected 
individuals. Age distribution amongst infected males was assessed. No 
significant differences could be observed. Symbols represent individuals 
within each group MF+ (n=92) and MF- (n=67).  
 
 
 
observed with the other stimuli (figure 3.25B-D). The only variable for which we found an 
interaction between age and MF status was total IgG3 secretion: here increases in age 
correlated with elevated IgG3 in MF- but less IgG3 in MF+ patients still the latter group had 
more IgG3. All statistical outcomes remained the same if the 12 clinical hydrocele patients 
were removed from the analysis as with the exception of TNF secretion upon B.m. specific 
re-stimulation. Here however, the trend remained (data not shown). 
 
3.3.11 Analysis of lymphangiogenesis factors 
Previous studies have revealed that patients suffering from severe pathology have increased 
levels of vascular angiogenesis factors in their plasma and depletion of the endosymbiotic 
Wolbachia with doxycycline leads to a decrease of these factors [78, 79, 161] arguing for an 
association between the endosymbiont and these factors. Therefore, a comparative analysis 
of microfilaremic and amicrofilaremic individuals was performed in order to gain information 
about the status of VEGFs in these asymptomatic individuals. Plasma samples of both 
patient groups were investigated concerning their levels of VEGF-A, VEGF-C and soluble 
VEGF-R3 as described in sections 2.3.13 and 2.3.14. Figure 3.32 A-C demonstrates that 
there were no significant differences at all with regards to the levels of VEGF-A, VEGF-C and 
the soluble receptor VEGF-R3 indicating that these factors are not influenced by the 
presence of circulating MF. If these lymphangiogenesis factors were correlated with one  
 
   
 Figure 3.32. Lymphangiogenesis factors of infected individuals. Plasma samples from all participants were 
investigated for the presence of (A) VEGF-A, (B) VEGF-C and (C) VEGF-R3. Graphs show box whiskers with 
median, interquartile ranges and outliers. Statistical significances between both groups were tested with Mann-
Whitney tests. 
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 Figure 3.33. VEGF-A and VEGF-C correlate with each other. Lymphangiogenesis factors measured from 
plasma samples were correlated to one other. Analysis was performed using Spearman correlation test. 
Correlation coefficients r are only shown if p values were <0.05. 
 
 
other (figure 3.33), there was only a significant positive correlation between VEGF-A and 
VEGF-C (figure 3.33A). Moreover, there were no correlations of any of these factors with the 
number of circulating MF and the number of worm nests (data not shown). However, VEGF-
A correlated negatively with the maximal lymph dilation (figure 3.34A) in contrast to VEGF-
R3 which correlated positively with this clinical parameter (figure 3.34C) if all infected 
individuals were analysed. If infected individuals were further subdivided into MF+ and MF-, 
there was a positive correlation between VEGF-R3 and the maximal dilation of lymphatic 
vessels and also with the dilation of lymph vessels at worm nests location (r= 0.215, p= 
0.048; data not shown). Correlations between the levels of angiogenesis factors and rounds 
of IVM/ALB intake were only seen for MF- with regards to VEGF-R3 (r= 0.317, p= 0.012, data 
not shown). 
 
3.4 Lymphatic filariasis – post-treatment 
The mutualistic association between Wolbachia and their filarial hosts has provided an 
alternative approach for novel chemotherapeutic strategies in filariasis. It has been shown in  
 
   
 Figure 3.34. Correlation of lymphangiogenesis factors with clinical parameters. Lymphangiogenesis factors 
were correlated to the maximal dilation of lymphatic vessels. Analysis was performed using Spearman correlation 
test. Correlation coefficients r are only shown if p values were <0.05. 
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several field studies that treatment regimes of 3-8 weeks with doxycycline lead to elimination 
of MF, female filariae sterility (due to interruption of embryogenesis), inhibition of larval 
development and adult worm death indicating macrofilaricidal effects as well [137-139]. 
However, improvement to the therapy is still required in order to shorten the time span of 
treatment which would consequentially increase compliance. For example, experimental 
trials with the already registered antibiotic rifampicin have also shown good activity against 
Wolbachia in mice [143]. In addition, a preliminary study in humans revealed that treatment 
of onchocerciasis with rifampicin causes a significant reduction of Wolbachia [144] and 
furthermore a pilot study showed that the combination of doxycycline with rifampicin is 
effective in patients infected with W. bancrofti [129]. As a follow up to the study described in 
section 3.3, W. bancrofti infected patients were analysed 12 and 24 months post-treatment 
with regards to changes in their immunological profile. All patients were part of a registered 
clinical study and herewith treated with one of the seven mentioned treatment arms as 
described in section 2.3.15. 
 
3.4.1 Reduction of microfilarial load 12 months post-treatment 
All participants of the study received doxycycline, doxycycline in combination with rifampicin 
or placebo followed by a single dose of IVM/ALB four months later. Figure 3.35 shows a 
schematic overview of study participants that finished their treatment and those that were 
included in the cytokine analysis 12 months post-treatment. Treatment regimes were 200 mg 
doxycycline for 4 weeks (treatment 1), 100 mg for 5 weeks (treatment 2), 100 mg for 4 weeks 
(treatment 3) or a combination of doxycycline (200 mg) and rifampicin (10 mg per kg body  
 
 301 individuals pre-treatment
Doxy 200 4w   Doxy 100 5w   Doxy 100 4w   Doxy/Rifa 3w    Doxy/Rifa 2w   Doxy/Rifa10d   Placebo
finished
treatment
n = 56
finished
treatment
n = 32
finished
treatment
n = 34
finished
treatment
n = 35
finished
treatment
n = 34
finished
treatment
n = 36
finished
treatment
n = 34
cytokine
analysis
n = 53
(53 MF-)
cytokine
analysis
n = 16
(16 MF-)
cytokine
analysis
n = 13
(13 MF-)
cytokine
analysis
n = 16
(15 MF-, 1 MF+)
cytokine
analysis
n = 16
(13 MF-, 3 MF+)
cytokine
analysis
n = 14
(10 MF-, 4 MF+)
cytokine
analysis
n = 25
(13 MF-, 12 MF+)
 
 
 Figure 3.35. Schematic overview of patients included in cytokine analysis 12 months post-treatment. 
Scheme shows amount of participants that finished treatment and was included in cytokine analysis 12 months 
after treatment. Within each group the amount of MF+ and MF- individuals was further determined. 
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 Figure 3.36. Microfilaremia 12 months after treatment of LF infected patients. Percentages of MF+                
W. bancrofti infected individuals were determined pre- (0 months) and post-treatment (12 months) and are depicted 
as bar graphs for each treatment arm and placebo for both time points. 
 
 
weight) for either 3 weeks, 2 weeks or 10 days (treatment arms 4-6 respectively). Moreover, 
34 patients were randomly allocated into the placebo group. 12 months post-treatment, blood 
was taken from each individual and analysed for microfilarial load as described in section 
2.3.1.4. In addition, changes in cytokine profiles were assessed in culture supernatant 
obtained from PBMCs that were re-stimulated with filarial specific antigens, anti-CD3/anti-
CD28, MSP-1 and LPS. These data are described in the following section.  
With regards to MF load, treatment with doxycycline alone, regardless of duration or dose 
resulted in a complete loss of MF. In contrast, in treatment group of combined antibiotic 
therapy several patients were MF positive. Previous studies have documented that following 
IVM/ALB therapy MF reappear in 77% of infected patients after 12 months [162]. In order to 
demonstrate the efficacy of individual treatments, microfilaremia was calculated as 
percentages pre- and post-treatment as depicted in figure 3.36. Within the placebo group 12 
out of 25 patients were found to be MF+ reflecting 48.0% compared to 68.0% MF+ individuals 
pre-treatment. However, comparing amounts of MF pre- and post-treatment those in 2009  
 
 
MF 2008 MF 2009
0
1000
2000
3000
4000
p = 0.002
M
F/
m
l
 
Figure 3.37. Reduction of microfilaremia. The amount of microfilaremia was 
compared within the MF+ placebo group (n=12) 0 and 12 months post-
treatment. Statistical significance between the indicated groups was obtained 
after Wilcoxon matched-pairs signed rank test. 
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were significantly reduced compared to levels before treatment as illustrated in figure 3.37. 
These data indicate that the treatment arms with doxycycline alone followed by a single dose 
of IVM/ALB were 100% microfilaricidal for a long time period. This was in contrast to the 
placebo treated group where MF reappeared within one year although all individuals took 
IVM/ALB four months after placebo intake. 
 
3.4.2 Analysis of Th2 responses following doxycycline treatment 
In order to discover the putative effects of the applied pharmaceuticals on the immunological 
profile, cell culture assays were performed as mentioned in section 2.3.9 with the same setup 
of stimuli. Results from the pre-treatment study demonstrated that cytokine profiles of patent 
and latent infected patients differed. More precisely, there was a general down-regulation of 
the immune responses in MF+ patients. Thus, individuals of the placebo group were split 
according to their microfilarial status in 2009 (reflecting the time point 12 months post- 
treatment) at the time blood was taken and their responses were then compared to the 
differently treated participants. Following this analysis strategy, measurement of IL-5 and  
 
  
 Figure 3.38. Influence of treatment on Th2 responses. Isolated PBMCs (2x 105/well) of doxycycline or placebo 
treated individuals were stimulated with either anti-CD3/anti-CD28 (10 µg/ml; 2.5 µg/ml; A and E), B.m. extract (5 
g/ml; B and F), MSP-1 (0.25 g/ml; C and G) or LPS (50 ng/ml; D and H) for 72 hours. Thereafter, levels of IL-5 
(A-D) or IL-13 (E-H) were measured in the culture supernatants via ELISA. Individuals of the placebo group were 
split according to their MF status at the time blood was taken. Different durations and concentrations of 
doxycycline intake are indicated in each graph. Graphs show box whiskers with median, interquartile ranges and 
outliers after background subtraction. Statistical significances between the indicated groups were obtained after 
Kruskal-Wallis and Mann-Whitney tests. 
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IL-13 (figure 3.38) did not reveal any significant differences between the different groups 
after stimulation with the T cell stimulus (figure 3.38A and E), the filarial-specific antigen 
(figure 3.38B and F) or LPS (figure 3.38D and H). Nevertheless, IL-5 secretion of PBMCs 
from individuals of the placebo group was decreased in MF+ patients following stimulation 
with B.m. extract when compared to MF- individuals (figure 3.38B), albeit not significant. 
These data confirmed the results from the pre-treatment study concerning IL-5 release 
(figure 3.23). Interestingly, IL-5 production was significantly increased in the first treatment 
group compared to the placebo MF+ individuals (figure 3.38C) following MSP-1 stimulation 
and also MF+ placebo treated individuals produced less IL-5 compared to amicrofilaremic 
placebo group (figure 3.38C). 
 
3.4.3 Alteration of IFN- production following treatment 
In addition to the Th2 immune responses described above, IFN- and IL-17 were also 
measured from the same cell culture supernatants (figure 3.39). Regarding the production of  
IL-17, there were no significant differences between the groups and this was independent of 
the applied stimulus (figure 3.39E-H).  
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 Figure 3.39. Doxycycline reduces T cell induced IFN- production. Isolated PBMCs (2x 105/well) of 
doxycycline or placebo treated individuals were stimulated with either anti-CD3/anti-CD28 (10 µg/ml; 2.5 µg/ml; A 
and E), B.m. extract (5 g/ml; B and F), MSP-1 (0.25 g/ml; C and G) or LPS (50 ng/ml; D and H) for 72 hours. 
Thereafter, levels of IFN- (A-D) or IL-17 (E-H) were measured in the culture supernatants via ELISA. Individuals 
of the placebo group were split according to their MF status at the time blood was taken. Different durations and 
concentrations of doxycycline intake are indicated in each graph. Graphs show box whiskers with median, 
interquartile ranges and outliers after background subtraction. Statistical significances between the indicated 
groups were obtained after Kruskal-Wallis and Mann-Whitney tests. 
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Secretion of IFN-was significantly reduced in the first and second treatment groups when 
compared to PBMCs from MF- individuals in the placebo group. After stimulation with B.m. 
extract there was a significant increase of the IFN- production in the case of the first 
treatment group compared to the MF+ placebo group and these patients also secrete less 
IFN- when compared to the MF- patients (figure 3.39B). Furthermore, individuals of the first 
and second treatment group produced significantly more IFN- following MSP-1 stimulation 
compared to the MF+ placebo group (figure 3.39C). 
 
3.4.4 Doxycycline modulates T cell-specific IL-10 and IL-6 secretion 
Supernatants from PBMC cultures of different treated individuals were investigated for the 
release of IL-10 and IL-6 (figure 3.40). Stimulation of PBMCs with anti-CD3/anti-CD28 
resulted in significantly reduced levels of IL-10 in the second treatment group compared to 
the MF- placebo treated individuals (figure 3.40A) whereas the production of IL-6 was 
increased compared to the microfilaremic placebo treated patients (figure 3.40E). 
Interestingly, MF+ individuals produced less IL-6 and significantly less IL-10 than MF- patients 
within the placebo group following T cell specific stimulation (figure 3.40A and E) which was  
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 Figure 3.40. Doxycycline alters T cell induced IL-10 and IL-6 secretion. Isolated PBMCs (2x 105/well) of 
doxycycline or placebo treated individuals were stimulated with either anti-CD3/anti-CD28 (10 µg/ml; 2.5 µg/ml; A 
and E), B.m. extract (5 g/ml; B and F), MSP-1 (0.25 g/ml; C and G) or LPS (50 ng/ml; D and H) for 72 hours. 
Thereafter, levels of IL-10 (A-D) or IL-6 (E-H) were measured in the culture supernatants via ELISA. Individuals of 
the placebo group were split according to their MF status at the time blood was taken. Different durations and 
concentrations of doxycycline intake are indicated in each graph. Graphs show box whiskers with median, 
interquartile ranges and outliers after background subtraction. Statistical significances between the indicated 
groups were obtained after Kruskal-Wallis and Mann-Whitney tests. 
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in line with results from the pre-treatment study. Stimulation with B.m. extract and LPS did 
not induce significant differences between any of the indicated groups (figure 3.40B, D, F 
and H). With regards to stimulation with MSP-1 there was a significant down-regulation of   
IL-6 in the MF+ patients when compared to the third treatment group and this stimulus did 
induce also a significantly higher IL-10 release in the MF- placebo patients when compared 
to MF+ individuals and the patients from the first and third treatment group (figure 3.40C). 
 
3.4.5 Determination of TNF response following treatment 
Finally, TNF was measured from the above mentioned supernatants (figure 3.41). In the pre-
treatment study, TNF release from re-stimulated PBMCs of MF+ individuals was strongly 
suppressed and this was independent of the stimuli (figure 3.26). Interestingly, when 
comparing responses of PBMCs isolated from MF- and MF+ individuals post IVM/ALB 
treatment, these suppressed responses were seen following treatment with all stimuli (figure 
3.41 A-D), albeit only significantly for MSP-1 (figure 3.41C). With regards to the doxycycline 
groups, treatment 3 induced higher levels of TNF following stimulation with anti-CD3/anti-
CD28 and LPS when compared to MF+ individuals (figure 3.41A and D). Relating to MSP-1 
stimulation, cells from the first treatment group showed also significantly higher levels of TNF 
when compared patent infected patients from the placebo group (figure 3.41C).  
 
   
 Figure 3.41. TNF production following doxycycline treatment. Isolated PBMCs (2x 105/well) of doxycycline or 
placebo treated individuals were stimulated with either (A) anti-CD3/anti-CD28 (10 µg/ml; 2.5 µg/ml), (B) B.m. 
extract (5 g/ml), (C) MSP-1 (0.25 g/ml) or (D) LPS (50 ng/ml) for 72 hours. Thereafter, levels of TNF were 
measured in the culture supernatants via ELISA. Individuals of the placebo group were split according to their MF 
status at the time blood was taken. Different durations and concentrations of doxycycline intake are indicated in 
each graph. Graphs show box whiskers with median, interquartile ranges and outliers after background 
subtraction. Statistical significances between the indicated groups were obtained after Kruskal-Wallis and Mann-
Whitney tests. 
 
 
3.4.6 Analysis of antigen-specific immunoglobulins 12 months post-treatment 
One year after treatment plasma samples of included participants were analysed for antigen-
specific Igs as described in section 2.3.12. As can be seen from the absolute values in figure 
3.42 there were no significant differences between the indicated groups. In addition, even the 
ratios of IgG4 to IgE (figure 3.43A) and to the other Ig subclasses (figure 3.43B-D) did not  
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 Figure 3.42. Specific Ig levels following doxycycline treatment. Plasma samples of doxycycline or placebo 
treated individuals were investigated for the presence of filarial-specific Igs by ELISA 12 months after treatment. 
Plates were coated overnight with 5 g/ml B.m. extract in PBS (pH = 9.6), incubated with patient and control 
plasma overnight and analysed for specific IgG1-4 and IgE. Data are depicted as absolute values expressed in 
arbitrary units [AU]. Individuals of the placebo group were split according to their MF status at the time blood was 
taken. Graphs show box whiskers with median, interquartile range and outliers. Statistical significances between 
the indicated groups were analysed using Kruskal-Wallis and Mann-Whitney tests. 
 
 
show any significant differences. However, levels of IgE were lower in MF+ compared to MF- 
placebo treated individuals (figure 3.42E) which was further reflected in a higher ratio of IgG4 
to IgE (figure 3.43A), albeit not significantly. These data were again in line with results from 
the pre-treatment study concerning MF+ and MF- patients but indicate also that treatment had 
no significant influence on Ig levels 12 months post-treatment. 
 
  
 Figure 3.43. Ratios of filarial-specific Igs are not significantly altered 12 months after treatment. Plasma 
samples of doxycycline or placebo treated individuals were investigated for the presence of filarial-specific Igs by 
ELISA 12 months after treatment. Plates were coated overnight with 5 g/ml B.m. extract in PBS (pH = 9.6), 
incubated with patient and control plasma overnight and analysed for specific IgG1-4 and IgE. Figures A-D show 
the ratio of the antigen-specific antibodies IgG4/IgE (A), IgG4/IgG1 (B), IgG4/IgG2 (C) and IgG4/IgG3 (D). 
Individuals of the placebo group were split according to their MF status at the time blood was taken. Graphs show 
box whiskers with median, interquartile ranges and outliers. Statistical significances between the indicated groups 
were analysed using Kruskal-Wallis and Mann-Whitney tests. 
 
 
3.4.7 Microfilaremia 24 months post-treatment 
In order to determine long-term effects of the different applied treatment arms, participants 
were analysed 24 months after treatment with regards to their antigen-specific Ig levels as 
described in section 2.3.12. Figure 3.44 shows a schematic overview of those patients that 
completed treatment and were included in Ig analysis two years later.  
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 Figure 3.44. Schematic overview of patients included in immunoglobulin analysis 24 months post-
treatment. Scheme shows amount of participants that finished treatment and was included in Ig analysis 24 
months after treatment. Within each group the numbers of MF+ and MF- individuals were further determined. 
 
 
Furthermore, microfilaremia was again evaluated and calculated as percentages for each 
individual treatment arm. As can be seen in figure 3.45 treatment group 2 had the longest 
microfilaricidal effect, whereas in all other treatment arms more MF were detected indicating 
that a longer treatment is required to achieve long term effects concerning the depletion of 
circulating MF and that a lower dose of 100 mg is also efficient. 
Analysis of the absolute values of Igs revealed that patients treated with 100 mg doxycycline 
for 5 weeks had significantly lower levels of specific IgG1 compared to both placebo groups 
 
   
 Figure 3.45. Microfilaremia 24 months after treatment of LF infected patients. Percentages of MF+ W. 
bancrofti infected individuals were determined pre- (0 months) and post-treatment (24 months) and are depicted 
as bar graphs for each treatment arm and placebo for both time points. 
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 Figure 3.46. Reduction of antigen-specific IgG1 levels 24 months after treatment. Plasma samples of 
doxycycline or placebo treated individuals were investigated for the presence of helminth-specific Igs by ELISA 24 
months after treatment. Plates were coated overnight with 5 g/ml B.m. extract in PBS (pH = 9.6), incubated with 
patient and control plasma overnight and analysed for specific IgG1-4 and IgE. Data are depicted as absolute 
values expressed in arbitrary units [AU]. Individuals of the placebo group were split according to their MF status at 
the time blood was taken. Graphs show box whiskers with median, interquartile ranges and outliers. Statistical 
significances between the indicated groups were obtained after Kruskal-Wallis and Mann-Whitney tests. 
 
 
(figure 3.46A) and decreased amounts of specific IgG4 compared to the MF+ placebo treated 
individuals (figure 3.46D). With regards to the ratios of IgG4 to the other subclasses, there 
were significant lower ratios of IgG4/IgE (figure 3.47A), IgG4/IgG1 (figure 3.47B) and 
IgG4/IgG3 (figure 3.47D) in the second treatment group when compared to the MF+ placebo 
patients. Interestingly, the difference in the IgG4/IgE ratio between MF+ and MF- was seen in 
the pre-treatment study and also 12 months later whereas the significant up-regulated 
IgG4/IgG1 ratio between both placebo groups observed here was not seen in the pre-
treatment data. 
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 Figure 3.47. Ratios of IgG4/IgE and IgG4/IgG3 are modulated by doxycycline treatment. Plasma samples of 
doxycycline or placebo treated individuals were investigated for the presence of helminth-specific Igs by ELISA 24 
months after treatment. Plates were coated overnight with 5 g/ml B.m. extract in PBS (pH = 9.6), incubated with 
patient and control plasma overnight and analysed for specific IgG1-4 and IgE. A-D show the ratio of the antigen-
specific antibodies IgG4/IgE (A), IgG4/IgG1 (B), IgG4/IgG2 (C) and IgG4/IgG3 (D). Graphs show box whiskers 
with median, interquartile ranges and outliers. Statistical significances between the indicated groups were 
analysed using Kruskal-Wallis and Mann-Whitney tests. 
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3.5 Gene expression in T cells of W. bancrofti patients and endemic individuals 
In order to obtain more in-depth information about differentially expressed genes in             
W. bancrofti infected individuals, distinct T cell subpopulations from EN, patent or latent 
infected individuals were sorted and analysed with a microarray. The FACS sorting was 
performed with the MoFlo cell sorter in the core facility at the Technical University in Munich. 
Cells were stained with anti-CD4, anti-CD25 and anti-CD8 as described in section 2.3.7.1. 
 
 A B
CD25 PE CD8 APC
C
D
4 
FI
TC
 
Figure 3.48. Gating strategy of sorted 
CD4+CD25high, CD4+CD25- and CD8+ T 
cells. Cells of EN, MF+ or MF- individuals 
were stained with CD4 FITC, CD25 PE 
and CD8 APC antibodies and sorted 
using the MoFlo sorter. Graphs show 
representative gating strategy for each 
subpopulation: R3 depicts CD4+CD25- T 
effector cells, R5 CD4+CD25+ Tregs and 
R4 CD8+ T cells. 
 
 
Figure 3.48 depicts the gating strategy for each subpopulation of T cells and is 
representative of one participant. PBMC samples contained a maximum of 5x 106 cells and 
sorted cell populations ranged between 5x 103 and 5x 104 for Treg populations, 3x 103 and 
4x 105 for CD4+CD25- populations and 4x 103 to 5x 105 for CD8+ T cells. Afterwards, sorted 
cells were resuspended in 1 ml Trizol and frozen at -80°C. 
 
  
 Figure 3.49. Quality control box plots and quality correlations (quantile data) of sorted T cell 
subpopulations. Box plots on the left side show the fluorescence intensity of each sample before quantile 
normalization was performed (depicted is the median, 25 and 75% percentile). The heat map on the right side 
depicts correlations (Pearson) of all used samples after performing quantile normalization. Courtesy of Dr. Svenja 
Debey-Pascher. 
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 Figure 3.50. Cluster and PCA variable genes (n = 820). Hierarchical clustering (left side) and principal 
component analysis (right sides) were performed on quantile normalized data using the most variable genes in the 
dataset. Courtesy of Dr. Svenja Debey-Pascher. 
 
 
RNA extraction was performed in the LIMES institute in Bonn as mentioned in section 2.3.20. 
Due to the small cell number extracted RNA amounts were to low for microarray analysis and 
were therefore amplified with an amplification kit as described in section 2.3.22. 
Determination of differentially expressed genes was performed using an Illumina microarray 
(HT12V4 Array, containing 47.231 probes) and analysis was conducted by Dr. Debey-
Pascher, Genomics and immunoregulation, LIMES Institute Universität Bonn (working group 
Prof. Joachim Schultze; see figures 3.49 and 3.50). 
CD4+ T effector cells (CD4+CD25-) of 3 individuals per group (EN, patent and latent infected 
individuals) were analysed with the Illumina microarray as described in section 2.3.26. The 
same amount of samples was determined with regards to CD8+ T cells. For Tregs 
(CD4+CD25high) 5 samples of infected individuals (2 MF+ and 3 MF-) and 4 probes from EN 
were determined. Signal intensities of all tested samples were within the normal range 
arguing for a sufficient control of the probes (figure 3.49 and 3.50). To identify differentially 
regulated genes within the three cell populations, a combination of filtering for absolute (max-
min 100) and relative (max/min 1.5) changes in average expression signals across all 
conditions, and statistical testing (t-test) was applied. The amounts of differentially expressed 
genes within each cell population are depicted in table 3.3. Concerning the expression 
profiles in Tregs when comparing all infected patients versus EN, there were actually only 68 
genes that were differentially expressed. Within this list of 68 genes, 13 were down- and 55 
were up-regulated in the infected group (e.g. the STAT1 gene). Upon closer inspection 191 
genes were differentially expressed between MF+ and EN (57 down- and 134 up-regulated). 
These included genes such as C-C chemokine receptor type 3 (CCR3), CD84, and STAT1. 
Similar amount of genes (194) were differentially regulated when comparing amicrofilaremic 
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and microfilaremic patients (86 down- and 108 up-regulated). Here, major histocompatibility 
complex, class II, DQ beta 1 (HLA-DQR) and nucleotide-binding oligomerization domain 
containing 1 (Nod1) were up-regulated genes whilst CD83 was one of the most strong down-
regulated genes. When comparing MF- and EN, there was almost a 50% reduction in the 
number of regulated genes (106), of which 29 were down- and 77 up-regulated. With regards 
to the effector CD4+ T cells, comparison of the EN and the infected groups revealed 100 
differentially expressed genes (34 down- and 66 up-regulated, e.g. lymphocyte 
transmembrane adaptor 1 (LAX1), VEGF-B, caspase 3) whereas patent infected individuals 
had 184 genes that were differentially regulated compared to EN (64 down- and 120 up-
regulated). Amicrofilaremic patients had 99 genes that were distinct from EN (40 down- and 
59 up-regulated) and the two infected groups were diverse in reference to 90 genes (40 were 
down-regulated in MF- individuals and 50 up-regulated, e.g. IL-15). Finally, with regards to 
the CD8+ T cell populations, all three groups had differences in their gene expression. 
Disparity involved only 41 genes between the infected and the EN individuals (17 down- and 
24 up-regulated) and here superoxide dismutase 2 (SOD2), serum/glucocorticoid regulated 
kinase (SGK) and Krueppel-like factor 4 (KLF4) were the most prominently down-regulated 
genes in the former group. Amongst the groups, 69 genes were regulated between MF+ and 
EN (37 down- and 32 up-regulated), 78 genes between MF- and EN (42 down- and 36 up-
regulated) and finally also 78 genes between the latent and patent infected patients (31 
down- and 47 up-regulated). These data reveal that not only immunological profiles but also 
gene expression levels are altered depending on the infectious state of the patient. With 
regards to CD8+ T cells, apoptosis-associated genes like B-cell lymphoma 6 protein (Bcl-6), 
inhibitor of growth 2 (ING2) and SUMO1/sentrin specific peptidase 5 (SENP5) are interesting 
candidates for further research since apoptosis was already linked to filariasis beforehand. 
From these up- and downregulated genes we have begun to cheery pick the most relevant 
and interesting genes for further investigation. These genes cover the field of cytokines (e.g. 
IL-10 receptor , TGF-receptor, IL-15), apoptosis (e.g. BCL-6, SGK), tumor necrosis factor 
(ligand) superfamily member 10 (TRAIL)), immune regulation (e.g. CD83), effector function 
(e.g. CXCR4) and cell signaling (e.g. STAT1). The functional relevance of these genes with 
regards to filarial infection is discussed in more detail in the following section. 
 
  CD4+CD25+ CD4+CD25- CD8+ 
Infected versus EN 68 100 41 
MF+ versus EN 191 184 69 
MF- versus EN 106 99 78 
MF+ versus MF- 194 90 78  
 
 Table 3.3. Overview of regulated genes within all T cell subpopulations.  
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4. Discussion 
 
Onchocerciasis and LF are neglected diseases in tropical regions and affect more than 150 
million people. Moreover, 1.3 billion people are estimated to be at risk of infection [3, 131]. 
These impressive numbers highlight the impact of both diseases and why they are 
considered major health problems with socioeconomic consequences. Although filarial 
infections are well established as tropical helminth diseases there are still many unresolved 
questions about the immunological processes that drive pathology. Both filarial species are 
renowned for their ability to immunomodulate the host’s immune system to ensure 
reproduction and long-term survival which accounts for the asymptomatic form of infection. 
Nevertheless, severe pathology can occur in the form of visual impairment, blindness, acute 
and chronic skin disease in onchocerciasis [5] and as hydrocele, lymphedema or 
elephantiasis and others in LF [74]. Since the two major poles of infections are reflected by 
asymptomatic infections and severe pathology, most previous studies focused on the 
comparison of hyperreactive and asymptomatic individuals or sometimes on the assessment 
of immunological responses in patent infected patients versus EN. However, an in-depth 
analysis on the possible differences between MF+ and MF- infected patients in both infections 
has never been performed and was therefore a primary objective of this thesis. Data 
obtained over the last few years have revealed that MF+ and MF- LF and onchocerciasis 
patients can be identified by distinct immunological profiles with regards to cytokine release 
and Ig levels. Moreover, in the case of LF infection further characterisation was obtained on 
a genetic level. In general, these results showed that the degree of immunomodulation was 
differently regulated between both filarial diseases.  
 
4.1 Interplay between MF status and pathology 
As mentioned above, an in-depth analysis of immune responses in MF- individuals has not 
been previously addressed. Actually MF- O. volvulus infected individuals have been a 
neglected cohort because of the difficulties to identify these patients due to the lack of an 
available antigen test and determination of nodules by palpation requires experienced 
medical training. In contrast, a conclusive determination of the infection status in LF can be 
achieved through the rapid card test [115, 116]. Nevertheless, up to the studies performed in 
this thesis this latent LF patient group was also neglected. These MF- patients are of 
considerable interest because they represent a dead end in parasite transmission and 
preventing the completion of the lifecycle is one of the main goals of programmes like the 
APOC and GPELF. 
Analyzing the pathological aspects in both diseases revealed that asymptomatic MF+ 
patients had higher parasite burden since the presented either increased amounts of nodules 
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and nodule sites or a higher number of scrotal worm nests. In contrast, in LF lymph dilation 
at either the worm nest location or maximal lymph dilation according to the staging system 
employed did not reveal any significant differences between latent and patent infected 
individuals. Interestingly, EN also possessed a certain degree of lymph dilation. Since there 
remains no available data for the spread of lymph dilation in non-endemic normals or healthy 
Europeans, it is difficult to conclude if these EN have already enlarged lymph vessels or if 
this represents the normal physiological situation. 
In line with this aspect was the observation that a certain percentage of individuals in the LF 
study possessed hydroceles which was also determined via ultrasonography. Hydroceles are 
a common manifestation in man with bancroftian filariasis infection and can be graded 
according to their developmental stage and size. In contrast to scrotal palpation, 
ultrasonography allows the detection of both subclinical (stage 1-2) and clinical (stage 3-4) 
manifestations [163]. Ultrasound studies have shown that many males in endemic areas with 
normal clinical examinations have subclinical hydroceles that can be asymptomatic [164-
166]. Patients with severe pathology are usually characterized by the absence of adult 
worms, but patients within this study all possessed adult filariae. Interestingly, our results 
showed that the presence of hydrocele did not influence the outcome of dampened 
responses in the patently LF infected group, indicating that these two separate pathological 
outcomes can influence the immune responses in a different manner. Therefore, we 
conclude that the presence of MF is more important to influence the immunological profile 
than the hydrocele status which is line with previous publications [167]. 
Nevertheless, further associations between the presence of MF and pathology were reflected 
by the positive correlation of MF load and the number of sites and nodules in O. volvulus 
infected persons and between MF and the amount of worm nests in LF patients. The 
application of ultrasonography has already shown a positive association of FDS with the 
amount of circulating MF in W. bancrofti infected individuals from Brazil [168]. However, no 
data have been accumulated regarding this aspect in endemic areas of Africa. In general, 
these findings indicate that although patently infected individuals have obviously more worms 
that are competing for the same ecological niches, there is still efficient down-modulation of 
the immune system since they did not suffer from severe pathology like lymphedema or 
symptomatic hydrocele. This is in accordance with previous findings describing that 
immunosuppression rises with parasite burden [25]. Interestingly, there was a negative 
correlation between the amount of MDA intake and the amount of MF in O. volvulus infected 
patients but this was not observed in LF infected individuals. This negative correlation in 
onchocerciasis patients indicates that MF- infected individuals were not “latently” infected as 
seen in LF but that MF levels had not recovered from previous IVM treatments and this was 
already described in earlier studies [16]. However, this scenario could be ruled out for 
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individuals of the LF study since patients were only included if they had not received MDA 
during the least 10 months and previous studies described that following such therapy MF 
reappear after 12 months in 77% of W. bancrofti infected patients [162].  
 
4.2 Are cytokine profiles of onchocerciasis and lymphatic filariasis infected 
individuals really comparable? 
Although both O. volvulus and W. bancrofti belong to filariae and share some general 
features, results described within this thesis show that there are major differences between 
both diseases with regards to the immunological profiles of MF+ and MF- individuals. 
Clearance of helminth infections is mediated by Th2 cells and includes cytokines like IL-3, 
IL-4, IL-5, IL-9, IL-10, IL-13, the presence of IgG1, IgG4 and IgE, and expanded cell 
populations such as eosinophils, basophils and mast cells [20]. IL-5 is considered to be a 
hallmark of helminth infections [169] and moreover, IL-5 induces eosinophils and also IgE 
[170]. Therefore, it was interesting to compare the level of IL-5 in both infection scenarios 
and between patent and MF- infected individuals. Interleukin-5 was significantly down-
regulated following filarial-specific stimulation of cells from patent infected individuals when 
compared to the MF- group in both diseases (see table 4.1). This was in contrast to a 
previous publication of Dimock et al [105] but in line with in vivo studies using the murine 
model of filariasis which showed that infected IL-5 deficient mice possessed higher levels of 
MF [171, 172]. Moreover, a human study revealed that IL-5 was negatively correlated with 
the amount of MF in O. volvulus infected individuals [29]. Interestingly, O. volvulus infected 
patent patients also produced significantly less IL-5 in response to an extract from B.m. 
females which could possibly be explained through cross-reactivity due to the close ancestral 
relationship between both filarial species. If levels of MF in O. volvulus infected individuals 
were correlated to IL-5 secretion following stimulation with O.v. extract or B.m. female 
extract, there was a significant negative correlation for both stimulation scenarios. This 
indicates that rising levels of MF induce down-regulation of IL-5 which can be detrimental to 
the parasite but also to the host itself due to the induction of eosinophils and also IgE which 
are both associated with pathology [170]. Although such negative correlation could not be 
confirmed between the amount of MF and secreted levels of IL-5 in LF, it could be shown 
that microfilaremic individuals produced less IL-5. However, reduced levels of the Th2 
cytokine IL-5 in patently infected patients was not reflected in IL-13 secretion since there 
were no significant differences between both infected groups with regards to both diseases. 
Reports have described that PI individuals in O. volvulus endemic areas have a strong 
Th1/Th2 mixed response. For example, when compared with those from GEO patients, both 
IFN- and IL-5 production in response to filarial-specific stimulation are readily detected and 
such profiles are thought to prevent establishment of active infection [13, 24, 57]. 
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  W. bancrofti O. volvulus 
IL-5 ↓ ↓ 
IL-13 ­ ­ 
IL-10 ↓ ↑ 
IL-17 ­ ­ 
IL-6 (↓) ­ 
TNF ↓ ­ 
IFN- ­ ­  
Table 4.1. Cytokine secretion from PBMCs 
of MF+ infected individuals following 
stimulation of filarial specific antigen in 
comparison to MF- individuals. 
 
 
However, the results described here do not confirm these data since Th1 responses 
(assessed through IFN- production) by PBMCs were similar for all three groups following 
antigen-specific stimulation. Stimulation with anti-CD3/anti-CD28 or PPD did also not result 
in any significant differences between the compared groups in the onchocerciasis cohort and 
this is in line with previous results [23]. Nonetheless, when compared to EN, IFN- secretion 
was significantly increased in both O. volvulus infected groups following MSP-1 stimulation 
and also in response to LPS in the case of MF+ individuals. In general, PBMCs from EN of 
the onchocerciasis study were characterized by lower cytokine secretion with regards to Th1 
and Th2 independent of the applied stimulus. Differences in results compared to those 
presented in previous publications could be explained by the use of varying experimental 
setups including different batches of antigen in varying concentrations, analysis of individuals 
from different genetic backgrounds or belonging to different endemic areas [15, 56, 57, 173, 
174]. Secretion of IFN- from LF infected patients was not detectable for any of the tested 
stimuli except direct T cell activation, which showed that microfilaremic patients produced 
less IFN- than latent infected individuals, albeit insignificantly. 
 
4.3 MF presence alters IgG4 and IL-10 levels 
Beside cytokines, Igs are also valuable tools in deciphering immunological processes since 
antibodies play an important role in the progress of parasite infections. In general, depending 
on the Ig subtype they can promote different functional mechanisms like opsonisation, 
neutralization of toxins, complement activation and antibody dependent cell-mediated 
cytotoxicity. In helminth infections and allergy, high levels of IgG4 are associated with 
moderate symptoms whereas high levels of IgE are common in patients with severe 
pathology [13, 67, 169]. IgG4 is a non-complement fixating Ig that can bind weakly to effector 
cell Fc receptors and then compete with IgE for antigen-binding sites.  
 
  W. bancrofti O. volvulus 
IgG4/IgG1 - - 
IgG4/IgG2 ↑ - 
IgG4/IgG3 ↑ - 
IgG4/IgGE ↑ (↑)  
Table 4.2. Ratio of filarial-specific IgG4 to 
other Ig subclasses of MF+ in comparison to 
MF- individuals. 
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Therefore, the relationship of the two Igs is of special interest during filariasis infections since 
their presence usually reflects the pathophysiological situation of the host [53, 175]. The 
quantities of specific IgG4 produced in LF patients can be remarkably high. In patients 
presenting elephantiasis, IgG4 levels are similar to those found in EN (57% and 55% of 
filarial-specific IgG respectively) whereas in MF+ carriers the amount is significantly higher 
(88%) [101]. Immunohistological stainings of nodules from hyperreactive or asymptomatic 
onchocerciasis patients have shown that IgG4 expression of the former is down-regulated 
supporting it’s important role in immunomodulation [9]. Upon analyzing filarial-specific Ig 
levels in the onchocerciasis study, both infected groups revealed significant differences in all 
Igs when compared to EN but not with each other. Significant differences between patent 
and MF- individuals were only found with regards to IgG3, which was increased in MF+ 
patients. Levels of IgG4 were slightly increased in MF+ patients when compared to MF- 
individuals, albeit not significant. Due to the competition between IgG4 and IgE for the same 
binding sites, determining the ratio provides essential insight about the pathophysiological 
conditions, that is, whether the antigen triggers an IgE mediated hypersensitivity response, or 
whether this response can be blocked by IgG4 [69]. In general, the prevalence of IgG4 
dominated filarial-specific Ig secretion was much more obvious in MF+ LF infected patients 
since the ratios of IgG4 to IgE, to IgG2 and to IgG3 were all significantly increased when 
compared to amicrofilaremic patients. MF+ onchocerciasis individuals showed only a trend 
concerning the IgG4/IgE ratio (p = 0.085) although MF+ and MF- patients produced 
significantly more antigen-specific Igs compared to the EN which is in line with previous 
reports [52, 176]. This increased ratio of IgG4 to IgE confirms studies performed by Jaoko et 
al in East Africa with W. bancrofti infected individuals and interestingly, this group found that 
specific antibodies levels reflect infection status rather than lymphatic disease [167]. 
Moreover, in the study performed here, patent LF infected individuals also had elevated 
polyclonal IgE levels when compared to latent individuals. Such high levels of IgE may 
facilitate the persistence of infection through the production of irrelevant (not parasite Ag-
specific) Igs, that saturate high affinity IgE receptors expressed on mast cells which renders 
them unable to be specifically cross-linked by parasite antigen [94]. 
Besides IgG4, IL-10 is also known to be a key player during filarial infections [74] and its 
presence is clearly connected with a protective immunological scenario in onchocerciasis: 
high IgG4, IL-10 and Tregs are associated with low pathology whereas high levels of IgE,   
IL-4 and eosinophilia are common in patients with severe pathology [9, 13, 67, 169]. 
However, the source of IL-10 remains inconclusive since studies have depicted that CD4+ 
(and not CD25+) T cells are the predominant IL-10 producing cells in the circulation of filaria 
infected patients [155, 156] whereas other studies have shown that IL-10 production is 
mediated by Tregs [18, 24]. Interestingly, there was an up-regulation of antigen-specific 
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induced IL-10 secretion in patent O. volvulus infected individuals which was further 
emphasized by a positive correlation between IL-10 levels and the amount of MF but there 
was no direct correlation between IL-10 and IgG4. In contrast, MF+ LF patients had 
significantly lower levels of IL-10 than amicrofilaremic individuals although the former ones 
were also characterized by elevated levels of antigen-specific IgG4. Therefore, one could 
conclude that in LF the observed immunoregulation is less dependent on IL-10 or there are 
some redundant mechanisms blocking inflammation and inducing IgG4. Interestingly, gene 
expression profiles of Tregs of MF- LF patients demonstrated a significant up-regulation of 
the IL-10 receptor  compared to MF+. This was in line with data obtained from the re-
stimulation assays although we used whole PBMCs in these assays and not isolated 
fractions of T cells. In contrast, MF+ patients had higher levels of this receptor in their effector 
T cells compared to EN. 
As mentioned above, patent O. volvulus infected patients had significantly up-regulated IL-10 
levels compared to MF- individuals but the differences concerning the anti-inflammatory IgG4 
were not as clear as in LF. Since the MF in O. volvulus infected individuals are found in the 
skin and not in the blood, one might speculate that the analysis of skin samples may reveal a 
difference with regards to antigen-specific Igs between MF- and patent patients and thus 
reflecting the results found in LF MF+ and MF- individuals. A previous study of Korten et al 
has already shown reduced levels of TGF- in the skin of hyperreactive patients in contrast 
to GEO individuals [9]. Therefore, it would be of special interest to analyze skin samples of 
MF+ and MF- patients concerning their expression of immunomodulatory factors and also of 
Igs.  
 
4.4 Role of IL-10 
As mentioned above, the regulatory cytokine IL-10 is quite dominant in certain subsets of 
filarial infected patients. Previous studies from our group have also demonstrated the 
necessity of this cytokine in inducing the secretion of IgG4 by B cells in a co-culture assay 
[50]. In this model, Tregs were shown to induce IgG4 production by B cells and this process 
was dependent of IL-10, TGF- and GITR/GITR-L [50]. Thus, the signaling pathway of IL-10 
was investigated through the phosphorylation of the transcription factor STAT3 since its 
activation reflects IL-10 production. A future aspect of the studies performed here would be 
the identification of the cellular source of IL-10. 
Experiments using Western blot analysis could demonstrate that phosphorylation of STAT3 
could only be induced by stimulation of PBMCs with recombinant IL-10 whereas the 
unphosphorylated form of STAT3 was constitutively expressed (data not shown). The 
induction of STAT3 phosphorylation could also be observed in isolated CD4+ and CD19+ B 
cells. However, these results could not be reproduced if flow cytometry was applied because 
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in this experimental setup IL-10 did not induce the phosphorylation of STAT3 compared to 
unstimulated cells. It has to be considered that the applied experimental setup consists of 
several isolation steps which could also influence intracellular signaling. With the Western 
blot setup, further experiments that pre-blocked GITR or GITR-L did not show any significant 
alterations with regards to STAT3 phosphorylation although an association of IL-10, GITR 
and IgG4 has been demonstrated in the aforementioned previous experiments [50]. 
Increasing doses of anti-GITR and parallel decreasing doses of recombinant IL-10 did also 
not significantly modify the phosphorylation status of STAT3. If analysis was performed on 
individual donor level the results were contradictory since some individuals revealed an 
influence on pSTAT3 expression when GITR was blocked whereas some did not. Therefore, 
basal levels of GITR and GITR-L expression on the cell surface were determined. Indeed, 
the levels of these molecules varied quite broadly between individuals and this could account 
for the different results observed via Western blots. The previous results that demonstrated 
an association between IL-10, GITR and IgG4 have used homogeneous cell populations 
(clones), therefore no conclusions can be drawn from these experiments and the ones 
performed within this study. In addition, since IL-10 does not only activate STAT3 but also 
STAT1 and, in certain cell types STAT5 [21] these transcriptions factors should be also 
analysed in future studies in order to rule out that blocking GITR does not interfere with the 
IL-10 pathway.  
Interestingly, analysis of differentially regulated genes in isolated Tregs of EN and infected 
individuals revealed that the transcription factor STAT1 was significantly up-regulated in 
infected individuals. STAT1 is an essential effector of IFNs since binding of IFN- or IFN- to 
their appropriate receptors induces the final the phosphorylation of STAT1 which is then 
translocated to the nucleus where it acts as a transcription factor of several genes. Due to 
the association between IFN- and STAT1 one would have perhaps expected a decrease of 
this gene in the infected group but this was not the case. As mentioned above, IL-10 can also 
act via STAT1 [177, 178], therefore a hypothetical explanation could be that CD25+ T cells 
from infected individuals produce more IL-10 in an autocrine manner or react to IL-10 
production (for example secreted by AAMs) which leads to the subsequent up-regulation of 
STAT1. If analysis of this gene expression was further divided into the groups of MF+ and 
MF- patients there was an up-regulation of STAT1 in both infected groups compared to EN 
but the fold change was higher in latently infected individuals which is in line with the up-
regulated secretion of IL-10 in MF- patients following antigenic stimulation when compared to 
patent infected individuals. The next step would be an analysis on protein level and 
furthermore, using our in vitro cell stimulation analysis, a proof of principle experiment to 
demonstrate that IL-10 induces alterations in STAT1 signaling. Analysis of regulated genes 
also revealed that STAT1 was up-regulated in effector T cells from infected individuals. Again 
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one can argue here that STAT1 is an essential transcription factor of IL-10-mediated 
responses. 
 
4.5 Novel aspects for future filarial-specific T cell research 
Several reports have deciphered the immunological status of MF+ LF infected patients and 
compared it to those presenting severe pathology. These studies have implied that the 
balance between Th1/Th2, Treg and the Ig milieu, alongside genetic factors of both the 
parasite and host, may define whether the infected individual is asymptomatic or develops 
pathology [92]. However, as mentioned above, little has been reported about the strength 
and character of immune responses elicited in asymptomatic amicrofilaremic individuals, a 
cohort of patients which are epidemiologically interesting since as mentioned beforehand 
they represent a dead end for the parasite’s transmission.  
Analysis of the gene expression profiles of T cell populations from LF infected MF+ and MF- 
individuals demonstrated that novel chemokine and cytokine related genes were found to be 
differentially regulated. When comparing the gene expression of Tregs from MF+ LF infected 
individuals and EN, most of the regulated genes were part of translation processes but some 
were involved in protein binding and phosphatase activity. Interestingly, CD84 was 
significantly up-regulated in MF+ individuals when compared to MF- patients and EN. CD84 is 
a self-binding receptor from the CD150 (or signaling lymphocyte activation molecule (SLAM) 
family and it is broadly expressed on hematopoietic cells including NK, NK T cells, B cells, T 
cells, monocytes, platelets, DC, eosinophils and neutrophils. Ligation of CD84 is associated 
with the enhanced induction of IFN- in activated T cells [179-181]. Moreover, previous 
experiments have revealed that CD84 contributes to T:B cell-mediated adhesion and also 
participates in stable T:B cell interactions in vitro. Interestingly, recently published results 
have demonstrated that CD84 is associated with a negative regulation of IgE high-affinity 
receptor signaling in human mast cells. In addition it was shown that CD84 deficient mice 
have defects in the formation of germinal centers [182] and all of these studies strengthen 
the arguments for the relevance of CD84 as a player in adaptive immunity and humoral 
responses. As mentioned beforehand helminthic parasites can trigger highly polarized 
immune responses which are typically characterized by increased numbers of Th2 cells, 
eosinophils, mast cells and IgE [37, 183]. It was also shown that CD84 can self-interact at a 
very high affinity in a “head to head” interaction, suggesting that CD84 could cooperate with 
another CD84 molecule on another cell rather than on the same cell [179, 184]. Since 
studies have also demonstrated that Tregs may interact with mast cells [185] a hypothetical 
scenario begins to emerge: CD84 on Tregs could serve as an inhibitory signal with regards 
to the up-regulation of IgE receptors on mast cells in order to prevent IgE binding and thus 
the induction of histamines. 
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 Figure 4.1. Hypothetical cooperation of Tregs in the context of LF infection according to their gene 
expression profiles. 
 
 
Given that LF infected MF+ patients were shown to have increased IgG4:IgE ratios, these 
mechanisms would be a further possibility to avert unwarranted IgE responses. In addition, 
CCR3 was down-regulated in the Treg population of MF+ patients when compared to EN and 
this receptor is associated with the enhanced recruitment of eosinophils by chemotaxis [186]. 
As mentioned before, eosinophils are involved in tissue damage during filarial infection [170] 
and prevention of their activation would be another possibility to prevent damaging immune 
responses. If Tregs of MF+ and MF- patients were further compared there were some more 
differences with regards to the immunological marker CD83: Tregs from MF+ individuals were 
characterized by a significantly up-regulated expression of this marker. This molecule 
belongs to the Ig superfamily and is associated with the maturation of dendritic cells. Besides 
its role during DC maturation, it was also shown that the soluble form of CD83 has inhibitory 
functions in terms of cell activation mediated by DCs resulting in decreased proliferation of T 
cells [187, 188]. Further studies have demonstrated that CD83 can also be found on T and B 
cells [187, 189]. Moreover, murine studies have demonstrated that naturally occurring Tregs 
are characterized by an increased expression of CD83 mRNA and overexpression of CD83 
confers suppressive capacity to naïve cells in vitro [190]. Together these studies indicate that 
CD83 represents a mechanism to control immune responses. This is in line with results 
mentioned before with regards to asymptomatic MF+ patients since these individuals were 
characterized by suppressed immune responses in terms of cytokine and Ig production. 
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Interestingly, the significant differences concerning CD83 were only detected within the 
infected group and not in comparison to EN. Given that previous results have shown that 
soluble CD83 molecules can be found in sera of healthy individuals [191] this offers a 
possibility to analyze the differences observed on the gene level with activities found on 
protein levels although murine studies have already shown that increased mRNA levels of 
CD83 in Tregs were not associated with increased protein expression [190]. In line with the 
pronounced immune regulation of MF+ patients was the finding that these individuals were 
characterized by increased levels of TGF- receptor and also by increased levels of the SGK 
mRNA when compared to latently infected individuals, the latter one is known to play a role 
in the prevention of apoptosis [192]. 
An additional interesting finding was the fact that Tregs from MF+ individuals had a 
significantly down-regulated expression of the intracellular receptor Nod1 when compared to 
MF- patients. This receptor belongs to a specialized group of intracellular proteins that play a 
critical role in the regulation of the host’s innate immune response [193]. It is widely 
expressed in many cell types and organs and detects fragments of bacterial peptidoglycans 
found in Gram-negative bacteria and some Gram-positive bacterial species [194]. Activation 
of Nod1 results mainly in the activation of nuclear factor (NF)-κB or mitogen-activated protein 
kinases (MAPKs) which drive the transcription of numerous genes involved in both innate 
and adaptive immune responses [193]. Interestingly, it was already shown that LF infected 
patients suffering from severe pathology show increased mRNA levels of Nod1 and Nod2 in 
contrast to asymptomatic individuals following re-stimulation with the specific filarial antigen 
[41]. In our study, differences in Nod1 gene expression were only found between MF+ and 
MF- patients and not in comparison to EN thus highlighting again that immune suppression is 
increased in MF+ patients.  
Comparing the gene expression profiles of CD4+ T effector cells revealed that most of the 
differences between infected and EN were found with regards to protein binding. One 
interesting candidate was the lymphocyte transmembrane adaptor 1 (LAX1) which was 
significantly up-regulated in CD4+ T cells of infected compared to uninfected individuals. This 
protein belongs to the transmembrane adapter protein (TRAPs) family and is able to exert 
both positive and negative effects on the complex signaling pathways that regulate immune 
responses in a variety of hematopoietic cells. LAX is expressed in B and T cells as well as 
NK cells and monocytes [195]. Interestingly, it was shown in murine studies that LAX1 is 
negatively associated with lymphocyte activation since T and B cells of mice deficient for 
LAX1 were hyperresponsive to stimulation via T cell or B cell receptor (TCR, BCR 
respectively). Moreover, it was shown that LAX1 blocks some signaling pathways although 
the mechanisms by which LAX1 negatively functions in TCR-mediated signaling are unclear 
[196]. Lack of T cell proliferation is a hallmark of asymptomatic filariasis infections [74]. Thus, 
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 Figure 4.2. Overview of regulated genes within the CD4+ effector T cell subpopulation.  
 
up-regulation of LAX1 and subsequent block of proliferation could be one mechanism 
induced by the parasite in order to suppress unwarranted immune reactions mediated by 
effector T cells. In line with this, levels of caspase 3 and TNF ligand superfamily member 10 
(also known as TRAIL) were also both significantly up-regulated in infected individuals 
compared to EN. Caspases are highly conserved through evolution and they play an 
important role during programmed cell death (apoptosis) [197]. Along with other members of 
the TNF family of cytokines, TRAIL transduces apoptotic signals through direct protein–
protein interactions [198] and as mentioned above apoptosis has been linked with various 
parasitic infections. For example, Babu et al have shown that NK cells from healthy donor 
samples became apoptotic following stimulation with live L3 in a caspase-dependent process 
[199]. Also, a TRAIL-dependent apoptosis was seen in monocyte derived DCs from healthy 
donors if they were incubated with live MF [200]. In addition, it was shown in a different 
helminth infection model that Schistosoma mansoni induced apoptosis in murine T cells 
[201]. All these studies indicate that parasites are able to modulate the immune system of 
their hosts via induction of apoptosis in order to evade immune responses which may be 
detrimental for the parasite and the host as well. 
In addition in the microarray analysis, IL-15 was found to be exclusively up-regulated in the T 
effector cell population of MF+ individuals. This pleiotropic cytokine has a broad range of 
biological functions in many diverse cell types and the effects of IL-15 expressing CD4+ T 
lymphocyte subsets differs according to their developmental and activation stage [202]. 
Although some reports have described that under normal conditions the homeostatic 
proliferation of CD4+ lymphocytes requires IL-15 [203], the general nature of IL-15 activity is 
critically dependent on the activation status of the T cells. For example, in the absence of a 
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TCR signal IL-15 induces a quiescent phenotype but during TCR engagement, T cells are 
resistant against TCR-induced cell death and can strongly proliferate [204]. In vitro, it was 
further shown that memory B cells develop into IgG secreting plasma cells in the presence of 
IL-15 [205] and a recent publication showed that IL-15 is important for the development of 
IgG-antibody secreting cells (ASC) and moreover, decreases the number of IgE-ASCs [206]. 
Since the LF infected MF+ patients were characterized by decreased total IgG4/IgE ratios, it 
would be of interest to determine whether levels of secreted IL-15 differed upon helminth-
specific stimulation. 
 
4.6 CD8+ T cells: a neglected player during helminth infection? 
In general, CD8+ T cells play a central role during adaptive immune responses since they are 
important for the recognition and clearance of cells infected by intracellular pathogens and 
moreover they are key players in anti-tumor immune response [207]. Surprisingly, there are 
only very few publications concerning their involvement during filarial infections. It was shown 
however, that in comparison to asymptomatic MF + individuals isolated PBMC fraction from 
elephantiasis patients contained higher proportions of CD8+ T cells [208]. These T cells were 
also found to be increased in limb biopsies of patients suffering from lymphedema and 
elephantiasis in comparison to asymptomatic individuals [209]. Both studies indicate that 
CD8+ T cells are involved in severe pathology. On the other hand, it was demonstrated that 
CD8+ T cells of filarial infected persons are able to produce IL-10 [155] and they are the main 
producers of IL-5 in CFA- patients with chronic disease in contrast to MF+ patients [210]. 
Moreover, CD8+ T cells of MF+ patients were also characterized by increased levels of CTLA-
4 compared to latent infected individuals [211]. Since CTLA-4 is a potent inhibitor of T cells 
and is involved in mediating T cell anergy and tolerance [212] these observations indicate 
that CD8+ T cells play also a protective role during filarial infections. Along these lines, it was 
shown in B. pahangi infected rats that CD8+ T cells were able to induce a non-specific 
immune suppression [213].  
Gene expression analysis performed in this study revealed that between infected and EN 
individuals only 41 genes were differentially regulated. One such gene was KLF4 which 
increased in CD8+ T cells from EN and this factor has been associated with the induction of 
cell cycle arrest of naïve CD8+ T cells in mice [214]. In contrast, SOD2 was the most strongly 
down-regulated gene in infected individuals when compared to EN. These SODs are a family 
of metalloenzymes involved in intracellular and extracellular antioxidant defense which they 
achieve through catalyzing the dismutation of superoxide radicals into hydrogen peroxide 
and oxygen in order to avoid toxicity mediated by these reactive oxygen species [215]. 
Thereby, SODs have been shown to be important factors in ameliorating and coping with 
injury from oxidative damage and they can help maintain redox homeostasis [216]. They are 
Kathrin Arndts   Discussion 
 95 
also considered to play a prominent role in protection against many apoptotic stimuli [217] an 
aspect already heavily described during filariasis infections [86, 200]. In line with this 
assumption was the finding that SGK was also down-regulated in CD8+ T cells of infected 
patients because as mentioned before SGK is associated with protection from apoptosis 
[192] indicating that T cells from filarial infected patients are more susceptible to apoptosis. 
This was further highlighted by increased expression levels of transcription factor Dp-1 
(TFDP1) in MF+ patients compared to latent infected individuals since up-regulation of 
TFDP1 has been also associated with the induction of apoptosis [218]. Interestingly, MF- 
patients had higher levels of SENP5 compared to patently infected individuals. Since SENP5 
is required for cell division [219] one could speculate that CD8+ T cells from MF+ patients are 
more tightly regulated or suppressed than those from MF- patients. Along these lines, we 
observed a down-regulation of the BCL-6 which was decreased in infected patients when 
compared to EN. In fact, BCL-6 is important for the generation and maintenance of memory 
CD8+ T cells [220] indicating that filarial infection can modulate activity of CD8+ T cells. 
Another apoptosis associated gene is ING2 [221] and this was up-regulated in cells from MF+ 
patients when compared to MF- individuals. In addition, CD8+ T cells from EN also expressed 
more ING2 than T cells from MF- patients. Moreover, the F-box protein 11 (FBXO11) was 
also found to be up-regulated in CD8+ T cells from MF+ patients when compared to EN and 
this protein is connected to TGF- signaling pathways in mice [222]. Recently, ING2 was 
also associated with the mediation of TGF--dependent responses [223]. These two genes 
could confirm previous findings which have demonstrated that TGF- is associated with the 
asymptomatic form of filarial infections [9, 32].  
Up-regulation of the prostaglandin D2 (PTGD) receptor (PTGDR) was observed in CD8+ T 
cells from all infected individuals, especially those that were MF+, when compared to EN. 
Interestingly, PTGDRs are linked with the inhibition of effector cell function in lymphocytes 
since binding of prostaglandin 2 increases intracellular cyclic adenosine monophosphate 
(cAMP) concentrations. In T cells and other inflammatory cells, the accumulation of cAMP is 
generally associated with the inhibition of effector cell functions [224] and cAMP represents a 
key regulator of human Treg function [225]. These receptors are broadly expressed and it 
was shown that stimulation with their ligands decreased levels of secreted IL-2 and IFN- in 
human CD8+ T cells [226]. Inhibition of IFN- and IL-2 production may skew the immune 
system towards a more Th2-like response which is a hallmark of filarial infection. 
Interestingly, it was shown that certain pathogens synthesize PTGD which in turn may 
subvert the host‘s immune functions. For example, the production of PTGD2 by the skin-
penetrating life-stage of S. mansoni inhibits the migration of epidermal Langerhans cells and 
the subsequent accumulation of DCs in the draining lymph nodes during murine 
schistosomiasis [227]. These effects were mediated by the PTGDR [228] since the secreted  
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 Figure 4.3. Overview of regulated genes within the CD8+ T cell subpopulation.  
 
PTGD2 homologue from Schistosoma binds to this receptor. This mechanism may be used 
by the parasite in order to evade the host’s immune system. No doubt there are still 
numerous mechanisms and immunomodulatory pathways that we are still unaware of. 
Another gene that warrants future investigations is CXCR4 which was up-regulated in MF+ 
patients when compared to latently infected individuals. This gene is actually associated with 
angiogenesis [229] and moreover, CXCR4 was previously shown to be present in nodules 
from O. volvulus infected patients [230]. Previous publications revealed that CXCR4 is highly 
expressed on naive subsets of human CD8+ T cells and that its surface expression is down-
regulated during differentiation from memory to effector subsets. Moreover, the expression of 
CXCR4 is negatively correlated with that of perforin [231] the latter one is part of the 
cytotoxic cell granule secretory pathway which is essential for host defense [232].  
 
4.7 Helminth modulation of innate cells 
Previous publications have already depicted the importance of innate immune responses 
during filarial diseases. For example, there have been various reports describing the 
involvement of TNF during LF [68, 89, 98]. However, the majority of these studies have 
investigated differences between infected and EN, between infected and CP patients or 
between MF+ patients and those with episodes of acute filariasis (adenolymphangitis). In 
studies with acute filariasis individuals had elevated levels of TNF in their sera when 
compared to MF+ patients [233]. In another study that compared EN with MF+ patients, TNF 
responses from PBMCs of microfilaremic patients were again dampened if their cells were 
stimulated with either live L3, live MF and also following stimulation with the filarial antigen 
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[68]. Reduced levels of TNF were also observed in asymptomatic patients (microfilaremia not 
determined) when compared to those with severe pathology [41]. Results obtained within this 
study showed that cells from patent LF infected individuals secreted less TNF and this was 
independent of the applied stimulus. Naturally, the dampening of not only antigen-specific 
responses but those to bystander antigens would greatly enhance the parasites chance of 
survival. Thus, in accordance with the findings of this study the presence of circulating MF in 
LF infected patients dampens TNF responses regardless of whether these are antigen-
specific, bystander or innate. Intriguingly, in vitro studies have implicated that Wolbachia 
endobacteria, but not the worm itself, elicit TNF secretion from innate host cells in a TLR-
dependent manner [28, 110] and that persistent exposure to Wolbachia, but not bacteria-free 
nematode extracts, drives homologous and heterologous tolerance of macrophages to TLR 
and CD40 ligands and protection from endotoxin shock in vivo [157]. Other studies have also 
linked TNF with promoting the production of VEGFs such as VEGF-C and VEGF-A [99, 234] 
which reportedly contribute to the development of lymphodema and hydrocele [78, 79]. 
Indeed, during LF levels of VEGFs are elevated in the plasma of CP patients and depletion 
of Wolbachia by doxycycline results in decreased levels of VEGF-A and VEGF-C [78, 79]. In 
addition to the decreased secretion of TNF from PBMCs of patently infected individuals there 
were also suppressed IL-17 responses. Interestingly, in vitro rIL-17 can drive TNF production 
in macrophages [235] and a combination of rIL-17 and rTNF was shown to increase the 
production of angiogenic factors like VEGF from fibroblasts [100]. Since there were also 
differences in IL-6 production between MF+ and amicrofilaremic LF infected individuals and it 
is well known that human IL-17 is induced by IL-6 in combination with TGF-β [236] a 
hypothetical scenario began to emerge: worm death could promote the release of Wolbachia 
and in turn elicit TNF production by triggering TLR [237]. Thus, enhanced TNF, and possibly 
IL-6, coupled to stronger IL-17 responses could instigate the production of VEGF and deviate 
the onset of pathology. In association, studies revolving around the immune responses of 
severe pathology patients observed elevated levels of IL-17 and TNF [41]. The presence of 
this cytokine combination in our latent LF individuals may reflect a higher susceptibility to 
pathology especially since a cross-sectional study has indicated that the onset of severe 
pathology is linked to the amicrofilaremic status [238]. Theoretically, the normal release of 
MF could counterbalance this immunological milieu circumventing unwarranted responses. 
However, in this study levels of VEGFs were not significantly different between latent and 
patent infected individuals, although one has to consider that included patients did not suffer 
from severe pathology like lymphedema. Moreover, the majority of them were not even 
aware that they were infected. The similar levels of VEGFs detected between both groups 
are also in line with the levels of lymph dilation which were also comparable between both 
groups. Again, the only way to determine if the aforementioned factors are prerequisites for 
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the induction of pathology would be long term surveillance of infected individuals but this 
would require no intake of MDA which is not feasible due to ethical reasons. 
In contrast to the results obtained within the LF study, the onchocerciasis study presented 
here demonstrated that secretion of IL-6 was significantly increased in PBMCs from infected 
individuals when compared to EN following all stimulation scenarios except B.m. extract. In 
addition, IL-6 release was higher in MF+ compared to MF- patients after stimulation with LPS 
in onchocerciasis. The same outcome could be observed for another pro-inflammatory 
cytokine, namely TNF. These increased levels could possibly be the result of the higher 
concentrations of endosymbiotic Wolbachia within MF+ patients, since the latter ones are 
found in all developmental stages of O. volvulus including MF. Nevertheless, patent 
individuals have also shown higher levels of immunosuppressive IL-10 which could 
counterbalance the effects induced by pro-inflammatory cytokines. Also, in contrast to        
W. bancrofti infected individuals, IL-17 production was not altered between all three groups 
with regards to all used stimuli within the onchocerciasis cohort. Until now, the role of IL-17 
during onchocerciasis infection has not been intensively analysed. However, since it is 
already described that IL-17 plays a role during pathogenesis in LF [41] and in addition, the 
presence of angiogenic and lymphangiogenic factors needed for vessel formation was 
already identified in onchocercomas, it would be interesting to determine if patients suffering 
of dermatitis or visual impairment have altered IL-17 levels in comparison to asymptomatic 
individuals.  
Interestingly, on the gene level, VEGF-B expression was higher in CD4+ T cells from LF 
infected patients when compared to EN. In fact, VEGF-B is an angiogenic factor but its actual 
role remains controversial. This factor is able to directly stimulate endothelial-cell growth and 
migration but some studies have revealed that it can indirectly stimulate angiogenesis by 
recruiting pro-angiogenic cells. In addition, under most conditions, VEGF-B has been shown 
to be dispensable for blood vessel growth but is critically required for blood vessel survival 
[239]. Additionally, some authors have claimed that VEGF-B is more an anti-apoptotic rather 
than a lymphangiogenesis marker [240]. A recent study further indicated that VEGF-B is 
involved in the regulation of energy metabolism by regulating fatty acid uptake since VEGF-B 
was co-expressed with mitochondrial protein genes. Mice deficient for VEGF-B showed less 
uptake of fatty acids but increased amounts of body fat and body weight [241, 242] 
highlighting the indispensable role of VEGF-B in metabolism. Another murine study revealed 
that in type-1 diabetes mRNA levels of VEGF-B were decreased [243]. Interestingly, it was 
already shown that mice infected with filariae are protected from developing type-1 diabetes 
[244] and human studies also demonstrated an inverse relationship between the prevalence 
of LF and diabetes [245, 246]. In conclusion, it is tempting to speculate that VEGF-B may be 
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an important factor induced during filarial infections and may be a factor in preventing the 
onset of diabetes. 
 
4.8 Influence of MF on PBMCs of healthy donors 
Since results from the LF study demonstrated an important role of MF with regards to 
immunosuppression, it was investigated if this influence of worm offspring was strong 
enough to induce the same effects in PBMCs from healthy individuals, e.g. blood donors that 
have never had contact with these parasites. Determination of cytokine levels of PBMCs 
cultivated in the presence of isolated MF and T cell specific stimulus anti-CD3/anti-CD28 
revealed no differences concerning IL-10 and IFN- release. Also, TNF was not affected, 
although data from LF infected patients have showed a clear decrease in the release of this 
cytokine in presence of MF and these results were independent of the applied stimulus. 
However, production of the pro-inflammatory cytokines IL-1 and IL-17 were significantly 
increased if MF or worm extract were added. In accordance with this result previous studies 
have shown that live B. malayi MF induced pro-inflammatory cytokine production (IL-1, IL-8, 
TNF) by monocyte derived DCs of healthy donors and additionally the up-regulation of 
apoptotic markers [86]. Interestingly, stimulation with L.s. extract resulted in a diminished 
TNF secretion and decreased IFN- response which seems to be in contrast to the results 
obtained for IL-1 and IL-17. Given that MF were isolated from infected cotton rats one could 
speculate that the immunomodulatory effects seen using human cells are species-specific or 
more precisely, suppression of pro-inflammatory cytokines requires either a well-adapted 
parasite-host interaction or an established infection. Therefore, it would be interesting to use 
MF from human W. bancrofti infections in order to see if they are able to alter the immune 
system of a “naïve” host but since huge numbers of MF are necessary for such assays this is 
not feasible. In principle, only MF from B. malayi infected jirds can be taken for these types of 
assays since the Brugia cycle can be maintained in an animal model in contrast to              
W. bancrofti whose adult worms are not generally obtainable because of the difficulty of 
maintaining this parasite outside the human host [103].  
 
4.9 Analysis of immunological profiles following treatment  
Control of human LF infections currently depends on chemotherapeutic strategies given as 
MDA annually or biannually [5, 62]. Since these drugs are mainly microfilaricidal, mass 
treatment has to continue at least as long as adult worms survive in humans. In an attempt to 
shorten such long-term treatments, doxycycline is used since it is efficient in inducing worm 
sterility and worm death rendering patients amicrofilaremic and thereby breaking 
transmission [2]. Utility of this drug for routine field use remains an issue of concern because 
doxycycline has to be given in extended daily dose regimen which involves huge logistical 
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challenges. Furthermore doxycycline is not suitable for children below 9 years, pregnant or 
breastfeeding women. Since pilot studies with the combination of doxycycline and rifampicin 
have shown promising results with regards to Wolbachia depletion [129] a large-scale study 
was conducted in order to confirm these results and moreover to test different periods of 
drug intake as well as different combinations. As part of this study, immunological profiles of 
participants were also analysed. Cytokine to specific and bystander antigens were analysed 
12 months post-treatment and filarial-specific Ig levels 12 and 24 months post-treatment. Of 
note, all participants received a 4 month post-treatment single dose of IVM/ALB including the 
placebo treated patients. 
Interestingly, in contrast to the combination regimens of doxycycline and rifampicin, 
treatment with doxycycline alone resulted in a complete loss of circulating MF 12 months 
post-treatment independent of the concentration or duration of doxycycline intake. This 
picture was even more obvious 24 months post-treatment since a higher percentage of 
individuals became microfilaremic after intake of the combination of both drugs in 
comparison to patients treated only with doxycycline. Decrease of MF burden in the placebo 
treated group was a result of IVM/ALB intake 4 months post-treatment but MF recovered 
after 12 months within this group and even more after 24 months although to a lesser extent 
than before. However, treatment for 5 weeks with 100 mg doxycycline showed the best 
results with regards to MF depletion indicating that the period of drug intake is also an 
important factor. Moreover, reduction of drug dosages is always preferable in terms of 
compliance. Since results from the pre-treatment study have shown that patent and latent 
patients behave differentially with regards to their cytokine and antigen-specific Ig production, 
analysis of immunological profiles post-treatment was also performed as comparison of 
doxycycline or rifampicin treated individuals to the placebo group, the latter one divided into 
MF+ and MF- patients. In addition, within the drug treated participants, only those were 
included that obtained doxycycline as drug regimen since only these patients were 
characterized by a long-term reduction of MF. Although treatment with doxycycline in any of 
the applied regimens did not result in significant differences with regards to the production of 
the key cytokine IL-5, following B.m. extract stimulation, treatment with 100 mg doxycycline 
for 5 weeks seems to decrease the amount of IL-5 to a comparable level as seen by cells 
from patients in the placebo MF+ group, albeit not significantly. Interestingly, IL-5 levels were 
decreased in MF+ patients of the placebo group in comparison to MF- individuals which 
reflects data from the pre-treatment study. The same picture was seen with regards to IL-10 
following anti-CD3/anti-CD28 stimulation and treatment regimen 2 significantly decreased the 
amount of IL-10 released from PBMCs of MF+ patients when compared to amicrofilaremic 
placebo treated individuals. Furthermore, MF+ produced less TNF than MF- patients as was 
seen in the pre-treatment study. In summary, analysis of cytokines 12 months after treatment 
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did not reveal any clear picture with regards to different treatment arms since there was no 
stringent up- or down-regulation of the measured cytokines. One has to consider again that 
all included participants received additionally IVM/ALB which could also influence immune 
responses. Earlier publications have shown that PBMCs of O. volvulus patients produce 
more IL-2 and IFN- but less IL-4 following treatment with IVM [247] and also monocytes of 
W. bancrofti infected individuals start to produce higher levels of IL-1, IL-8 and IL-10 [248]. 
Therefore, in order to evaluate possible effects of different regimens of doxycycline on the 
immunological profile of infected individuals one has to perform this type of studies without 
any application of IVM/ALB but this would not be in accordance with any ethical rules since 
individuals have to be given the best available treatment. Alternatively, analysis could be 
performed in the interval between antibiotic treatment and IVM/ALB administration to observe 
immediate alterations in the patients. In addition, it would be interesting to carry out 
longitudinal studies, thus measure cytokines profiles after two or more years of treatment in 
order to analyse the long-lasting effects of the used drugs. 
Regarding levels of antigen-specific Igs there were no significant alterations 12 months post-
treatment independent of the applied treatment although levels of IgE were reduced in MF+ 
patients of the placebo group compared to MF- which confirms previous findings. This was 
further reflected in the ratios of IgG4 to IgE and IgG1 but here again treatment could not 
show any significant differences. Interestingly, data from the 24 month post-treatment study 
showed a significant decrease with regards to IgG1 following treatment regimen 2 in 
comparison to both placebo treated groups and also reduced levels of IgG4 after treatment 
with regimen 2 when compared to MF+ individuals. In addition, the ratio of IgG4 to IgE was 
decreased in this group and also following treatment 3 when compared to MF+ patients. The 
ratios of IgG4/IgG1 and IgG4/IgG3 were decreased in treatment group 2 in comparison to the 
patent placebo treated patients. Moreover, within the placebo treated group there were 
significant differences with regards to the IgG4/IgE and IgG4/IgG1 ratio which highlights 
again the stronger immunosuppression of MF+ patients when compared to latent infected 
individuals. In summary, treatment with 100 mg doxycycline for 5 weeks had the strongest 
effect on the production of filarial-specific immunoglobulins. 
 
4.10 Conclusion 
Results from this study highlight immunological disparity between patent and MF- infected 
individuals. With regards to infection with O. volvulus it was shown that patently infected 
patients were characterized by lower levels of IL-5 when compared to MF- individuals upon 
filarial-specific stimulation whereas the opposite was found for filarial-induced IL-10 secretion 
and antigen-specific IgG4/IgE ratios. The picture of immunoregulation in patently infected 
patients was more obvious in LF infected indiviudals. In summary, upon comparison with MF+ 
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individuals, amicrofilaremic LF patients display an increased immune profile of TNF, Th17, 
IL-10, IL-6 and filarial specific Th2 responses. This elevated cytokine milieu, both filarial-
specific and bystander induced, may contribute to the induction of other immunological 
pathways such as VEGF which in turn promotes overt pathology. In contrast, the 
immunosuppressive pattern in LF MF+ patients is complemented by the high ratio of specific 
IgG4/IgE. In general the prevalence of IgG4 provides protection to both host and parasite 
since it presents a mechanism in order to counter-regulate high IgE and thus avoid excessive 
immunopathology. Interestingly, the described differences between the two infected groups, 
which did not suffer from severe pathology, indicate again that the presence of MF seems to 
be relevant to induce immunosuppression in an established infection. Such tempered 
immune responses would provide an environment that benefits the transmission phase of the 
parasite. The findings herein provide novel insight into the immunology of asymptomatic MF- 
individuals, a previously neglected cohort of patients. Their elevated immune responses may 
provide the key into elucidating alternative therapeutic treatments which would essentially 
block transmission and consequently eliminate the infection. In addition, since infected MF- 
individuals were characterized by higher levels of antigen-specific IL-5, that is associated 
with induction of pathology, one might speculate that these patients are more prone to 
develop severe pathology which is further reflected by their decreased ratios of IgG4/IgE. In 
principle, only long term studies could demystify the questions regarding the development of 
severe pathology but this would not be in accordance with ethical clearance and moreover 
with MDA programmes which aim to break transmission and to eliminate the infection. 
However, in the small in vitro study with non-endemic normals we observed an alteration of 
IL-1 and IL-17 secretion upon stimulation with MF whereas, unexpectedly, IL-10 was not 
affected, although this cytokine is strongly associated with filariasis. Nevertheless, IL-1 and 
IL-17 are interesting candidates for prospective in-depths experiments in the context of filarial 
infections and the same appears for molecules like CD84 or cytokines like IL-15 that were 
found to be differentially regulated between the compared groups. 
Kathrin Arndts   References 
 103 
5. References 
1. Taylor, M.J., A. Hoerauf, and M. Bockarie, Lymphatic filariasis and onchocerciasis. Lancet, 2010. 376: p. 
1175-85. 
2. Hoerauf, A., et al., Filariasis in Africa-treatment challenges and prospects. Clin Microbiol Infect, 2011. 
17(7): p. 977-85. 
3. Hoerauf, A.M., Onchocerciasis, in Tropical Infectious Diseases: Principles, Pathogens and Practice. 
2010, R. L. Guerrant, D. H. Walker, Peter F. Weller,. 
4. WHO-APOC. Onchocerciasis – the disease and its impact.  2011; Available from: 
http://www.who.int/apoc/onchocerciasis/disease/en/index.html. 
5. Tamarozzi, F., et al., Onchocerciasis: the role of wolbachia bacterial endosymbionts in parasite biology, 
disease pathogenesis, and treatment. Clin Microbiol Rev, 2011. 24(3): p. 459-68. 
6. Duerr, H.P., G. Raddatz, and M. Eichner, Diagnostic value of nodule palpation in onchocerciasis. Trans 
R Soc Trop Med Hyg, 2008. 102(2): p. 148-54. 
7. Brattig, N.W., Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae 
and Wolbachia endobacteria. Microbes Infect, 2004. 6(1): p. 113-28. 
8. Hoerauf, A., et al., Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus. Parasitol 
Res, 2009. 104(2): p. 437-47. 
9. Korten, S., et al., Low levels of transforming growth factor-beta (TGF-beta) and reduced suppression of 
Th2-mediated inflammation in hyperreactive human onchocerciasis. Parasitology, 2010. 138(1): p. 35-
45. 
10. Ottesen, E.A., Immune responsiveness and the pathogenesis of human onchocerciasis. J Infect Dis, 
1995. 171(3): p. 659-71. 
11. King, C.L. and T.B. Nutman, Regulation of the immune response in lymphatic filariasis and 
onchocerciasis. Immunol Today, 1991. 12(3): p. A54-8. 
12. Hise, A.G., et al., Innate immune responses to endosymbiotic Wolbachia bacteria in Brugia malayi and 
Onchocerca volvulus are dependent on TLR2, TLR6, MyD88, and Mal, but not TLR4, TRIF, or TRAM. J 
Immunol, 2007. 178(2): p. 1068-76. 
13. Hoerauf, A. and N. Brattig, Resistance and susceptibility in human onchocerciasis--beyond Th1 vs. Th2. 
Trends Parasitol, 2002. 18(1): p. 25-31. 
14. Hoerauf, A., et al., Onchocerciasis. BMJ, 2003. 326(7382): p. 207-10. 
15. Soboslay, P.T., et al., The diverse expression of immunity in humans at distinct states of Onchocerca 
volvulus infection. Immunology, 1997. 90(4): p. 592-9. 
16. Lechner, C.J., et al., Chemokines and cytokines in patients with an occult Onchocerca volvulus infection. 
Microbes Infect, 2011. 
17. Hoerauf, A., et al., The variant Arg110Gln of human IL-13 is associated with an immunologically hyper-
reactive form of onchocerciasis (sowda). Microbes Infect, 2002. 4(1): p. 37-42. 
18. Satoguina, J., et al., Antigen-specific T regulatory-1 cells are associated with immunosuppression in a 
chronic helminth infection (onchocerciasis). Microbes Infect, 2002. 4(13): p. 1291-300. 
19. Maizels, R.M., et al., Regulation of pathogenesis and immunity in helminth infections. J Exp Med, 2009. 
206(10): p. 2059-66. 
20. Allen, J.E. and R.M. Maizels, Diversity and dialogue in immunity to helminths. Nat Rev Immunol, 2011. 
11(6): p. 375-88. 
21. Sabat, R., et al., Biology of interleukin-10. Cytokine Growth Factor Rev, 2010. 21(5): p. 331-44. 
22. Goswami, R. and M.H. Kaplan, A brief history of IL-9. J Immunol, 2011. 186(6): p. 3283-8. 
Kathrin Arndts   References 
 104 
23. Steel, C. and T.B. Nutman, Regulation of IL-5 in onchocerciasis. A critical role for IL-2. J Immunol, 1993. 
150(12): p. 5511-8. 
24. Doetze, A., et al., Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is 
mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to 
T(h)2 shift. Int Immunol, 2000. 12(5): p. 623-30. 
25. Maizels, R.M. and M. Yazdanbakhsh, Immune regulation by helminth parasites: cellular and molecular 
mechanisms. Nat Rev Immunol, 2003. 3(9): p. 733-44. 
26. Smits, H.H., et al., Chronic helminth infections protect against allergic diseases by active regulatory 
processes. Curr Allergy Asthma Rep, 2010. 10(1): p. 3-12. 
27. Mahanty, S., et al., Stage-specific induction of cytokines regulates the immune response in lymphatic 
filariasis. Exp Parasitol, 1996. 84(2): p. 282-90. 
28. Brattig, N.W., et al., The major surface protein of Wolbachia endosymbionts in filarial nematodes elicits 
immune responses through TLR2 and TLR4. J Immunol, 2004. 173(1): p. 437-45. 
29. Brattig, N.W., et al., Onchocerca volvulus-exposed persons fail to produce interferon-gamma in response 
to O. volvulus antigen but mount proliferative responses with interleukin-5 and IL-13 production that 
decrease with increasing microfilarial density. J Infect Dis, 2002. 185(8): p. 1148-54. 
30. Schnoeller, C., et al., A helminth immunomodulator reduces allergic and inflammatory responses by 
induction of IL-10-producing macrophages. J Immunol, 2008. 180(6): p. 4265-72. 
31. Babu, S., V. Kumaraswami, and T.B. Nutman, Alternatively activated and immunoregulatory monocytes 
in human filarial infections. J Infect Dis, 2009. 199(12): p. 1827-37. 
32. Korten, S., et al., Transforming growth factor-beta expression by host cells is elicited locally by the filarial 
nematode Onchocerca volvulus in hyporeactive patients independently from Wolbachia. Microbes Infect, 
2010. 12(7): p. 555-64. 
33. Babu, S., et al., Cutting edge: diminished T cell TLR expression and function modulates the immune 
response in human filarial infection. J Immunol, 2006. 176(7): p. 3885-9. 
34. Sakaguchi, S., et al., Regulatory T cells and immune tolerance. Cell, 2008. 133(5): p. 775-87. 
35. Sasisekhar, B., et al., Diminished monocyte function in microfilaremic patients with lymphatic filariasis 
and its relationship to altered lymphoproliferative responses. Infect Immun, 2005. 73(6): p. 3385-93. 
36. Babu, S., et al., Diminished expression and function of TLR in lymphatic filariasis: a novel mechanism of 
immune dysregulation. J Immunol, 2005. 175(2): p. 1170-6. 
37. Kreider, T., et al., Alternatively activated macrophages in helminth infections. Curr Opin Immunol, 2007. 
19(4): p. 448-53. 
38. Gordon, S. and F.O. Martinez, Alternative activation of macrophages: mechanism and functions. 
Immunity, 2010. 32(5): p. 593-604. 
39. Saint Andre, A., et al., The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river 
blindness. Science, 2002. 295(5561): p. 1892-5. 
40. Daehnel, K., et al., Filaria/Wolbachia activation of dendritic cells and development of Th1-associated 
responses is dependent on Toll-like receptor 2 in a mouse model of ocular onchocerciasis (river 
blindness). Parasite Immunol, 2007. 29(9): p. 455-65. 
41. Babu, S., et al., Filarial lymphedema is characterized by antigen-specific Th1 and th17 proinflammatory 
responses and a lack of regulatory T cells. PLoS Negl Trop Dis, 2009. 3(4): p. 1-9. 
42. Babu, S., et al., Filarial Lymphatic Pathology Reflects Augmented TLR-mediated, MAPK-mediated Pro-
inflammatory Cytokine Production. Infect Immun, 2011: p. 4600–4608. 
43. Li, M.O., et al., Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol, 
2006. 24: p. 99-146. 
Kathrin Arndts   References 
 105 
44. Debrah, A.Y., et al., Transforming growth factor-beta1 variant Leu10Pro is associated with both lack of 
microfilariae and differential microfilarial loads in the blood of persons infected with lymphatic filariasis. 
Hum Immunol, 2011: p. 1143-1148. 
45. Korten, S., et al., The nematode parasite Onchocerca volvulus generates the transforming growth factor-
beta (TGF-beta). Parasitol Res, 2009. 105(3): p. 731-41. 
46. Ouyang, W., et al., Regulation and functions of the IL-10 family of cytokines in inflammation and disease. 
Annu Rev Immunol, 2011. 29: p. 71-109. 
47. Pestka, S., et al., Interleukin-10 and related cytokines and receptors. Annu Rev Immunol, 2004. 22: p. 
929-79. 
48. Cooper, P.J., et al., Early human infection with Onchocerca volvulus is associated with an enhanced 
parasite-specific cellular immune response. J Infect Dis, 2001. 183(11): p. 1662-8. 
49. Satoguina, J.S., et al., T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol, 
2005. 174(8): p. 4718-26. 
50. Satoguina, J.S., et al., Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through 
GITR/GITR-L interaction, IL-10 and TGF-beta. Eur J Immunol, 2008. 38(11): p. 3101-13. 
51. Ottesen, E.A., et al., Prominence of IgG4 in the IgG antibody response to human filariasis. J Immunol, 
1985. 134(4): p. 2707-12. 
52. Dafa'alla, T.H., et al., The profile of IgG and IgG subclasses of onchocerciasis patients. Clin Exp 
Immunol, 1992. 88(2): p. 258-63. 
53. Hussain, R. and E.A. Ottesen, IgE responses in human filariasis. IV. Parallel antigen recognition by IgE 
and IgG4 subclass antibodies. J Immunol, 1986. 136(5): p. 1859-63. 
54. Adjobimey, T. and A. Hoerauf, Induction of immunoglobulin G4 in human filariasis: an indicator of 
immunoregulation. Ann Trop Med Parasitol, 2010. 104(6): p. 455-64. 
55. Korten, S., et al., Mast cells in onchocercomas from patients with hyperreactive onchocerciasis (sowda). 
Acta Trop, 1998. 70(2): p. 217-31. 
56. Elson, L.H., et al., Immunity to onchocerciasis: putative immune persons produce a Th1-like response to 
Onchocerca volvulus. J Infect Dis, 1995. 171(3): p. 652-8. 
57. Turaga, P.S., et al., Immunity to onchocerciasis: cells from putatively immune individuals produce 
enhanced levels of interleukin-5, gamma interferon, and granulocyte-macrophage colony-stimulating 
factor in response to Onchocerca volvulus larval and male worm antigens. Infect Immun, 2000. 68(4): p. 
1905-11. 
58. Doetze, A., et al., Production of both IFN-gamma and IL-5 by Onchocerca volvulus S1 antigen-specific 
CD4+ T cells from putatively immune individuals. Int Immunol, 1997. 9(5): p. 721-9. 
59. Hussain, R., R.W. Poindexter, and E.A. Ottesen, Control of allergic reactivity in human filariasis. 
Predominant localization of blocking antibody to the IgG4 subclass. J Immunol, 1992. 148(9): p. 2731-7. 
60. WHO, Weekly epidemiological record - African Programme for Onchocerciasis Control – report of the 
sixth meeting of national task forces, October 2009. 2010. p. 21-28. 
61. WHO, Global programme to eliminate lymphatic filariasis (GPELF). Progress report 2000-2009 and 
strategic plan 2010-2020. 2010: p. 1-79. 
62. Bockarie, M.J. and R.M. Deb, Elimination of lymphatic filariasis: do we have the drugs to complete the 
job? Curr Opin Infect Dis, 2010. 23(6): p. 617-20. 
63. Ramaiah, K.D., et al., The economic burden of lymphatic filariasis in India. Parasitol Today, 2000. 16(6): 
p. 251-3. 
64. Ramaiah, K.D., et al., Functional impairment caused by lymphatic filariasis in rural areas of south India. 
Trop Med Int Health, 1997. 2(9): p. 832-8. 
Kathrin Arndts   References 
 106 
65. Ottesen, E.A., Lymphatic filariasis: Treatment, control and elimination. Adv Parasitol, 2006. 61: p. 395-
441. 
66. Manguin, S., et al., Review on global co-transmission of human Plasmodium species and Wuchereria 
bancrofti by Anopheles mosquitoes. Infect Genet Evol, 2010. 10(2): p. 159-77. 
67. Hoerauf, A., et al., Immunomodulation by filarial nematodes. Parasite Immunol, 2005. 27(10-11): p. 417-
29. 
68. Babu, S., et al., Regulatory networks induced by live parasites impair both Th1 and Th2 pathways in 
patent lymphatic filariasis: implications for parasite persistence. J Immunol, 2006. 176(5): p. 3248-56. 
69. Maizels, R.M., et al., T-cell activation and the balance of antibody isotypes in human lymphatic filariasis. 
Parasitol Today, 1995. 11(2): p. 50-6. 
70. Nutman, T.B. and V. Kumaraswami, Regulation of the immune response in lymphatic filariasis: 
perspectives on acute and chronic infection with Wuchereria bancrofti in South India. Parasite Immunol, 
2001. 23(7): p. 389-99. 
71. Addiss, D.G. and M.A. Brady, Morbidity management in the Global Programme to Eliminate Lymphatic 
Filariasis: a review of the scientific literature. Filaria J, 2007. 6: p. 1-19. 
72. Dreyer, G., et al., Acute attacks in the extremities of persons living in an area endemic for bancroftian 
filariasis: differentiation of two syndromes. Trans R Soc Trop Med Hyg, 1999. 93(4): p. 413-7. 
73. Simonsen, P.E., Filariases, in Manson's tropical diseases. 2009. p. 1477-1513. 
74. Pfarr, K.M., et al., Filariasis and lymphoedema. Parasite Immunol, 2009. 31(11): p. 664-72. 
75. Jungmann, P., J. Figueredo-Silva, and G. Dreyer, Bancroftian lymphadenopathy: a histopathologic study 
of fifty-eight cases from northeastern Brazil. Am J Trop Med Hyg, 1991. 45(3): p. 325-31. 
76. Ottesen, E.A., Immunopathology of Lymphatic Filariasis in Man. Springer Semininars Immunopathology, 
1980. 2: p. 373-385. 
77. Shenoy, R.K., Clinical and pathological aspects of filarial lymphedema and its management. Korean J 
Parasitol, 2008. 46(3): p. 119-25. 
78. Debrah, A.Y., et al., Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in 
lymphatic filariasis. PLoS Pathog, 2006. 2(9): p. 0829-43. 
79. Debrah, A.Y., et al., Plasma vascular endothelial growth Factor-A (VEGF-A) and VEGF-A gene 
polymorphism are associated with hydrocele development in lymphatic filariasis. Am J Trop Med Hyg, 
2007. 77(4): p. 601-8. 
80. Ong, R.K. and R.L. Doyle, Tropical pulmonary eosinophilia. Chest, 1998. 113(6): p. 1673-9. 
81. Solanki, A. and J. Ahluwalia, Asymptomatic filariasis. Blood, 2011. 117(14): p. 3707. 
82. Lobos, E., et al., A major allergen of lymphatic filarial nematodes is a parasite homolog of the gamma-
glutamyl transpeptidase. Mol Med, 1996. 2(6): p. 712-24. 
83. Dreyer, G., et al., Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. 
Parasitol Today, 2000. 16(12): p. 544-8. 
84. Steel, C., et al., Long-term effect of prenatal exposure to maternal microfilaraemia on immune 
responsiveness to filarial parasite antigens. Lancet, 1994. 343(8902): p. 890-3. 
85. Semnani, R.T., et al., Filarial antigens impair the function of human dendritic cells during differentiation. 
Infect Immun, 2001. 69(9): p. 5813-22. 
86. Semnani, R.T., et al., Brugia malayi microfilariae induce cell death in human dendritic cells, inhibit their 
ability to make IL-12 and IL-10, and reduce their capacity to activate CD4+ T cells. J Immunol, 2003. 
171(4): p. 1950-60. 
87. Semnani, R.T., et al., Filaria-induced immune evasion: suppression by the infective stage of Brugia 
malayi at the earliest host-parasite interface. J Immunol, 2004. 172(10): p. 6229-38. 
Kathrin Arndts   References 
 107 
88. Babu, S. and T.B. Nutman, Proinflammatory cytokines dominate the early immune response to filarial 
parasites. J Immunol, 2003. 171(12): p. 6723-32. 
89. Das, B.K., P.K. Sahoo, and B. Ravindran, A role for tumour necrosis factor-alpha in acute lymphatic 
filariasis. Parasite Immunol, 1996. 18(8): p. 421-4. 
90. Mahanty, S. and T.B. Nutman, Immunoregulation in human lymphatic filariasis: the role of interleukin 10. 
Parasite Immunol, 1995. 17(8): p. 385-92. 
91. Semnani, R.T. and T.B. Nutman, Toward an understanding of the interaction between filarial parasites 
and host antigen-presenting cells. Immunol Rev, 2004. 201: p. 127-38. 
92. King, C.L., et al., Immunologic tolerance in lymphatic filariasis. Diminished parasite-specific T and B 
lymphocyte precursor frequency in the microfilaremic state. J Clin Invest, 1992. 89(5): p. 1403-10. 
93. Mahanty, S., et al., High levels of spontaneous and parasite antigen-driven interleukin-10 production are 
associated with antigen-specific hyporesponsiveness in human lymphatic filariasis. J Infect Dis, 1996. 
173(3): p. 769-73. 
94. King, C.L., et al., Cytokine control of parasite-specific anergy in human lymphatic filariasis. Preferential 
induction of a regulatory T helper type 2 lymphocyte subset. J Clin Invest, 1993. 92(4): p. 1667-73. 
95. Nutman, T.B., V. Kumaraswami, and E.A. Ottesen, Parasite-specific anergy in human filariasis. Insights 
after analysis of parasite antigen-driven lymphokine production. J Clin Invest, 1987. 79(5): p. 1516-23. 
96. Maizels, R.M., et al., Vaccination against helminth parasites--the ultimate challenge for vaccinologists? 
Immunol Rev, 1999. 171: p. 125-47. 
97. Ottesen, E.A., P.F. Weller, and L. Heck, Specific cellular immune unresponsiveness in human filariasis. 
Immunology, 1977. 33(3): p. 413-21. 
98. Satapathy, A.K., et al., Human bancroftian filariasis: immunological markers of morbidity and infection. 
Microbes Infect, 2006. 8(9-10): p. 2414-23. 
99. Ristimaki, A., et al., Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen 
vascular endothelial growth factor-C. J Biol Chem, 1998. 273(14): p. 8413-8. 
100. Numasaki, M., M.T. Lotze, and H. Sasaki, Interleukin-17 augments tumor necrosis factor-alpha-induced 
elaboration of proangiogenic factors from fibroblasts. Immunol Lett, 2004. 93(1): p. 39-43. 
101. Kurniawan, A., et al., Differential expression of IgE and IgG4 specific antibody responses in 
asymptomatic and chronic human filariasis. J Immunol, 1993. 150(9): p. 3941-50. 
102. Hussain, R., et al., IgE responses in human filariasis. I. Quantitation of filaria-specific IgE. J Immunol, 
1981. 127(4): p. 1623-9. 
103. Hussain, R., M. Grogl, and E.A. Ottesen, IgG antibody subclasses in human filariasis. Differential 
subclass recognition of parasite antigens correlates with different clinical manifestations of infection. J 
Immunol, 1987. 139(8): p. 2794-8. 
104. Ravindran, B., et al., Protective immunity in human lymphatic filariasis: problems and prospects. Med 
Microbiol Immunol, 2003. 192(1): p. 41-6. 
105. Dimock, K.A., M.L. Eberhard, and P.J. Lammie, Th1-like antifilarial immune responses predominate in 
antigen-negative persons. Infect Immun, 1996. 64(8): p. 2962-7. 
106. Steel, C., A. Guinea, and E.A. Ottesen, Evidence for protective immunity to bancroftian filariasis in the 
Cook Islands. J Infect Dis, 1996. 174(3): p. 598-605. 
107. Hoerauf, A., et al., Doxycycline in the treatment of human onchocerciasis: Kinetics of Wolbachia 
endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes 
Infect, 2003. 5(4): p. 261-73. 
108. Hoerauf, A., et al., Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has 
macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol 
Immunol, 2008. 197(3): p. 295-311. 
Kathrin Arndts   References 
 108 
109. Taylor, M.J. and A. Hoerauf, Wolbachia bacteria of filarial nematodes. Parasitol Today, 1999. 15(11): p. 
437-42. 
110. Turner, J.D., et al., Wolbachia lipoprotein stimulates innate and adaptive immunity through Toll-like 
receptors 2 and 6 to induce disease manifestations of filariasis. J Biol Chem, 2009. 284(33): p. 22364-
78. 
111. Brattig, N.W., et al., Lipopolysaccharide-like molecules derived from Wolbachia endobacteria of the 
filaria Onchocerca volvulus are candidate mediators in the sequence of inflammatory and 
antiinflammatory responses of human monocytes. Microbes Infect, 2000. 2(10): p. 1147-57. 
112. Pfarr, K.M., K. Fischer, and A. Hoerauf, Involvement of Toll-like receptor 4 in the embryogenesis of the 
rodent filaria Litomosoides sigmodontis. Med Microbiol Immunol, 2003. 192(1): p. 53-6. 
113. Osei-Atweneboana, M.Y., et al., Prevalence and intensity of Onchocerca volvulus infection and efficacy 
of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet, 2007. 
369(9578): p. 2021-9. 
114. Palumbo, E., Filariasis: diagnosis, treatment and prevention. Acta Biomed, 2008. 79(2): p. 106-9. 
115. Weil, G.J., P.J. Lammie, and N. Weiss, The ICT Filariasis Test: A rapid-format antigen test for diagnosis 
of bancroftian filariasis. Parasitol Today, 1997. 13(10): p. 401-4. 
116. Simonsen, P.E. and S.K. Dunyo, Comparative evaluation of three new tools for diagnosis of bancroftian 
filariasis based on detection of specific circulating antigens. Trans R Soc Trop Med Hyg, 1999. 93(3): p. 
278-82. 
117. Turner, P., et al., A comparison of the Og4C3 antigen capture ELISA, the Knott test, an IgG4 assay and 
clinical signs, in the diagnosis of Bancroftian filariasis. Trop Med Parasitol, 1993. 44(1): p. 45-8. 
118. Dreyer, G., et al., Ultrasonographic evidence for stability of adult worm location in bancroftian filariasis. 
Trans R Soc Trop Med Hyg, 1994. 88(5): p. 558. 
119. Mand, S., et al., Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis. Filaria J, 
2003. 2(1): p. 1-11. 
120. Shenoy, R.K., et al., Apparent failure of ultrasonography to detect adult worms of Brugia malayi. Ann 
Trop Med Parasitol, 2000. 94(1): p. 77-82. 
121. Mand, S., et al., Detection of adult Brugia malayi filariae by ultrasonography in humans in India and 
Indonesia. Trop Med Int Health, 2006. 11(9): p. 1375-81. 
122. Haarbrink, M., et al., Anti-filarial IgG4 in men and women living in Brugia malayi-endemic areas. Trop 
Med Int Health, 1999. 4(2): p. 93-7. 
123. Moreno, Y., et al., Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of 
Brugia malayi. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20120-5. 
124. Fernando, S.D., C. Rodrigo, and S. Rajapakse, Current evidence on the use of antifilarial agents in the 
management of bancroftian filariasis. J Trop Med, 2011. 2011: p. 1-12. 
125. Omura, S. and A. Crump, The life and times of ivermectin - a success story. Nat Rev Microbiol, 2004. 
2(12): p. 984-9. 
126. Ottesen, E.A. and W.C. Campbell, Ivermectin in human medicine. J Antimicrob Chemother, 1994. 34(2): 
p. 195-203. 
127. Horton, J., Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations. 
Curr Opin Infect Dis, 2002. 15(6): p. 599-608. 
128. Dadzie, K.Y., et al., Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine 
versus placebo in the treatment of onchocerciasis. Br J Ophthalmol, 1987. 71(2): p. 78-85. 
129. Debrah, A.Y., et al., Macrofilaricidal Activity in Wuchereria bancrofti after 2 Weeks Treatment with a 
Combination of Rifampicin plus Doxycycline. J Parasitol Res, 2011. 2011: p. 1-9. 
Kathrin Arndts   References 
 109 
130. WHO, weekly epidemiological record: InterAmerican Conference on Onchocerciasis, 2010: progress 
towards eliminating river blindness in the WHO Region of the Americas. 2011. 86(38): p. 417-424. 
131. WHO, Global Programme to Eliminate Lymphatic Filariasis: progress report on mass drug 
administration, 2010. 2011. 86: p. 377–388. 
132. Hoerauf, A., Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr 
Opin Infect Dis, 2008. 21(6): p. 673-81. 
133. Osei-Atweneboana, M.Y., et al., Phenotypic evidence of emerging ivermectin resistance in Onchocerca 
volvulus. PLoS Negl Trop Dis, 2011. 5(3): p. e998. 
134. Cross, H.F., et al., Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts 
into blood. Lancet, 2001. 358(9296): p. 1873-5. 
135. Hoerauf, A., et al., Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. 
Lancet, 2000. 355(9211): p. 1242-3. 
136. Hoerauf, A., et al., Tetracycline therapy targets intracellular bacteria in the filarial nematode 
Litomosoides sigmodontis and results in filarial infertility. J Clin Invest, 1999. 103(1): p. 11-8. 
137. Hoerauf, A., et al., Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia 
endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol, 
2003. 192(4): p. 211-6. 
138. Taylor, M.J., et al., Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-
blind, randomised placebo-controlled trial. Lancet, 2005. 365(9477): p. 2116-21. 
139. Mand, S., D.W. Buttner, and A. Hoerauf, Bancroftian filariasis--absence of Wolbachia after doxycycline 
treatment. Am J Trop Med Hyg, 2008. 78(6): p. 854-5. 
140. Mand, S., et al., Macrofilaricidal activity and amelioration of lymphatic pathology in bancroftian filariasis 
after 3 weeks of doxycycline followed by single-dose diethylcarbamazine. Am J Trop Med Hyg, 2009. 
81(4): p. 702-11. 
141. Coulibaly, Y.I., et al., A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med, 
2009. 361(15): p. 1448-58. 
142. Hoerauf, A., et al., Depletion of wolbachia endobacteria in Onchocerca volvulus by doxycycline and 
microfilaridermia after ivermectin treatment. Lancet, 2001. 357(9266): p. 1415-6. 
143. Volkmann, L., et al., Antibiotic therapy in murine filariasis (Litomosoides sigmodontis): comparative 
effects of doxycycline and rifampicin on Wolbachia and filarial viability. Trop Med Int Health, 2003. 8(5): 
p. 392-401. 
144. Specht, S., et al., Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca 
volvulus. Parasitol Res, 2008. 103(6): p. 1303-9. 
145. Schulz-Key, H., E.J. Albiez, and D.W. Buttner, Isolation of living adult Onchocerca volvulus from 
nodules. Tropenmed Parasitol, 1977. 28(4): p. 428-30. 
146. Mand, S., et al., Frequent detection of worm movements in onchocercal nodules by ultrasonography. 
Filaria J, 2005. 4(1): p. 1-11. 
147. Mand, S., et al., The role of ultrasonography in the differentiation of the various types of filaricele due to 
bancroftian filariasis. Acta Trop, 2010. 120 S: p. S23-32. 
148. Ayad, S.R., M. Fox, and D. Winstanley, The use of ficoll gradient centrifugation to produce synchronous 
mouse lymphoma cells. Biochem Biophys Res Commun, 1969. 37(4): p. 551-8. 
149. Arakaki, D.T. and R.S. Sparkes, Microtechnique for Culturing Leukocytes from Whole Blood. 
Cytogenetics, 1963. 85: p. 57-60. 
150. Lowrie, R.C., Jr., Cryopreservation of the microfilariae of Brugia malayi, Dirofilaria corynodes, and 
Wuchereria bancrofti. Am J Trop Med Hyg, 1983. 32(1): p. 138-45. 
Kathrin Arndts   References 
 110 
151. Klonisch, T., et al., The sheaths of Brugia microfilariae: isolation and composition. Parasitol Res, 1991. 
77(5): p. 448-51. 
152. Al-Qaoud, K.M., et al., Infection of BALB/c mice with the filarial nematode Litomosoides sigmodontis: role 
of CD4+ T cells in controlling larval development. Infect Immun, 1997. 65(6): p. 2457-61. 
153. Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. 
Nature, 1970. 227(5259): p. 680-5. 
154. Debey-Pascher, S., et al., RNA-stabilized whole blood samples but not peripheral blood mononuclear 
cells can be stored for prolonged time periods prior to transcriptome analysis. J Mol Diagn, 2011. 13(4): 
p. 452-60. 
155. Mitre, E., D. Chien, and T.B. Nutman, CD4(+) (and not CD25+) T cells are the predominant interleukin-
10-producing cells in the circulation of filaria-infected patients. J Infect Dis, 2008. 197(1): p. 94-101. 
156. Metenou, S., et al., At Homeostasis Filarial Infections Have Expanded Adaptive T Regulatory but Not 
Classical Th2 Cells. J Immunol, 2010. 184(9): p. 5375-82. 
157. Turner, J.D., et al., Wolbachia endosymbiotic bacteria of Brugia malayi mediate macrophage tolerance to 
TLR- and CD40-specific stimuli in a MyD88/TLR2-dependent manner. J Immunol, 2006. 177(2): p. 1240-
9. 
158. Sartono, E., et al., Depression of antigen-specific interleukin-5 and interferon-gamma responses in 
human lymphatic filariasis as a function of clinical status and age. J Infect Dis, 1997. 175(5): p. 1276-80. 
159. Sweiss, N.J., et al., Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis 
manifestations and ancestry. PLoS One, 2011. 6(12): p. e29126. 
160. Hubner, M.P., et al., Echinococcus multilocularis metacestodes modulate cellular cytokine and 
chemokine release by peripheral blood mononuclear cells in alveolar echinococcosis patients. Clin Exp 
Immunol, 2006. 145(2): p. 243-51. 
161. Bennuru, S., et al., Elevated levels of plasma angiogenic factors are associated with human lymphatic 
filarial infections. Am J Trop Med Hyg, 2010. 83(4): p. 884-90. 
162. Dunyo, S.K., F.K. Nkrumah, and P.E. Simonsen, Single-dose treatment of Wuchereria bancrofti 
infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control 
at 12 months after treatment. Trans R Soc Trop Med Hyg, 2000. 94(4): p. 437-43. 
163. Hussein, O., et al., Duplex Doppler sonographic assessment of the effects of diethylcarbamazine and 
albendazole therapy on adult filarial worms and adjacent host tissues in Bancroftian filariasis. Am J Trop 
Med Hyg, 2004. 71(4): p. 471-7. 
164. Senbagavalli, P., et al., Heightened measures of immune complex and complement function and 
immune complex-mediated granulocyte activation in human lymphatic filariasis. Am J Trop Med Hyg, 
2011. 85(1): p. 89-96. 
165. Tobian, A.A., et al., Sensitivity and specificity of ultrasound detection and risk factors for filarial-
associated hydroceles. Am J Trop Med Hyg, 2003. 68(6): p. 638-42. 
166. Faris, R., et al., Bancroftian filariasis in Egypt: visualization of adult worms and subclinical lymphatic 
pathology by scrotal ultrasound. Am J Trop Med Hyg, 1998. 59(6): p. 864-7. 
167. Jaoko, W.G., et al., Filarial-specific antibody response in East African bancroftian filariasis: effects of 
host infection, clinical disease, and filarial endemicity. Am J Trop Med Hyg, 2006. 75(1): p. 97-107. 
168. Noroes, J., et al., Occurrence of living adult Wuchereria bancrofti in the scrotal area of men with 
microfilaraemia. Trans R Soc Trop Med Hyg, 1996. 90(1): p. 55-6. 
169. Yazdanbakhsh, M., A. van den Biggelaar, and R.M. Maizels, Th2 responses without atopy: 
immunoregulation in chronic helminth infections and reduced allergic disease. Trends Immunol, 2001. 
22(7): p. 372-7. 
Kathrin Arndts   References 
 111 
170. Chitkara, R.K. and G. Krishna, Parasitic pulmonary eosinophilia. Semin Respir Crit Care Med, 2006. 
27(2): p. 171-84. 
171. Volkmann, L., et al., Murine filariasis: interleukin 4 and interleukin 5 lead to containment of different worm 
developmental stages. Med Microbiol Immunol, 2003. 192(1): p. 23-31. 
172. Saeftel, M., et al., Synergism of gamma interferon and interleukin-5 in the control of murine filariasis. 
Infect Immun, 2003. 71(12): p. 6978-85. 
173. Brattig, N., et al., Differences in cytokine responses to Onchocerca volvulus extract and recombinant 
Ov33 and OvL3-1 proteins in exposed subjects with various parasitologic and clinical states. J Infect Dis, 
1997. 176(3): p. 838-42. 
174. Soboslay, P.T., et al., Regulatory effects of Th1-type (IFN-gamma, IL-12) and Th2-type cytokines (IL-10, 
IL-13) on parasite-specific cellular responsiveness in Onchocerca volvulus-infected humans and 
exposed endemic controls. Immunology, 1999. 97(2): p. 219-25. 
175. Aalberse, R.C., et al., Immunoglobulin G4: an odd antibody. Clin Exp Allergy, 2009. 39(4): p. 469-77. 
176. Brattig, N.W., et al., Strong IgG isotypic antibody response in sowdah type onchocerciasis. J Infect Dis, 
1994. 170(4): p. 955-61. 
177. Finbloom, D.S. and K.D. Winestock, IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the 
differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J 
Immunol, 1995. 155(3): p. 1079-90. 
178. Wehinger, J., et al., IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) 
and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett, 1996. 394(3): p. 
365-70. 
179. Martin, M., et al., CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma 
secretion: adhesion is mediated by Ig-like domain 1. J Immunol, 2001. 167(7): p. 3668-76. 
180. Tangye, S.G., et al., Functional requirements for interactions between CD84 and Src homology 2 
domain-containing proteins and their contribution to human T cell activation. J Immunol, 2003. 171(5): p. 
2485-95. 
181. Alvarez-Errico, D., et al., CD84 Negatively Regulates IgE High-Affinity Receptor Signaling in Human 
Mast Cells. J Immunol, 2011: p. 5577-86. 
182. Cannons, J.L., et al., Optimal germinal center responses require a multistage T cell:B cell adhesion 
process involving integrins, SLAM-associated protein, and CD84. Immunity, 2010. 32(2): p. 253-65. 
183. Maizels, R.M., et al., Helminth parasites--masters of regulation. Immunol Rev, 2004. 201: p. 89-116. 
184. Yan, Q., et al., Structure of CD84 provides insight into SLAM family function. Proc Natl Acad Sci U S A, 
2007. 104(25): p. 10583-8. 
185. Gri, G., et al., CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses 
through OX40-OX40L interaction. Immunity, 2008. 29(5): p. 771-81. 
186. Shakoory, B., et al., The role of human mast cell-derived cytokines in eosinophil biology. J Interferon 
Cytokine Res, 2004. 24(5): p. 271-81. 
187. Lechmann, M., et al., The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation 
and binds to a ligand on dendritic cells. J Exp Med, 2001. 194(12): p. 1813-21. 
188. Lechmann, M., et al., CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol, 
2002. 23(6): p. 273-5. 
189. Breloer, M. and B. Fleischer, CD83 regulates lymphocyte maturation, activation and homeostasis. 
Trends Immunol, 2008. 29(4): p. 186-94. 
190. Reinwald, S., et al., CD83 expression in CD4+ T cells modulates inflammation and autoimmunity. J 
Immunol, 2008. 180(9): p. 5890-7. 
Kathrin Arndts   References 
 112 
191. Hock, B.D., et al., A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, 
and is detectable in normal human sera. Int Immunol, 2001. 13(7): p. 959-67. 
192. Mikosz, C.A., et al., Glucocorticoid receptor-mediated protection from apoptosis is associated with 
induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem, 2001. 276(20): p. 16649-54. 
193. Franchi, L., et al., Function of Nod-like receptors in microbial recognition and host defense. Immunol 
Rev, 2009. 227(1): p. 106-28. 
194. Magalhaes, J.G., et al., What is new with Nods? Curr Opin Immunol, 2011. 23(1): p. 29-34. 
195. Fuller, D.M. and W. Zhang, Regulation of lymphocyte development and activation by the LAT family of 
adapter proteins. Immunol Rev, 2009. 232(1): p. 72-83. 
196. Zhu, M., et al., Negative regulation of lymphocyte activation by the adaptor protein LAX. J Immunol, 
2005. 174(9): p. 5612-9. 
197. Hengartner, M.O., The biochemistry of apoptosis. Nature, 2000. 407(6805): p. 770-6. 
198. Choi, E.H., et al., Genetic polymorphisms in molecules of innate immunity and susceptibility to infection 
with Wuchereria bancrofti in South India. Genes Immun, 2001. 2(5): p. 248-53. 
199. Babu, S., C.P. Blauvelt, and T.B. Nutman, Filarial parasites induce NK cell activation, type 1 and type 2 
cytokine secretion, and subsequent apoptotic cell death. J Immunol, 2007. 179(4): p. 2445-56. 
200. Semnani, R.T., et al., Induction of TRAIL- and TNF-alpha-dependent apoptosis in human monocyte-
derived dendritic cells by microfilariae of Brugia malayi. J Immunol, 2008. 181(10): p. 7081-9. 
201. Chen, L., et al., Skin-stage schistosomula of Schistosoma mansoni produce an apoptosis-inducing factor 
that can cause apoptosis of T cells. J Biol Chem, 2002. 277(37): p. 34329-35. 
202. Perera, P.Y., J.H. Lichy, and L.P. Perera, The role of interleukin-15 in inflammation and immune 
responses to infection: Implications for its therapeutic use. Microbes Infect, 2011. 
203. van Leeuwen, E.M., J. Sprent, and C.D. Surh, Generation and maintenance of memory CD4(+) T Cells. 
Curr Opin Immunol, 2009. 21(2): p. 167-72. 
204. Dooms, H., et al., Quiescence-inducing and antiapoptotic activities of IL-15 enhance secondary CD4+ T 
cell responsiveness to antigen. J Immunol, 1998. 161(5): p. 2141-50. 
205. Bernasconi, N.L., E. Traggiai, and A. Lanzavecchia, Maintenance of serological memory by polyclonal 
activation of human memory B cells. Science, 2002. 298(5601): p. 2199-202. 
206. Esen, M., et al., Effect of IL-15 on IgG versus IgE antibody-secreting cells in vitro. J Immunol Methods, 
2011: p. 7-13  
207. Strioga, M., V. Pasukoniene, and D. Characiejus, CD8+ CD28- and CD8+ CD57+ T cells and their role in 
health and disease. Immunology, 2011. 134(1): p. 17-32. 
208. Lal, R.B., et al., Lymphocyte subpopulations in Bancroftian filariasis: activated (DR+) CD8+ T cells in 
patients with chronic lymphatic obstruction. Clin Exp Immunol, 1989. 77(1): p. 77-82. 
209. Freedman, D.O., et al., Predominant CD8+ infiltrate in limb biopsies of individuals with filarial 
lymphedema and elephantiasis. Am J Trop Med Hyg, 1995. 53(6): p. 633-8. 
210. de Almeida, A.B., et al., The presence or absence of active infection, not clinical status, is most closely 
associated with cytokine responses in lymphatic filariasis. J Infect Dis, 1996. 173(6): p. 1453-9. 
211. Steel, C. and T.B. Nutman, CTLA-4 in filarial infections: implications for a role in diminished T cell 
reactivity. J Immunol, 2003. 170(4): p. 1930-8. 
212. Taylor, M.D., et al., CTLA-4 and CD4+ CD25+ regulatory T cells inhibit protective immunity to filarial 
parasites in vivo. J Immunol, 2007. 179(7): p. 4626-34. 
213. Owhashi, M., et al., Non-specific immune suppression by CD8+ T cells in Brugia pahangi-infected rats. 
Int J Parasitol, 1990. 20(7): p. 951-6. 
214. Yamada, T., et al., Transcription factor ELF4 controls the proliferation and homing of CD8+ T cells via 
the Kruppel-like factors KLF4 and KLF2. Nat Immunol, 2009. 10(6): p. 618-26. 
Kathrin Arndts   References 
 113 
215. Henkle-Duhrsen, K., et al., Localization and functional analysis of the cytosolic and extracellular CuZn 
superoxide dismutases in the human parasitic nematode Onchocerca volvulus. Mol Biochem Parasitol, 
1997. 88(1-2): p. 187-202. 
216. Miao, L. and D.K. St Clair, Regulation of superoxide dismutase genes: implications in disease. Free 
Radic Biol Med, 2009. 47(4): p. 344-56. 
217. Pardo, M., J.A. Melendez, and O. Tirosh, Manganese superoxide dismutase inactivation during Fas 
(CD95)-mediated apoptosis in Jurkat T cells. Free Radic Biol Med, 2006. 41(12): p. 1795-806. 
218. Hitchens, M.R. and P.D. Robbins, The role of the transcription factor DP in apoptosis. Apoptosis, 2003. 
8(5): p. 461-8. 
219. Di Bacco, A., et al., The SUMO-specific protease SENP5 is required for cell division. Mol Cell Biol, 2006. 
26(12): p. 4489-98. 
220. Ichii, H., et al., Role for Bcl-6 in the generation and maintenance of memory CD8+ T cells. Nat Immunol, 
2002. 3(6): p. 558-63. 
221. Ythier, D., et al., Sumoylation of ING2 regulates the transcription mediated by Sin3A. Oncogene, 2010. 
29(44): p. 5946-56. 
222. Rye, M.S., et al., FBXO11, a regulator of the TGFbeta pathway, is associated with severe otitis media in 
Western Australian children. Genes Immun, 2011. 12(5): p. 352-9. 
223. Sarker, K.P., et al., ING2 as a novel mediator of transforming growth factor-beta-dependent responses in 
epithelial cells. J Biol Chem, 2008. 283(19): p. 13269-79. 
224. Tilley, S.L., T.M. Coffman, and B.H. Koller, Mixed messages: modulation of inflammation and immune 
responses by prostaglandins and thromboxanes. J Clin Invest, 2001. 108(1): p. 15-23. 
225. Klein, M., et al., Repression of Cyclic Adenosine Monophosphate Upregulation Disarms and Expands 
Human Regulatory T Cells. J Immunol, 2011. 
226. Tanaka, K., et al., Effects of prostaglandin D2 on helper T cell functions. Biochem Biophys Res 
Commun, 2004. 316(4): p. 1009-14. 
227. Angeli, V., et al., Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans 
cell migration during schistosomiasis infection. J Exp Med, 2001. 193(10): p. 1135-47. 
228. Herve, M., et al., Pivotal roles of the parasite PGD2 synthase and of the host D prostanoid receptor 1 in 
schistosome immune evasion. Eur J Immunol, 2003. 33(10): p. 2764-72. 
229. Petit, I., D. Jin, and S. Rafii, The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-
angiogenesis. Trends Immunol, 2007. 28(7): p. 299-307. 
230. Attout, T., et al., Lymphatic vascularisation and involvement of Lyve-1+ macrophages in the human 
onchocerca nodule. PLoS One, 2009. 4(12): p. e8234. 
231. Kobayashi, N., et al., Down-regulation of CXCR4 expression on human CD8+ T cells during peripheral 
differentiation. Eur J Immunol, 2004. 34(12): p. 3370-8. 
232. Metkar, S.S., et al., Perforin rapidly induces plasma membrane phospholipid flip-flop. PLoS One, 2011. 
6(9): p. e24286. 
233. Metenou, S., et al., Filarial Infection Suppresses Malaria-Specific Multifunctional Th1 and Th17 
Responses in Malaria and Filarial Coinfections. J Immunol, 2011. 186(8): p. 4725-33. 
234. Asano-Kato, N., et al., TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth 
factor production from conjunctival fibroblasts. Exp Eye Res, 2005. 80(4): p. 555-60. 
235. Jovanovic, D.V., et al., IL-17 stimulates the production and expression of proinflammatory cytokines, IL-
beta and TNF-alpha, by human macrophages. J Immunol, 1998. 160(7): p. 3513-21. 
236. Kimura, A. and T. Kishimoto, IL-6: regulator of Treg/Th17 balance. Eur J Immunol, 2010. 40(7): p. 1830-
5. 
Kathrin Arndts   References 
 114 
237. Keiser, P.B., et al., Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of 
posttreatment reactions. J Infect Dis, 2002. 185(6): p. 805-11. 
238. Dissanayake, S., In Wuchereria bancrofti filariasis, asymptomatic microfilaraemia does not progress to 
amicrofilaraemic lymphatic disease. Int J Epidemiol, 2001. 30(2): p. 394-9. 
239. Zhang, F., et al., VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-
B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A, 2009. 106(15): p. 6152-7. 
240. Li, X., et al., VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr, 2009. 3(4): p. 322-7. 
241. Hagberg, C.E., et al., Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature, 
2010. 464(7290): p. 917-21. 
242. Li, X., VEGF-B: a thing of beauty. Cell Res, 2010. 20(7): p. 741-4. 
243. Kivela, R., et al., Exercise-induced expression of angiogenic growth factors in skeletal muscle and in 
capillaries of healthy and diabetic mice. Cardiovasc Diabetol, 2008. 7: p. 13. 
244. Hubner, M.P., J.T. Stocker, and E. Mitre, Inhibition of type 1 diabetes in filaria-infected non-obese 
diabetic mice is associated with a T helper type 2 shift and induction of FoxP3+ regulatory T cells. 
Immunology, 2009. 127(4): p. 512-22. 
245. Aravindhan, V., et al., Decreased prevalence of lymphatic filariasis among diabetic subjects associated 
with a diminished pro-inflammatory cytokine response (CURES 83). PLoS Negl Trop Dis, 2010. 4(6): p. 
e707. 
246. Aravindhan, V., et al., Decreased prevalence of lymphatic filariasis among subjects with type-1 diabetes. 
Am J Trop Med Hyg, 2010. 83(6): p. 1336-9. 
247. Soboslay, P.T., et al., Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific 
Th1-type responses with subclinical Onchocerca volvulus infection. Clin Exp Immunol, 1994. 96(2): p. 
238-44. 
248. Semnani, R.T., et al., Filaria-induced monocyte dysfunction and its reversal following treatment. Infect 
Immun, 2006. 74(8): p. 4409-17. 
 
 
Kathrin Arndts   Appendix 
 115 
Appendix A: Equipment 
Automatic pipettes (10-1000µl)   Eppendorf AG, Hamburg, Germany 
Automatic pipettes (10-1000µl)   Biohit, Rosbach v. d. Höhe, Germany 
BD FACSCanto™ I flow cytometer   BD™ Biosciences, Heidelberg, Germany 
BD FACS Diva flow cytometer    BD™ Biosciences, Heidelberg, Germany 
Bioanalyzer Agilent 2100   Agilent Technologies, Waldbronn, Germany 
Centrifuge (Eppendorf 5415 R)    Eppendorf AG, Hamburg, Germany 
Centrifuge (Multifuge 4KR)    Heraeus Holding GmbH, Hanau, Germany 
Combs (1.5 mm)     Bio-Rad, Munich, Germany 
ELISA Plate reader (Spectra Max 340pc384) Molecular Devices, Sunnyvale, USA 
Films      Kodak, Stuttgart, Germany 
Filter (Whatman Nucleopore, 5 m)  Carl Roth, Karlsruhe, Germany 
Freezer (-20°C)     Bosch GmbH, Stuttgart, Germany 
Freezer (-80°C)     Heraeus Holding GmbH, Hanau, Germany 
Fridge       Bosch GmbH, Stuttgart, Germany 
Gel tray     Bio-Rad, Munich, Germany 
Gel documentation  
(BioDocAnalyze digital)    Biometra GmbH, Göttingen, Germany 
Glass pipettes (1-20 ml)   Brand GmbH & Co KG, Wertheim, Germany 
Glass mortar      VWR, Langenfeld, Germany 
Glass plates (1.5 mm)    Bio-Rad, Munich, Germany 
Glassware      Schott AG, Mainz, Germany 
Heating Block     Eppendorf AG, Hamburg, Germany 
Ice machine (Scotsman AF 80)    Gastro Handel GmbH, Wien, Austria 
Incubator      Binder GmbH, Tuttlingen, Germany 
MACS® columns (MS)    Miltenyi Biotech GmbH, Bergisch Gladbach Germany 
MACS® separator Miltenyi Biotech GmbH, Bergisch Gladbach, Germany 
Magnet (Dynal MPC®)    Invitrogen GmbH, Darmstadt, Germany 
Microscope (Leica DM IL) Leica Microsystems GmbH, Wetzlar, Germany 
Microarray Scanning(Illumina HiScan SQ) Illumina Inc., San Diego, USA 
Mixer (Dynal MX1)    Invitrogen GmbH, Darmstadt, Germany 
MoFlo      Beckman Coulter, Miami, USA 
Nanodrop     Peqlab, Erlangen, Germany 
Needles (BD Microlance™, 21G)   BD™ Biosciences, Heidelberg, Germany 
Neubauer counting chamber    LO Laboroptik GmbH, Bad Homburg, Germany 
PH meter      Mettler Toledo GmbH, Giessen, Germany 
Pipetboy (pipetus®-akku)    Hirschmann Laborgeräte, Eberstadt, Germany 
Power supply     Bio-Rad, Munich, Germany 
Punch (Holth corneoscleral punch 2mm) Koch, Hamburg, Germany 
PVDF membrane (0.45 m)   Sigma-Aldrich GmbH, Munich, Germany 
Reflotron® Plus    Roche Diagnostics, Mannheim, Germany 
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Rocker      Bio-Rad, Munich, Germany 
Scanner ScanMaker i900   Microtek, Willich, Germany  
Sedgewick rafter chamber   VWR, Langenfeld, Germany 
Spacer (1.5 mm)     Bio-Rad, Munich, Germany 
Syringes (5 ml, 10 ml)    BD™ Biosciences, Heidelberg, Germany 
Thermocycler     Biometra GmbH, Göttingen, Germany 
Thermo magnetic stirrer    IKA® GmbH & Co.KG, Staufen, Germany 
Trans-blot semi dry transfer cell   Bio-Rad, Munich, Germany 
Ultrasound machine (Sonosite 180 Plus) Sonosite, Bothell, USA 
Vortex mixer (Minishaker)    IKA® GmbH & Co.KG, Staufen, Germany 
Water bath      VWR, Langenfeld, Germany 
Water purifier Milli-Q plus    Millipore, Schwalbach, Germany 
Weighing machine     Sartorius AG, Göttingen, Germany 
Western blotting filter paper   Bio-Rad, Munich, Germany 
Wrapping film     Staples Advantage, Cologne, Germany 
 
 
Appendix B: Chemicals and Reagents 
Advanced Protein Assay™    Cytoskeleton, Inc., Denver, USA 
Agarose     Fermentas. St. Leon-Rot, Germany 
Agilent RNA 6000 Pico Kit   Agilent Technologies, Waldbronn, Germany 
Ammoniumpersulfate (10%)  Sigma-Aldrich GmbH, Munich, Germany 
autoMACS running buffer   Miltenyi Biotech GmbH, Bergisch Gladbach, Germany 
B cell isolation kit     Invitrogen GmbH, Darmstadt, Germany 
BD Phosflow starter kit BD™ Biosciences, Heidelberg, Germany 
-Mercaptoethanol    Sigma-Aldrich GmbH, Munich, Germany 
Bromophenol blue    Sigma-Aldrich GmbH, Munich, Germany 
BSA       PAA Laboratories GmbH, Pasching, Austria 
CD14 Microbeads    Miltenyi Biotech GmbH, Bergisch Gladbach, Germany 
CD4+ T cell isolation kit    Invitrogen GmbH, Darmstadt, Germany 
Chloroform     Sigma-Aldrich GmbH, Munich, Germany 
Cytometric bead assay  
(IgG1, IgG2, IgG3, IgG4, IgE) BD™ Biosciences, Heidelberg, Germany 
DMSO       Sigma-Aldrich GmbH, Munich, Germany 
DNA Loading dye (6x)    Fermentas. St. Leon-Rot, Germany 
dNTP Mix (10 mM each)   Invitrogen GmbH, Darmstadt, Germany 
ELISA kits Ready-SET-Go 
(IL-6, IL-10, IFN-, TNF)   eBiosciences, Inc., San Diego, USA 
ELISA kits (IL-5, IL-6, IL-10, 
IL-13, IL-17, IFN-, TNF)    R&D, Wiesbaden-Nordenstadt, Germany 
Ethanol      Merck KGAA, Darmstadt, Germany 
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FCS       PAA Laboratories GmbH, Pasching, Austria 
Gel Loading Dye, Blue (6X)   NEW ENGLAND BioLabs, Frankfurt, Gemany 
Gentamycin      PAA Laboratories GmbH, Pasching, Austria 
Giemsa's azur eosin methylene blue solution  Merck KGAA, Darmstadt, Germany 
Hydrogen peroxide (H2O2)    Sigma-Aldrich GmbH, Munich, Germany 
Illumina® Whole-Genome Gene Expression  
Direct Hybridization Assay system  Illumina Inc., San Diego, USA 
Immun-StarTM AP substrate   Bio-Rad, Munich, Germany 
Isopropanol     Merck KGAA, Darmstadt, Germany 
Leucosep tubes     Greiner Bio-one, Frickenhausen, Germany 
L-glutamine      PAA Laboratories GmbH, Pasching, Austria 
Limulus amoebocyte  lysate assay  Charles River, Wilmington, USA 
Liquid nitrogen     Linde, Düsseldorf, Germany 
LPS       Sigma-Aldrich GmbH, Munich, Germany 
LSM 1077     PAA Laboratories GmbH, Pasching, Austria 
Malaria test  
(Nadal® Malaria test 4species)   Nal von Minden, Moers, Germany 
miRNeasy Kit     Qiagen, Hilden, Germany 
Monosodium phosphate    Merck KGAA, Darmstadt, Germany 
Normal Rat serum    eBiosciences, Inc., San Diego, USA 
Paraformaldehyde     Merck KGAA, Darmstadt, Germany 
PBS (endotoxin free)     PAA Laboratories GmbH, Pasching, Austria 
Penicillin/Streptomycin     PAA Laboratories GmbH, Pasching, Austria 
Potassium chloride (KCl)    Merck KGAA, Darmstadt, Germany 
Potassium dihydrogen phosphate   Merck KGAA, Darmstadt, Germany 
Protein Standard (MagicMarkTM)  Invitrogen GmbH, Darmstadt, Germany  
PPD      Statens Serum Institut, Copenhagen, Denmark 
Random decamer primers   Ambion, Darmstadt, Germany 
Recombinant human IL-10   R&D, Wiesbaden-Nordenstadt, Germany 
RedSafe™ Nucleic Acid Staining Solution HISS Diagnostics GmbH, Freiburg, Germany 
RIPA lysis buffer   Santa Cruz Biotechnology Inc., Heidelberg, Germany 
RNA Clean & Concentrator™- 5  Zymo Research Cooperation, Irvine, USA 
RNase-free water    Qiagen, Hilden, Germany 
RNaseOUT™ Recombinant  
Ribonuclease Inhibitor    Invitrogen GmbH, Darmstadt, Germany 
RNeasy MiniElute Cleanup Kit   Qiagen, Hilden, Germany 
RNA ladder      Invitrogen GmbH, Darmstadt, Germany 
Roti®-block      Carl Roth, Karlsruhe, Germany  
RPMI-1640      PAA Laboratories GmbH, Pasching, Austria 
Saccharose      Sigma-Aldrich GmbH, Munich, Germany 
Sodium chloride (NaCl)    Merck KGAA, Darmstadt, Germany 
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Stop solution 2N H2SO4    Merck KGAA, Darmstadt, Germany 
Streptavidin-Peroxidase    Roche Diagnostics, Mannheim, Germany 
SuperScript III Reverse Transcriptase  Invitrogen GmbH, Darmstadt, Germany 
SuperScript II Reverse Transcriptase  Invitrogen GmbH, Darmstadt, Germany 
TargetAmp™ 2-Round Biotin  
aRNA Amplification Kit 3.0   Epicentre Biotechnologies, Madison, USA 
TBE buffer 10x      Biomol GmbH, Hamburg, Germany 
TEMED     Bio-Rad, Munich, Germany 
TMB       Sigma-Aldrich GmbH, Munich, Germany 
TropBio® ELISA    TropBio, Townsville, Australia 
Tris       Merck KGAA, Darmstadt, Germany 
Trizol (Qiazol lysis reagent)   Qiagen, Hilden, Germany 
Trypan Blue      Sigma-Aldrich GmbH, Munich, Germany 
Tween 20      Sigma-Aldrich GmbH, Munich, Germany 
 
 
Appendic C: Buffers, Media and Solutions 
 
20x phosphate buffer saline (PBS): 
360 g NaCl 
8.0 g KCl 
46.4 g Na2HPO4 
8.0 g KH2PO4 
 
Volume was then adjusted to 1 liter of distilled water. 
For 1x phosphate buffer saline (PBS): 50 ml of 20x PBS solution was diluted in 900 ml distilled water. 
The pH was adjusted to 7.3 and the solution was topped up to 1 liter and autoclaved. 
 
Fetal calf serum  
FCS used for medium supplementations was heated for 30 minutes at 56°C to inactivate the 
complement factors. Aliquots were then stored at -20°C until required. 
 
Cells culture reagents 
Complete medium 
RPMI 1640 
2 mM L-glutamine 
50 g/ml penicillin/streptomycin 
50 g/ml gentamicin 
 
 
 
Kathrin Arndts   Appendix 
 119 
Cell culture medium 
RPMI 1640 
2 mM L-glutamine 
50 g/ml penicillin/streptomycin 
50 g/ml gentamicin 
10% FCS 
 
Freezing medium 
80% FCS 
20% Dimethylsulfoxid (DMSO) 
 
ELISA: 
Coating solution 
0.1 M NaHCO3, pH 9.6 
 
Washing buffer 
1x PBS 
0.05% Tween 20 
 
Blocking solution 
1x PBS 
1% BSA 
 
Substrate buffer  
0.1 M NaH2PO4.2H2O, pH 5.5 
 
Substrate 
3,3’, 5,5’ Tetramethylbenzidine, dissolved to a concentration of 6 mg/ml in DMSO. 
 
Substrate solution 
12 ml substrate buffer 
200 µl substrate 
1.2 µl 30% H2O2 
 
Stop solution 
2N H2SO4 
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SDS-Page and Western blot 
7% separation gel (total volume 15 ml) 
7.75 ml H20 
3.5 ml Acrylamide (30%) 
3.75 ml 4x Lower Tris TEMED 
30 l APS (10%) 
 
5% stacking gel (total volume 10 ml) 
6.5 ml H20 
1.3 ml Acrylamide (30%) 
2.5 ml 4x Upper Tris  
30 l TEMED 
30 l APS (10%)  
 
Laemmli buffer (pH 6.8) 
4% SDS 
0.5% bromophenol blue 
1% β-mercaptoethanol 
0.5% glycerol 
0.5 M Tris-HCl  
 
Electrophoresis running buffer (pH 8.3) 
192 mM glycine 
25 mM Tris, 
0.1% SDS 
 
Transfer buffer (pH 8.53) 
10 mM Tris 
100 mM glycine 
20% methanol 
 
Western blot wash buffer 
1x PBS 
0.15% Tween 20 
 
Flow cytometry 
FACS buffer 
1x PBS 
1% FCS 
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Fixation buffer 
1x PBS 
4% Paraformaldehyde 
 
 
Appendix D: Primer sequences 
 
5´ß-Aktin Fragment: 269 bp 
fw primer 5`end:  TGGTGGGCATGGGTCAGA  
rv primer 5`end:  GTACATGGCTGGGGTGTTGA 
 
3´ß-Aktin Fragment: 456 bp 
fw primer 3`end:  AACAAGATGAGATTGGCA  
rv primer 3`end:   GACCAAAAGCCTTCATACAT 
 
 
Appendix E: Software 
 
BD FACSDiva software 3.0 
Flow cytometry software obtained from BD™ Biosciences, Heidelberg, Germany. 
 
Fiji software 
Fiji is an open source imaging software. 
 
GraphPad Prism 5 
Analyze, Graph and Organize Software obtained from GraphPad Software, Inc., La Jolla, USA. 
 
SoftMax Pro 
Microplate Data Acquisition and Analysis Software obtained from Molecular Devices, 
Sunnyvale, USA. 
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Appendix F: Microarray data 
 
Comparison CD4+CD25hihg T cells of infected individuals versus EN 
Symbol Definition mean_Treg_inf mean_Treg_healthy FC pvalue diff 
C14orf80 Homo sapiens chromosome 14 open reading frame 80 (C14orf80), mRNA. 130.96 343.55 -2.62 0.017 212.59 
EMILIN2 Homo sapiens elastin microfibril interfacer 2 (EMILIN2), mRNA. 261.48 495.64 -1.90 0.019 234.16 
WDR36 Homo sapiens WD repeat domain 36 (WDR36), mRNA. 163.35 298.22 -1.83 0.001 134.87 
EIF4A1 Homo sapiens eukaryotic translation initiation factor 4A, isoform 1 (EIF4A1), mRNA. 310.14 560.08 -1.81 0.012 249.94 
RARS Homo sapiens arginyl-tRNA synthetase (RARS), mRNA. 657.38 1121.84 -1.71 0.020 464.47 
C6orf125 Homo sapiens chromosome 6 open reading frame 125 (C6orf125), mRNA. 182.46 309.35 -1.70 6.00E-04 126.89 
PGM1 Homo sapiens phosphoglucomutase 1 (PGM1), mRNA. 596.24 1003.63 -1.68 0.004 407.39 
C7orf26 Homo sapiens chromosome 7 open reading frame 26 (C7orf26), mRNA. 263.03 436.54 -1.66 5.00E-04 173.51 
CHKB Homo sapiens choline kinase beta (CHKB), transcript variant 1, mRNA. 569.14 936.93 -1.65 0.009 367.79 
ZFYVE20 Homo sapiens zinc finger, FYVE domain containing 20 (ZFYVE20), mRNA. 170.40 274.60 -1.61 0.000 104.19 
DGUOK Homo sapiens deoxyguanosine kinase (DGUOK), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 551.51 857.06 -1.55 0.040 305.55 
TDRD1 Homo sapiens tudor domain containing 1 (TDRD1), mRNA. 216.45 333.79 -1.54 0.020 117.35 
C15orf17 Homo sapiens chromosome 15 open reading frame 17 (C15orf17), mRNA. 219.38 335.64 -1.53 0.000 116.26 
DENR Homo sapiens density-regulated protein (DENR), mRNA. 852.71 566.85 1.50 0.029 285.86 
LOC728855 Homo sapiens hypothetical LOC728855 (LOC728855), non-coding RNA. 1308.39 860.91 1.52 0.012 447.47 
CCDC115 Homo sapiens coiled-coil domain containing 115 (CCDC115), mRNA. 509.65 325.20 1.57 0.025 184.46 
ST6GAL1 Homo sapiens ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 (ST6GAL1), transcript variant 2, mRNA. 923.78 588.98 1.57 0.040 334.8 
CAPRIN2 Homo sapiens caprin family member 2 (CAPRIN2), transcript variant 1, mRNA. 311.54 197.38 1.58 0.015 114.15 
SETD3 Homo sapiens SET domain containing 3 (SETD3), transcript variant 1, mRNA. 2673.25 1691.14 1.58 0.000 982.11 
C18orf25 Homo sapiens chromosome 18 open reading frame 25 (C18orf25), transcript variant 2, mRNA. 477.45 296.84 1.61 0.012 180.61 
PRKAB2 Homo sapiens protein kinase, AMP-activated, beta 2 non-catalytic subunit (PRKAB2), mRNA. 303.61 183.34 1.66 0.007 120.27 
SRP54 Homo sapiens signal recognition particle 54kDa (SRP54), mRNA. 980.97 589.69 1.66 0.043 391.28 
COPS5 Homo sapiens COP9 constitutive photomorphogenic homolog subunit 5 (Arabidopsis) (COPS5), mRNA. 1241.43 743.49 1.67 0.047 497.94 
COPS3 Homo sapiens COP9 constitutive photomorphogenic homolog subunit 3 (Arabidopsis) (COPS3), mRNA. 715.53 424.61 1.69 0.006 290.92 
STAT1 Homo sapiens signal transducer and activator of transcription 1, 91kDa (STAT1), transcript variant alpha, mRNA. 2180.10 1290.43 1.69 0.002 889.67 
EIF2B1 Homo sapiens eukaryotic translation initiation factor 2B, subunit 1 alpha, 26kDa (EIF2B1), mRNA. 647.37 381.63 1.70 0.013 265.75 
GMFB Homo sapiens glia maturation factor, beta (GMFB), mRNA. 659.24 381.72 1.73 0.012 277.52 
ADCY7 Homo sapiens adenylate cyclase 7 (ADCY7), mRNA. 504.66 289.77 1.74 0.032 214.89 
PNKP Homo sapiens polynucleotide kinase 3'-phosphatase (PNKP), mRNA. 358.86 206.21 1.74 0.027 152.65 
ATP6V1D Homo sapiens ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D (ATP6V1D), mRNA. 889.84 508.36 1.75 0.003 381.48 
CPNE3 Homo sapiens copine III (CPNE3), mRNA. 487.84 277.73 1.76 0.038 210.11 
SRP54 PREDICTED: Homo sapiens signal recognition particle 54kDa (SRP54), mRNA. 925.94 527.47 1.76 0.034 398.47 
ACLY Homo sapiens ATP citrate lyase (ACLY), transcript variant 2, mRNA. 874.16 487.06 1.79 0.002 387.1 
COPB2 Homo sapiens coatomer protein complex, subunit beta 2 (beta prime) (COPB2), mRNA. 354.97 197.46 1.80 0.024 157.51 
SEC11C Homo sapiens SEC11 homolog C (S. cerevisiae) (SEC11C), mRNA. 1063.33 589.43 1.80 0.025 473.9 
TBK1 Homo sapiens TANK-binding kinase 1 (TBK1), mRNA. 781.06 433.53 1.80 0.002 347.53 
PIAS4 Homo sapiens protein inhibitor of activated STAT, 4 (PIAS4), mRNA. 226.26 125.07 1.81 0.048 101.2 
LOC651894 PREDICTED: Homo sapiens similar to ribosomal protein S12 (LOC651894), mRNA. 852.84 468.03 1.82 0.003 384.82 
WDR19 Homo sapiens WD repeat domain 19 (WDR19), mRNA. 232.33 126.52 1.84 0.000 105.81 
SEC23IP Homo sapiens SEC23 interacting protein (SEC23IP), mRNA. 226.32 122.39 1.85 0.006 103.93 
ZNF845 Homo sapiens zinc finger protein 845 (ZNF845), mRNA. XM_039908 238.56 128.06 1.86 0.000 110.5 
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ST3GAL5 Homo sapiens ST3 beta-galactoside alpha-2,3-sialyltransferase 5 (ST3GAL5), transcript variant 2, mRNA. 367.35 196.8 1.87 0.000 170.55 
ZNF721 Homo sapiens zinc finger protein 721 (ZNF721), mRNA. 345.94 185.12 1.87 0.024 160.83 
AKR1A1 Homo sapiens aldo-keto reductase family 1, member A1 (aldehyde reductase) (AKR1A1), transcript variant 1, mRNA. 822.73 431.33 1.91 0.005 391.4 
GSPT2 Homo sapiens G1 to S phase transition 2 (GSPT2), mRNA. 261.17 136.22 1.92 0.003 124.95 
ATAD1 Homo sapiens ATPase family, AAA domain containing 1 (ATAD1), mRNA. 243.02 124.18 1.96 5.00E-04 118.84 
ITGB1 
Homo sapiens integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) (ITGB1), transcript variant 1D, 
mRNA. 353.74 179.21 1.97 0.033 174.52 
ZHX2 Homo sapiens zinc fingers and homeoboxes 2 (ZHX2), mRNA. 359.92 182.89 1.97 0.046 177.04 
LACTB Homo sapiens lactamase, beta (LACTB), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 715.05 360.78 1.98 0.043 354.27 
HDDC3 Homo sapiens HD domain containing 3 (HDDC3), mRNA. 324.36 163.04 1.99 0.001 161.32 
SNX5 Homo sapiens sorting nexin 5 (SNX5), transcript variant 2, mRNA. 235.08 116.14 2.02 0.014 118.94 
TOR1AIP1 Homo sapiens torsin A interacting protein 1 (TOR1AIP1), mRNA. 331.58 162.42 2.04 0.000 169.16 
CDK7 Homo sapiens cyclin-dependent kinase 7 (MO15 homolog, Xenopus laevis, cdk-activating kinase) (CDK7), mRNA. 602.30 294.32 2.05 0.011 307.98 
C13orf23 Homo sapiens chromosome 13 open reading frame 23 (C13orf23), transcript variant 1, mRNA. 272.86 131.32 2.08 0.004 141.54 
C13orf23 Homo sapiens chromosome 13 open reading frame 23 (C13orf23), transcript variant 1, mRNA. 280.37 132.94 2.11 0.001 147.44 
PRKAR1A Homo sapiens protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) (PRKAR1A), transcript variant 3, mRNA. 727.01 345.24 2.11 0.035 381.77 
SDAD1 Homo sapiens SDA1 domain containing 1 (SDAD1), mRNA. 714.28 331.02 2.16 0.003 383.26 
FBXO28 Homo sapiens F-box protein 28 (FBXO28), mRNA. 227.92 104.97 2.17 0.041 122.95 
ZNHIT6 Homo sapiens zinc finger, HIT type 6 (ZNHIT6), mRNA. 262.49 120.79 2.17 0.007 141.7 
C8orf76 Homo sapiens chromosome 8 open reading frame 76 (C8orf76), mRNA. 412.7 179.1 2.30 0.040 233.6 
C17orf97 Homo sapiens chromosome 17 open reading frame 97 (C17orf97), mRNA. 221.92 93.73 2.37 0.012 128.19 
DHX29 Homo sapiens DEAH (Asp-Glu-Ala-His) box polypeptide 29 (DHX29), mRNA. 269.91 113.53 2.38 0.003 156.37 
PSMB5 Homo sapiens proteasome (prosome, macropain) subunit, beta type, 5 (PSMB5), mRNA. 447.32 187.96 2.38 0.013 259.36 
HAVCR2 Homo sapiens hepatitis A virus cellular receptor 2 (HAVCR2), mRNA. 290.16 121.52 2.39 0.004 168.64 
RSBN1 Homo sapiens round spermatid basic protein 1 (RSBN1), mRNA. 304.85 125.89 2.42 0.003 178.96 
TOR1AIP1 Homo sapiens torsin A interacting protein 1 (TOR1AIP1), mRNA. 646.24 267.27 2.42 0.013 378.97 
DHX29 Homo sapiens DEAH (Asp-Glu-Ala-His) box polypeptide 29 (DHX29), mRNA. 424.44 161.47 2.63 0.000 262.96 
FAM69A Homo sapiens family with sequence similarity 69, member A (FAM69A), mRNA. 335.09 105.31 3.18 0.004 229.78 
 
 
Comparison CD4+CD25high T cells of MF- versus MF+ individuals 
Symbol Definition mean_Treg_MFneg mean_Treg_MFpos FC pvalue diff 
MYOM2 Homo sapiens myomesin (M-protein) 2, 165kDa (MYOM2), mRNA. 170.21 1021.80 -6.00 0.000 851.59 
CD83 Homo sapiens CD83 molecule (CD83), transcript variant 2, mRNA. 187.41 567.67 -3.03 0.000 380.26 
MYNN Homo sapiens myoneurin (MYNN), mRNA. 122.18 340.64 -2.79 0.000 218.46 
NBPF20 Homo sapiens neuroblastoma breakpoint family, member 20 (NBPF20), mRNA. 161.62 421.89 -2.61 0.000 260.27 
RCBTB2 Homo sapiens regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 2 (RCBTB2), mRNA. 151.19 393.09 -2.60 0.000 241.90 
VCAN Homo sapiens versican (VCAN), mRNA. 151.84 392.22 -2.58 0.000 240.38 
CD83 Homo sapiens CD83 molecule (CD83), transcript variant 1, mRNA. 113.99 282.12 -2.47 0.000 168.13 
SNORD3A Homo sapiens small nucleolar RNA, C/D box 3A (SNORD3A), small nucleolar RNA. 519.25 1213.06 -2.34 0.000 693.82 
SGK Homo sapiens serum/glucocorticoid regulated kinase (SGK), mRNA. 129.41 296.34 -2.29 0.001 166.92 
GART 
Homo sapiens phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole 
synthetase (GART), transcript variant 1, mRNA. 390.16 873.82  0.031 483.66 
FLJ38717 Homo sapiens FLJ38717 protein (FLJ38717), mRNA. 167.65 368.09 -2.20 1.00E-04 200.44 
TNFRSF19 Homo sapiens tumor necrosis factor receptor superfamily, member 19 (TNFRSF19), transcript variant 2, mRNA. 151.24 328.88 -2.17 0.000 177.64 
COBLL1 Homo sapiens COBL-like 1 (COBLL1), mRNA. 123.80 267.01 -2.16 4.00E-04 143.22 
ZNF529 Homo sapiens zinc finger protein 529 (ZNF529), mRNA. 117.02 246.89 -2.11 0.000 129.87 
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PPARBP Homo sapiens PPAR binding protein (PPARBP), mRNA. 127.65 268.68 -2.10 0.011 141.03 
TGFBR3 Homo sapiens transforming growth factor, beta receptor III (TGFBR3), mRNA. 179.21 369.13 -2.06 0.015 189.92 
ZYG11B Homo sapiens zyg-11 homolog B (C. elegans) (ZYG11B), mRNA. 337.69 692.25 -2.05 0.000 354.56 
KLF11 PREDICTED: Homo sapiens Kruppel-like factor 11 (KLF11), mRNA. 337.11 687.70 -2.04 0.003 350.59 
PHC3 Homo sapiens polyhomeotic homolog 3 (Drosophila) (PHC3), mRNA. 134.84 275.28 -2.04 0.012 140.45 
OXR1 Homo sapiens oxidation resistance 1 (OXR1), mRNA. 123.74 249.60 -2.02 0.000 125.86 
RAB12 Homo sapiens RAB12, member RAS oncogene family (RAB12), mRNA. 106.62 212.86 2.00 0.004 106.24 
C14orf131 Homo sapiens chromosome 14 open reading frame 131 (C14orf131), mRNA. 378.02 747.81 -1.98 0.300 369.80 
TAGAP Homo sapiens T-cell activation RhoGTPase activating protein (TAGAP), transcript variant 3, mRNA. 115.15 226.91 -1.97 0.010 111.76 
FBXO11 Homo sapiens F-box protein 11 (FBXO11), transcript variant 1, mRNA. 425.99 831.65 -1.95 0.000 405.66 
NDFIP1 Homo sapiens Nedd4 family interacting protein 1 (NDFIP1), mRNA. 124.99 242.02 -1.94 1.00E-04 117.04 
C7orf54 Homo sapiens chromosome 7 open reading frame 54 (C7orf54), mRNA. 173.22 333.43 -1.92 8.00E-04 160.21 
CD84 Homo sapiens CD84 molecule (CD84), mRNA. 138.65 261.99 -1.89 0.000 123.35 
SMAD5 Homo sapiens SMAD family member 5 (SMAD5), transcript variant 1, mRNA. 162.96 303.99 -1.87 0.000 141.02 
STAMBP Homo sapiens STAM binding protein (STAMBP), transcript variant 1, mRNA. 354.05 662.07 -1.87 0.015 308.02 
LOC727762 
PREDICTED: Homo sapiens similar to NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15kDa, transcript variant 1 (LOC727762), 
mRNA. 196.75 365.27 -1.86 0.002 168.53 
SNRNP200 Homo sapiens small nuclear ribonucleoprotein 200kDa (U5) (SNRNP200), mRNA. 258.14 478.61 -1.85 0.000 220.47 
RNF38 Homo sapiens ring finger protein 38 (RNF38), transcript variant 1, mRNA. 581.75 1064.1 -1.83 0.029 482.35 
STAMBPL1 Homo sapiens STAM binding protein-like 1 (STAMBPL1), mRNA. 419.75 766.15 -1.83 0.041 346.39 
CEP350 Homo sapiens centrosomal protein 350kDa (CEP350), mRNA. 140.95 254.90 -1.81 0.000 113.96 
ERP27 Homo sapiens endoplasmic reticulum protein 27 kDa (ERP27), mRNA. 185.14 334.80 -1.81 0.008 149.65 
EEF1G Homo sapiens eukaryotic translation elongation factor 1 gamma (EEF1G), mRNA. XM_935976 XM_935977 XM_935978 XM_935979 937.36 1686.19 -1.80 0.008 748.83 
MTX3 Homo sapiens metaxin 3 (MTX3), mRNA. 224.07 401.29 -1.79 0.013 177.21 
TAGAP Homo sapiens T-cell activation RhoGTPase activating protein (TAGAP), transcript variant 2, mRNA. 151.71 270.95 -1.79 0.000 119.24 
PLEKHA1 
Homo sapiens pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 1 (PLEKHA1), transcript variant 
2, mRNA. 184.52 327.88 -1.78 0.000 143.36 
SMG1 Homo sapiens PI-3-kinase-related kinase SMG-1 (SMG1), mRNA. 292.75 516.87 -1.77 0.019 224.12 
LOC644033 PREDICTED: Homo sapiens similar to similar to RPL23AP7 protein (LOC644033), mRNA. 348.13 613.32 -1.76 0.000 265.19 
CHRAC1 Homo sapiens chromatin accessibility complex 1 (CHRAC1), mRNA. 241.90 421.73 -1.74 0.017 179.82 
A2LD1 Homo sapiens AIG2-like domain 1 (A2LD1), mRNA. 168.01 288.9 -1.72 0.000 120.89 
CMAS Homo sapiens cytidine monophosphate N-acetylneuraminic acid synthetase (CMAS), mRNA. 240.33 413.22 -1.72 1.00E-04 172.89 
GAB2 Homo sapiens GRB2-associated binding protein 2 (GAB2), transcript variant 1, mRNA. 141.78 241.98 -1.71 0.003 100.20 
NKTR Homo sapiens natural killer-tumor recognition sequence (NKTR), mRNA. 1069.57 1825.25 -1.71 0.019 755.68 
SH3BGRL Homo sapiens SH3 domain binding glutamic acid-rich protein like (SH3BGRL), mRNA. 474.03 810.42 -1.71 0.000 336.38 
C14orf138 Homo sapiens chromosome 14 open reading frame 138 (C14orf138), transcript variant 1, mRNA. 153.93 261.76 -1.70 0.004 107.83 
S100A8 Homo sapiens S100 calcium binding protein A8 (S100A8), mRNA. 205.20 348.86 -1.70 0.000 143.66 
VAMP4 Homo sapiens vesicle-associated membrane protein 4 (VAMP4), transcript variant 1, mRNA. 186.81 317.31 -1.70 0.000 130.50 
AGTPBP1 Homo sapiens ATP/GTP binding protein 1 (AGTPBP1), mRNA. 367.79 623.15 -1.69 0.000 255.36 
MAP3K7 Homo sapiens mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant B, mRNA. 604.31 1023.03 -1.69 6.00E-04 418.71 
TMED2 Homo sapiens transmembrane emp24 domain trafficking protein 2 (TMED2), mRNA. 595.09 1008.2 -1.69 0.000 413.11 
JMJD1C Homo sapiens jumonji domain containing 1C (JMJD1C), transcript variant 1, mRNA. 264.42 441.62 -1.67 1.00E-04 177.2 
ZNF211 Homo sapiens zinc finger protein 211 (ZNF211), transcript variant 1, mRNA. 201.07 335.95 -1.67 6.00E-04 134.87 
CBLL1 Homo sapiens Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1 (CBLL1), mRNA. 350.97 584.23 -1.66 0.000 233.26 
YOD1 Homo sapiens YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae) (YOD1), mRNA. 154.36 256.00 -1.66 0.009 101.64 
DOCK11 Homo sapiens dedicator of cytokinesis 11 (DOCK11), mRNA. 1020.09 1681.86 -1.65 0.000 661.77 
UFSP2 Homo sapiens UFM1-specific peptidase 2 (UFSP2), mRNA. 222.47 368.01 -1.65 0.000 145.55 
BCLAF1 Homo sapiens BCL2-associated transcription factor 1 (BCLAF1), transcript variant 2, mRNA. 510.77 837.68 -1.64 0.023 326.91 
DOCK10 Homo sapiens dedicator of cytokinesis 10 (DOCK10), mRNA. 672.35 1098.04 -1.63 0.000 425.69 
GNPDA1 Homo sapiens glucosamine-6-phosphate deaminase 1 (GNPDA1), mRNA. 535.09 872.63 -1.63 0.004 337.54 
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NGDN Homo sapiens neuroguidin, EIF4E binding protein (NGDN), transcript variant 1, mRNA. 229.23 374.18 -1.63 9.00E-04 144.95 
SNORD3C Homo sapiens small nucleolar RNA, C/D box 3C (SNORD3C), small nucleolar RNA. 363.57 588.02 -1.62 0.000 224.45 
AMY2A Homo sapiens amylase, alpha 2A (pancreatic) (AMY2A), mRNA. 265.38 427.12 -1.61 8.00E-04 161.74 
ZNF786 Homo sapiens zinc finger protein 786 (ZNF786), mRNA. 385.91 620.53 -1.61 0.000 234.62 
DTWD2 Homo sapiens DTW domain containing 2 (DTWD2), mRNA. 529.28 845.09 -1.60 0.000 315.82 
RNF130 Homo sapiens ring finger protein 130 (RNF130), mRNA. 280.52 444.43 -1.58 0.000 163.91 
FBXO34 Homo sapiens F-box protein 34 (FBXO34), mRNA. 254.13 398.71 -1.57 8.00E-04 144.58 
SRGN Homo sapiens serglycin (SRGN), mRNA. 314.56 493.47 -1.57 1.00E-04 178.9 
COQ5 Homo sapiens coenzyme Q5 homolog, methyltransferase (S. cerevisiae) (COQ5), mRNA. 317.64 494.53 -1.56 0.015 176.89 
LOC401397 PREDICTED: Homo sapiens hypothetical LOC401397 (LOC401397), mRNA. 218.92 341.58 -1.56 0.034 122.66 
TMEM126B Homo sapiens transmembrane protein 126B (TMEM126B), mRNA. 303.41 473.28 -1.56 0.000 169.87 
C8orf45 Homo sapiens chromosome 8 open reading frame 45 (C8orf45), mRNA. 1343.16 2083.5 -1.55 0.031 740.34 
C21orf24 Homo sapiens chromosome 21 open reading frame 24 (C21orf24), mRNA. 1136.36 1735.72 -1.53 0.043 599.36 
CBX6 Homo sapiens chromobox homolog 6 (CBX6), mRNA. 199.65 306.03 -1.53 1.00E-04 106.38 
PAG1 Homo sapiens phosphoprotein associated with glycosphingolipid microdomains 1 (PAG1), mRNA. 700.59 1074.96 -1.53 0.002 374.38 
PRKAR1A 
Homo sapiens protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) (PRKAR1A), transcript variant 3, 
mRNA. 599.31 918.57 -1.53 0.045 319.26 
CMPK1 Homo sapiens cytidine monophosphate (UMP-CMP) kinase 1, cytosolic (CMPK1), mRNA. 224.74 342.10 -1.52 0.026 117.37 
CYP20A1 Homo sapiens cytochrome P450, family 20, subfamily A, polypeptide 1 (CYP20A1), mRNA. 200.36 304.64 -1.52 0.000 104.28 
DYRK1A Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A), transcript variant 4, mRNA. 301.70 459.56 -1.52 0.017 157.87 
FAM73A Homo sapiens family with sequence similarity 73, member A (FAM73A), mRNA. 380.31 576.57 -1.52 0.000 196.26 
KCTD5 Homo sapiens potassium channel tetramerisation domain containing 5 (KCTD5), mRNA. 260.91 397.48 -1.52 0.003 136.56 
SNRK Homo sapiens SNF related kinase (SNRK), mRNA. 825.21 1257.22 -1.52 0.042 432.01 
PAXIP1 Homo sapiens PAX interacting (with transcription-activation domain) protein 1 (PAXIP1), mRNA. 250.21 378.33 -1.51 0.000 128.12 
SLC11A2 Homo sapiens solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 (SLC11A2), mRNA. 325.37 488.83 -1.50 0.021 163.46 
EFTUD1 Homo sapiens elongation factor Tu GTP binding domain containing 1 (EFTUD1), transcript variant 1, mRNA. 479.11 319.05 1.50 0.028 160.05 
ECHDC2 Homo sapiens enoyl Coenzyme A hydratase domain containing 2 (ECHDC2), mRNA. 1747.48 1156.02 1.51 0.000 591.46 
GNAI2 Homo sapiens guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 (GNAI2), transcript variant 1, mRNA. 826.69 541.38 1.53 0.009 285.31 
HNRNPAB Homo sapiens heterogeneous nuclear ribonucleoprotein A/B (HNRNPAB), transcript variant 2, mRNA. 879.72 573.68 1.53 0.002 306.04 
LOC100129681 PREDICTED: Homo sapiens similar to NPC-A-7 (LOC100129681), mRNA. 959.20 625.10 1.53 0.023 334.10 
SAPS3 Homo sapiens SAPS domain family, member 3 (SAPS3), mRNA. 498.23 326.39 1.53 0.000 171.84 
STK40 Homo sapiens serine/threonine kinase 40 (STK40), mRNA. 508.60 332.58 1.53 0.000 176.02 
EGLN2 Homo sapiens egl nine homolog 2 (C. elegans) (EGLN2), transcript variant 3, mRNA. 1273.21 828.64 1.54 0.017 444.57 
LOC641768 PREDICTED: Homo sapiens similar to ribosomal protein S26, transcript variant 2 (LOC641768), mRNA. 1642.73 1061.34 1.55 0.041 581.38 
MVP Homo sapiens major vault protein (MVP), transcript variant 2, mRNA. 1117.34 720.61 1.55 0.008 396.73 
SAMM50 Homo sapiens sorting and assembly machinery component 50 homolog (S. cerevisiae) (SAMM50), mRNA. 1698.49 1092.58 1.55 0.000 605.92 
TMEM63A Homo sapiens transmembrane protein 63A (TMEM63A), mRNA. 650.13 419.42 1.55 0.003 230.71 
TPP1 Homo sapiens tripeptidyl peptidase I (TPP1), mRNA. 889.66 575.17 1.55 0.009 314.49 
TRADD Homo sapiens TNFRSF1A-associated via death domain (TRADD), transcript variant 1, mRNA. 843.72 545.55 1.55 0.000 298.18 
RAB37 Homo sapiens RAB37, member RAS oncogene family (RAB37), transcript variant 3, mRNA. 1303.31 834.26 1.56 0.020 469.05 
MRPL18 Homo sapiens mitochondrial ribosomal protein L18 (MRPL18), nuclear gene encoding mitochondrial protein, mRNA. 591.86 377.79 1.57 2.00E-04 214.07 
BLOC1S1 Homo sapiens biogenesis of lysosome-related organelles complex-1, subunit 1 (BLOC1S1), mRNA. 303.72 191.69 1.58 0.002 112.03 
SHISA5 Homo sapiens shisa homolog 5 (Xenopus laevis) (SHISA5), mRNA. 1783.58 1128.14 1.58 0.000 655.44 
VPS28 Homo sapiens vacuolar protein sorting 28 homolog (S. cerevisiae) (VPS28), transcript variant 1, mRNA. 415.45 262.99 1.58 2.00E-04 152.46 
ARL6IP4 Homo sapiens ADP-ribosylation-like factor 6 interacting protein 4 (ARL6IP4), transcript variant 1, mRNA. 430.51 270.01 1.59 2.00E-04 160.50 
ZNF277 Homo sapiens zinc finger protein 277 (ZNF277), mRNA. 379.85 238.36 1.59 0.036 141.49 
PEBP1 Homo sapiens phosphatidylethanolamine binding protein 1 (PEBP1), mRNA. 571.59 356.94 1.60 0.000 214.65 
SMCR7L Homo sapiens Smith-Magenis syndrome chromosome region, candidate 7-like (SMCR7L), mRNA. 609.14 381.57 1.60 0.000 227.57 
DEDD2 Homo sapiens death effector domain containing 2 (DEDD2), mRNA. 929.83 578.22 1.61 1.00E-04 351.61 
FRYL Homo sapiens FRY-like (FRYL), mRNA. 1042.33 649.17 1.61 0.024 393.16 
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GZMK Homo sapiens granzyme K (granzyme 3; tryptase II) (GZMK), mRNA. 307.37 190.50 1.61 0.003 116.87 
MYO1G Homo sapiens myosin IG (MYO1G), mRNA. 925.41 576.45 1.61 0.000 348.96 
RASAL3 Homo sapiens RAS protein activator like 3 (RASAL3), mRNA. 472.20 291.32 1.62 1.00E-04 180.88 
SAMD9 Homo sapiens sterile alpha motif domain containing 9 (SAMD9), mRNA. 634.27 391.36 1.62 0.019 242.91 
C20orf100 Homo sapiens chromosome 20 open reading frame 100 (C20orf100), mRNA. 329.44 201.95 1.63 0.017 127.48 
TRIM21 Homo sapiens tripartite motif-containing 21 (TRIM21), mRNA. 278.21 170.94 1.63 0.050 107.26 
IL10RB Homo sapiens interleukin 10 receptor, beta (IL10RB), mRNA. 1123.71 685.83 1.64 0.013 437.87 
MSRB2 Homo sapiens methionine sulfoxide reductase B2 (MSRB2), mRNA. 366.04 223.77 1.64 0.045 142.27 
SEC22B Homo sapiens SEC22 vesicle trafficking protein homolog B (S. cerevisiae) (SEC22B), mRNA. 355.74 216.87 1.64 0.000 138.88 
JMJD6 Homo sapiens jumonji domain containing 6 (JMJD6), transcript variant 2, mRNA. 273.77 166.14 1.65 0.011 107.63 
NDUFA6 
Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14kDa (NDUFA6), nuclear gene encoding mitochondrial protein, 
mRNA. 495.87 300.79 1.65 2.00E-04 195.07 
PDCL3 Homo sapiens phosducin-like 3 (PDCL3), mRNA. 306.94 186.47 1.65 0.014 120.48 
FAM53C Homo sapiens family with sequence similarity 53, member C (FAM53C), mRNA. 534.85 322.13 1.66 0.005 212.71 
LIME1 Homo sapiens Lck interacting transmembrane adaptor 1 (LIME1), mRNA. 1091.52 658.49 1.66 0.002 433.03 
NUP133 Homo sapiens nucleoporin 133kDa (NUP133), mRNA. 363.05 219.07 1.66 0.000 143.98 
DHPS Homo sapiens deoxyhypusine synthase (DHPS), transcript variant 2, mRNA. 412.48 246.29 1.67 0.000 166.19 
GGA3 Homo sapiens golgi associated, gamma adaptin ear containing, ARF binding protein 3 (GGA3), transcript variant long, mRNA. 451.54 270.32 1.67 0.000 181.22 
LDLRAP1 Homo sapiens low density lipoprotein receptor adaptor protein 1 (LDLRAP1), mRNA. 263.00 157.86 1.67 0.034 105.14 
KLHDC3 Homo sapiens kelch domain containing 3 (KLHDC3), mRNA. 559.83 332.27 1.68 0.003 227.56 
RIPK3 Homo sapiens receptor-interacting serine-threonine kinase 3 (RIPK3), mRNA. 280.32 166.48 1.68 0.041 113.84 
NOL11 Homo sapiens nucleolar protein 11 (NOL11), mRNA. 740.98 437.53 1.69 0.000 303.46 
C5orf51 Homo sapiens chromosome 5 open reading frame 51 (C5orf51), mRNA. 276.35 162.89 1.70 0.002 113.46 
CIAO1 Homo sapiens cytosolic iron-sulfur protein assembly 1 homolog (S. cerevisiae) (CIAO1), mRNA. 898.86 528.02 1.70 0.022 370.83 
MRPS15 Homo sapiens mitochondrial ribosomal protein S15 (MRPS15), nuclear gene encoding mitochondrial protein, mRNA. 582.83 342.20 1.70 0.012 240.63 
PIK3CD Homo sapiens phosphoinositide-3-kinase, catalytic, delta polypeptide (PIK3CD), mRNA. 646.39 379.88 1.70 0.035 266.50 
LOC88523 Homo sapiens CG016 (LOC88523), mRNA. 641.30 375.85 1.71 0.039 265.45 
URM1 Homo sapiens ubiquitin related modifier 1 homolog (S. cerevisiae) (URM1), mRNA. 827.47 482.73 1.71 0.043 344.75 
B9D2 Homo sapiens B9 protein domain 2 (B9D2), mRNA. 304.10 176.79 1.72 0.000 127.31 
ECHS1 Homo sapiens enoyl Coenzyme A hydratase, short chain, 1, mitochondrial (ECHS1), nuclear gene encoding mitochondrial protein, mRNA. 569.00 330.88 1.72 0.006 238.13 
GRAP Homo sapiens GRB2-related adaptor protein (GRAP), mRNA. 925.18 538.24 1.72 0.002 386.94 
SCYL1 Homo sapiens SCY1-like 1 (S. cerevisiae) (SCYL1), transcript variant A, mRNA. 970.52 564.64 1.72 0.006 405.88 
ATG16L1 Homo sapiens ATG16 autophagy related 16-like 1 (S. cerevisiae) (ATG16L1), transcript variant 1, mRNA. 1611.24 933.75 1.73 0.000 677.48 
NUCB2 Homo sapiens nucleobindin 2 (NUCB2), mRNA. 421.54 243.80 1.73 1.00E-04 177.74 
SUMF2 Homo sapiens sulfatase modifying factor 2 (SUMF2), transcript variant 4, mRNA. 1141.24 650.91 1.75 0.000 490.33 
DHPS Homo sapiens deoxyhypusine synthase (DHPS), transcript variant 2, mRNA. 342.87 194.38 1.76 0.000 148.49 
RALGDS Homo sapiens ral guanine nucleotide dissociation stimulator (RALGDS), transcript variant 1, mRNA. 613.44 348.98 1.76 0.000 264.46 
TYSND1 Homo sapiens trypsin domain containing 1 (TYSND1), transcript variant 2, mRNA. 363.75 206.31 1.76 0.000 157.44 
APPL2 Homo sapiens adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2 (APPL2), mRNA. 361.89 204.40 1.77 0.001 157.50 
GBA Homo sapiens glucosidase, beta; acid (includes glucosylceramidase) (GBA), transcript variant 3, mRNA. 347.99 195.50 1.78 0.023 152.49 
MRPL23 Homo sapiens mitochondrial ribosomal protein L23 (MRPL23), nuclear gene encoding mitochondrial protein, mRNA. 449.72 252.15 1.78 0.000 197.57 
EGLN2 Homo sapiens egl nine homolog 2 (C. elegans) (EGLN2), transcript variant 1, mRNA. 473.73 264.25 1.79 0.007 209.47 
PPP4C Homo sapiens protein phosphatase 4 (formerly X), catalytic subunit (PPP4C), mRNA. 597.57 332.64 1.80 0.000 264.94 
PRPF8 Homo sapiens PRP8 pre-mRNA processing factor 8 homolog (S. cerevisiae) (PRPF8), mRNA. 1361.06 756.23 1.80 0.000 604.84 
ZBTB33 Homo sapiens zinc finger and BTB domain containing 33 (ZBTB33), mRNA. 704.50 389.31 1.81 0.034 315.20 
ATG16L1 Homo sapiens ATG16 autophagy related 16-like 1 (S. cerevisiae) (ATG16L1), transcript variant 2, mRNA. 841.75 462.89 1.82 0.000 378.86 
ERCC3 
Homo sapiens excision repair cross-complementing rodent repair deficiency, complementation group 3 (xeroderma pigmentosum group B 
complementing) (ERCC3), mRNA. 465.83 256.63 1.82 8.00E-04 209.20 
MRPL27 Homo sapiens mitochondrial ribosomal protein L27 (MRPL27), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA. 310.38 170.10 1.82 0.015 140.28 
DNTTIP1 Homo sapiens deoxynucleotidyltransferase, terminal, interacting protein 1 (DNTTIP1), mRNA. 242.40 130.77 1.85 1.00E-04 111.64 
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TCP1 Homo sapiens t-complex 1 (TCP1), transcript variant 1, mRNA. 219.72 117.51 1.87 6.00E-04 102.21 
IDH3G 
Homo sapiens isocitrate dehydrogenase 3 (NAD+) gamma (IDH3G), nuclear gene encoding mitochondrial protein, transcript variant 2, 
mRNA. 467.25 248.57 1.88 7.00E-04 218.67 
TMEM101 Homo sapiens transmembrane protein 101 (TMEM101), mRNA. 291.48 155.27 1.88 0.009 136.21 
FAM160A2 Homo sapiens family with sequence similarity 160, member A2 (FAM160A2), transcript variant 2, mRNA. 287.42 152.37 1.89 7.00E-04 135.05 
HAX1 Homo sapiens HCLS1 associated protein X-1 (HAX1), transcript variant 1, mRNA. 968.01 512.48 1.89 0.000 455.53 
RP9 Homo sapiens retinitis pigmentosa 9 (autosomal dominant) (RP9), mRNA. 547.28 289.12 1.89 0.000 258.16 
PGLS Homo sapiens 6-phosphogluconolactonase (PGLS), mRNA. 476.49 249.59 1.91 0.000 226.89 
ATP6V0E2 Homo sapiens ATPase, H+ transporting V0 subunit e2 (ATP6V0E2), transcript variant 1, mRNA. 985.70 513.44 1.92 0.002 472.26 
TULP4 Homo sapiens tubby like protein 4 (TULP4), transcript variant 2, mRNA. 269.50 140.40 1.92 0.000 129.10 
SCYL1 Homo sapiens SCY1-like 1 (S. cerevisiae) (SCYL1), mRNA. 465.74 241.81 1.93 0.000 223.93 
P4HTM Homo sapiens prolyl 4-hydroxylase, transmembrane (endoplasmic reticulum) (P4HTM), transcript variant 3, mRNA. 316.89 163.24 1.94 0.001 153.65 
PRKAG1 Homo sapiens protein kinase, AMP-activated, gamma 1 non-catalytic subunit (PRKAG1), transcript variant 1, mRNA. 271.27 139.80 1.94 0.033 131.48 
DYRK4 Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4 (DYRK4), mRNA. 274.69 140.59 1.95 0.000 134.10 
CBY1 Homo sapiens chibby homolog 1 (Drosophila) (CBY1), transcript variant 1, mRNA. 232.57 118.06 1.97 0.000 114.50 
SELS Homo sapiens selenoprotein S (SELS), transcript variant 2, mRNA. 391.24 197.35 1.98 0.000 193.89 
WDR51A Homo sapiens WD repeat domain 51A (WDR51A), mRNA. 207.80 104.13 2.00 1.00E-04 103.67 
SLC5A6 Homo sapiens solute carrier family 5 (sodium-dependent vitamin transporter), member 6 (SLC5A6), mRNA. 389.67 192.21 2.03 0.000 197.46 
TMEM115 Homo sapiens transmembrane protein 115 (TMEM115), mRNA. 315.32 155.13 2.03 0.017 160.19 
CEP55 Homo sapiens centrosomal protein 55kDa (CEP55), mRNA. 198.52 97.15 2.04 0.024 101.38 
SLC24A6 Homo sapiens solute carrier family 24 (sodium/potassium/calcium exchanger), member 6 (SLC24A6), mRNA. 306.31 149.95 2.04 0.000 156.37 
DSCR3 Homo sapiens Down syndrome critical region gene 3 (DSCR3), mRNA. 518.76 253.28 2.05 0.000 265.48 
WDR23 Homo sapiens WD repeat domain 23 (WDR23), transcript variant 1, mRNA. 866.31 416.77 2.08 0.000 449.54 
NOD1 Homo sapiens nucleotide-binding oligomerization domain containing 1 (NOD1), mRNA. 325.70 156.03 2.09 0.000 169.68 
PKP4 Homo sapiens plakophilin 4 (PKP4), transcript variant 1, mRNA. 519.08 243.16 2.13 0.007 275.92 
ABCB6 Homo sapiens ATP-binding cassette, sub-family B (MDR/TAP), member 6 (ABCB6), nuclear gene encoding mitochondrial protein, mRNA. 234.42 107.92 2.17 0.042 126.50 
PLIN2 Homo sapiens perilipin 2 (PLIN2), mRNA. 737.37 331.91 2.22 0.005 405.46 
PTPN4 Homo sapiens protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) (PTPN4), mRNA. 675.95 303.08 2.23 0.032 372.87 
ZBTB42 Homo sapiens zinc finger and BTB domain containing 42 (ZBTB42), mRNA. 254.34 109.84 2.32 0.000 144.50 
CISH Homo sapiens cytokine inducible SH2-containing protein (CISH), mRNA. 355.92 152.46 2.33 0.010 203.46 
C1orf50 Homo sapiens chromosome 1 open reading frame 50 (C1orf50), mRNA. 349.97 134.85 2.60 0.022 215.13 
PRPF4 Homo sapiens PRP4 pre-mRNA processing factor 4 homolog (yeast) (PRPF4), mRNA. 453.50 170.42 2.66 0.019 283.08 
ZBP1 Homo sapiens Z-DNA binding protein 1 (ZBP1), mRNA. 432.80 160.00 2.71 0.000 272.80 
HLA-DQB1 Homo sapiens major histocompatibility complex, class II, DQ beta 1 (HLA-DQB1), mRNA. 405.82 148.33 2.74 1.00E-04 257.49 
NUSAP1 Homo sapiens nucleolar and spindle associated protein 1 (NUSAP1), transcript variant 2, mRNA. 437.93 151.71 2.89 0.030 286.22 
C19orf12 Homo sapiens chromosome 19 open reading frame 12 (C19orf12), transcript variant 1, mRNA. 744.45 196.04 3.80 0.000 548.41 
 
 
Comparison CD4+CD25high T cells of MF- individuals versus EN 
Symbol Definition mean_Treg_MFneg mean_Treg_EN FC pvalue diff 
ZNF25 Homo sapiens zinc finger protein 25 (ZNF25), mRNA. 167.95 414.44 -2.47 0.005 246.49 
C14orf80 Homo sapiens chromosome 14 open reading frame 80 (C14orf80), mRNA. 139.80 343.55 -2.46 0.016 203.76 
C5orf28 Homo sapiens chromosome 5 open reading frame 28 (C5orf28), mRNA. 461.16 962.96 -2.09 0.003 501.80 
KLF11 PREDICTED: Homo sapiens Kruppel-like factor 11 (KLF11), mRNA. 337.11 673.06 -2.00 0.050 335.94 
EMILIN2 Homo sapiens elastin microfibril interfacer 2 (EMILIN2), mRNA. 256.94 495.64 -1.93 0.033 238.70 
NUFIP2 Homo sapiens nuclear fragile X mental retardation protein interacting protein 2 (NUFIP2), mRNA. 463.78 885.99 -1.91 0.005 422.21 
LOC10012809
8 PREDICTED: Homo sapiens hypothetical protein LOC100128098 (LOC100128098), mRNA. 350.72 660.87 -1.88 0.039 310.15 
WDR36 Homo sapiens WD repeat domain 36 (WDR36), mRNA. 161.41 298.22 -1.85 0.010 136.8 
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CTBS Homo sapiens chitobiase, di-N-acetyl- (CTBS), mRNA. 138.56 248.84 -1.80 0.000 110.28 
EIF4A1 Homo sapiens eukaryotic translation initiation factor 4A, isoform 1 (EIF4A1), mRNA. 316.44 560.08 -1.77 0.011 243.63 
TNFSF15 Homo sapiens tumor necrosis factor (ligand) superfamily, member 15 (TNFSF15), mRNA. 144.89 254.41 -1.76 0.012 109.52 
NDUFS3 Homo sapiens NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-coenzyme Q reductase) (NDUFS3), mRNA. 736.94 1286.87 -1.75  549.92 
TGFBR3 Homo sapiens transforming growth factor, beta receptor III (TGFBR3), mRNA. 179.21 310.57 -1.73 0.002 131.35 
GSTTP2 Homo sapiens glutathione S-transferase theta pseudogene 2 (GSTTP2), non-coding RNA. XM_941198 XM_945014 XM_945016 159.46 270.16 -1.69 0.038 110.69 
C7orf26 Homo sapiens chromosome 7 open reading frame 26 (C7orf26), mRNA. 262.59 436.54 -1.66 0.000 173.94 
CDCA4 Homo sapiens cell division cycle associated 4 (CDCA4), transcript variant 14, mRNA. 253.65 418.88 -1.65  165.23 
DUSP19 Homo sapiens dual specificity phosphatase 19 (DUSP19), mRNA. 1280.88 2112.64 -1.65 0.039 831.75 
HCG2P7 Homo sapiens HLA complex group 2 pseudogene 7 (HCG2P7), non-coding RNA. 1651.11 2713.9 -1.64 0.033 1062.8 
RARS Homo sapiens arginyl-tRNA synthetase (RARS), mRNA. 685.23 1121.84 -1.64 0.050 436.62 
TDRD1 Homo sapiens tudor domain containing 1 (TDRD1), mRNA. 206.62 333.79 -1.62 0.004 127.17 
CREB1 Homo sapiens cAMP responsive element binding protein 1 (CREB1), transcript variant A, mRNA. 907.14 1458.17 -1.61 0.015 551.03 
FCAR Homo sapiens Fc fragment of IgA, receptor for (FCAR), transcript variant 9, mRNA. 175.43 280.67 -1.60 0.039 105.24 
FAM63A Homo sapiens family with sequence similarity 63, member A (FAM63A), transcript variant 1, mRNA. 292.52 463.15 -1.58 0.014 170.63 
SNAPC1 Homo sapiens small nuclear RNA activating complex, polypeptide 1, 43kDa (SNAPC1), mRNA. 176.48 279.15 -1.58 0.026 102.67 
C15orf17 Homo sapiens chromosome 15 open reading frame 17 (C15orf17), mRNA. 213.69 335.64 -1.57 0.006 121.95 
C6orf125 Homo sapiens chromosome 6 open reading frame 125 (C6orf125), mRNA. 198.26 309.35 -1.56 0.003 111.09 
DGUOK Homo sapiens deoxyguanosine kinase (DGUOK), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 548.61 857.06 -1.56 0.025 308.45 
C9orf80 Homo sapiens chromosome 9 open reading frame 80 (C9orf80), mRNA. 1759.62 2725.44 -1.55 0.024 965.82 
ZNF577 Homo sapiens zinc finger protein 577 (ZNF577), mRNA. 289.07 445.30 -1.54 0.016 156.23 
HDGF Homo sapiens hepatoma-derived growth factor (high-mobility group protein 1-like) (HDGF), mRNA. 403.88 268.45 1.50 0.000 135.43 
POLR3GL Homo sapiens polymerase (RNA) III (DNA directed) polypeptide G (32kD)-like (POLR3GL), mRNA. 1282.69 854.63 1.50 0.042 428.06 
SASH3 Homo sapiens SAM and SH3 domain containing 3 (SASH3), mRNA. 509.26 336.81 1.51 0.004 172.46 
LOC728855 Homo sapiens hypothetical LOC728855 (LOC728855), non-coding RNA. 1310.43 860.91 1.52 0.036 449.52 
MTDH Homo sapiens metadherin (MTDH), mRNA. 486.72 319.40 1.52 0.034 167.32 
ACTB Homo sapiens actin, beta (ACTB), mRNA. 7970.05 5201.06 1.53 0.024 2768.98 
COPZ1 Homo sapiens coatomer protein complex, subunit zeta 1 (COPZ1), mRNA. 521.25 339.61 1.53 0.000 181.64 
HLA-H Homo sapiens major histocompatibility complex, class I, H (pseudogene) (HLA-H), non-coding RNA. 2708.25 1771.84 1.53 0.043 936.41 
LRP10 Homo sapiens low density lipoprotein receptor-related protein 10 (LRP10), mRNA. 1079.75 705.31 1.53 0.024 374.44 
ACTB Homo sapiens actin, beta (ACTB), mRNA. 6116.64 3933.68 1.55 0.016 2182.96 
AP1G2 Homo sapiens adaptor-related protein complex 1, gamma 2 subunit (AP1G2), mRNA. 403.43 260.67 1.55 0.040 142.76 
ACTL6A Homo sapiens actin-like 6A (ACTL6A), transcript variant 1, mRNA. 300.87 192.68 1.56 0.036 108.19 
 full-length cDNA clone CS0DI056YK21 of Placenta Cot 25-normalized of Homo sapiens (human) 4649.60 2989.98 1.56 0.047 1659.63 
CMTM6 Homo sapiens CKLF-like MARVEL transmembrane domain containing 6 (CMTM6), mRNA. 491.17 312.14 1.57 0.027 179.04 
TMED9 Homo sapiens transmembrane emp24 protein transport domain containing 9 (TMED9), mRNA. 759.35 484.26 1.57 0.024 275.09 
UGP2 Homo sapiens UDP-glucose pyrophosphorylase 2 (UGP2), transcript variant 1, mRNA. 767.97 489.61 1.57 0.034 278.36 
ZFP106 Homo sapiens zinc finger protein 106 homolog (mouse) (ZFP106), mRNA. 374.39 238.15 1.57 0.030 136.24 
NUCB2 Homo sapiens nucleobindin 2 (NUCB2), mRNA. 421.54 266.81 1.58 0.022 154.73 
C2orf28 Homo sapiens chromosome 2 open reading frame 28 (C2orf28), transcript variant 2, mRNA. 1143.09 717.91 1.59 0.001 425.18 
C5orf51 Homo sapiens chromosome 5 open reading frame 51 (C5orf51), mRNA. 276.35 171.79 1.61 9.00E-04 104.56 
SETD3 Homo sapiens SET domain containing 3 (SETD3), transcript variant 1, mRNA. 2732.58 1691.14 1.62 1.00E-04 1041.44 
PTPRCAP Homo sapiens protein tyrosine phosphatase, receptor type, C-associated protein (PTPRCAP), mRNA. 1199.45 725.18 1.65 0.007 474.27 
ZHX2 Homo sapiens zinc fingers and homeoboxes 2 (ZHX2), mRNA. 302.63 182.89 1.65 0.004 119.74 
LOC647000 PREDICTED: Homo sapiens similar to tubulin, beta 5 (LOC647000), mRNA. 574.26 345.86 1.66 0.026 228.40 
TRAPPC6A Homo sapiens trafficking protein particle complex 6A (TRAPPC6A), mRNA. 1005.63 599.62 1.68 0.030 406.01 
EFTUD1 Homo sapiens elongation factor Tu GTP binding domain containing 1 (EFTUD1), transcript variant 1, mRNA. 479.11 284.22 1.69 0.006 194.89 
GBP1 Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA. 576.91 341.13 1.69 0.025 235.79 
GGA3 Homo sapiens golgi associated, gamma adaptin ear containing, ARF binding protein 3 (GGA3), transcript variant long, mRNA. 451.54 265.21 1.70 0.042 186.33 
HAX1 Homo sapiens HCLS1 associated protein X-1 (HAX1), transcript variant 1, mRNA. 968.01 569.18 1.70 4.00E-04 398.83 
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CCDC115 Homo sapiens coiled-coil domain containing 115 (CCDC115), mRNA. 555.72 325.20 1.71 0.005 230.52 
LOC651894 PREDICTED: Homo sapiens similar to ribosomal protein S12 (LOC651894), mRNA. 799.74 468.03 1.71 0.048 331.71 
STRADB Homo sapiens STE20-related kinase adaptor beta (STRADB), mRNA. 369.55 216.63 1.71 0.005 152.93 
PRKAB2 Homo sapiens protein kinase, AMP-activated, beta 2 non-catalytic subunit (PRKAB2), mRNA. 317.91 183.34 1.73 4.00E-04 134.58 
PAPSS1 Homo sapiens 3'-phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1), mRNA. 258.25 148.80 1.74 0.026 109.45 
ACLY Homo sapiens ATP citrate lyase (ACLY), transcript variant 2, mRNA. 852.70 487.06 1.75 0.014 365.64 
KATNA1 Homo sapiens katanin p60 (ATPase-containing) subunit A 1 (KATNA1), mRNA. 394.41 225.13 1.75 0.031 169.29 
EFTUD1 Homo sapiens elongation factor Tu GTP binding domain containing 1 (EFTUD1), transcript variant 1, mRNA. 470.30 267.29 1.76 3.00E-04 203.00 
SEC11C Homo sapiens SEC11 homolog C (S. cerevisiae) (SEC11C), mRNA. 1051.34 589.43 1.78 0.011 461.91 
STAT1 Homo sapiens signal transducer and activator of transcription 1, 91kDa (STAT1), transcript variant alpha, mRNA. 2334.42 1290.43 1.81 1.00E-04 1043.99 
ATAD1 Homo sapiens ATPase family, AAA domain containing 1 (ATAD1), mRNA. 226.36 124.18 1.82 6.00E-04 102.18 
MTMR10 Homo sapiens myotubularin related protein 10 (MTMR10), mRNA. 249.05 135.66 1.84 0.013 113.39 
UNG Homo sapiens uracil-DNA glycosylase (UNG), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 801.35 435.34 1.84 0.031 366.01 
KIAA1712 Homo sapiens KIAA1712 (KIAA1712), mRNA. 240.55 130.18 1.85 0.007 110.38 
TYW1 Homo sapiens tRNA-yW synthesizing protein 1 homolog (S. cerevisiae) (TYW1), mRNA. 269.78 145.52 1.85 0.021 124.26 
GBP1 Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA. 798.38 425.20 1.88 0.001 373.18 
ST3GAL5 Homo sapiens ST3 beta-galactoside alpha-2,3-sialyltransferase 5 (ST3GAL5), transcript variant 2, mRNA. 370.70 196.80 1.88 0.000 173.90 
NMRAL1 Homo sapiens NmrA-like family domain containing 1 (NMRAL1), mRNA. 404.64 214.63 1.89 0.040 190.01 
CDK7 Homo sapiens cyclin-dependent kinase 7 (MO15 homolog, Xenopus laevis, cdk-activating kinase) (CDK7), mRNA. 567.30 294.32 1.93 0.047 272.98 
ATP6V1D Homo sapiens ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D (ATP6V1D), mRNA. 986.61 508.36 1.94 4.00E-04 478.25 
CCT4 Homo sapiens chaperonin containing TCP1, subunit 4 (delta) (CCT4), mRNA. 211.97 108.48 1.95 0.005 103.48 
ZNF721 Homo sapiens zinc finger protein 721 (ZNF721), mRNA. 364.58 185.12 1.97 0.015 179.46 
ZC3HC1 Homo sapiens zinc finger, C3HC-type containing 1 (ZC3HC1), mRNA. 595.91 297.95 2.00 0.045 297.96 
ZNF845 Homo sapiens zinc finger protein 845 (ZNF845), mRNA. XM_039908 255.64 128.06 2.00 1.00E-04 127.57 
TOR1AIP1 Homo sapiens torsin A interacting protein 1 (TOR1AIP1), mRNA. 327.09 162.42 2.01 1.00E-04 164.67 
TULP4 Homo sapiens tubby like protein 4 (TULP4), transcript variant 2, mRNA. 269.50 133.28 2.02 0.003 136.22 
C13orf23 Homo sapiens chromosome 13 open reading frame 23 (C13orf23), transcript variant 1, mRNA. 267.11 131.32 2.03 0.018 135.79 
C13orf23 Homo sapiens chromosome 13 open reading frame 23 (C13orf23), transcript variant 1, mRNA. 270.96 132.94 2.04 0.006 138.02 
SPIN3 Homo sapiens spindlin family, member 3 (SPIN3), mRNA. 214.40 105.10 2.04 4.00E-04 109.29 
ERGIC3 Homo sapiens ERGIC and golgi 3 (ERGIC3), transcript variant 1, mRNA. 599.19 291.97 2.05 0.016 307.21 
AKR1A1 Homo sapiens aldo-keto reductase family 1, member A1 (aldehyde reductase) (AKR1A1), transcript variant 1, mRNA. 887.22 431.33 2.06 0.000 455.89 
HDDC3 Homo sapiens HD domain containing 3 (HDDC3), mRNA. 342.90 163.04 2.10 3.00E-04 179.86 
ZNF160 Homo sapiens zinc finger protein 160 (ZNF160), transcript variant 2, mRNA. 208.38 99.01 2.10 0.000 109.37 
PTPRE Homo sapiens protein tyrosine phosphatase, receptor type, E (PTPRE), transcript variant 2, mRNA. 313.64 147.67 2.12 0.004 165.98 
LOC88523 Homo sapiens CG016 (LOC88523), mRNA. 641.30 298.34 2.15 0.010 342.96 
GLB1 Homo sapiens galactosidase, beta 1 (GLB1), transcript variant 179423, mRNA. 646.62 297.54 2.17 0.024 349.08 
SDAD1 Homo sapiens SDA1 domain containing 1 (SDAD1), mRNA. 725.52 331.02 2.19 0.015 394.50 
AGBL5 Homo sapiens ATP/GTP binding protein-like 5 (AGBL5), transcript variant 3, mRNA. 244.79 110.02 2.22 0.000 134.76 
 Homo sapiens cDNA FLJ46527 fis, clone THYMU3034853 700.65 307.32 2.28 0.013 393.34 
DHX29 Homo sapiens DEAH (Asp-Glu-Ala-His) box polypeptide 29 (DHX29), mRNA. 376.41 161.47 2.33 0.000 214.94 
PSMB5 Homo sapiens proteasome (prosome, macropain) subunit, beta type, 5 (PSMB5), mRNA. 440.08 187.96 2.34 0.009 252.12 
HAVCR2 Homo sapiens hepatitis A virus cellular receptor 2 (HAVCR2), mRNA. 288.43 121.52 2.37 0.008 166.91 
TM9SF1 Homo sapiens transmembrane 9 superfamily member 1 (TM9SF1), transcript variant 1, mRNA. 253.47 105.56 2.40 0.027 147.91 
FLJ14213 Homo sapiens protor-2 (FLJ14213), mRNA. 447.49 177.52 2.52 0.050 269.98 
FBXO28 Homo sapiens F-box protein 28 (FBXO28), mRNA. 266.26 104.97 2.54 0.000 161.30 
FAM69A Homo sapiens family with sequence similarity 69, member A (FAM69A), mRNA. 375.80 105.31 3.57 1.00E-04 270.49 
D4S234E Homo sapiens DNA segment on chromosome 4 (unique) 234 expressed sequence (D4S234E), transcript variant 2, mRNA. 314.39 85.62 3.67 0.000 228.77 
HBB Homo sapiens hemoglobin, beta (HBB), mRNA. 1184.93 134.17 8.83 0.004 1050.77 
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Comparison CD4+CD25high T cells of MF+ individuals versus EN 
Symbol Definition mean_Treg_Mfpos mean_Treg_EN FC pvalue diff 
LOC729708 PREDICTED: Homo sapiens similar to rcTPI1, transcript variant 1 (LOC729708), mRNA. 205.33 1117.91 -5.44 0.049 912.58 
CASZ1 Homo sapiens castor zinc finger 1 (CASZ1), transcript variant 2, mRNA. 84.59 324.37 -3.83 0.035 239.78 
NUSAP1 Homo sapiens nucleolar and spindle associated protein 1 (NUSAP1), transcript variant 2, mRNA. 151.71 533.66 -3.52 0.022 381.95 
CCR3 Homo sapiens chemokine (C-C motif) receptor 3 (CCR3), transcript variant 2, mRNA. 107.61 321.38 -2.99 0.042 213.77 
C14orf80 Homo sapiens chromosome 14 open reading frame 80 (C14orf80), mRNA. 117.71 343.55 -2.92 0.003 225.85 
ARHGAP10 Homo sapiens Rho GTPase activating protein 10 (ARHGAP10), mRNA. 112.63 310.32 -2.76 0.019 197.69 
C19orf12 Homo sapiens chromosome 19 open reading frame 12 (C19orf12), transcript variant 1, mRNA. 196.04 491.80 -2.51 0.039 295.76 
PLIN2 Homo sapiens perilipin 2 (PLIN2), mRNA. 331.91 742.70 -2.24 0.003 410.79 
WDR23 Homo sapiens WD repeat domain 23 (WDR23), transcript variant 1, mRNA. 416.77 934.72 -2.24 0.000 517.95 
C20orf20 Homo sapiens chromosome 20 open reading frame 20 (C20orf20), mRNA. 376.94 820.99 -2.18 0.009 444.05 
C3orf75 Homo sapiens chromosome 3 open reading frame 75 (C3orf75), mRNA. 141.79 307.72 -2.17 0.032 165.94 
DPH3 Homo sapiens DPH3, KTI11 homolog (S. cerevisiae) (DPH3), transcript variant 2, mRNA. 118.62 252.77 -2.13 0.026 134.15 
E4F1 Homo sapiens E4F transcription factor 1 (E4F1), mRNA. 319.10 670.87 -2.10 0.006 351.77 
NDUFA6 
Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14kDa (NDUFA6), nuclear gene encoding mitochondrial protein, 
mRNA. 300.79 630.14 -2.09 9.00E-04 329.35 
MED20 Homo sapiens mediator complex subunit 20 (MED20), mRNA. 128.04 266.14 -2.08 0.000 138.10 
MRPL23 Homo sapiens mitochondrial ribosomal protein L23 (MRPL23), nuclear gene encoding mitochondrial protein, mRNA. 252.15 525.26 -2.08 0.002 273.11 
VPS18 Homo sapiens vacuolar protein sorting 18 homolog (S. cerevisiae) (VPS18), mRNA. 97.02 202.05 -2.08 3.00E-04 105.03 
B4GALT4 Homo sapiens UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 4 (B4GALT4), transcript variant 2, mRNA. 104.36 208.99 -2.00 0.007 104.64 
TFIP11 Homo sapiens tuftelin interacting protein 11 (TFIP11), transcript variant 2, mRNA. 165.54 330.18 -1.99 0.000 164.64 
NASP Homo sapiens nuclear autoantigenic sperm protein (histone-binding) (NASP), transcript variant 2, mRNA. 194.59 385.22 -1.98 0.043 190.62 
TCP1 Homo sapiens t-complex 1 (TCP1), transcript variant 1, mRNA. 117.51 232.77 -1.98 0.000 115.26 
DPH3 Homo sapiens DPH3, KTI11 homolog (S. cerevisiae) (DPH3), transcript variant 1, mRNA. 111.44 219.25 -1.97 0.017 107.81 
PMM2 Homo sapiens phosphomannomutase 2 (PMM2), mRNA. 172.62 340.81 -1.97 0.041 168.19 
RABL4 Homo sapiens RAB, member of RAS oncogene family-like 4 (RABL4), mRNA. 154.62 304.58 -1.97 0.029 149.96 
C6orf125 Homo sapiens chromosome 6 open reading frame 125 (C6orf125), mRNA. 158.76 309.35 -1.95 4.00E-04 150.59 
MED22 Homo sapiens mediator complex subunit 22 (MED22), transcript variant c, mRNA. 264.49 509.62 -1.93 0.025 245.13 
PGM1 Homo sapiens phosphoglucomutase 1 (PGM1), mRNA. 524.53 1003.63 -1.91 0.000 479.11 
LAIR2 Homo sapiens leukocyte-associated immunoglobulin-like receptor 2 (LAIR2), transcript variant 1, mRNA. 120.38 229.24 -1.90 0.022 108.86 
MAD2L2 Homo sapiens MAD2 mitotic arrest deficient-like 2 (yeast) (MAD2L2), mRNA. 175.41 332.78 -1.90 0.004 157.37 
TFIP11 Homo sapiens tuftelin interacting protein 11 (TFIP11), transcript variant 2, mRNA. 265.59 505.62 -1.90 0.000 240.02 
C9orf119 Homo sapiens chromosome 9 open reading frame 119 (C9orf119), mRNA. 153.16 285.58 -1.86 0.007 132.42 
EIF4A1 Homo sapiens eukaryotic translation initiation factor 4A, isoform 1 (EIF4A1), mRNA. 300.68 560.08 -1.86 0.003 259.40 
DCPS Homo sapiens decapping enzyme, scavenger (DCPS), mRNA. 144.34 262.91 -1.82 0.006 118.56 
ERCC3 
Homo sapiens excision repair cross-complementing rodent repair deficiency, complementation group 3 (xeroderma pigmentosum group B 
complementing) (ERCC3), mRNA. 256.63 467.88 -1.82 0.010 211.24 
NDUFB11 Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11, 17.3kDa (NDUFB11), mRNA. 544.28 991.59 -1.82 0.003 447.31 
RALGDS Homo sapiens ral guanine nucleotide dissociation stimulator (RALGDS), transcript variant 1, mRNA. 348.98 635.06 -1.82 0.000 286.09 
PRPF38A Homo sapiens PRP38 pre-mRNA processing factor 38 (yeast) domain containing A (PRPF38A), mRNA. 173.05 313.46 -1.81 0.035 140.41 
DDX56 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 56 (DDX56), mRNA. 233.17 420.06 -1.80 0.002 186.89 
WDR36 Homo sapiens WD repeat domain 36 (WDR36), mRNA. 166.25 298.22 -1.79 0.000 131.96 
PGLS Homo sapiens 6-phosphogluconolactonase (PGLS), mRNA. 249.59 437.79 -1.75 0.044 188.19 
C16orf63 Homo sapiens chromosome 16 open reading frame 63 (C16orf63), mRNA. 217.28 377.21 -1.74 0.025 159.94 
ZFYVE20 Homo sapiens zinc finger, FYVE domain containing 20 (ZFYVE20), mRNA. 157.98 274.60 -1.74 0.000 116.62 
NOL11 Homo sapiens nucleolar protein 11 (NOL11), mRNA. 437.53 756.41 -1.73 0.000 318.89 
C16orf33 Homo sapiens chromosome 16 open reading frame 33 (C16orf33), mRNA. 181.19 311.20 -1.72 0.043 130.00 
ECHDC2 Homo sapiens enoyl Coenzyme A hydratase domain containing 2 (ECHDC2), mRNA. 1156.02 1985.37 -1.72 0.000 829.35 
CCS Homo sapiens copper chaperone for superoxide dismutase (CCS), mRNA. 196.03 335.98 -1.71 0.005 139.95 
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STK39 Homo sapiens serine threonine kinase 39 (STE20/SPS1 homolog, yeast) (STK39), mRNA. 473.65 803.38 -1.70 0.018 329.73 
IDH3G 
Homo sapiens isocitrate dehydrogenase 3 (NAD+) gamma (IDH3G), nuclear gene encoding mitochondrial protein, transcript variant 2, 
mRNA. 248.57 419.37 -1.69 0.002 170.8 
CHKB Homo sapiens choline kinase beta (CHKB), transcript variant 1, mRNA. 562.71 936.93 -1.67 0.041 374.21 
PMPCA Homo sapiens peptidase (mitochondrial processing) alpha (PMPCA), nuclear gene encoding mitochondrial protein, mRNA. 358.60 593.32 -1.65 0.046 234.72 
ATP6V0E2 Homo sapiens ATPase, H+ transporting V0 subunit e2 (ATP6V0E2), transcript variant 1, mRNA. 513.44 839.12 -1.63 0.047 325.68 
CCDC23 Homo sapiens coiled-coil domain containing 23 (CCDC23), mRNA. 204.06 321.85 -1.58 0.002 117.78 
RNF166 Homo sapiens ring finger protein 166 (RNF166), mRNA. 268.49 423.24 -1.58 0.010 154.76 
ATP6V1E1 Homo sapiens ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 (ATP6V1E1), transcript variant 3, mRNA. 1156.63 1810.84 -1.57 0.029 654.21 
C3orf37 Homo sapiens chromosome 3 open reading frame 37 (C3orf37), transcript variant 2, mRNA. 366.05 571.88 -1.56 2.00E-04 205.84 
C6orf153 Homo sapiens chromosome 6 open reading frame 153 (C6orf153), mRNA. 441.46 690.08 -1.56 0.026 248.62 
DAZAP1 Homo sapiens DAZ associated protein 1 (DAZAP1), transcript variant 1, mRNA. 232.75 357.00 -1.53 0.041 124.25 
ESD Homo sapiens esterase D/formylglutathione hydrolase (ESD), mRNA. 472.70 314.39 1.50 0.013 158.30 
STAT1 Homo sapiens signal transducer and activator of transcription 1, 91kDa (STAT1), transcript variant alpha, mRNA. 1948.62 1290.43 1.51 9.00E-04 658.19 
AHNAK Homo sapiens AHNAK nucleoprotein (AHNAK), transcript variant 1, mRNA. 2396.45 1573.23 1.52 0.029 823.22 
EDEM1 Homo sapiens ER degradation enhancer, mannosidase alpha-like 1 (EDEM1), mRNA. 441.97 290.29 1.52 0.048 151.68 
LOC728855 Homo sapiens hypothetical LOC728855 (LOC728855), non-coding RNA. 1305.32 860.91 1.52 0.001 444.41 
ATM Homo sapiens ataxia telangiectasia mutated (ATM), transcript variant 1, mRNA. 384.86 252.14 1.53 0.024 132.72 
ERH Homo sapiens enhancer of rudimentary homolog (Drosophila) (ERH), mRNA. 390.41 255.61 1.53 0.013 134.8 
PCID2 Homo sapiens PCI domain containing 2 (PCID2), mRNA. 1384.23 904.68 1.53 0.000 479.55 
SETD3 Homo sapiens SET domain containing 3 (SETD3), transcript variant 1, mRNA. 2584.25 1691.14 1.53 0.000 893.12 
ARL2BP Homo sapiens ADP-ribosylation factor-like 2 binding protein (ARL2BP), mRNA. 1346.08 875.39 1.54 0.014 470.69 
BAG3 Homo sapiens BCL2-associated athanogene 3 (BAG3), mRNA. 438.71 284.19 1.54 0.033 154.53 
CFL1 Homo sapiens cofilin 1 (non-muscle) (CFL1), mRNA. 2029.13 1321.30 1.54 0.000 707.83 
SRP14 Homo sapiens signal recognition particle 14kDa (homologous Alu RNA binding protein) (SRP14), mRNA. 494.85 320.27 1.55 0.000 174.58 
ACTB Homo sapiens actin, beta (ACTB), mRNA. 737.59 471.36 1.56 0.000 266.23 
ACTL6A Homo sapiens actin-like 6A (ACTL6A), transcript variant 2, mRNA. 578.00 369.75 1.56 0.035 208.24 
EEF1G Homo sapiens eukaryotic translation elongation factor 1 gamma (EEF1G), mRNA. XM_935976 XM_935977 XM_935978 XM_935979 1686.19 1081.67 1.56 0.005 604.52 
TPT1 Homo sapiens tumor protein, translationally-controlled 1 (TPT1), mRNA. 2987.72 1903.72 1.57 0.031 1084.00 
BIRC3 Homo sapiens baculoviral IAP repeat-containing 3 (BIRC3), transcript variant 1, mRNA. 2115.91 1332.42 1.59 0.004 783.49 
CBLL1 Homo sapiens Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1 (CBLL1), mRNA. 584.23 366.64 1.59 0.000 217.59 
SERBP1 Homo sapiens SERPINE1 mRNA binding protein 1 (SERBP1), transcript variant 3, mRNA. 286.23 179.43 1.60 0.023 106.80 
ATRIP Homo sapiens ATR interacting protein (ATRIP), transcript variant 2, mRNA. 363.05 225.43 1.61 0.008 137.62 
KDM3B Homo sapiens lysine (K)-specific demethylase 3B (KDM3B), mRNA. 351.63 218.73 1.61 0.046 132.91 
LOC644033 PREDICTED: Homo sapiens similar to similar to RPL23AP7 protein (LOC644033), mRNA. 613.32 377.84 1.62 0.000 235.47 
VAMP4 Homo sapiens vesicle-associated membrane protein 4 (VAMP4), transcript variant 1, mRNA. 317.31 195.73 1.62 0.007 121.58 
YY1 Homo sapiens YY1 transcription factor (YY1), mRNA. 489.69 302.14 1.62 0.003 187.55 
DOCK10 Homo sapiens dedicator of cytokinesis 10 (DOCK10), mRNA. 1098.04 674.47 1.63 0.013 423.57 
PHKB Homo sapiens phosphorylase kinase, beta (PHKB), transcript variant 1, mRNA. 397.44 244.38 1.63 3.00E-04 153.06 
SFRS1 Homo sapiens splicing factor, arginine/serine-rich 1 (SFRS1), transcript variant 2, mRNA. 1508.62 920.30 1.64 0.004 588.32 
CYFIP2 Homo sapiens cytoplasmic FMR1 interacting protein 2 (CYFIP2), transcript variant 3, mRNA. 3762.35 2283.71 1.65 1.00E-04 1478.63 
PARP9 Homo sapiens poly (ADP-ribose) polymerase family, member 9 (PARP9), mRNA. 559.37 338.08 1.65 0.030 221.29 
AKR1A1 Homo sapiens aldo-keto reductase family 1, member A1 (aldehyde reductase) (AKR1A1), transcript variant 1, mRNA. 725.99 431.33 1.68 0.012 294.66 
EIF2B1 Homo sapiens eukaryotic translation initiation factor 2B, subunit 1 alpha, 26kDa (EIF2B1), mRNA. 643.18 381.63 1.69 0.029 261.56 
XBP1 Homo sapiens X-box binding protein 1 (XBP1), transcript variant 1, mRNA. 726.60 430.46 1.69 0.030 296.14 
CAPRIN2 Homo sapiens caprin family member 2 (CAPRIN2), transcript variant 1, mRNA. 337.45 197.38 1.71 0.000 140.06 
EIF1AY Homo sapiens eukaryotic translation initiation factor 1A, Y-linked (EIF1AY), mRNA. 262.31 153.78 1.71 0.032 108.52 
COPS5 Homo sapiens COP9 constitutive photomorphogenic homolog subunit 5 (Arabidopsis) (COPS5), mRNA. 1281.88 743.49 1.72 0.005 538.38 
CYFIP2 Homo sapiens cytoplasmic FMR1 interacting protein 2 (CYFIP2), transcript variant 1, mRNA. 680.33 392.05 1.74 0.011 288.28 
FAM107B Homo sapiens family with sequence similarity 107, member B (FAM107B), mRNA. 2204.07 1259.4 1.75 0.012 944.68 
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ADAM17 Homo sapiens ADAM metallopeptidase domain 17 (ADAM17), mRNA. 432.84 244.35 1.77 0.023 188.50 
DUSP6 Homo sapiens dual specificity phosphatase 6 (DUSP6), transcript variant 2, mRNA. 319.83 181.15 1.77 1.00E-04 138.68 
PNKP Homo sapiens polynucleotide kinase 3'-phosphatase (PNKP), mRNA. 370.73 206.21 1.80 0.016 164.52 
TMEM126B Homo sapiens transmembrane protein 126B (TMEM126B), mRNA. 473.28 262.8 1.80 0.000 210.48 
COPS7A Homo sapiens COP9 constitutive photomorphogenic homolog subunit 7A (Arabidopsis) (COPS7A), mRNA. 454.71 251.16 1.81 0.003 203.55 
LOC200030 Homo sapiens neuroblastoma breakpoint family, member 11-like (LOC200030), mRNA. 1424.19 785.32 1.81 0.020 638.87 
TBK1 Homo sapiens TANK-binding kinase 1 (TBK1), mRNA. 785.24 433.53 1.81 0.007 351.71 
COPS3 Homo sapiens COP9 constitutive photomorphogenic homolog subunit 3 (Arabidopsis) (COPS3), mRNA. 775.11 424.61 1.83 0.000 350.50 
ST3GAL5 Homo sapiens ST3 beta-galactoside alpha-2,3-sialyltransferase 5 (ST3GAL5), transcript variant 2, mRNA. 362.32 196.80 1.84 0.000 165.52 
NAT5 Homo sapiens N-acetyltransferase 5 (GCN5-related, putative) (NAT5), transcript variant 3, mRNA. 1842.96 997.27 1.85 0.028 845.69 
PITPNB Homo sapiens phosphatidylinositol transfer protein, beta (PITPNB), mRNA. 287.3 155.51 1.85 0.000 131.79 
SRP9 Homo sapiens signal recognition particle 9kDa (SRP9), mRNA. 1347.65 726.92 1.85 0.023 620.73 
TERF2IP Homo sapiens telomeric repeat binding factor 2, interacting protein (TERF2IP), mRNA. 1244.83 672.72 1.85 0.044 572.11 
ACLY Homo sapiens ATP citrate lyase (ACLY), transcript variant 2, mRNA. 906.35 487.06 1.86 0.001 419.29 
CYP2E1 Homo sapiens cytochrome P450, family 2, subfamily E, polypeptide 1 (CYP2E1), mRNA. 261.82 141.01 1.86 0.004 120.81 
LOC647150 PREDICTED: Homo sapiens misc_RNA (LOC647150), miscRNA. 256.94 138.12 1.86 0.026 118.82 
CDC14A Homo sapiens CDC14 cell division cycle 14 homolog A (S. cerevisiae) (CDC14A), transcript variant 3, mRNA. 218.32 116.86 1.87 0.000 101.46 
PATL1 Homo sapiens protein associated with topoisomerase II homolog 1 (yeast) (PATL1), mRNA. 745.27 399.36 1.87 0.031 345.91 
CMAS Homo sapiens cytidine monophosphate N-acetylneuraminic acid synthetase (CMAS), mRNA. 331.84 175.22 1.89 0.000 156.63 
PKIA Homo sapiens protein kinase (cAMP-dependent, catalytic) inhibitor alpha (PKIA), transcript variant 7, mRNA. 277.79 147.10 1.89 0.016 130.69 
ZBED5 Homo sapiens zinc finger, BED-type containing 5 (ZBED5), mRNA. 541.97 287.44 1.89 5.00E-04 254.53 
TMED2 Homo sapiens transmembrane emp24 domain trafficking protein 2 (TMED2), mRNA. 1008.2 530.68 1.90 5.00E-04 477.52 
VBP1 Homo sapiens von Hippel-Lindau binding protein 1 (VBP1), mRNA. 347.03 182.68 1.90 0.003 164.35 
LOC653226 PREDICTED: Homo sapiens similar to Signal recognition particle 9 kDa protein (SRP9) (LOC653226), mRNA. 1249.96 649.79 1.92 0.014 600.17 
DUSP18 Homo sapiens dual specificity phosphatase 18 (DUSP18), mRNA. 268.42 139.14 1.93 0.049 129.28 
RABEP1 Homo sapiens rabaptin, RAB GTPase binding effector protein 1 (RABEP1), transcript variant 2, mRNA. 385.55 200.12 1.93 5.00E-04 185.42 
ATM Homo sapiens ataxia telangiectasia mutated (ATM), transcript variant 1, mRNA. 881.71 455.44 1.94 0.004 426.28 
CD84 Homo sapiens CD84 molecule (CD84), mRNA. 261.99 134.77 1.94 0.000 127.22 
WDR19 Homo sapiens WD repeat domain 19 (WDR19), mRNA. 245.72 126.52 1.94 0.000 119.20 
ZFR Homo sapiens zinc finger RNA binding protein (ZFR), mRNA. 411.21 209.74 1.96 7.00E-04 201.47 
CPNE3 Homo sapiens copine III (CPNE3), mRNA. 546.61 277.73 1.97 0.004 268.89 
PIAS4 Homo sapiens protein inhibitor of activated STAT, 4 (PIAS4), mRNA. 247.32 125.07 1.98 6.00E-04 122.25 
LOC651894 PREDICTED: Homo sapiens similar to ribosomal protein S12 (LOC651894), mRNA. 932.50 468.03 1.99 0.016 464.47 
SMG1 Homo sapiens PI-3-kinase-related kinase SMG-1 (SMG1), mRNA. 516.87 258.07 2.00 0.003 258.79 
PAG1 Homo sapiens phosphoprotein associated with glycosphingolipid microdomains 1 (PAG1), mRNA. 1074.96 535.06 2.01 0.005 539.91 
ACTR2 Homo sapiens ARP2 actin-related protein 2 homolog (yeast) (ACTR2), transcript variant 1, mRNA. 1473.36 729.32 2.02 0.025 744.04 
KLRB1 Homo sapiens killer cell lectin-like receptor subfamily B, member 1 (KLRB1), mRNA. 3274.95 1621.33 2.02 0.003 1653.62 
LOC399804 PREDICTED: Homo sapiens misc_RNA (LOC399804), miscRNA. 658.16 323.37 2.04 0.002 334.79 
FLJ22662 Homo sapiens hypothetical protein FLJ22662 (FLJ22662), mRNA. 337.16 164.42 2.05 0.018 172.75 
RAD21 Homo sapiens RAD21 homolog (S. pombe) (RAD21), mRNA. 438.97 213.61 2.05 0.032 225.35 
ITGB1 
Homo sapiens integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) (ITGB1), transcript variant 1D, 
mRNA. 372.48 179.21 2.08 0.041 193.27 
PLEKHA1 
Homo sapiens pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 1 (PLEKHA1), transcript variant 
2, mRNA. 327.88 157.47 2.08 0.000 170.41 
RAB12 Homo sapiens RAB12, member RAS oncogene family (RAB12), mRNA. 212.86 102.51 2.08 0.003 110.35 
SKAP1 Homo sapiens src kinase associated phosphoprotein 1 (SKAP1), transcript variant 2, mRNA. 400.17 192.09 2.08 0.050 208.08 
TOR1AIP1 Homo sapiens torsin A interacting protein 1 (TOR1AIP1), mRNA. 338.31 162.42 2.08 0.000 175.89 
DUSP12 Homo sapiens dual specificity phosphatase 12 (DUSP12), mRNA. 699.08 334.30 2.09 8.00E-04 364.78 
GNA13 Homo sapiens guanine nucleotide binding protein (G protein), alpha 13 (GNA13), mRNA. 726.58 345.62 2.10 0.014 380.95 
SEC23IP Homo sapiens SEC23 interacting protein (SEC23IP), mRNA. 257.07 122.39 2.10 0.000 134.67 
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GMFB Homo sapiens glia maturation factor, beta (GMFB), mRNA. 803.55 381.72 2.11 0.000 421.83 
MAP3K7 Homo sapiens mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant B, mRNA. 1023.03 485.78 2.11 0.033 537.24 
SDAD1 Homo sapiens SDA1 domain containing 1 (SDAD1), mRNA. 697.43 331.02 2.11 0.028 366.41 
SLC11A2 Homo sapiens solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 (SLC11A2), mRNA. 488.83 232.00 2.11 0.034 256.84 
GNPDA1 Homo sapiens glucosamine-6-phosphate deaminase 1 (GNPDA1), mRNA. 872.63 411.67 2.12 0.001 460.96 
GSPT2 Homo sapiens G1 to S phase transition 2 (GSPT2), mRNA. 289.87 136.22 2.13 0.000 153.66 
LOC650215 PREDICTED: Homo sapiens similar to Exportin-T (tRNA exportin) (Exportin(tRNA)) (LOC650215), mRNA. 465.14 218.08 2.13 0.028 247.05 
C13orf23 Homo sapiens chromosome 13 open reading frame 23 (C13orf23), transcript variant 1, mRNA. 281.48 131.32 2.14 0.001 150.16 
ATAD1 Homo sapiens ATPase family, AAA domain containing 1 (ATAD1), mRNA. 268.01 124.18 2.16 0.003 143.83 
CTSK Homo sapiens cathepsin K (CTSK), mRNA. 358.37 165.62 2.16 0.030 192.75 
ZNF383 Homo sapiens zinc finger protein 383 (ZNF383), mRNA. 216.58 99.36 2.18 0.049 117.23 
C14orf131 Homo sapiens chromosome 14 open reading frame 131 (C14orf131), mRNA. 747.81 339.31 2.20 0.000 408.50 
CMAS Homo sapiens cytidine monophosphate N-acetylneuraminic acid synthetase (CMAS), mRNA. 413.22 188.23 2.20 0.000 225.00 
C13orf23 Homo sapiens chromosome 13 open reading frame 23 (C13orf23), transcript variant 1, mRNA. 294.49 132.94 2.22 0.002 161.55 
CDK7 Homo sapiens cyclin-dependent kinase 7 (MO15 homolog, Xenopus laevis, cdk-activating kinase) (CDK7), mRNA. 654.80 294.32 2.22 4.00E-04 360.48 
ZCCHC6 Homo sapiens zinc finger, CCHC domain containing 6 (ZCCHC6), mRNA. 184.07 82.39 2.23 0.027 101.67 
FBXO11 Homo sapiens F-box protein 11 (FBXO11), transcript variant 1, mRNA. 831.65 368.60 2.26 0.005 463.05 
WBSCR22 Homo sapiens Williams Beuren syndrome chromosome region 22 (WBSCR22), mRNA. 1435.84 631.05 2.28 0.016 804.80 
CBX6 Homo sapiens chromobox homolog 6 (CBX6), mRNA. 306.03 132.57 2.31 0.000 173.45 
SEMA4B 
Homo sapiens sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4B 
(SEMA4B), transcript variant 2, mRNA. 280.11 121.42 2.31 0.001 158.70 
LACTB Homo sapiens lactamase, beta (LACTB), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 842.44 360.78 2.34 0.006 481.66 
ARFGEF1 Homo sapiens ADP-ribosylation factor guanine nucleotide-exchange factor 1(brefeldin A-inhibited) (ARFGEF1), mRNA. 619.98 258.81 2.40 0.000 361.17 
CMPK1 Homo sapiens cytidine monophosphate (UMP-CMP) kinase 1, cytosolic (CMPK1), mRNA. 841.68 350.41 2.40 0.043 491.28 
ZYG11B Homo sapiens zyg-11 homolog B (C. elegans) (ZYG11B), mRNA. 692.25 284.70 2.43 0.000 407.55 
TOR1AIP1 Homo sapiens torsin A interacting protein 1 (TOR1AIP1), mRNA. 652.74 267.27 2.44 0.016 385.47 
RCBTB2 Homo sapiens regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 2 (RCBTB2), mRNA. 393.09 159.58 2.46 0.000 233.51 
TCTEX1D2 Homo sapiens Tctex1 domain containing 2 (TCTEX1D2), mRNA. 698.07 282.95 2.47 0.026 415.12 
MYNN Homo sapiens myoneurin (MYNN), mRNA. 340.64 137.46 2.48 1.00E-04 203.17 
C1orf19 Homo sapiens chromosome 1 open reading frame 19 (C1orf19), mRNA. 588.53 234.98 2.50 0.027 353.55 
STAMBPL1 Homo sapiens STAM binding protein-like 1 (STAMBPL1), mRNA. 766.15 304.92 2.51 0.021 461.23 
DHX29 Homo sapiens DEAH (Asp-Glu-Ala-His) box polypeptide 29 (DHX29), mRNA. 286.14 113.53 2.52 2.00E-04 172.61 
A2LD1 Homo sapiens AIG2-like domain 1 (A2LD1), mRNA. 288.90 114.23 2.53 0.000 174.67 
IL18RAP Homo sapiens interleukin 18 receptor accessory protein (IL18RAP), mRNA. 316.05 122.72 2.58 2.00E-04 193.33 
CREG1 Homo sapiens cellular repressor of E1A-stimulated genes 1 (CREG1), mRNA. 608.53 233.89 2.6 0.001 374.64 
CRYZ Homo sapiens crystallin, zeta (quinone reductase) (CRYZ), mRNA. 373.00 142.02 2.63 0.009 230.99 
PRKAR1A 
Homo sapiens protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) (PRKAR1A), transcript variant 3, 
mRNA. 918.57 345.24 2.66 0.000 573.32 
DAAM1 Homo sapiens dishevelled associated activator of morphogenesis 1 (DAAM1), mRNA. 366.01 134.16 2.73 5.00E-04 231.84 
TNFRSF19 Homo sapiens tumor necrosis factor receptor superfamily, member 19 (TNFRSF19), transcript variant 2, mRNA. 328.88 120.67 2.73 0.000 208.21 
RSBN1 Homo sapiens round spermatid basic protein 1 (RSBN1), mRNA. 346.98 125.89 2.76 0.000 221.08 
ATAD1 Homo sapiens ATPase family, AAA domain containing 1 (ATAD1), mRNA. 441.47 156.17 2.83 0.041 285.30 
 Homo sapiens cDNA FLJ34428 fis, clone HLUNG2000761 668.08 235.74 2.83 0.007 432.35 
NBPF20 Homo sapiens neuroblastoma breakpoint family, member 20 (NBPF20), mRNA. 421.89 146.49 2.88 0.000 275.40 
C17orf97 Homo sapiens chromosome 17 open reading frame 97 (C17orf97), mRNA. 271.10 93.73 2.89 0.012 177.37 
DHX29 Homo sapiens DEAH (Asp-Glu-Ala-His) box polypeptide 29 (DHX29), mRNA. 496.48 161.47 3.07 0.000 335.00 
LYN Homo sapiens v-yes-1 Yamaguchi sarcoma viral related oncogene homolog (LYN), mRNA. 641.83 174.12 3.69 0.049 467.71 
LOC644936 Homo sapiens cytoplasmic beta-actin pseudogene (LOC644936), non-coding RNA. 476.94 124.04 3.85 0.017 352.9 
MYOM2 Homo sapiens myomesin (M-protein) 2, 165kDa (MYOM2), mRNA. 1021.8 223.90 4.56 0.000 797.90 
D4S234E Homo sapiens DNA segment on chromosome 4 (unique) 234 expressed sequence (D4S234E), transcript variant 2, mRNA. 962.66 85.62 11.24 0.010 877.04 
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Comparison CD4+CD25- T cells of infected individuals versus EN 
Symbol Definition mean_CD4_inf mean_CD4_healthy FC pvalue diff 
EIF4A2 Homo sapiens eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2), mRNA. 346.93 2213.11 -6.38 3.00E-04 1866.19 
LOC388796 Homo sapiens hypothetical LOC388796 (LOC388796), non-coding RNA. 213.35 517.01 -2.42 0.038 303.66 
LOC286512 PREDICTED: Homo sapiens misc_RNA (LOC286512), miscRNA. 108.53 255.68 -2.36 0.000 147.16 
ERP27 Homo sapiens endoplasmic reticulum protein 27 kDa (ERP27), mRNA. 372.85 808.21 -2.17 0.012 435.35 
EXOSC7 Homo sapiens exosome component 7 (EXOSC7), mRNA. 352.77 757.97 -2.15 0.034 405.20 
CLASP1 Homo sapiens cytoplasmic linker associated protein 1 (CLASP1), mRNA. 223.78 464.81 -2.08 4.00E-04 241.02 
ITPRIP Homo sapiens inositol 1,4,5-triphosphate receptor interacting protein (ITPRIP), mRNA. 245.00 507.09 -2.07 0.029 262.10 
ENO2 Homo sapiens enolase 2 (gamma, neuronal) (ENO2), mRNA. 342.33 706.42 -2.06 0.000 364.09 
SKP1 Homo sapiens S-phase kinase-associated protein 1 (SKP1), transcript variant 1, mRNA. 447.99 923.15 -2.06 8.00E-04 475.16 
SGK1 Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1), transcript variant 1, mRNA. 156.16 305.55 -1.96 0.040 149.40 
C16orf33 Homo sapiens chromosome 16 open reading frame 33 (C16orf33), mRNA. 166.94 321.21 -1.92 0.040 154.27 
 Homo sapiens cDNA clone IMAGE:30332316 210.38 375.92 -1.79 0.021 165.55 
LOC440354 Homo sapiens PI-3-kinase-related kinase SMG-1 pseudogene (LOC440354), non-coding RNA. 177.73 311.55 -1.75 0.023 133.82 
TSC22D3 Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 1, mRNA. 2241.24 3845.93 -1.72 0.042 1604.7 
METT11D1 Homo sapiens methyltransferase 11 domain containing 1 (METT11D1), transcript variant 1, mRNA. 352.93 596.66 -1.69 0.046 243.73 
SPATS2L Homo sapiens spermatogenesis associated, serine-rich 2-like (SPATS2L), transcript variant 2, mRNA. 194.44 329.45 -1.69 0.003 135.01 
VIPR1 Homo sapiens vasoactive intestinal peptide receptor 1 (VIPR1), mRNA. 226.86 380.15 -1.68 0.025 153.29 
PRPS1 Homo sapiens phosphoribosyl pyrophosphate synthetase 1 (PRPS1), mRNA. 234.34 388.39 -1.66 0.001 154.05 
RRBP1 Homo sapiens ribosome binding protein 1 homolog 180kDa (dog) (RRBP1), transcript variant 1, mRNA. 229.08 375.94 -1.64 0.035 146.85 
DBNDD2 Homo sapiens dysbindin (dystrobrevin binding protein 1) domain containing 2 (DBNDD2), transcript variant 3, mRNA. 426.85 691.70 -1.62 7.00E-04 264.85 
CRIPAK Homo sapiens cysteine-rich PAK1 inhibitor (CRIPAK), mRNA. 502.24 804.64 -1.60 0.032 302.39 
RNF135 Homo sapiens ring finger protein 135 (RNF135), transcript variant 2, mRNA. 167.97 268.47 -1.60 0.041 100.51 
C8orf33 Homo sapiens chromosome 8 open reading frame 33 (C8orf33), mRNA. 237.55 378.77 -1.59 0.021 141.22 
LOC731049 
PREDICTED: Homo sapiens similar to Ubiquitin-conjugating enzyme E2S (Ubiquitin-conjugating enzyme E2-24 kDa) (Ubiquitin-protein 
ligase) (Ubiquitin carrier protein) (E2-EPF5) (LOC731049), mRNA. 359.35 567.10 -1.58 0.007 207.75 
SPG7 
Homo sapiens spastic paraplegia 7 (pure and complicated autosomal recessive) (SPG7), nuclear gene encoding mitochondrial protein, 
transcript variant 1, mRNA. 1283.53 1989.08 -1.55 0.000 705.55 
LOC100130092 PREDICTED: Homo sapiens misc_RNA (LOC100130092), miscRNA. 272.38 420.02 -1.54 3.00E-04 147.63 
SCAP Homo sapiens SREBF chaperone (SCAP), mRNA. 740.76 1139.96 -1.54 1.00E-04 399.20 
UBA52 Homo sapiens ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52), transcript variant 2, mRNA. 215.15 330.46 -1.54 0.041 115.31 
ZSCAN18 Homo sapiens zinc finger and SCAN domain containing 18 (ZSCAN18), mRNA. 184.65 285.20 -1.54 0.012 100.55 
TUBGCP2 Homo sapiens tubulin, gamma complex associated protein 2 (TUBGCP2), mRNA. 238.13 365.52 -1.53 0.000 127.39 
PLEKHM2 Homo sapiens pleckstrin homology domain containing, family M (with RUN domain) member 2 (PLEKHM2), mRNA. 345.89 526.93 -1.52 0.046 181.04 
ARHGAP9 Homo sapiens Rho GTPase activating protein 9 (ARHGAP9), transcript variant 3, mRNA. 434.96 655.12 -1.51 0.025 220.17 
C9orf78 Homo sapiens chromosome 9 open reading frame 78 (C9orf78), mRNA. 1325.40 1999.78 -1.51 0.005 674.38 
TRPC4AP 
Homo sapiens transient receptor potential cation channel, subfamily C, member 4 associated protein (TRPC4AP), transcript variant 1, 
mRNA. 483.16 728.79 -1.51 0.07 245.62 
CSK Homo sapiens c-src tyrosine kinase (CSK), mRNA. 799.39 528.69 1.51 0.012 270.71 
NCOA4 Homo sapiens nuclear receptor coactivator 4 (NCOA4), mRNA. 4186.65 2772.01 1.51 0.000 1414.63 
DNMT1 Homo sapiens DNA (cytosine-5-)-methyltransferase 1 (DNMT1), mRNA. 2041.95 1345.03 1.52 0.027 696.93 
FAM38A Homo sapiens family with sequence similarity 38, member A (FAM38A), mRNA. 816.77 537.41 1.52 0.004 279.36 
LAX1 Homo sapiens lymphocyte transmembrane adaptor 1 (LAX1), mRNA. 455.33 298.69 1.52 0.009 156.65 
SUSD1 Homo sapiens sushi domain containing 1 (SUSD1), mRNA. 535.57 351.47 1.52 0.013 184.10 
ROD1 Homo sapiens ROD1 regulator of differentiation 1 (S. pombe) (ROD1), mRNA. 1790.70 1171.73 1.53 0.010 618.97 
TRIM44 Homo sapiens tripartite motif-containing 44 (TRIM44), mRNA. 349.94 228.38 1.53 0.028 121.56 
VEGFB Homo sapiens vascular endothelial growth factor B (VEGFB), mRNA. 627.49 409.39 1.53 0.022 218.10 
 Homo sapiens cDNA clone IMAGE:5277162 465.63 301.43 1.54 0.042 164.20 
LOC651894 PREDICTED: Homo sapiens similar to ribosomal protein S12 (LOC651894), mRNA. 785.97 509.54 1.54 0.036 276.43 
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POGK Homo sapiens pogo transposable element with KRAB domain (POGK), mRNA. 723.20 470.79 1.54 0.022 252.42 
PSMA4 Homo sapiens proteasome (prosome, macropain) subunit, alpha type, 4 (PSMA4), mRNA. 1893.54 1228 1.54 0.008 665.54 
SH3BGRL Homo sapiens SH3 domain binding glutamic acid-rich protein like (SH3BGRL), mRNA. 482.52 311.05 1.55 0.006 171.46 
XRN1 Homo sapiens 5'-3' exoribonuclease 1 (XRN1), mRNA. 498.55 320.95 1.55 0.006 177.60 
ALDH9A1 Homo sapiens aldehyde dehydrogenase 9 family, member A1 (ALDH9A1), mRNA. 4157.34 2645.26 1.57 0.000 1512.07 
AP1S2 Homo sapiens adaptor-related protein complex 1, sigma 2 subunit (AP1S2), mRNA. 1701.82 1074.58 1.58 0.018 627.25 
CASP3 Homo sapiens caspase 3, apoptosis-related cysteine peptidase (CASP3), transcript variant beta, mRNA. 468.82 297.18 1.58 0.004 171.63 
PTPLB Homo sapiens protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b (PTPLB), mRNA. 334.78 211.51 1.58 0.014 123.28 
DYRK1A Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A), transcript variant 5, mRNA. 501.12 315.97 1.59 0.013 185.15 
CLINT1 Homo sapiens clathrin interactor 1 (CLINT1), mRNA. 444.25 277.31 1.60 0.036 166.94 
CUL5 Homo sapiens cullin 5 (CUL5), mRNA. 345.42 215.47 1.60 0.046 129.94 
CLIP1 Homo sapiens CAP-GLY domain containing linker protein 1 (CLIP1), transcript variant 1, mRNA. 396.78 246.16 1.61 0.005 150.62 
ZNF337 Homo sapiens zinc finger protein 337 (ZNF337), mRNA. 539.23 334.80 1.61 0.017 204.43 
SH3KBP1 Homo sapiens SH3-domain kinase binding protein 1 (SH3KBP1), transcript variant 1, mRNA. 1640.31 1012.12 1.62 0.037 628.19 
C1orf131 Homo sapiens chromosome 1 open reading frame 131 (C1orf131), mRNA. 324.30 199.18 1.63 0.012 125.11 
WASPIP Homo sapiens Wiskott-Aldrich syndrome protein interacting protein (WASPIP), mRNA. 714.99 438.21 1.63 0.004 276.78 
C5orf15 Homo sapiens chromosome 5 open reading frame 15 (C5orf15), mRNA. 946.06 576.73 1.64 0.000 369.32 
C1orf24 Homo sapiens chromosome 1 open reading frame 24 (C1orf24), transcript variant 2, mRNA. 482.53 292.50 1.65 0.047 190.03 
DNASE2 Homo sapiens deoxyribonuclease II, lysosomal (DNASE2), mRNA. 300.32 180.39 1.66 0.006 119.93 
KLRB1 Homo sapiens killer cell lectin-like receptor subfamily B, member 1 (KLRB1), mRNA. 3555.44 2129.00 1.67 0.001 1426.44 
ACSL5 Homo sapiens acyl-CoA synthetase long-chain family member 5 (ACSL5), transcript variant 2, mRNA. 313.07 184.78 1.69 0.002 128.29 
BMI1 Homo sapiens BMI1 polycomb ring finger oncogene (BMI1), mRNA. 467.37 275.23 1.70 0.025 192.15 
ST13 Homo sapiens suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) (ST13), mRNA. 359.12 211.59 1.70 0.039 147.53 
UBE2Q2 Homo sapiens ubiquitin-conjugating enzyme E2Q family member 2 (UBE2Q2), mRNA. 593.86 348.35 1.70 0.013 245.51 
XBP1 Homo sapiens X-box binding protein 1 (XBP1), transcript variant 1, mRNA. 918.23 536.54 1.71 0.003 381.69 
AGL Homo sapiens amylo-1, 6-glucosidase, 4-alpha-glucanotransferase (AGL), transcript variant 5, mRNA. 337.24 193.21 1.75 0.042 144.03 
ARL5A Homo sapiens ADP-ribosylation factor-like 5A (ARL5A), transcript variant 3, mRNA. 780.10 446.17 1.75 0.050 333.93 
ARL6IP1 Homo sapiens ADP-ribosylation factor-like 6 interacting protein 1 (ARL6IP1), mRNA. 1463.73 831.30 1.76 0.002 632.43 
RAP2A Homo sapiens RAP2A, member of RAS oncogene family (RAP2A), mRNA. 337.99 190.06 1.78 0.043 147.93 
SRPK1 Homo sapiens SFRS protein kinase 1 (SRPK1), mRNA. 356.37 200.37 1.78 0.006 156.00 
CDS2 Homo sapiens CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 (CDS2), mRNA. 305.11 169.27 1.80 0.001 135.84 
FANCE Homo sapiens Fanconi anemia, complementation group E (FANCE), mRNA. 267.57 148.38 1.80 0.036 119.18 
GEMIN4 Homo sapiens gem (nuclear organelle) associated protein 4 (GEMIN4), mRNA. 432.27 240.62 1.80 0.037 191.66 
 Homo sapiens cDNA clone IMAGE:5261213 1001.42 553.52 1.81 0.046 447.89 
PIP5K1C Homo sapiens phosphatidylinositol-4-phosphate 5-kinase, type I, gamma (PIP5K1C), mRNA. 317.87 175.12 1.82 0.002 142.75 
YWHAQ Homo sapiens tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide (YWHAQ), mRNA. 3439.00 1892.13 1.82 5.00E-04 1546.87 
MLKL Homo sapiens mixed lineage kinase domain-like (MLKL), mRNA. 1774.43 971.05 1.83 0.007 803.39 
STAT1 Homo sapiens signal transducer and activator of transcription 1, 91kDa (STAT1), transcript variant alpha, mRNA. 2181.94 1186.49 1.84 0.046 995.45 
FGD2 Homo sapiens FYVE, RhoGEF and PH domain containing 2 (FGD2), mRNA. 329.39 177.66 1.85 0.000 151.73 
HIGD1A Homo sapiens HIG1 hypoxia inducible domain family, member 1A (HIGD1A), transcript variant 1, mRNA. 375.36 202.05 1.86 0.042 173.32 
ZMYM1 Homo sapiens zinc finger, MYM-type 1 (ZMYM1), mRNA. 235.19 125.75 1.87 0.002 109.44 
FOXN2 Homo sapiens forkhead box N2 (FOXN2), mRNA. 559.87 295.43 1.90 0.038 264.44 
CDC2L5 Homo sapiens cell division cycle 2-like 5 (cholinesterase-related cell division controller) (CDC2L5), transcript variant 1, mRNA. 430.67 225.11 1.91 0.025 205.55 
B4GALT7 Homo sapiens xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 (galactosyltransferase I) (B4GALT7), mRNA. 284.67 147.65 1.93 0.019 137.02 
HEATR1 Homo sapiens HEAT repeat containing 1 (HEATR1), mRNA. 418.38 215.15 1.94 0.001 203.23 
ZNF302 Homo sapiens zinc finger protein 302 (ZNF302), transcript variant 1, mRNA. 364.61 183.56 1.99 0.016 181.05 
CHST7 Homo sapiens carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 (CHST7), mRNA. 275.61 136.51 2.02 0.024 139.11 
RFX7 Homo sapiens regulatory factor X, 7 (RFX7), mRNA. 519.42 255.03 2.04 4.00E-04 264.39 
VPS4B Homo sapiens vacuolar protein sorting 4 homolog B (S. cerevisiae) (VPS4B), mRNA. 690.37 337.34 2.05 0.034 353.03 
ATP6AP2 Homo sapiens ATPase, H+ transporting, lysosomal accessory protein 2 (ATP6AP2), mRNA. 820.81 390.95 2.10 2.00E-04 429.86 
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TMEM209 Homo sapiens transmembrane protein 209 (TMEM209), mRNA. 290.13 137.86 2.10 0.017 152.27 
IQGAP2 Homo sapiens IQ motif containing GTPase activating protein 2 (IQGAP2), mRNA. 702.85 332.08 2.12 0.017 370.76 
TNFSF10 Homo sapiens tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10), mRNA. 568.49 258.23 2.2 0.001 310.26 
PTGDR Homo sapiens prostaglandin D2 receptor (DP) (PTGDR), mRNA. 327.56 145.43 2.25 0.007 182.13 
ZW10 Homo sapiens ZW10, kinetochore associated, homolog (Drosophila) (ZW10), mRNA. 386.47 152.43 2.54 0.001 234.04 
 
 
Comparison CD4+CD25- T cells of MF- versus MF+ individuals 
Symbol Definition mean_CD4_Mfneg mean_CD4_Mfpos FC pvalue diff 
SOD2 Homo sapiens superoxide dismutase 2, mitochondrial (SOD2), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA. 261.63 994.61 -3.80 0.000 732.98 
LILRA3 Homo sapiens leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 3 (LILRA3), mRNA. 523.26 1785.06 -3.41 0.006 1261.79 
IL8 Homo sapiens interleukin 8 (IL8), mRNA. 100.25 297.87 -2.97 0.038 197.62 
SFXN4 Homo sapiens sideroflexin 4 (SFXN4), mRNA. 148.17 395.57 -2.67 0.047 247.39 
SDCCAG10 Homo sapiens serologically defined colon cancer antigen 10 (SDCCAG10), mRNA. 206.11 478.32 -2.32 2.00E-04 272.21 
NFKBIA Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA), mRNA. 506.30 1145.58 -2.26 0.019 639.28 
HSD17B12 Homo sapiens hydroxysteroid (17-beta) dehydrogenase 12 (HSD17B12), mRNA. 243.75 506.99 -2.08 2.00E-04 263.24 
ZNF101 Homo sapiens zinc finger protein 101 (ZNF101), mRNA. 139.07 282.56 -2.03 0.039 143.48 
PTS Homo sapiens 6-pyruvoyltetrahydropterin synthase (PTS), mRNA. 278.76 562.36 -2.02 0.048 283.60 
FECH Homo sapiens ferrochelatase (protoporphyria) (FECH), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA. 141.80 284.39 -2.01 2.00E-04 142.59 
KLF6 Homo sapiens Kruppel-like factor 6 (KLF6), transcript variant 2, mRNA. 1170.61 2313.46 -1.98 0.021 1142.85 
FGL2 Homo sapiens fibrinogen-like 2 (FGL2), mRNA. 309.46 608.4 -1.97 0.043 298.94 
GLCE Homo sapiens glucuronic acid epimerase (GLCE), mRNA. 108.91 213.22 -1.96 4.00E-04 104.31 
HPS4 Homo sapiens Hermansky-Pudlak syndrome 4 (HPS4), transcript variant 2, mRNA. 123.09 241.14 -1.96 0.012 118.05 
SLC11A1 Homo sapiens solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 (SLC11A1), mRNA. 195.44 383.02 -1.96 0.000 187.58 
C14orf109 Homo sapiens chromosome 14 open reading frame 109 (C14orf109), transcript variant 2, mRNA. 139.45 272.36 -1.95 2.00E-04 132.91 
HSD17B12 Homo sapiens hydroxysteroid (17-beta) dehydrogenase 12 (HSD17B12), mRNA. 137.51 262.64 -1.91 0.023 125.14 
KLF11 PREDICTED: Homo sapiens Kruppel-like factor 11 (KLF11), mRNA. 455.61 871.89 -1.91 0.000 416.27 
ACVR1 Homo sapiens activin A receptor, type I (ACVR1), mRNA. 198.71 374.64 -1.89 0.017 175.93 
GZMK Homo sapiens granzyme K (granzyme 3; tryptase II) (GZMK), mRNA. 1122.7 2121.28 -1.89 0.040 998.57 
NOD2 Homo sapiens nucleotide-binding oligomerization domain containing 2 (NOD2), mRNA. 153.14 288.38 -1.88 0.000 135.24 
GBP1 Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA. 359.24 670.65 -1.87 0.000 311.41 
CREG1 Homo sapiens cellular repressor of E1A-stimulated genes 1 (CREG1), mRNA. 165.38 306.63 -1.85 0.000 141.25 
NFKBIZ Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta (NFKBIZ), transcript variant 2, mRNA. 466.51 863.42 -1.85 0.033 396.91 
PUM1 Homo sapiens pumilio homolog 1 (Drosophila) (PUM1), transcript variant 1, mRNA. 206.04 374.93 -1.82 0.000 168.89 
MCEE Homo sapiens methylmalonyl CoA epimerase (MCEE), mRNA. 154.45 279.69 -1.81 0.000 125.24 
SRI Homo sapiens sorcin (SRI), transcript variant 1, mRNA. 157.55 284.40 -1.81 0.044 126.84 
COQ2 Homo sapiens coenzyme Q2 homolog, prenyltransferase (yeast) (COQ2), mRNA. 132.94 237.73 -1.79 0.037 104.8 
LOC650215 PREDICTED: Homo sapiens similar to Exportin-T (tRNA exportin) (Exportin(tRNA)) (LOC650215), mRNA. 218.25 388.79 -1.78 0.029 170.55 
PARP9 Homo sapiens poly (ADP-ribose) polymerase family, member 9 (PARP9), mRNA. 337.14 591.83 -1.76 0.001 254.69 
SPCS3 Homo sapiens signal peptidase complex subunit 3 homolog (S. cerevisiae) (SPCS3), mRNA. 199.54 352.05 -1.76 3.00E-04 152.52 
WARS Homo sapiens tryptophanyl-tRNA synthetase (WARS), transcript variant 2, mRNA. 307.50 531.60 -1.73 0.020 224.1 
GBP1 Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA. 441.73 758.77 -1.72 0.011 317.04 
KLF4 Homo sapiens Kruppel-like factor 4 (gut) (KLF4), mRNA. 174.03 300.13 -1.72 0.009 126.1 
MED4 Homo sapiens mediator complex subunit 4 (MED4), mRNA. 189.45 323.51 -1.71 0.014 134.06 
CCNB1IP1 Homo sapiens cyclin B1 interacting protein 1 (CCNB1IP1), transcript variant 3, mRNA. 463.28 780.51 -1.68 0.002 317.24 
WWP2 Homo sapiens WW domain containing E3 ubiquitin protein ligase 2 (WWP2), transcript variant 3, mRNA. 242.19 406.44 -1.68 0.000 164.25 
KLF6 Homo sapiens Kruppel-like factor 6 (KLF6), transcript variant 1, mRNA. 179.70 297.07 -1.65 3.00E-04 117.38 
LILRB2 
Homo sapiens leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2 (LILRB2), transcript variant 
2, mRNA. 343.55 561.28 -1.63 0.003 217.73 
CCNB1IP1 Homo sapiens cyclin B1 interacting protein 1 (CCNB1IP1), transcript variant 2, mRNA. 240.02 388.41 -1.62 0.013 148.39 
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LOC729217 PREDICTED: Homo sapiens misc_RNA (LOC729217), miscRNA. 220.37 354.84 -1.61 9.00E-04 134.46 
ME2 Homo sapiens malic enzyme 2, NAD(+)-dependent, mitochondrial (ME2), nuclear gene encoding mitochondrial protein, mRNA. 200.48 315.03 -1.57 0.013 114.55 
ECGF1 Homo sapiens endothelial cell growth factor 1 (platelet-derived) (ECGF1), mRNA. 969.73 1511.66 -1.56 0.018 541.93 
PPA1 Homo sapiens pyrophosphatase (inorganic) 1 (PPA1), mRNA. 977.32 1528.2 -1.56 0.007 550.87 
DNAJA2 Homo sapiens DnaJ (Hsp40) homolog, subfamily A, member 2 (DNAJA2), mRNA. 352.07 545.26 -1.55 2.00E-04 193.19 
CCDC53 Homo sapiens coiled-coil domain containing 53 (CCDC53), mRNA. 223.56 343.71 -1.54 0.039 120.16 
SUCLG2 Homo sapiens succinate-CoA ligase, GDP-forming, beta subunit (SUCLG2), mRNA. 208.16 321.08 -1.54 0.023 112.92 
IFITM3 Homo sapiens interferon induced transmembrane protein 3 (1-8U) (IFITM3), mRNA. 388.29 592.77 -1.53 0.035 204.48 
OAT Homo sapiens ornithine aminotransferase (gyrate atrophy) (OAT), nuclear gene encoding mitochondrial protein, mRNA. 229.97 347.95 -1.51 0.019 117.98 
YPEL5 Homo sapiens yippee-like 5 (Drosophila) (YPEL5), mRNA. 1224.68 1854.75 -1.51 0.047 630.07 
ZNF721 Homo sapiens zinc finger protein 721 (ZNF721), mRNA. 450.46 299.84 1.50 0.029 150.62 
RAP2A Homo sapiens RAP2A, member of RAS oncogene family (RAP2A), mRNA. 408.03 267.95 1.52 0.049 140.08 
LOC440348 Homo sapiens similar to nuclear pore complex interacting protein (LOC440348), mRNA. 372.89 243.45 1.53 0.000 129.43 
ZNF142 Homo sapiens zinc finger protein 142 (ZNF142), transcript variant 2, mRNA. 445.72 291.29 1.53 0.000 154.43 
SBK1 Homo sapiens SH3-binding domain kinase 1 (SBK1), mRNA. 1054.14 682.07 1.55 0.000 372.07 
SLAMF6 Homo sapiens SLAM family member 6 (SLAMF6), mRNA. 3391.56 2188.44 1.55 0.0169 1203.12 
CCDC28A Homo sapiens coiled-coil domain containing 28A (CCDC28A), mRNA. 812.83 520.17 1.56 0.0429 292.66 
KLHL8 Homo sapiens kelch-like 8 (Drosophila) (KLHL8), mRNA. 292.44 187.50 1.56 0.000 104.93 
MBD6 Homo sapiens methyl-CpG binding domain protein 6 (MBD6), mRNA. 329.79 209.33 1.58 0.000 120.47 
RBM33 Homo sapiens RNA binding motif protein 33 (RBM33), transcript variant 1, mRNA. 865.24 543.78 1.59 0.0103 321.46 
IP6K1 Homo sapiens inositol hexakisphosphate kinase 1 (IP6K1), transcript variant 2, mRNA. 323.00 201.90 1.60 1.00E-04 121.1 
MZF1 Homo sapiens myeloid zinc finger 1 (MZF1), transcript variant 2, mRNA. 454.58 284.14 1.60 0,0000 170.44 
EDG4 Homo sapiens endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 4 (EDG4), mRNA. 634.95 390.61 1.63 0.0197 244.33 
FRAP1 Homo sapiens FK506 binding protein 12-rapamycin associated protein 1 (FRAP1), mRNA. 675.49 412.19 1.64 0.0043 263.29 
MFSD6 Homo sapiens major facilitator superfamily domain containing 6 (MFSD6), mRNA. 256.64 154.80 1.66 0.0038 101.85 
SNTB1 Homo sapiens syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic component 1) (SNTB1), mRNA. 287.49 171.96 1.67 0.000 115.54 
TMEM115 Homo sapiens transmembrane protein 115 (TMEM115), mRNA. 296.93 174.90 1.70 0.0188 122.03 
LRSAM1 Homo sapiens leucine rich repeat and sterile alpha motif containing 1 (LRSAM1), transcript variant 1, mRNA. 351.98 203.26 1.73 0.0014 148.72 
SLC25A42 Homo sapiens solute carrier family 25, member 42 (SLC25A42), mRNA. 764.11 438.89 1.74 0.0075 325.22 
SEC22A Homo sapiens SEC22 vesicle trafficking protein homolog A (S. cerevisiae) (SEC22A), mRNA. 425.45 243.63 1.75 0.0301 181.82 
SYTL3 Homo sapiens synaptotagmin-like 3 (SYTL3), mRNA. 661.50 378.09 1.75 0.000 283.42 
ABCC5 Homo sapiens ATP-binding cassette, sub-family C (CFTR/MRP), member 5 (ABCC5), transcript variant 2, mRNA. 311.36 176.35 1.77 0.027 135.00 
OSBP Homo sapiens oxysterol binding protein (OSBP), mRNA. 658.43 368.91 1.78 0.015 289.53 
ASTE1 Homo sapiens asteroid homolog 1 (Drosophila) (ASTE1), mRNA. 278.08 154.47 1.80 6.00E-04 123.61 
NCRNA00092 Homo sapiens non-protein coding RNA 92 (NCRNA00092), non-coding RNA. 235.97 130.82 1.80 0.021 105.15 
C9orf103 Homo sapiens chromosome 9 open reading frame 103 (C9orf103), mRNA. 388.28 214.65 1.81 0.016 173.64 
MFSD6 Homo sapiens major facilitator superfamily domain containing 6 (MFSD6), mRNA. 468.71 258.31 1.81 0.034 210.40 
DIDO1 Homo sapiens death inducer-obliterator 1 (DIDO1), transcript variant 3, mRNA. 297.44 162.50 1.83 0.024 134.94 
LPAR5 Homo sapiens lysophosphatidic acid receptor 5 (LPAR5), mRNA. 240.27 130.80 1.84 0.005 109.47 
POMGNT1 Homo sapiens protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase (POMGNT1), mRNA. 474.14 257.29 1.84 0.003 216.84 
LOC730432 PREDICTED: Homo sapiens similar to serine/threonine/tyrosine interacting protein, transcript variant 1 (LOC730432), mRNA. 652.13 350.57 1.86 0.009 301.56 
ZNF493 Homo sapiens zinc finger protein 493 (ZNF493), transcript variant 3, mRNA. 315.36 168.56 1.87 0.004 146.81 
WDR4 Homo sapiens WD repeat domain 4 (WDR4), transcript variant 2, mRNA. 295.85 156.65 1.89 0.000 139.20 
RNF149 Homo sapiens ring finger protein 149 (RNF149), mRNA. 1127.05 565.71 1.99 0.004 561.34 
PLEKHA9 Homo sapiens pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 9 (PLEKHA9), mRNA. 489.71 244.19 2.01 0.006 245.52 
PROK2 Homo sapiens prokineticin 2 (PROK2), mRNA. 446.87 211.13 2.12 0.031 235.74 
TATDN3 Homo sapiens TatD DNase domain containing 3 (TATDN3), transcript variant 1, mRNA. 372.80 175.26 2.13 0.028 197.55 
 PREDICTED: Homo sapiens hypothetical LOC400999 (LOC400999), mRNA 277.67 127.98 2.17 0.000 149.69 
ADRB2 Homo sapiens adrenergic, beta-2-, receptor, surface (ADRB2), mRNA. 1433.37 589.94 2.43 0.000 843.43 
LOC729708 PREDICTED: Homo sapiens similar to rcTPI1, transcript variant 1 (LOC729708), mRNA. 930.10 192.97 4.82 0.033 737.12 
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Comparison CD4+CD25- T cells of MF- individuals EN  
Symbol Definition mean_CD4_Mfneg mean_CD4_EN FC pvalue diff 
ERP27 Homo sapiens endoplasmic reticulum protein 27 kDa (ERP27), mRNA. 270.52 808.21 -2.99 2.00E-04 537.69 
SGK1 Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1), transcript variant 1, mRNA. 124.24 305.55 -2.46 0.002 181.31 
CPVL Homo sapiens carboxypeptidase, vitellogenic-like (CPVL), transcript variant 1, mRNA. 273.63 638.42 -2.33 0.025 364.79 
C16orf33 Homo sapiens chromosome 16 open reading frame 33 (C16orf33), mRNA. 144.65 321.21 -2.22 0.002 176.56 
SMAGP Homo sapiens small cell adhesion glycoprotein (SMAGP), transcript variant 2, mRNA. 99.59 216.48 -2.17 0.005 116.89 
LOC440354 Homo sapiens PI-3-kinase-related kinase SMG-1 pseudogene (LOC440354), non-coding RNA. 144.03 311.55 -2.16 0.000 167.51 
LOC286512 PREDICTED: Homo sapiens misc_RNA (LOC286512), miscRNA. 126.13 255.68 -2.03 0.018 129.55 
ENO2 Homo sapiens enolase 2 (gamma, neuronal) (ENO2), mRNA. 352.04 706.42 -2.01 4.00E-04 354.38 
HPS4 Homo sapiens Hermansky-Pudlak syndrome 4 (HPS4), transcript variant 2, mRNA. 123.09 246.49 -2,00 0.002 123.40 
SGK1 Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1), transcript variant 1, mRNA. 114.84 227.37 -1.98 2.00E-04 112.53 
DBNDD2 Homo sapiens dysbindin (dystrobrevin binding protein 1) domain containing 2 (DBNDD2), transcript variant 3, mRNA. 360.14 691.70 -1.92 0.024 331.56 
CCNB1IP1 Homo sapiens cyclin B1 interacting protein 1 (CCNB1IP1), transcript variant 2, mRNA. 240.02 451.91 -1.88 0.014 211.89 
SKP1 Homo sapiens S-phase kinase-associated protein 1 (SKP1), transcript variant 1, mRNA. 490.55 923.15 -1.88 0.003 432.59 
VIPR1 Homo sapiens vasoactive intestinal peptide receptor 1 (VIPR1), mRNA. 206.11 380.15 -1.84 0.002 174.04 
SPATS2L Homo sapiens spermatogenesis associated, serine-rich 2-like (SPATS2L), transcript variant 2, mRNA. 180.43 329.45 -1.83 0.013 149.02 
CLASP1 Homo sapiens cytoplasmic linker associated protein 1 (CLASP1), mRNA. 258.98 464.81 -1.79 0.004 205.83 
UBQLN1 Homo sapiens ubiquilin 1 (UBQLN1), transcript variant 2, mRNA. 140.42 247.88 -1.77 0.039 107.46 
ARHGAP9 Homo sapiens Rho GTPase activating protein 9 (ARHGAP9), transcript variant 3, mRNA. 373.11 655.12 -1.76 0.000 282.02 
MED10 Homo sapiens mediator complex subunit 10 (MED10), mRNA. 433.77 763.83 -1.76 0.003 330.06 
CCNB1IP1 Homo sapiens cyclin B1 interacting protein 1 (CCNB1IP1), transcript variant 3, mRNA. 463.28 797.04 -1.72 0.027 333.76 
METT11D1 Homo sapiens methyltransferase 11 domain containing 1 (METT11D1), transcript variant 1, mRNA. 355.33 596.66 -1.68 0.041 241.34 
ZSCAN18 Homo sapiens zinc finger and SCAN domain containing 18 (ZSCAN18), mRNA. 169.91 285.2 -1.68 0.010 115.29 
LOC642333 PREDICTED: Homo sapiens similar to M-phase phosphoprotein, mpp8 (LOC642333), mRNA. 326.02 544.88 -1.67 0.003 218.87 
LOC10012819
6 PREDICTED: Homo sapiens misc_RNA (LOC100128196), miscRNA. 244.63 406.86 -1.66 0.000 162.23 
LOC10013318
5 PREDICTED: Homo sapiens misc_RNA (LOC100133185), miscRNA. 199.41 329.66 -1.65 0.000 130.25 
CIRBP Homo sapiens cold inducible RNA binding protein (CIRBP), mRNA. 2218.4 3636.87 -1.64 0.029 1418.46 
BRI3 Homo sapiens brain protein I3 (BRI3), mRNA. 269.23 438.33 -1.63 2.00E-04 169.10 
SFRS14 Homo sapiens splicing factor, arginine/serine-rich 14 (SFRS14), transcript variant 1, mRNA. 257.33 418.91 -1.63 0.008 161.58 
TCEB3 Homo sapiens transcription elongation factor B (SIII), polypeptide 3 (110kDa, elongin A) (TCEB3), mRNA. 170.22 277.18 -1.63 0.001 106.96 
PRPS1 Homo sapiens phosphoribosyl pyrophosphate synthetase 1 (PRPS1), mRNA. 239.95 388.39 -1.62 0.010 148.45 
SCAP Homo sapiens SREBF chaperone (SCAP), mRNA. 709.62 1139.96 -1.61 0.000 430.35 
SNHG5 Homo sapiens small nucleolar RNA host gene (non-protein coding) 5 (SNHG5) on chromosome 6. 176.73 283.81 -1.61 0.003 107.08 
SSBP1 Homo sapiens single-stranded DNA binding protein 1 (SSBP1), mRNA. 295.63 472.36 -1.6 0.000 176.73 
GARS Homo sapiens glycyl-tRNA synthetase (GARS), mRNA. 390.46 621.52 -1.59 0.020 231.06 
PTPMT1 Homo sapiens protein tyrosine phosphatase, mitochondrial 1 (PTPMT1), nuclear gene encoding mitochondrial protein, mRNA. 251.13 394.93 -1.57 0.038 143.80 
KIAA0391 Homo sapiens KIAA0391 (KIAA0391), mRNA. 301.01 469.99 -1.56 3.00E-04 168.98 
CCDC53 Homo sapiens coiled-coil domain containing 53 (CCDC53), mRNA. 223.56 346.36 -1.55 0.000 122.80 
LOC10013009
2 PREDICTED: Homo sapiens misc_RNA (LOC100130092), miscRNA. 270.28 420.02 -1.55 1.00E-04 149.74 
SYF2 Homo sapiens SYF2 homolog, RNA splicing factor (S. cerevisiae) (SYF2), transcript variant 1, mRNA. 228.81 348.18 -1.52 0.016 119.37 
DTD1 Homo sapiens D-tyrosyl-tRNA deacylase 1 homolog (S. cerevisiae) (DTD1), nuclear gene encoding mitochondrial protein, mRNA. 518.44 783.93 -1.51 4.00E-04 265.48 
PTPLB Homo sapiens protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b (PTPLB), mRNA. 320.22 211.51 1.51 0.041 108.71 
RNF34 Homo sapiens ring finger protein 34 (RNF34), transcript variant 2, mRNA. 923.36 612.38 1.51 0.008 310.98 
UBP1 Homo sapiens upstream binding protein 1 (LBP-1a) (UBP1), mRNA. 755.68 500.26 1.51 0.009 255.42 
ZGPAT Homo sapiens zinc finger, CCCH-type with G patch domain (ZGPAT), transcript variant 1, mRNA. 668.75 443.73 1.51 0.000 225.02 
ARHGEF6 Homo sapiens Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 (ARHGEF6), mRNA. 3414.4 2241.45 1.52 0.002 1172.95 
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CDC2L5 Homo sapiens cell division cycle 2-like 5 (cholinesterase-related cell division controller) (CDC2L5), transcript variant 2, mRNA. 326.31 213.99 1.52 2.00E-04 112.32 
CCDC25 Homo sapiens coiled-coil domain containing 25 (CCDC25), mRNA. 649.56 422.85 1.54 0.004 226.71 
CKAP5 Homo sapiens cytoskeleton associated protein 5 (CKAP5), transcript variant 1, mRNA. 905.28 587.59 1.54 1.00E-04 317.70 
MRI1 Homo sapiens methylthioribose-1-phosphate isomerase homolog (S. cerevisiae) (MRI1), transcript variant 1, mRNA. 564.06 365.59 1.54 4.00E-04 198.47 
TBP Homo sapiens TATA box binding protein (TBP), mRNA. 377.26 244.64 1.54 0.000 132.62 
C14orf135 Homo sapiens chromosome 14 open reading frame 135 (C14orf135), mRNA. 305.88 196.4 1.56 6.00E-04 109.47 
AP1S2 Homo sapiens adaptor-related protein complex 1, sigma 2 subunit (AP1S2), mRNA. 1682.09 1074.58 1.57 0.034 607.52 
ANGEL2 Homo sapiens angel homolog 2 (Drosophila) (ANGEL2), mRNA. 890.28 564.54 1.58 0.013 325.74 
FAM38A Homo sapiens family with sequence similarity 38, member A (FAM38A), mRNA. 847.71 537.41 1.58 0.002 310.30 
ALDH9A1 Homo sapiens aldehyde dehydrogenase 9 family, member A1 (ALDH9A1), mRNA. 4193.07 2645.26 1.59 0.000 1547.8 
CDS2 Homo sapiens CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 (CDS2), mRNA. 273.79 169.27 1.62 0.040 104.52 
KLRB1 Homo sapiens killer cell lectin-like receptor subfamily B, member 1 (KLRB1), mRNA. 3453.31 2129 1.62 0.003 1324.31 
SH3KBP1 Homo sapiens SH3-domain kinase binding protein 1 (SH3KBP1), transcript variant 1, mRNA. 1636.06 1012.12 1.62 0.033 623.94 
C5orf15 Homo sapiens chromosome 5 open reading frame 15 (C5orf15), mRNA. 940.75 576.73 1.63 0.005 364.01 
RAB11A Homo sapiens RAB11A, member RAS oncogene family (RAB11A), mRNA. 1494.19 916.21 1.63 0.000 577.97 
ZNF721 Homo sapiens zinc finger protein 721 (ZNF721), mRNA. 450.46 273.78 1.65 0.004 176.68 
CLIP1 Homo sapiens CAP-GLY domain containing linker protein 1 (CLIP1), transcript variant 1, mRNA. 411.43 246.16 1.67 0.011 165.27 
FANCE Homo sapiens Fanconi anemia, complementation group E (FANCE), mRNA. 248.43 148.38 1.67 0.026 100.05 
ARHGAP30 Homo sapiens Rho GTPase activating protein 30 (ARHGAP30), transcript variant 1, mRNA. 1858.45 1102.01 1.69 0.020 756.44 
POGK Homo sapiens pogo transposable element with KRAB domain (POGK), mRNA. 793.91 470.79 1.69 0.000 323.13 
KATNB1 Homo sapiens katanin p80 (WD repeat containing) subunit B 1 (KATNB1), mRNA. 277.06 162.93 1.7 5.00E-04 114.14 
RAB40C Homo sapiens RAB40C, member RAS oncogene family (RAB40C), mRNA. 716.94 418.11 1.71 0.0318 298.83 
GFI1 Homo sapiens growth factor independent 1 transcription repressor (GFI1), mRNA. 739.52 425.69 1.74 0.000 313.82 
C1orf131 Homo sapiens chromosome 1 open reading frame 131 (C1orf131), mRNA. 354.43 199.18 1.78 2.00E-04 155.25 
ARL5A Homo sapiens ADP-ribosylation factor-like 5A (ARL5A), transcript variant 3, mRNA. 466.45 261.28 1.79 0.0036 205.17 
CASP3 Homo sapiens caspase 3, apoptosis-related cysteine peptidase (CASP3), transcript variant beta, mRNA. 533.35 297.18 1.79 1.00E-04 236.16 
GEMIN4 Homo sapiens gem (nuclear organelle) associated protein 4 (GEMIN4), mRNA. 439.11 240.62 1.82 0.000 198.50 
UBE2Q2 Homo sapiens ubiquitin-conjugating enzyme E2Q family member 2 (UBE2Q2), mRNA. 642.78 348.35 1.85 0.049 294.43 
ZNF322A Homo sapiens zinc finger protein 322A (ZNF322A), mRNA. 324.09 174.97 1.85 0.013 149.12 
FGD2 Homo sapiens FYVE, RhoGEF and PH domain containing 2 (FGD2), mRNA. 333.36 177.66 1.88 0.000 155.70 
 Homo sapiens cDNA clone IMAGE:5261213 1042.66 553.52 1.88 0.001 489.13 
TNFSF10 Homo sapiens tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10), mRNA. 486.50 258.23 1.88 0.019 228.26 
ATP6AP2 Homo sapiens ATPase, H+ transporting, lysosomal accessory protein 2 (ATP6AP2), mRNA. 738.70 390.95 1.89 0.000 347.75 
ZNF434 Homo sapiens zinc finger protein 434 (ZNF434), mRNA. 298.73 158.11 1.89 0.001 140.62 
TOR1AIP1 Homo sapiens torsin A interacting protein 1 (TOR1AIP1), mRNA. 750.62 395.23 1.9 0.045 355.39 
MYBL1 Homo sapiens v-myb myeloblastosis viral oncogene homolog (avian)-like 1 (MYBL1), mRNA. 330.65 172.33 1.92 0.015 158.32 
MLKL Homo sapiens mixed lineage kinase domain-like (MLKL), mRNA. 1884.5 971.05 1.94 0.006 913.46 
PIP5K1C Homo sapiens phosphatidylinositol-4-phosphate 5-kinase, type I, gamma (PIP5K1C), mRNA. 349.36 175.12 1.99 0.032 174.24 
CLCN7 Homo sapiens chloride channel 7 (CLCN7), mRNA. 1009.75 499.35 2.02 0.029 510.4 
LOC10013290
1 PREDICTED: Homo sapiens similar to KIAA1874 protein (LOC100132901), mRNA. 228.28 112.98 2.02 0.001 115.29 
LPAR5 Homo sapiens lysophosphatidic acid receptor 5 (LPAR5), mRNA. 240.27 116.40 2.06 0.002 123.87 
WDR4 Homo sapiens WD repeat domain 4 (WDR4), transcript variant 2, mRNA. 295.85 143.2 2.07 3.00E-04 152.65 
ZW10 Homo sapiens ZW10, kinetochore associated, homolog (Drosophila) (ZW10), mRNA. 317.48 152.43 2.08 0.011 165.05 
CDC2L5 Homo sapiens cell division cycle 2-like 5 (cholinesterase-related cell division controller) (CDC2L5), transcript variant 1, mRNA. 473.91 225.11 2.11 0.001 248.79 
RAP2A Homo sapiens RAP2A, member of RAS oncogene family (RAP2A), mRNA. 408.03 190.06 2.15 0.000 217.97 
LOC730432 PREDICTED: Homo sapiens similar to serine/threonine/tyrosine interacting protein, transcript variant 1 (LOC730432), mRNA. 652.13 301.41 2.16 1.00E-04 350.72 
ZNF493 Homo sapiens zinc finger protein 493 (ZNF493), transcript variant 3, mRNA. 315.36 145.24 2.17 0.013 170.13 
TATDN3 Homo sapiens TatD DNase domain containing 3 (TATDN3), transcript variant 1, mRNA. 372.80 169.84 2.2 0.018 202.96 
B4GALT7 Homo sapiens xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 (galactosyltransferase I) (B4GALT7), mRNA. 332.19 147.65 2.25 0.036 184.54 
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RFX7 Homo sapiens regulatory factor X, 7 (RFX7), mRNA. 594.94 255.03 2.33 0.011 339.91 
LRSAM1 Homo sapiens leucine rich repeat and sterile alpha motif containing 1 (LRSAM1), transcript variant 1, mRNA. 351.98 142.92 2.46 1.00E-04 209.06 
PTGDR Homo sapiens prostaglandin D2 receptor (DP) (PTGDR), mRNA. 362.77 145.43 2.49 9.00E-04 217.34 
WDR92 Homo sapiens WD repeat domain 92 (WDR92), mRNA. 214.21 84.72 2.53 2.00E-04 129.49 
MXRA7 Homo sapiens matrix-remodelling associated 7 (MXRA7), transcript variant 1, mRNA. 376.40 137.14 2.74 0.015 239.26 
 
 
Comparison CD4+CD25- T cells of MF+ individuals EN  
Symbol Definition mean_CD4_Mfpos mean_CD4_EN FC pvalue diff 
EIF4A2 Homo sapiens eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2), mRNA. 126.72 2213.11 -17.46 0.000 2086.39 
LOC729708 PREDICTED: Homo sapiens similar to rcTPI1, transcript variant 1 (LOC729708), mRNA. 192.97 621.22 -3.22 0.000 428.24 
LOC286512 PREDICTED: Homo sapiens misc_RNA (LOC286512), miscRNA. 90.92 255.68 -2.81 0.000 164.76 
LOC388796 Homo sapiens hypothetical LOC388796 (LOC388796), non-coding RNA. 199.80 517.01 -2.59 0.012 317.21 
CLASP1 Homo sapiens cytoplasmic linker associated protein 1 (CLASP1), mRNA. 188.59 464.81 -2.46 0.000 276.22 
SKP1 Homo sapiens S-phase kinase-associated protein 1 (SKP1), transcript variant 1, mRNA. 405.42 923.15 -2.28 2.00E-04 517.73 
RRBP1 Homo sapiens ribosome binding protein 1 homolog 180kDa (dog) (RRBP1), transcript variant 1, mRNA. 168.41 375.94 -2.23 0.000 207.53 
C9orf102 Homo sapiens chromosome 9 open reading frame 102 (C9orf102), mRNA. 118.21 262.67 -2.22 0.003 144.46 
ITPRIP Homo sapiens inositol 1,4,5-triphosphate receptor interacting protein (ITPRIP), mRNA. 230.99 507.09 -2.20 0.009 276.11 
BANP Homo sapiens BTG3 associated nuclear protein (BANP), transcript variant 2, mRNA. 1132.63 2426.44 -2.14 0.046 1293.81 
CCL4L1 Homo sapiens chemokine (C-C motif) ligand 4-like 1 (CCL4L1), mRNA. 157.41 336.32 -2.14 1.00E-04 178.91 
ENO2 Homo sapiens enolase 2 (gamma, neuronal) (ENO2), mRNA. 332.61 706.42 -2.12 0.000 373.81 
TPM2 Homo sapiens tropomyosin 2 (beta) (TPM2), transcript variant 2, mRNA. 253.82 528.87 -2.08 0.029 275.05 
EXOSC7 Homo sapiens exosome component 7 (EXOSC7), mRNA. 367.35 757.97 -2.06 0.021 390.62 
ZNF419 Homo sapiens zinc finger protein 419 (ZNF419), transcript variant 6, mRNA. 119.29 241.99 -2.03 0.003 122.70 
ZNF792 Homo sapiens zinc finger protein 792 (ZNF792), mRNA. 156.03 313.44 -2.01 0.011 157.42 
TPM2 Homo sapiens tropomyosin 2 (beta) (TPM2), transcript variant 2, mRNA. 219.84 439.07 -2.00 0.035 219.23 
KLF2 Homo sapiens Kruppel-like factor 2 (lung) (KLF2), mRNA. 1845.82 3643.46 -1.97 0.003 1797.64 
PASK Homo sapiens PAS domain containing serine/threonine kinase (PASK), mRNA. 151.72 297.85 -1.96 0.032 146.13 
 Homo sapiens cDNA clone IMAGE:30332316 198.33 375.92 -1.90 0.027 177.59 
TMEM41B Homo sapiens transmembrane protein 41B (TMEM41B), mRNA. 531.75 1001.39 -1.88 4.00E-04 469.64 
C8orf33 Homo sapiens chromosome 8 open reading frame 33 (C8orf33), mRNA. 202.81 378.77 -1.87 1.00E-04 175.96 
DDX24 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 (DDX24), mRNA. 704.06 1293.38 -1.84 0.007 589.32 
RNF135 Homo sapiens ring finger protein 135 (RNF135), transcript variant 2, mRNA. 149.53 268.47 -1.80 0.006 118.94 
PLEKHM2 Homo sapiens pleckstrin homology domain containing, family M (with RUN domain) member 2 (PLEKHM2), mRNA. 295.41 526.93 -1.78 5.00E-04 231.52 
TSC22D3 Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 1, mRNA. 2185.19 3845.93 -1.76 0.041 1660.74 
LOC731049 
PREDICTED: Homo sapiens similar to Ubiquitin-conjugating enzyme E2S (Ubiquitin-conjugating enzyme E2-24 kDa) (Ubiquitin-protein ligase) 
(Ubiquitin carrier protein) (E2-EPF5) (LOC731049), mRNA. 324.97 567.1 -1.75 9.00E-04 242.13 
POMGNT1 Homo sapiens protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase (POMGNT1), mRNA. 257.29 444.65 -1.73 6.00E-04 187.36 
CYTH1 Homo sapiens cytohesin 1 (CYTH1), transcript variant 2, mRNA. 955.19 1638.42 -1.72 0.030 683.23 
POLR2C Homo sapiens polymerase (RNA) II (DNA directed) polypeptide C, 33kDa (POLR2C), mRNA. 150.11 256.02 -1.71 0.002 105.91 
METT11D1 Homo sapiens methyltransferase 11 domain containing 1 (METT11D1), transcript variant 1, mRNA. 350.54 596.66 -1.70 0.039 246.12 
PRPS1 Homo sapiens phosphoribosyl pyrophosphate synthetase 1 (PRPS1), mRNA. 228.73 388.39 -1.70 7.00E-04 159.66 
SPG7 
Homo sapiens spastic paraplegia 7 (pure and complicated autosomal recessive) (SPG7), nuclear gene encoding mitochondrial protein, 
transcript variant 1, mRNA. 1171.66 1989.08 -1.70 0.000 817.42 
CCDC93 Homo sapiens coiled-coil domain containing 93 (CCDC93), mRNA. 419.42 699.06 -1.67 0.028 279.64 
ELMO1 Homo sapiens engulfment and cell motility 1 (ELMO1), transcript variant 1, mRNA. 148.50 248.59 -1.67 0.000 100.09 
ADPRHL2 Homo sapiens ADP-ribosylhydrolase like 2 (ADPRHL2), mRNA. 264.24 437.94 -1.66 0.026 173.7 
CLYBL Homo sapiens citrate lyase beta like (CLYBL), mRNA. 224.65 371.57 -1.65 0.002 146.91 
E4F1 Homo sapiens E4F transcription factor 1 (E4F1), mRNA. 446.72 738.18 -1.65 0.042 291.46 
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MCRS1 Homo sapiens microspherule protein 1 (MCRS1), transcript variant 1, mRNA. 284.00 468.14 -1.65 0.000 184.14 
TMEM97 Homo sapiens transmembrane protein 97 (TMEM97), mRNA. 159.02 261.96 -1.65 1.00E-04 102.93 
CHMP1A Homo sapiens chromatin modifying protein 1A (CHMP1A), transcript variant 2, mRNA. 281.94 463.09 -1.64 0.001 181.16 
EDG4 Homo sapiens endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 4 (EDG4), mRNA. 390.61 640.58 -1.64 0.000 249.96 
AK1 Homo sapiens adenylate kinase 1 (AK1), mRNA. 220.77 360.03 -1.63 0.000 139.26 
SLC2A1 Homo sapiens solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1), mRNA. 263.51 425.62 -1.62 0.008 162.11 
SNRPN Homo sapiens small nuclear ribonucleoprotein polypeptide N (SNRPN), transcript variant 2, mRNA. 377.04 612.37 -1.62 0.016 235.33 
TUBGCP2 Homo sapiens tubulin, gamma complex associated protein 2 (TUBGCP2), mRNA. 225.20 365.52 -1.62 0.000 140.32 
AMT Homo sapiens aminomethyltransferase (AMT), mRNA. 265.40 427.26 -1.61 0.020 161.87 
C9orf78 Homo sapiens chromosome 9 open reading frame 78 (C9orf78), mRNA. 1242.62 1999.78 -1.61 0.000 757.15 
NDUFS3 Homo sapiens NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-coenzyme Q reductase) (NDUFS3), mRNA. 738.99 1187.73 -1.61 0.000 448.74 
SFRS14 Homo sapiens splicing factor, arginine/serine-rich 14 (SFRS14), transcript variant 2, mRNA. 922.01 1481.73 -1.61 0.000 559.72 
C18orf8 Homo sapiens chromosome 18 open reading frame 8 (C18orf8), mRNA. 473.19 756.52 -1.60 0.005 283.33 
TRPC4AP Homo sapiens transient receptor potential cation channel, subfamily C, member 4 associated protein (TRPC4AP), transcript variant 1, mRNA. 455.83 728.79 -1.60 0.08 272.95 
IP6K1 Homo sapiens inositol hexakisphosphate kinase 1 (IP6K1), transcript variant 2, mRNA. 201.90 320.25 -1.59 3.00E-04 118.35 
TMEM219 Homo sapiens transmembrane protein 219 (TMEM219), transcript variant 1, mRNA. 419.07 666.29 -1.59 0.034 247.22 
LOC652685 PREDICTED: Homo sapiens similar to PMS1 protein homolog 2 (DNA mismatch repair protein PMS2) (LOC652685), mRNA. 206.61 326.66 -1.58 0.017 120.05 
SPATS2L Homo sapiens spermatogenesis associated, serine-rich 2-like (SPATS2L), transcript variant 2, mRNA. 208.45 329.45 -1.58 0.004 120.99 
MTRF1 Homo sapiens mitochondrial translational release factor 1 (MTRF1), nuclear gene encoding mitochondrial protein, mRNA. 185.83 289.16 -1.56 0.045 103.33 
LOC387841 PREDICTED: Homo sapiens similar to ribosomal protein L13a, transcript variant 2 (LOC387841), mRNA. 1196.54 1857.12 -1.55 0.006 660.58 
SLC25A28 Homo sapiens solute carrier family 25, member 28 (SLC25A28), mRNA. 761.89 1183.17 -1.55 0.038 421.29 
KIAA0182 Homo sapiens KIAA0182 (KIAA0182), mRNA. 315.81 482.18 -1.53 0.030 166.37 
LOC100130092 PREDICTED: Homo sapiens misc_RNA (LOC100130092), miscRNA. 274.49 420.02 -1.53 0.012 145.53 
OXA1L Homo sapiens oxidase (cytochrome c) assembly 1-like (OXA1L), mRNA. 433.56 658.64 -1.52 0.000 225.08 
PSME3 Homo sapiens proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki) (PSME3), transcript variant 1, mRNA. 197.36 299.58 -1.52 0.000 102.22 
STAU1 Homo sapiens staufen, RNA binding protein, homolog 1 (Drosophila) (STAU1), transcript variant T1, mRNA. 1224.09 1865.74 -1.52 0.011 641.65 
TM9SF2 Homo sapiens transmembrane 9 superfamily member 2 (TM9SF2), mRNA. 977.59 650.89 1.50 6.00E-04 326.7 
TTC37 Homo sapiens tetratricopeptide repeat domain 37 (TTC37), mRNA. 504.46 335.48 1.50 0.049 168.98 
CAP1 Homo sapiens CAP, adenylate cyclase-associated protein 1 (yeast) (CAP1), mRNA. 5129.00 3399.89 1.51 8.00E-04 1729.1 
LOC730288 PREDICTED: Homo sapiens similar to 40S ribosomal protein S28 (LOC730288), mRNA. 418.89 276.83 1.51 0.000 142.05 
RHOT1 Homo sapiens ras homolog gene family, member T1 (RHOT1), transcript variant 2, mRNA. 537.23 355.86 1.51 0.011 181.36 
PARP9 Homo sapiens poly (ADP-ribose) polymerase family, member 9 (PARP9), mRNA. 591.83 388.51 1.52 1.00E-04 203.31 
NCOA4 Homo sapiens nuclear receptor coactivator 4 (NCOA4), mRNA. 4253.75 2772.01 1.53 0.000 1481.74 
RASGRP1 Homo sapiens RAS guanyl releasing protein 1 (calcium and DAG-regulated) (RASGRP1), mRNA. 1090.09 711.62 1.53 3.00E-04 378.48 
PCID2 Homo sapiens PCI domain containing 2 (PCID2), mRNA. 2071.8 1348.15 1.54 0.000 723.65 
BMI1 Homo sapiens BMI1 polycomb ring finger oncogene (BMI1), mRNA. 425.29 275.23 1.55 1.00E-04 150.07 
TSSC1 Homo sapiens tumor suppressing subtransferable candidate 1 (TSSC1), mRNA. 490.43 315.83 1.55 0.045 174.59 
ALDH9A1 Homo sapiens aldehyde dehydrogenase 9 family, member A1 (ALDH9A1), mRNA. 4121.61 2645.26 1.56 0.022 1476.34 
MBNL1 Homo sapiens muscleblind-like (Drosophila) (MBNL1), transcript variant 5, mRNA. 733.49 469.30 1.56 0.016 264.19 
CSK Homo sapiens c-src tyrosine kinase (CSK), mRNA. 829.13 528.69 1.57 0.011 300.45 
DEK Homo sapiens DEK oncogene (DNA binding) (DEK), mRNA. 935.21 594.98 1.57 5.00E-04 340.23 
XRN1 Homo sapiens 5'-3' exoribonuclease 1 (XRN1), mRNA. 503.68 320.95 1.57 0.005 182.73 
LOC341457 PREDICTED: Homo sapiens similar to peptidylprolyl isomerase A isoform 1 (LOC341457), mRNA. 298.78 189.28 1.58 0.000 109.50 
LOC399748 PREDICTED: Homo sapiens misc_RNA (LOC399748), miscRNA. 1674.12 1061.76 1.58 0.046 612.36 
ME2 Homo sapiens malic enzyme 2, NAD(+)-dependent, mitochondrial (ME2), nuclear gene encoding mitochondrial protein, mRNA. 335.57 212.46 1.58 0.000 123.11 
PPP2R3C Homo sapiens protein phosphatase 2 (formerly 2A), regulatory subunit B'', gamma (PPP2R3C), mRNA. 378.82 240.51 1.58 0.005 138.31 
PGRMC1 Homo sapiens progesterone receptor membrane component 1 (PGRMC1), mRNA. 458.83 287.84 1.59 0.029 170.98 
ATP2B4 Homo sapiens ATPase, Ca++ transporting, plasma membrane 4 (ATP2B4), transcript variant 1, mRNA. 1092.84 684.64 1.60 0.011 408.19 
MAP3K7 Homo sapiens mitogen-activated protein kinase kinase kinase 7 (MAP3K7), transcript variant B, mRNA. 890.61 555.95 1.60 0.000 334.66 
CREG1 Homo sapiens cellular repressor of E1A-stimulated genes 1 (CREG1), mRNA. 306.63 190.37 1.61 0.0224 116.26 
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SRP54 PREDICTED: Homo sapiens signal recognition particle 54kDa (SRP54), mRNA. 1087.87 676.56 1.61 0,0000 411.31 
SRPK1 Homo sapiens SFRS protein kinase 1 (SRPK1), mRNA. 322.86 200.37 1.61 0.006 122.5 
TRAM1 Homo sapiens translocation associated membrane protein 1 (TRAM1), mRNA. 3297.43 2052.29 1.61 2.00E-04 1245.14 
SH3KBP1 Homo sapiens SH3-domain kinase binding protein 1 (SH3KBP1), transcript variant 1, mRNA. 1644.57 1012.12 1.62 0.032 632.45 
WDR7 Homo sapiens WD repeat domain 7 (WDR7), transcript variant 1, mRNA. 300.88 186.3 1.62 1.00E-04 114.58 
CUL5 Homo sapiens cullin 5 (CUL5), mRNA. 350.98 215.47 1.63 0.050 135.51 
HMGN4 Homo sapiens high mobility group nucleosomal binding domain 4 (HMGN4), mRNA. 1535.30 943.24 1.63 0.000 592.06 
LAX1 Homo sapiens lymphocyte transmembrane adaptor 1 (LAX1), mRNA. 487.84 298.69 1.63 0.000 189.15 
ACOT7 Homo sapiens acyl-CoA thioesterase 7 (ACOT7), transcript variant hBACHb, mRNA. 479.34 292.33 1.64 0.004 187.02 
CMPK1 Homo sapiens cytidine monophosphate (UMP-CMP) kinase 1, cytosolic (CMPK1), mRNA. 608.08 371.04 1.64 0.033 237.04 
PIP5K1C Homo sapiens phosphatidylinositol-4-phosphate 5-kinase, type I, gamma (PIP5K1C), mRNA. 286.38 175.12 1.64 0.002 111.25 
C5orf15 Homo sapiens chromosome 5 open reading frame 15 (C5orf15), mRNA. 951.37 576.73 1.65 0.012 374.64 
CKLF Homo sapiens chemokine-like factor (CKLF), transcript variant 5, mRNA. 646.58 392.66 1.65 4.00E-04 253.92 
PTPLB Homo sapiens protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b (PTPLB), mRNA. 349.35 211.51 1.65 0.034 137.84 
ATXN1 Homo sapiens ataxin 1 (ATXN1), mRNA. 259.37 156.06 1.66 6.00E-04 103.32 
DNASE2 Homo sapiens deoxyribonuclease II, lysosomal (DNASE2), mRNA. 299.59 180.39 1.66 0.002 119.20 
EXOC2 Homo sapiens exocyst complex component 2 (EXOC2), mRNA. 383.61 230.87 1.66 0.000 152.74 
C14orf109 Homo sapiens chromosome 14 open reading frame 109 (C14orf109), transcript variant 2, mRNA. 272.36 163.5 1.67 0.015 108.86 
DOCK10 Homo sapiens dedicator of cytokinesis 10 (DOCK10), mRNA. 1740.06 1043.43 1.67 0.009 696.63 
LOC644330 PREDICTED: Homo sapiens similar to tropomyosin 3 isoform 2 (LOC644330), mRNA. 423.24 252.89 1.67 0.011 170.35 
PUM2 Homo sapiens pumilio homolog 2 (Drosophila) (PUM2), mRNA. 1200.63 720.41 1.67 0.012 480.22 
SUSD1 Homo sapiens sushi domain containing 1 (SUSD1), mRNA. 585.39 351.47 1.67 0.011 233.92 
DNMT1 Homo sapiens DNA (cytosine-5-)-methyltransferase 1 (DNMT1), mRNA. 2264.26 1345.03 1.68 0.000 919.23 
LOC729148 PREDICTED: Homo sapiens similar to lethal (2) k00619 CG4775-PA (LOC729148), mRNA. 536.69 319.55 1.68 0.049 217.14 
ABCB10 Homo sapiens ATP-binding cassette, sub-family B (MDR/TAP), member 10 (ABCB10), nuclear gene encoding mitochondrial protein, mRNA. 249.93 148.03 1.69 0.046 101.90 
PPP2R5E Homo sapiens protein phosphatase 2, regulatory subunit B', epsilon isoform (PPP2R5E), mRNA. 455.40 268.91 1.69 0.005 186.48 
DYRK1A Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A), transcript variant 4, mRNA. 602.89 354.75 1.70 0.036 248.15 
DYRK1A Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A), transcript variant 5, mRNA. 538.40 315.97 1.70 0.000 222.43 
OAT Homo sapiens ornithine aminotransferase (gyrate atrophy) (OAT), nuclear gene encoding mitochondrial protein, mRNA. 347.95 204.21 1.70 0.014 143.74 
PSMA4 Homo sapiens proteasome (prosome, macropain) subunit, alpha type, 4 (PSMA4), mRNA. 2081.73 1228.00 1.70 0.000 853.73 
ROD1 Homo sapiens ROD1 regulator of differentiation 1 (S. pombe) (ROD1), mRNA. 1987.19 1171.73 1.70 0.000 815.46 
ZMYND11 Homo sapiens zinc finger, MYND domain containing 11 (ZMYND11), transcript variant 1, mRNA. 1181.10 696.80 1.70 0.030 484.30 
CTSC Homo sapiens cathepsin C (CTSC), transcript variant 1, mRNA. 523.02 304.98 1.71 0.050 218.04 
VAMP4 Homo sapiens vesicle-associated membrane protein 4 (VAMP4), transcript variant 1, mRNA. 349.88 204.44 1.71 0.014 145.44 
C1orf24 Homo sapiens chromosome 1 open reading frame 24 (C1orf24), transcript variant 2, mRNA. 503.04 292.50 1.72 0.000 210.54 
KLRB1 Homo sapiens killer cell lectin-like receptor subfamily B, member 1 (KLRB1), mRNA. 3657.58 2129.00 1.72 0.033 1528.58 
ME2 Homo sapiens malic enzyme 2, NAD(+)-dependent, mitochondrial (ME2), nuclear gene encoding mitochondrial protein, mRNA. 315.03 183.36 1.72 2.00E-04 131.67 
IFI44L Homo sapiens interferon-induced protein 44-like (IFI44L), mRNA. 239.60 137.87 1.74 0.011 101.73 
RFX7 Homo sapiens regulatory factor X, 7 (RFX7), mRNA. 443.91 255.03 1.74 0.000 188.88 
TMX1 Homo sapiens thioredoxin-related transmembrane protein 1 (TMX1), mRNA. 236.55 135.63 1.74 0.029 100.92 
CLINT1 Homo sapiens clathrin interactor 1 (CLINT1), mRNA. 485.76 277.31 1.75 0.043 208.45 
7-Mar Homo sapiens membrane-associated ring finger (C3HC4) 7 (MARCH7), mRNA. 310.46 177.87 1.75 0.001 132.59 
SH3BGRL Homo sapiens SH3 domain binding glutamic acid-rich protein like (SH3BGRL), mRNA. 545.97 311.05 1.76 0.002 234.92 
SRI Homo sapiens sorcin (SRI), transcript variant 1, mRNA. 284.40 161.39 1.76 0.027 123.00 
TRIM44 Homo sapiens tripartite motif-containing 44 (TRIM44), mRNA. 401.89 228.38 1.76 3.00E-04 173.5 
XBP1 Homo sapiens X-box binding protein 1 (XBP1), transcript variant 1, mRNA. 942.25 536.54 1.76 0.003 405.71 
WASPIP Homo sapiens Wiskott-Aldrich syndrome protein interacting protein (WASPIP), mRNA. 785.62 438.21 1.79 0.000 347.41 
LACTB Homo sapiens lactamase, beta (LACTB), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 535.09 297.95 1.80 0.021 237.13 
LOC100128510 PREDICTED: Homo sapiens hypothetical protein LOC100128510 (LOC100128510), mRNA. 254.45 141.17 1.80 0.004 113.28 
 qk02b10.x1 NCI_CGAP_Kid3 Homo sapiens cDNA clone IMAGE:1867771 3, mRNA sequence 319.87 176.55 1.81 1.00E-04 143.32 
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PRKAR1A 
Homo sapiens protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) (PRKAR1A), transcript variant 3, 
mRNA. 679.88 374.70 1.81 0.015 305.18 
GBP1 Homo sapiens guanylate binding protein 1, interferon-inducible, 67kDa (GBP1), mRNA. 670.65 369.39 1.82 0.000 301.26 
IL15 Homo sapiens interleukin 15 (IL15), transcript variant 3, mRNA. 477.59 262.14 1.82 0.047 215.46 
RECQL Homo sapiens RecQ protein-like (DNA helicase Q1-like) (RECQL), transcript variant 1, mRNA. 266.29 146.07 1.82 1.00E-04 120.22 
SCAMP1 Homo sapiens secretory carrier membrane protein 1 (SCAMP1), mRNA. 1007.63 553.17 1.82 0.002 454.46 
FGD2 Homo sapiens FYVE, RhoGEF and PH domain containing 2 (FGD2), mRNA. 325.42 177.66 1.83 0.000 147.76 
EMR2 Homo sapiens egf-like module containing, mucin-like, hormone receptor-like 2 (EMR2), transcript variant 2, mRNA. 398.79 216.31 1.84 0.000 182.48 
SMG1 Homo sapiens PI-3-kinase-related kinase SMG-1 (SMG1), mRNA. 534.73 290.33 1.84 0.023 244.40 
ST13 Homo sapiens suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) (ST13), mRNA. 391.99 211.59 1.85 0.005 180.40 
TMEM123 Homo sapiens transmembrane protein 123 (TMEM123), mRNA. 1749.82 948.28 1.85 0.0134 801.54 
ARL5A Homo sapiens ADP-ribosylation factor-like 5A (ARL5A), transcript variant 3, mRNA. 827.67 446.17 1.86 0.006 381.49 
LAMP2 Homo sapiens lysosomal-associated membrane protein 2 (LAMP2), transcript variant LAMP2B, mRNA. 424.04 227.90 1.86 0.047 196.14 
PHYH Homo sapiens phytanoyl-CoA 2-hydroxylase (PHYH), transcript variant 2, mRNA. 339.60 182.56 1.86 0.002 157.04 
ZCCHC7 Homo sapiens zinc finger, CCHC domain containing 7 (ZCCHC7), mRNA. 278.52 149.74 1.86 0.010 128.78 
KIAA0528 Homo sapiens KIAA0528 (KIAA0528), mRNA. 486.84 259.25 1.88 4.00E-04 227.59 
SLC25A43 Homo sapiens solute carrier family 25, member 43 (SLC25A43), mRNA. 248.95 132.69 1.88 0.036 116.26 
ACSL5 Homo sapiens acyl-CoA synthetase long-chain family member 5 (ACSL5), transcript variant 2, mRNA. 348.95 184.78 1.89 0.021 164.17 
YWHAQ Homo sapiens tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide (YWHAQ), mRNA. 3647.07 1892.13 1.93 2.00E-04 1754.94 
ARL6IP1 Homo sapiens ADP-ribosylation factor-like 6 interacting protein 1 (ARL6IP1), mRNA. 1608.58 831.30 1.94 0.000 777.27 
HNRNPA0 Homo sapiens heterogeneous nuclear ribonucleoprotein A0 (HNRNPA0), mRNA. 472.05 240.29 1.96 0.027 231.76 
ACTR2 Homo sapiens ARP2 actin-related protein 2 homolog (yeast) (ACTR2), transcript variant 1, mRNA. 1650.45 836.23 1.97 0.024 814.22 
THUMPD1 Homo sapiens THUMP domain containing 1 (THUMPD1), mRNA. 613.84 309.83 1.98 0.007 304.02 
CDS2 Homo sapiens CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 (CDS2), mRNA. 336.43 169.27 1.99 4.00E-04 167.17 
HEATR1 Homo sapiens HEAT repeat containing 1 (HEATR1), mRNA. 428.28 215.15 1.99 0.000 213.13 
SH2D1A Homo sapiens SH2 domain protein 1A, Duncan's disease (lymphoproliferative syndrome) (SH2D1A), mRNA. 1127.50 562.54 2.00 0.027 564.95 
RALB Homo sapiens v-ral simian leukemia viral oncogene homolog B (ras related; GTP binding protein) (RALB), mRNA. 688.16 340.20 2.02 0.001 347.96 
MAP4K5 Homo sapiens mitogen-activated protein kinase kinase kinase kinase 5 (MAP4K5), transcript variant 2, mRNA. 359.90 177.11 2.03 0.044 182.79 
CHST7 Homo sapiens carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 (CHST7), mRNA. 277.83 136.51 2.04 8.00E-04 141.32 
ZMYM1 Homo sapiens zinc finger, MYM-type 1 (ZMYM1), mRNA. 256.10 125.75 2.04 0.000 130.35 
IQGAP2 Homo sapiens IQ motif containing GTPase activating protein 2 (IQGAP2), mRNA. 683.06 332.08 2.06 0.003 350.98 
 Homo sapiens cDNA FLJ33738 fis, clone BRAWH2018527 197.27 95.12 2.07 0.032 102.15 
TMEM156 Homo sapiens transmembrane protein 156 (TMEM156), mRNA. 1007.69 485.23 2.08 0.002 522.46 
TMEM209 Homo sapiens transmembrane protein 209 (TMEM209), mRNA. 286.83 137.86 2.08 0.009 148.97 
UCP2 Homo sapiens uncoupling protein 2 (mitochondrial, proton carrier) (UCP2), nuclear gene encoding mitochondrial protein, mRNA. 493.53 236.86 2.08 0.005 256.67 
IL10RB Homo sapiens interleukin 10 receptor, beta (IL10RB), mRNA. 1041.19 497.58 2.09 0.023 543.62 
CEACAM1 Homo sapiens carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) (CEACAM1), transcript variant 2, mRNA. 191.30 91.18 2.10 0.003 100.12 
DHFRL1 Homo sapiens dihydrofolate reductase-like 1 (DHFRL1), mRNA. 190.31 90.21 2.11 0.000 100.10 
STS-1 Homo sapiens Cbl-interacting protein Sts-1 (STS-1), mRNA. 497.62 234.7 2.12 0.003 262.92 
NOD2 Homo sapiens nucleotide-binding oligomerization domain containing 2 (NOD2), mRNA. 288.38 134.35 2.15 0.008 154.03 
HIGD1A Homo sapiens HIG1 hypoxia inducible domain family, member 1A (HIGD1A), transcript variant 1, mRNA. 449.25 202.05 2.22 0.008 247.20 
KYNU Homo sapiens kynureninase (L-kynurenine hydrolase) (KYNU), transcript variant 1, mRNA. 358.89 156.57 2.29 0.007 202.33 
ATP6AP2 Homo sapiens ATPase, H+ transporting, lysosomal accessory protein 2 (ATP6AP2), mRNA. 902.91 390.95 2.31 0.014 511.97 
TNFSF10 Homo sapiens tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10), mRNA. 650.48 258.23 2.52 0.000 392.25 
SDCCAG10 Homo sapiens serologically defined colon cancer antigen 10 (SDCCAG10), mRNA. 478.32 187.66 2.55 3.00E-04 290.66 
ZW10 Homo sapiens ZW10, kinetochore associated, homolog (Drosophila) (ZW10), mRNA. 455.47 152.43 2.99 8.00E-04 303.03 
LILRA3 Homo sapiens leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 3 (LILRA3), mRNA. 1785.06 327.48 5.45 0.000 1457.58 
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Comparison CD8+ T cells of infected individuals versus EN 
Symbol Definition mean_CD8_inf mean_CD8_healthy FC pvalue diff 
SOD2 Homo sapiens superoxide dismutase 2, mitochondrial (SOD2), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA. 361.70 884.22 -2.44 0.000 522.53 
LOC338758 PREDICTED: Homo sapiens hypothetical protein LOC338758 (LOC338758), mRNA. 280.00 668.89 -2.39 0.006 388.9 
BTBD7 Homo sapiens BTB (POZ) domain containing 7 (BTBD7), transcript variant 2, mRNA. 163.16 360.10 -2.21 0.008 196.95 
SGK Homo sapiens serum/glucocorticoid regulated kinase (SGK), mRNA. 224.32 494.4 -2.20 7.00E-04 270.08 
C7orf40 Homo sapiens chromosome 7 open reading frame 40 (C7orf40), non-coding RNA. 238.98 500.25 -2.09 0.004 261.27 
KLF4 Homo sapiens Kruppel-like factor 4 (gut) (KLF4), mRNA. 120.15 249.90 -2.08 0,000 129.74 
NFKBIZ Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta (NFKBIZ), transcript variant 2, mRNA. 601.55 1189.31 -1.98 0.027 587.76 
SERTAD3 Homo sapiens SERTA domain containing 3 (SERTAD3), transcript variant 1, mRNA. 140.78 266.87 -1.90 0.024 126.09 
ACSL3 Homo sapiens acyl-CoA synthetase long-chain family member 3 (ACSL3), transcript variant 2, mRNA. 294.53 518.23 -1.76 0,000 223.71 
 Homo sapiens cDNA clone IMAGE:30332316 202.03 343.18 -1.70 0.003 141.15 
MYLIP Homo sapiens myosin regulatory light chain interacting protein (MYLIP), mRNA. 1749.65 2935.22 -1.68 4.00E-04 1185.57 
LRP5L Homo sapiens low density lipoprotein receptor-related protein 5-like (LRP5L), mRNA. 263.56 428.72 -1.63 0.035 165.16 
BCL6 Homo sapiens B-cell CLL/lymphoma 6 (zinc finger protein 51) (BCL6), transcript variant 1, mRNA. 529.75 859.96 -1.62 0.029 330.21 
PHAX Homo sapiens phosphorylated adaptor for RNA export (PHAX), mRNA. 225.61 354.27 -1.57 0.004 128.65 
GSK3B Homo sapiens glycogen synthase kinase 3 beta (GSK3B), mRNA. 393.89 602.69 -1.53 0.045 208.8 
FBXO44 Homo sapiens F-box protein 44 (FBXO44), transcript variant 4, mRNA. 192.28 293.23 -1.52 0.004 100.95 
CGRRF1 Homo sapiens cell growth regulator with ring finger domain 1 (CGRRF1), mRNA. 210.00 316.76 -1.51 0.025 106.76 
LOC606724 Homo sapiens coronin, actin binding protein, 1A pseudogene (LOC606724), non-coding RNA. 1639.11 1082.57 1.51 0.007 556.53 
SRP68 Homo sapiens signal recognition particle 68kDa (SRP68), mRNA. 661.14 433.38 1.53 0.002 227.76 
WDR40A Homo sapiens WD repeat domain 40A (WDR40A), mRNA. 329.84 215.38 1.53 0.011 114.45 
POMGNT1 Homo sapiens protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase (POMGNT1), mRNA. 350.44 227.96 1.54 0,000 122.47 
C9orf69 Homo sapiens chromosome 9 open reading frame 69 (C9orf69), mRNA. 338.91 216.67 1.56 0,000 122.24 
LOC730415 PREDICTED: Homo sapiens hypothetical LOC730415, transcript variant 2 (LOC730415), mRNA. 1647.72 1053.23 1.56 0.046 594.49 
LRP10 Homo sapiens low density lipoprotein receptor-related protein 10 (LRP10), mRNA. 897.20 562.20 1.60 0.044 335.01 
TMBIM4 Homo sapiens transmembrane BAX inhibitor motif containing 4 (TMBIM4), mRNA. 2526.66 1541.72 1.64 0.050 984.93 
SRXN1 Homo sapiens sulfiredoxin 1 homolog (S. cerevisiae) (SRXN1), mRNA. 258.19 155.44 1.66 0.047 102.75 
SGSH Homo sapiens N-sulfoglucosamine sulfohydrolase (sulfamidase) (SGSH), mRNA. 655.14 385.11 1.70 0,000 270.02 
NME1 Homo sapiens non-metastatic cells 1, protein (NM23A) expressed in (NME1), transcript variant 2, mRNA. 431.35 252.21 1.71 0.0230 179.14 
RNF121 Homo sapiens ring finger protein 121 (RNF121), transcript variant 1, mRNA. 250.24 145.07 1.72 0.022 105.16 
 Homo sapiens cDNA FLJ12874 fis, clone NT2RP2003769 449.14 238.55 1.88 0.017 210.59 
PKP4 Homo sapiens plakophilin 4 (PKP4), transcript variant 1, mRNA. 237.86 126.45 1.88 0.016 111.41 
UBL4A Homo sapiens ubiquitin-like 4A (UBL4A), mRNA. 458.02 242.77 1.89 2.00E-04 215.25 
ARL17P1 Homo sapiens ADP-ribosylation factor-like 17 pseudogene 1 (ARL17P1), mRNA. 273.87 138.25 1.98 0.020 135.62 
WIBG Homo sapiens within bgcn homolog (Drosophila) (WIBG), mRNA. 278.42 135.55 2.05 0.006 142.86 
ACVR1 Homo sapiens activin A receptor, type I (ACVR1), mRNA. 285.08 136.16 2.09 0.025 148.93 
RABEP1 Homo sapiens rabaptin, RAB GTPase binding effector protein 1 (RABEP1), transcript variant 2, mRNA. 453.53 215.90 2.10 0,000 237.63 
METT10D Homo sapiens methyltransferase 10 domain containing (METT10D), mRNA. 201.87 85.45 2.36 0.002 116.43 
APPBP2 Homo sapiens amyloid beta precursor protein (cytoplasmic tail) binding protein 2 (APPBP2), mRNA. 203.09 85.38 2.38 0,000 117.72 
ZNF232 Homo sapiens zinc finger protein 232 (ZNF232), mRNA. 245.29 103.27 2.38 1.00E-04 142.01 
PTGDR Homo sapiens prostaglandin D2 receptor (DP) (PTGDR), mRNA. 554.81 215.00 2.58 0.003 339.81 
FANCD2 Homo sapiens Fanconi anemia, complementation group D2 (FANCD2), transcript variant 2, mRNA. 279.10 99.42 2.81 0.005 179.68 
 
  145 
Comparison CD8+ T cells of MF+ versus MF- individuals 
Symbol Definition mean_CD8_Mfneg mean_CD8_Mfpos FC pvalue diff 
MYOM2 Homo sapiens myomesin (M-protein) 2, 165kDa (MYOM2), mRNA. 97.84 3806.31 -38.9 0.042 3708.47 
HAVCR2 Homo sapiens hepatitis A virus cellular receptor 2 (HAVCR2), mRNA. 340.25 1095.55 -3.22 0.000 755.30 
VPS13C Homo sapiens vacuolar protein sorting 13 homolog C (S. cerevisiae) (VPS13C), transcript variant 1B, mRNA. 103.33 294.16 -2.85 1.00E-04 190.83 
CDC42SE1 Homo sapiens CDC42 small effector 1 (CDC42SE1), transcript variant 1, mRNA. 100.84 236.50 -2.35 0.000 135.66 
MIER1 Homo sapiens mesoderm induction early response 1 homolog (Xenopus laevis) (MIER1), transcript variant 1, mRNA. 184.21 385.53 -2.09 0.035 201.32 
COMMD7 Homo sapiens COMM domain containing 7 (COMMD7), transcript variant 2, mRNA. 563.70 1150.54 -2.04 0.000 586.84 
LOC440093 Homo sapiens histone H3-like (LOC440093), mRNA. 604.94 1188.75 -1.97 0.000 583.81 
RUSC1 Homo sapiens RUN and SH3 domain containing 1 (RUSC1), mRNA. 370.93 702.77 -1.89 0.010 331.84 
CCDC53 Homo sapiens coiled-coil domain containing 53 (CCDC53), mRNA. 207.11 370.11 -1.79 1.00E-04 163,00 
WIPI1 Homo sapiens WD repeat domain, phosphoinositide interacting 1 (WIPI1), mRNA. 183.00 321.58 -1.76 0.003 138.58 
CCT2 Homo sapiens chaperonin containing TCP1, subunit 2 (beta) (CCT2), mRNA. 529.37 924.18 -1.75 0.006 394.81 
STK17B Homo sapiens serine/threonine kinase 17b (STK17B), mRNA. 234.60 409.55 -1.75 0.002 174.95 
SAE1 Homo sapiens SUMO1 activating enzyme subunit 1 (SAE1), mRNA. 815.21 1417.47 -1.74 0.037 602.26 
AGTPBP1 Homo sapiens ATP/GTP binding protein 1 (AGTPBP1), mRNA. 527.25 900.71 -1.71 0.000 373.46 
C9orf114 Homo sapiens chromosome 9 open reading frame 114 (C9orf114), mRNA. 154.38 264.42 -1.71 0.028 110.04 
ING2 Homo sapiens inhibitor of growth family, member 2 (ING2), mRNA. 140.92 240.94 -1.71 0.000 100.02 
TFDP1 Homo sapiens transcription factor Dp-1 (TFDP1), mRNA. 343.59 586.31 -1.71 0.000 242.72 
DDX3X Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked (DDX3X), mRNA. 583.74 988.33 -1.69 0.008 404.59 
ADNP2 Homo sapiens ADNP homeobox 2 (ADNP2), mRNA. 319.49 535.12 -1.67 0.007 215.63 
RPAIN Homo sapiens RPA interacting protein (RPAIN), mRNA. 268.13 447.34 -1.67 0.002 179.22 
HPRT1 Homo sapiens hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan syndrome) (HPRT1), mRNA. 365.19 604.52 -1.66 0.005 239.33 
LOC100131531 PREDICTED: Homo sapiens similar to hCG1644658 (LOC100131531), mRNA. 483.58 796.32 -1.65 0.003 312.74 
SHFM1 Homo sapiens split hand/foot malformation (ectrodactyly) type 1 (SHFM1), mRNA. 222.41 365.98 -1.65 0.018 143.58 
LRPAP1 Homo sapiens low density lipoprotein receptor-related protein associated protein 1 (LRPAP1), mRNA. 263.14 430.91 -1.64 0.031 167.77 
FASTKD5 Homo sapiens FAST kinase domains 5 (FASTKD5), mRNA. 291.27 476.19 -1.63 0.000 184.92 
GSDMB Homo sapiens gasdermin B (GSDMB), transcript variant 2, mRNA. 307.92 497.54 -1.62 0.006 189.62 
NHP2 Homo sapiens NHP2 ribonucleoprotein homolog (yeast) (NHP2), transcript variant 1, mRNA. 254.47 411.78 -1.62 0.024 157.30 
C5orf21 Homo sapiens chromosome 5 open reading frame 21 (C5orf21), mRNA. 252.51 396.11 -1.57 0.047 143.60 
AZIN1 Homo sapiens antizyme inhibitor 1 (AZIN1), transcript variant 1, mRNA. 635.96 989.35 -1.56 0.046 353.40 
CXCR4 Homo sapiens chemokine (C-X-C motif) receptor 4 (CXCR4), transcript variant 1, mRNA. 447.63 683.04 -1.53 0.003 235.41 
PSMB9 Homo sapiens proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2) (PSMB9), transcript variant 1, mRNA. 497.57 746.84 -1.50 0.044 249.28 
ACADM Homo sapiens acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain (ACADM), nuclear gene encoding mitochondrial protein, mRNA. 338.73 222.53 1.52 0.003 116.20 
NOP2 Homo sapiens NOP2 nucleolar protein homolog (yeast) (NOP2), transcript variant 2, mRNA. 651.85 427.72 1.52 0.000 224.13 
ASB1 Homo sapiens ankyrin repeat and SOCS box-containing 1 (ASB1), mRNA. 640.02 419.01 1.53 0.042 221.01 
TUBA4A Homo sapiens tubulin, alpha 4a (TUBA4A), mRNA. 1615.24 1052.71 1.53 0.000 562.53 
C6orf170 Homo sapiens chromosome 6 open reading frame 170 (C6orf170), mRNA. 390.55 251.19 1.55 0.012 139.37 
FRYL Homo sapiens FRY-like (FRYL), mRNA. 1254.74 810.78 1.55 0.010 443.97 
ZNF75D Homo sapiens zinc finger protein 75D (ZNF75D), mRNA. 301.76 193.37 1.56 0.000 108.39 
INTS8 Homo sapiens integrator complex subunit 8 (INTS8), mRNA. 325.25 207.28 1.57 0.001 117.96 
ZNF33B Homo sapiens zinc finger protein 33B (ZNF33B), mRNA. 322.64 203.72 1.58 0.030 118.92 
ZNF395 Homo sapiens zinc finger protein 395 (ZNF395), mRNA. 453.54 285.05 1.59 0.000 168.49 
MRPS31 Homo sapiens mitochondrial ribosomal protein S31 (MRPS31), nuclear gene encoding mitochondrial protein, mRNA. 745.56 462.52 1.61 0.003 283.04 
LHPP Homo sapiens phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP), mRNA. 291.37 180.26 1.62 1.00E-04 111.11 
GIMAP5 Homo sapiens GTPase, IMAP family member 5 (GIMAP5), mRNA. 2073.99 1272.79 1.63 0.029 801.20 
POLR3F Homo sapiens polymerase (RNA) III (DNA directed) polypeptide F, 39 kDa (POLR3F), mRNA. 347.89 211.47 1.65 0.000 136.42 
ZMYM6 Homo sapiens zinc finger, MYM-type 6 (ZMYM6), mRNA. 359.76 217.67 1.65 0.000 142.08 
GALT Homo sapiens galactose-1-phosphate uridylyltransferase (GALT), mRNA. 461.12 275.63 1.67 0.005 185.49 
SERGEF Homo sapiens secretion regulating guanine nucleotide exchange factor (SERGEF), mRNA. 559.03 335.40 1.67 0.001 223.64 
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C12orf52 Homo sapiens chromosome 12 open reading frame 52 (C12orf52), mRNA. 276.31 164.70 1.68 0.000 111.60 
GCLC Homo sapiens glutamate-cysteine ligase, catalytic subunit (GCLC), mRNA. 301.25 179.69 1.68 0.000 121.56 
 full-length cDNA clone CS0DF005YI08 of Fetal brain of Homo sapiens (human) 325.61 193.78 1.68 1.00E-04 131.83 
KLHDC3 Homo sapiens kelch domain containing 3 (KLHDC3), mRNA. 551.83 329.41 1.68 3.00E-04 222.43 
TMUB2 Homo sapiens transmembrane and ubiquitin-like domain containing 2 (TMUB2), transcript variant 1, mRNA. 321.10 189.52 1.69 0.000 131.59 
PDE4B Homo sapiens phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila) (PDE4B), transcript variant a, mRNA. 720.05 422.45 1.70 0.001 297.60 
MRPL35 Homo sapiens mitochondrial ribosomal protein L35 (MRPL35), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 373.23 214.63 1.74 0.000 158.60 
IFIH1 Homo sapiens interferon induced with helicase C domain 1 (IFIH1), mRNA. 344.35 194.44 1.77 6.00E-04 149.91 
DEGS1 Homo sapiens degenerative spermatocyte homolog 1, lipid desaturase (Drosophila) (DEGS1), transcript variant 1, mRNA. 728.54 410.24 1.78 1.00E-04 318.30 
DDX19A Homo sapiens DEAD (Asp-Glu-Ala-As) box polypeptide 19A (DDX19A), mRNA. 449.50 251.46 1.79 4.00E-04 198.04 
TBL1X Homo sapiens transducin (beta)-like 1X-linked (TBL1X), mRNA. 416.48 227.17 1.83 0.008 189.31 
VAV3 Homo sapiens vav 3 guanine nucleotide exchange factor (VAV3), transcript variant 1, mRNA. 354.17 192.19 1.84 0.010 161.98 
CYTSA Homo sapiens cytospin A (CYTSA), mRNA. 904.41 488.36 1.85 0.023 416.05 
TM7SF2 Homo sapiens transmembrane 7 superfamily member 2 (TM7SF2), mRNA. 260.06 138.27 1.88 0.043 121.79 
SENP5 Homo sapiens SUMO1/sentrin specific peptidase 5 (SENP5), mRNA. 358.17 189.97 1.89 0.025 168.21 
C17orf44 Homo sapiens chromosome 17 open reading frame 44 (C17orf44), mRNA. 338.32 178.35 1.90 0.000 159.97 
ASTE1 Homo sapiens asteroid homolog 1 (Drosophila) (ASTE1), mRNA. 227.61 117.12 1.94 0.014 110.50 
USP7 Homo sapiens ubiquitin specific peptidase 7 (herpes virus-associated) (USP7), mRNA. 907.59 458.78 1.98 0.025 448.81 
KLHL3 Homo sapiens kelch-like 3 (Drosophila) (KLHL3), mRNA. 348.51 174.85 1.99 0.033 173.66 
SLC26A11 PREDICTED: Homo sapiens solute carrier family 26, member 11 (SLC26A11), mRNA. 439.78 217.69 2.02 0.000 222.09 
ADRB2 Homo sapiens adrenergic, beta-2-, receptor, surface (ADRB2), mRNA. 1887.73 925.7 2.04 0.000 962.03 
NCF2 Homo sapiens neutrophil cytosolic factor 2 (65kDa, chronic granulomatous disease, autosomal 2) (NCF2), mRNA. 307.95 149.47 2.06 0.024 158.49 
CHST7 Homo sapiens carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 (CHST7), mRNA. 312.63 150.87 2.07 0.036 161.75 
DHFRL1 Homo sapiens dihydrofolate reductase-like 1 (DHFRL1), mRNA. 200.70 95.02 2.11 0.016 105.68 
ZBTB48 Homo sapiens zinc finger and BTB domain containing 48 (ZBTB48), mRNA. 365.21 164.51 2.22 1.00E-04 200.70 
WHSC1L1 Homo sapiens Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1), transcript variant short, mRNA. 196.78 86.23 2.28 0.000 110.55 
WDR36 Homo sapiens WD repeat domain 36 (WDR36), mRNA. 302.97 120.75 2.51 7.00E-04 182.22 
EIF2B4 Homo sapiens eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa (EIF2B4), transcript variant 3, mRNA. 851.89 328.27 2.60 0.024 523.62 
C3orf19 Homo sapiens chromosome 3 open reading frame 19 (C3orf19), mRNA. 495.51 151.67 3.27 0.000 343.84 
LOC729708 PREDICTED: Homo sapiens similar to rcTPI1, transcript variant 1 (LOC729708), mRNA. 898.41 216.65 4.15 0.000 681.76 
 
 
Comparison CD8+ T cells of MF- individuals versus EN 
7 Definition mean_CD8_Mfneg mean_CD8_EN FC pvalue diff 
FOS Homo sapiens v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS), mRNA. 349.32 1608.68 -4.61 0.003 1259.35 
PPP1R15A Homo sapiens protein phosphatase 1, regulatory (inhibitor) subunit 15A (PPP1R15A), mRNA. 382.73 1625.30 -4.25 0.044 1242.57 
DUSP1 Homo sapiens dual specificity phosphatase 1 (DUSP1), mRNA. 1319.64 5150.74 -3.90 0.034 3831.09 
SGK Homo sapiens serum/glucocorticoid regulated kinase (SGK), mRNA. 137.71 494.40 -3.59 0.000 356.68 
LOC338758 PREDICTED: Homo sapiens hypothetical protein LOC338758 (LOC338758), mRNA. 191.42 668.89 -3.49 0.000 477.47 
NFKBIZ Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta (NFKBIZ), transcript variant 2, mRNA. 423.81 1189.31 -2.81 3.00E-04 765.51 
TIPARP Homo sapiens TCDD-inducible poly(ADP-ribose) polymerase (TIPARP), mRNA. 472.43 1270.95 -2.69 0.014 798.52 
BTBD7 Homo sapiens BTB (POZ) domain containing 7 (BTBD7), transcript variant 2, mRNA. 148.37 360.10 -2.43 7.00E-04 211.73 
KLF4 Homo sapiens Kruppel-like factor 4 (gut) (KLF4), mRNA. 104.36 249.90 -2.39 0.000 145.54 
SGK1 Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1), transcript variant 1, mRNA. 110.71 240.41 -2.17 0.000 129.70 
SERTAD3 Homo sapiens SERTA domain containing 3 (SERTAD3), transcript variant 1, mRNA. 125.44 266.87 -2.13 0.004 141.43 
TMEM170A Homo sapiens transmembrane protein 170A (TMEM170A), mRNA. 139.62 293.19 -2.10 0.000 153.57 
TSC22D3 Homo sapiens TSC22 domain family, member 3 (TSC22D3), transcript variant 2, mRNA. 744.39 1540.5 -2.07 0.022 796.11 
SOD2 Homo sapiens superoxide dismutase 2, mitochondrial (SOD2), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA. 428.65 884.22 -2.06 0.000 455.57 
EIF2C2 Homo sapiens eukaryotic translation initiation factor 2C, 2 (EIF2C2), mRNA. 169.02 339.18 -2.01 0.014 170.16 
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SGK1 Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1), transcript variant 1, mRNA. 111.64 224.81 -2.01 0.037 113.17 
TARSL2 Homo sapiens threonyl-tRNA synthetase-like 2 (TARSL2), mRNA. 122.47 244.50 -2.00 0.010 122.03 
GATS Homo sapiens opposite strand transcription unit to STAG3 (GATS), mRNA. 165.00 322.29 -1.95 0.041 157.29 
CGRRF1 Homo sapiens cell growth regulator with ring finger domain 1 (CGRRF1), mRNA. 164.56 316.76 -1.92 1.00E-04 152.20 
ZFAND5 Homo sapiens zinc finger, AN1-type domain 5 (ZFAND5), mRNA. 537.57 1014.89 -1.89 0.000 477.32 
CYCSL1 Homo sapiens cytochrome c, somatic-like 1 (CYCSL1) on chromosome 6. 171.50 317.51 -1.85 0.018 146.01 
PCCB Homo sapiens propionyl Coenzyme A carboxylase, beta polypeptide (PCCB), nuclear gene encoding mitochondrial protein, mRNA. 261.68 483.32 -1.85 0.012 221.64 
LOC440093 Homo sapiens histone H3-like (LOC440093), mRNA. 604.94 1100.74 -1.82 0.000 495.80 
LRPAP1 Homo sapiens low density lipoprotein receptor-related protein associated protein 1 (LRPAP1), mRNA. 263.14 479.84 -1.82 0.042 216.70 
BCL6 Homo sapiens B-cell CLL/lymphoma 6 (zinc finger protein 51) (BCL6), transcript variant 1, mRNA. 477.19 859.96 -1.80 0.034 382.77 
CHUK Homo sapiens conserved helix-loop-helix ubiquitous kinase (CHUK), mRNA. 279.12 502.22 -1.80 0.002 223.10 
LRP5L Homo sapiens low density lipoprotein receptor-related protein 5-like (LRP5L), mRNA. 242.82 428.72 -1.77 0.037 185.9 
ING2 Homo sapiens inhibitor of growth family, member 2 (ING2), mRNA. 140.92 248.38 -1.76 0.035 107.46 
MED30 Homo sapiens mediator complex subunit 30 (MED30), mRNA. 174.34 295.76 -1.70 0.008 121.42 
CCT2 Homo sapiens chaperonin containing TCP1, subunit 2 (beta) (CCT2), mRNA. 529.37 884.04 -1.67 0.002 354.67 
ACSL3 Homo sapiens acyl-CoA synthetase long-chain family member 3 (ACSL3), transcript variant 2, mRNA. 314.66 518.23 -1.65 0.000 203.57 
CGGBP1 Homo sapiens CGG triplet repeat binding protein 1 (CGGBP1), transcript variant 2, mRNA. 501.34 817.47 -1.63 0.049 316.13 
MAP3K5 Homo sapiens mitogen-activated protein kinase kinase kinase 5 (MAP3K5), mRNA. 178.72 290.30 -1.62 0.003 111.58 
NDUFA6 
Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14kDa (NDUFA6), nuclear gene encoding mitochondrial protein, 
mRNA. 322.21 522.76 -1.62 0.026 200.55 
UBE2J1 Homo sapiens ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) (UBE2J1), mRNA. 412.89 666.74 -1.61 4.00E-04 253.85 
VAMP3 Homo sapiens vesicle-associated membrane protein 3 (cellubrevin) (VAMP3), mRNA. 306.54 483.98 -1.58 0.017 177.43 
ARHGAP19 Homo sapiens Rho GTPase activating protein 19 (ARHGAP19), mRNA. 267.56 418.84 -1.57 0.000 151.28 
EIF2A Homo sapiens eukaryotic translation initiation factor 2A, 65kDa (EIF2A), mRNA. 497.41 773.65 -1.56 9.00E-04 276.24 
BCCIP Homo sapiens BRCA2 and CDKN1A interacting protein (BCCIP), transcript variant B, mRNA. 396.66 602.13 -1.52 0.030 205.47 
MRFAP1 Homo sapiens Mof4 family associated protein 1 (MRFAP1), mRNA. 972.90 1479.89 -1.52 0.024 506.99 
ODC1 Homo sapiens ornithine decarboxylase 1 (ODC1), mRNA. 738.79 1121.6 -1.52 0.013 382.81 
FASTKD5 Homo sapiens FAST kinase domains 5 (FASTKD5), mRNA. 291.27 439.00 -1.51 0.000 147.73 
KLHDC3 Homo sapiens kelch domain containing 3 (KLHDC3), mRNA. 551.83 361.17 1.53 0.026 190.66 
PTP4A2 Homo sapiens protein tyrosine phosphatase type IVA, member 2 (PTP4A2), transcript variant 2, mRNA. XM_944930 XM_944934 3019.32 1967.91 1.53 0.035 1051.41 
C9orf69 Homo sapiens chromosome 9 open reading frame 69 (C9orf69), mRNA. 335.20 216.67 1.55 0.000 118.53 
RPS6KA1 Homo sapiens ribosomal protein S6 kinase, 90kDa, polypeptide 1 (RPS6KA1), transcript variant 1, mRNA. 854.60 552.26 1.55 0.000 302.34 
POGK Homo sapiens pogo transposable element with KRAB domain (POGK), mRNA. 848.49 544.15 1.56 0.038 304.34 
LOC606724 Homo sapiens coronin, actin binding protein, 1A pseudogene (LOC606724), non-coding RNA. 1696.37 1082.57 1.57 0.007 613.79 
TMEM203 Homo sapiens transmembrane protein 203 (TMEM203), mRNA. 919.25 578.01 1.59 0.025 341.24 
MRP63 Homo sapiens mitochondrial ribosomal protein 63 (MRP63), nuclear gene encoding mitochondrial protein, mRNA. 270.51 168.94 1.60 0.001 101.57 
RUFY3 Homo sapiens RUN and FYVE domain containing 3 (RUFY3), transcript variant 1, mRNA. 327.65 205.08 1.60 0.023 122.57 
PRPF31 Homo sapiens PRP31 pre-mRNA processing factor 31 homolog (S. cerevisiae) (PRPF31), mRNA. 644.07 400.03 1.61 0.000 244.04 
TMBIM4 Homo sapiens transmembrane BAX inhibitor motif containing 4 (TMBIM4), mRNA. 2478.92 1541.72 1.61 0.048 937.20 
CALHM2 Homo sapiens calcium homeostasis modulator 2 (CALHM2), mRNA. 374.61 231.76 1.62 0.017 142.85 
LRP10 Homo sapiens low density lipoprotein receptor-related protein 10 (LRP10), mRNA. 916.97 562.20 1.63 0.002 354.77 
VKORC1 Homo sapiens vitamin K epoxide reductase complex, subunit 1 (VKORC1), transcript variant 1, mRNA. 1378.8 829.06 1.66 0.017 549.74 
WDR40A Homo sapiens WD repeat domain 40A (WDR40A), mRNA. 359.35 215.38 1.67 0.000 143.97 
TM7SF2 Homo sapiens transmembrane 7 superfamily member 2 (TM7SF2), mRNA. 260.06 147.71 1.76 0.004 112.35 
C3orf19 Homo sapiens chromosome 3 open reading frame 19 (C3orf19), mRNA. 495.51 273.14 1.81 0.002 222.37 
FRYL Homo sapiens FRY-like (FRYL), mRNA. 1254.74 691.90 1.81 2.00E-04 562.84 
NCF2 Homo sapiens neutrophil cytosolic factor 2 (65kDa, chronic granulomatous disease, autosomal 2) (NCF2), mRNA. 307.95 167.77 1.84 0.049 140.18 
PRKAA1 Homo sapiens protein kinase, AMP-activated, alpha 1 catalytic subunit (PRKAA1), transcript variant 1, mRNA. 298.88 162.59 1.84 1.00E-04 136.29 
SGSH Homo sapiens N-sulfoglucosamine sulfohydrolase (sulfamidase) (SGSH), mRNA. 715.43 385.11 1.86 0.000 330.32 
UBL4A Homo sapiens ubiquitin-like 4A (UBL4A), mRNA. 454.95 242.77 1.87 0.001 212.19 
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ZNF75D Homo sapiens zinc finger protein 75D (ZNF75D), mRNA. 301.76 159.24 1.89 0.000 142.52 
TFB1M Homo sapiens transcription factor B1, mitochondrial (TFB1M), mRNA. 347.58 181.28 1.92 0.005 166.3 
ADRB2 Homo sapiens adrenergic, beta-2-, receptor, surface (ADRB2), mRNA. 1887.73 960.35 1.97 0.023 927.38 
RABEP1 Homo sapiens rabaptin, RAB GTPase binding effector protein 1 (RABEP1), transcript variant 2, mRNA. 430.89 215.90 2.00 1.00E-04 214.98 
SHMT1 Homo sapiens serine hydroxymethyltransferase 1 (soluble) (SHMT1), transcript variant 1, mRNA. 273.36 134.14 2.04 2.00E-04 139.22 
PKP4 Homo sapiens plakophilin 4 (PKP4), transcript variant 1, mRNA. 263.00 126.45 2.08 0.019 136.55 
PRAGMIN Homo sapiens homolog of rat pragma of Rnd2 (PRAGMIN), mRNA. 285.24 131.07 2.18 2.00E-04 154.17 
WIBG Homo sapiens within bgcn homolog (Drosophila) (WIBG), mRNA. 295.41 135.55 2.18 0.014 159.86 
APPBP2 Homo sapiens amyloid beta precursor protein (cytoplasmic tail) binding protein 2 (APPBP2), mRNA. 191.40 85.38 2.24 0.000 106.02 
LMNB2 Homo sapiens lamin B2 (LMNB2), mRNA. 496.34 210.12 2.36 2.00E-04 286.22 
ZNF232 Homo sapiens zinc finger protein 232 (ZNF232), mRNA. 248.51 103.27 2.41 0.013 145.23 
METT10D Homo sapiens methyltransferase 10 domain containing (METT10D), mRNA. 239.22 85.45 2.80 0.000 153.77 
FANCD2 Homo sapiens Fanconi anemia, complementation group D2 (FANCD2), transcript variant 2, mRNA. 285.13 99.42 2.87 0.033 185.70 
VAV3 Homo sapiens vav 3 guanine nucleotide exchange factor (VAV3), transcript variant 1, mRNA. 626.60 90.29 6.94 1.00E-04 536.31 
 
 
Comparison CD8+ T cells of MF+ individuals versus EN 
Symbol Definition mean_CD8_Mfpos mean_CD8_EN FC pvalue diff 
SOD2 Homo sapiens superoxide dismutase 2, mitochondrial (SOD2), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA. 294.74 884.22 -3.0 0.000 589.48 
ETF1 Homo sapiens eukaryotic translation termination factor 1 (ETF1), mRNA. 525.62 1436.46 -2.73 0.024 910.84 
FLJ10986 Homo sapiens hypothetical protein FLJ10986 (FLJ10986), mRNA. 82.92 220.40 -2.66 0.000 137.49 
PYHIN1 Homo sapiens pyrin and HIN domain family, member 1 (PYHIN1), transcript variant b2, mRNA. 152.93 368.55 -2.41 0.020 215.62 
 CR743533 Soares_testis_NHT Homo sapiens cDNA clone IMAGp971L1944 ; IMAGE:727458 5, mRNA sequence 120.28 284.3 -2.36 0.038 164.02 
SPHK2 Homo sapiens sphingosine kinase 2 (SPHK2), mRNA. 186.57 427.48 -2.29 1.00E-04 240.91 
C7orf40 Homo sapiens chromosome 7 open reading frame 40 (C7orf40), non-coding RNA. 224.47 500.25 -2.23 0.001 275.78 
ZCWPW1 Homo sapiens zinc finger, CW type with PWWP domain 1 (ZCWPW1), mRNA. 135.01 300.95 -2.23 0.009 165.94 
 Homo sapiens clone TESTIS-609 mRNA sequence 101.02 215.32 -2.13 0.001 114.30 
SLC37A4 Homo sapiens solute carrier family 37 (glucose-6-phosphate transporter), member 4 (SLC37A4), mRNA. 174.34 369.38 -2.12 5.00E-04 195.05 
RAB11FIP1 Homo sapiens RAB11 family interacting protein 1 (class I) (RAB11FIP1), transcript variant 3, mRNA. 216.36 440.96 -2.04 0.000 224.59 
AZI1 Homo sapiens 5-azacytidine induced 1 (AZI1), transcript variant 1, mRNA. 165.28 332.67 -2.01 0.003 167.40 
HBP1 Homo sapiens HMG-box transcription factor 1 (HBP1), mRNA. 246.88 495.07 -2.01 0.004 248.20 
EEF2K Homo sapiens eukaryotic elongation factor-2 kinase (EEF2K), mRNA. 134.83 265.51 -1.97 0.000 130.68 
LOC652685 PREDICTED: Homo sapiens similar to PMS1 protein homolog 2 (DNA mismatch repair protein PMS2) (LOC652685), mRNA. 179.28 352.58 -1.97 0.000 173.31 
HIBADH Homo sapiens 3-hydroxyisobutyrate dehydrogenase (HIBADH), mRNA. 220.26 422.93 -1.92 0.038 202.67 
ACSL3 Homo sapiens acyl-CoA synthetase long-chain family member 3 (ACSL3), transcript variant 2, mRNA. 274.39 518.23 -1.89 0.000 243.85 
PPOX Homo sapiens protoporphyrinogen oxidase (PPOX), nuclear gene encoding mitochondrial protein, mRNA. 164.21 310.27 -1.89 0.017 146.06 
AUTS2 Homo sapiens autism susceptibility candidate 2 (AUTS2), mRNA. 337.51 633.78 -1.88 0.020 296.27 
KLF4 Homo sapiens Kruppel-like factor 4 (gut) (KLF4), mRNA. 135.95 249.9 -1.84 0.003 113.95 
CRIPAK Homo sapiens cysteine-rich PAK1 inhibitor (CRIPAK), mRNA. 410.02 723.99 -1.77 0.033 313.97 
RMND5A Homo sapiens required for meiotic nuclear division 5 homolog A (S. cerevisiae) (RMND5A), mRNA. 177.87 315.42 -1.77 0.035 137.56 
TMUB2 Homo sapiens transmembrane and ubiquitin-like domain containing 2 (TMUB2), transcript variant 1, mRNA. 189.52 335.37 -1.77 0.000 145.85 
SERTAD3 Homo sapiens SERTA domain containing 3 (SERTAD3), transcript variant 1, mRNA. 156.13 266.87 -1.71 0.050 110.74 
MYLIP Homo sapiens myosin regulatory light chain interacting protein (MYLIP), mRNA. 1727.68 2935.22 -1.70 0.023 1207.53 
HBP1 Homo sapiens HMG-box transcription factor 1 (HBP1), mRNA. 166.46 280.92 -1.69 2.00E-04 114.46 
DCTN5 Homo sapiens dynactin 5 (p25) (DCTN5), mRNA. 455.95 756.54 -1.66 0.002 300.58 
ZNF211 Homo sapiens zinc finger protein 211 (ZNF211), transcript variant 1, mRNA. 219.27 362.78 -1.65 0.032 143.52 
NARF Homo sapiens nuclear prelamin A recognition factor (NARF), transcript variant 3, mRNA. 455.31 743.36 -1.63 0.007 288.05 
 Homo sapiens cDNA clone IMAGE:30332316 211.51 343.18 -1.62 4.00E-04 131.67 
FBXO44 Homo sapiens F-box protein 44 (FBXO44), transcript variant 4, mRNA. 182.37 293.23 -1.61 0.045 110.86 
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FN3KRP Homo sapiens fructosamine-3-kinase-related protein (FN3KRP), mRNA. 424.16 672.65 -1.59 0.000 248.49 
KIF22 Homo sapiens kinesin family member 22 (KIF22), mRNA. 365.59 581.24 -1.59 0.006 215.65 
PHAX Homo sapiens phosphorylated adaptor for RNA export (PHAX), mRNA. 223.77 354.27 -1.58 0.017 130.50 
ALG8 Homo sapiens asparagine-linked glycosylation 8, alpha-1,3-glucosyltransferase homolog (S. cerevisiae) (ALG8), transcript variant 1, mRNA. 192.45 300.70 -1.56 0.000 108.26 
LSM1 Homo sapiens LSM1 homolog, U6 small nuclear RNA associated (S. cerevisiae) (LSM1), mRNA. 1106.08 1710.97 -1.55 0.001 604.88 
CNNM3 Homo sapiens cyclin M3 (CNNM3), transcript variant 1, mRNA. 293.57 448.57 -1.53 0.002 155,00 
SGSH Homo sapiens N-sulfoglucosamine sulfohydrolase (sulfamidase) (SGSH), mRNA. 594.84 385.11 1.54 0.001 209.73 
C9orf69 Homo sapiens chromosome 9 open reading frame 69 (C9orf69), mRNA. 342.63 216.67 1.58 0.039 125.95 
RFX5 Homo sapiens regulatory factor X, 5 (influences HLA class II expression) (RFX5), transcript variant 2, mRNA. 990.73 617.09 1.61 0.023 373.64 
FBXO11 Homo sapiens F-box protein 11 (FBXO11), transcript variant 1, mRNA. 702.60 434.36 1.62 0.015 268.24 
LRRFIP2 Homo sapiens leucine rich repeat (in FLII) interacting protein 2 (LRRFIP2), transcript variant 2, mRNA. 290.62 177.43 1.64 0.025 113.19 
SRXN1 Homo sapiens sulfiredoxin 1 homolog (S. cerevisiae) (SRXN1), mRNA. 255.57 155.44 1.64 0.003 100.13 
POMGNT1 Homo sapiens protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase (POMGNT1), mRNA. 376.80 227.96 1.65 0.000 148.83 
ACTB Homo sapiens actin, beta (ACTB), mRNA. 534.58 319.71 1.67 0.012 214.87 
LAMP2 Homo sapiens lysosomal-associated membrane protein 2 (LAMP2), transcript variant LAMP2B, mRNA. 335.13 196.86 1.70 0.035 138.27 
RAB11A Homo sapiens RAB11A, member RAS oncogene family (RAB11A), mRNA. 1383.15 803.49 1.72 0.002 579.66 
GSDMB Homo sapiens gasdermin B (GSDMB), transcript variant 2, mRNA. 497.54 283.14 1.76 0.000 214.4 
LAMP2 Homo sapiens lysosomal-associated membrane protein 2 (LAMP2), transcript variant LAMP2B, mRNA. 387.28 220.47 1.76 0.014 166.81 
CDC42SE1 Homo sapiens CDC42 small effector 1 (CDC42SE1), transcript variant 1, mRNA. 236.50 129.34 1.83 0.000 107.15 
RNF121 Homo sapiens ring finger protein 121 (RNF121), transcript variant 1, mRNA. 272.74 145.07 1.88 0.002 127.67 
ZNF83 Homo sapiens zinc finger protein 83 (ZNF83), mRNA. 254.95 134.7 1.89 0.013 120.25 
UBL4A Homo sapiens ubiquitin-like 4A (UBL4A), mRNA. 461.08 242.77 1.90 0.002 218.32 
WIPI1 Homo sapiens WD repeat domain, phosphoinositide interacting 1 (WIPI1), mRNA. 321.58 167.7 1.92 0.003 153.88 
AHCTF1 Homo sapiens AT hook containing transcription factor 1 (AHCTF1), mRNA. 443.59 229.34 1.93 0.015 214.25 
ARFIP1 Homo sapiens ADP-ribosylation factor interacting protein 1 (ARFIP1), transcript variant 2, mRNA. 254.04 131.68 1.93 0.010 122.36 
NME1 Homo sapiens non-metastatic cells 1, protein (NM23A) expressed in (NME1), transcript variant 2, mRNA. 506.07 252.21 2.01 0.000 253.86 
 Homo sapiens cDNA FLJ12874 fis, clone NT2RP2003769 487.59 238.55 2.04 0.045 249.04 
NDUFB5 
Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16kDa (NDUFB5), nuclear gene encoding mitochondrial protein, 
mRNA. 718.51 332.16 2.16 0.027 386.35 
ARL17P1 Homo sapiens ADP-ribosylation factor-like 17 pseudogene 1 (ARL17P1), mRNA. 304.28 138.25 2.20 0.014 166.04 
RABEP1 Homo sapiens rabaptin, RAB GTPase binding effector protein 1 (RABEP1), transcript variant 2, mRNA. 476.17 215.90 2.21 0.035 260.27 
RCOR3 Homo sapiens REST corepressor 3 (RCOR3), mRNA. 667.98 295.89 2.26 1.00E-04 372.08 
RHBDD1 Homo sapiens rhomboid domain containing 1 (RHBDD1), mRNA. 221.47 95.85 2.31 0.014 125.62 
ZNF232 Homo sapiens zinc finger protein 232 (ZNF232), mRNA. 242.07 103.27 2.34 0.028 138.79 
APPBP2 Homo sapiens amyloid beta precursor protein (cytoplasmic tail) binding protein 2 (APPBP2), mRNA. 214.79 85.38 2.52 0.001 129.42 
PTGDR Homo sapiens prostaglandin D2 receptor (DP) (PTGDR), mRNA. 572.73 215,00 2.66 0.006 357.73 
VPS13C Homo sapiens vacuolar protein sorting 13 homolog C (S. cerevisiae) (VPS13C), transcript variant 1B, mRNA. 294.16 106.22 2.77 1.00E-04 187.94 
HAVCR2 Homo sapiens hepatitis A virus cellular receptor 2 (HAVCR2), mRNA. 1095.55 391.70 2.80 9.00E-04 703.85 
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Erklärung 
An Eides statt versichere ich, dass die vorgelegte Arbeit – abgesehen von den ausdrücklich 
bezeichneten Hilfsmitteln – persönlich, selbständig und ohne Benutzung anderer als der 
angegebenen Hilfsmittel angefertigt wurde, die aus anderen Quellen direkt oder indirekt 
übernommenen Daten und Konzepte unter Angabe der Quelle kenntlich gemacht sind, die 
vorgelegte Arbeit oder ähnliche Arbeiten nicht bereits anderweitig als Dissertation eingereicht 
worden ist bzw. sind, sowie eine Erklärung über frühere Promotionsversuche und deren 
Resultate, für die inhaltlich-materielle Erstellung der vorgelegten Arbeit keine fremde Hilfe, 
insbesondere keine entgeltliche Hilfe von Vermittlungs- bzw. Beratungsdiensten 
(Promotionsberater oder andere Personen) in Anspruch genommen wurde sowie keinerlei 
Dritte vom Doktoranden unmittelbar oder mittelbar geldwerte Leistungen für Tätigkeiten 
erhalten haben, die im Zusammenhang mit dem Inhalt der vorgelegten Arbeit stehen. 
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